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Organic synthesis has paramount importance in science and society. Since the emergence of 
organic synthesis in early 19th century as marked by revolutionary discovery of the preparation 
of urea by Wöhler in 1828 in Germany,[1] organic synthesis has changed the world with its 
gigantic applications for the benefit of society.[2] Organic synthesis has direct impact on several 
new domains ranging from the development of modern medicines to the production of 
nutritional goods, cosmetics, functional materials, including polymers, plastic, among others. 
Despite the vast applications of organic synthesis in resolving societal issues, there are rising 
concerns for the economical and environmental impact of its processes. Consumption of 
nonrenewable resources, including energy and materials, emissions of toxic and hazardous 
waste have detrimental effect on the environment.[3]  
Thus, efforts have been devoted to the discovery and emergence of resource-economical, 
environmentally-benign strategies in the field of organic synthesis,[4] providing the guidelines 
of green chemistry as put forwarded by Anastas and Warner in their 12 Principles of Green 
Chemistry.[5] Among these guidelines, the application of catalytic processes rather than 
stoichiometric transformations, easily available starting materials, minimization of waste 
formations, mild reactions conditions are of prime importance to elevate the power of organic 
transformations to the standards of Nature and beyond.[6]  
1.1. Transition Metal-Catalyzed C–H Activation 
 
Initial discoveries in the rich history of transition metal-catalyzed cross-coupling reactions[7] 
originate from the pioneering, 150 years old, reactions by Glaser[8] and Ullman[9] on copper-
promoted or -catalyzed cross-coupling reactions. These intriguing studies set the stage for 
metal-catalyzed C–C/C–Het bond forming reactions between two structural units.[10] 
Nevertheless, starting from the 1950s palladium started to gain its market value with the 
development of well known palladium on charcoal[11] and Lindlar catalysts.[12] Later, Hafner 
discovered the famous Wacker process for the syntheses of acetaldehyde which became a 
benchmark study on exhibiting the potential of palladium in the synthesis of organic 
molecules.[13] Meanwhile, Heck found the application of palladium catalyst in cross-coupling 
reactions with organomercurial compounds.[14] Few years later, almost at the same time, 
Mizoroki[15] and later Heck[16] independently demonstrated palladium-catalyzed cross 
couplings between organic halides and alkenes, the Mizoroki–Heck reaction. With this 




cross-coupling reactions. A broad range of organometallic coupling partners has been 
employed, which has originated in a series of named reactions, like Suzuki–Miyaura,[17] 
Negishi,[18] Kumada–Corriu,[19] Hiyama,[20] Stille[21] and Sonogashira–Hagihara[22] cross-
coupling reactions. Furthermore, the Tsuji–Trost reaction[23] and the Buchwald-Hartwig 
amination[24] should be mentioned in the context of palladium-catalyzed chemistry. These 
important discoveries and their highly practical applications both in academia and in industry 
were recognized with the 2010 Nobel Prize to Heck, Negishi and Suzuki for palladium 
catalyzed cross-coupling reactions.[25] 
 
Despite enormous developments, transition metal-catalyzed cross-coupling reactions[26] 
associated with several limitations. The need of the pre-functionalized starting materials as well 
as air- and moisture-sensitive organometallic coupling partners jeopardize the atom-economy 
and sustainability of this otherwise powerful approach. More importantly, the generation of 
stoichiometric, potentially toxic organometallic compounds as by-products are highly 
undesirable to conserve the environmental integrity.  
 
In stark contrast, metal-catalyzed direct C–H activation represents a more sustainable approach 
towards excellent atom- and step-economy, given the ubiquitous presence of C−H bonds in 
organic molecules.[27] Thereby, C–H activation offers more environmentally-benign, practical 
approaches for large-scale syntheses without the lengthy prefunctionalization of starting 
materials, thereby providing improved step-economy and preventing concurrent undesired 
waste generation. Thus over the past years, transition metal catalyzed C–H activation has 
surfaced as a powerful tool to improve the efficacy of molecular synthesis with notable 
applications in late-stage diversification,[28] material sciences,[29] and pharmaceutical 
industries,[30] among others. Nevertheless, the applications of cost-effective Earth-abundant 3d 







Scheme 1. Traditional cross-coupling vs C−H Activation. 
Despite the enormous importance of organometallic C−H activation approach, the formation 
of C−Metal bond from C−H bond is far more challenging as the C−H bond is generally 
stronger than the C−X bond.[33] Thus, over the past years several studies have been directed 
towards elucidating the mechanistic pathways of the key C–H activation step to enable better 
catalytic processes. In this respect, different modes of action have been proposed for the 
elementary C–H metalation event.[34] These include: a) the oxidative addition pathway is more 
feasible for late transition metal at lower oxidation states, where achieving higher oxidation 
states are much easier (Scheme 2a). b) In contrast, σ-bond metathesis is more prominent for 
early transition metals where concerted breaking of C–H bond and formation of C–Met bond 
occurs (Scheme 2b). c) Electrophilic substitution pathway is proposed for late transition metals 
in high oxidation states usually in polar medium (Scheme 2c). d) Like σ-bond metathesis, 1,2-
addition pathways are more feasible for early transition metals featuring multiple unsaturated 
double bonds (Scheme 2d). This type of pathway operates via [2σ+2π] reaction. e) Finally, the 
most common pathway is the base-assisted C–H cleavage, where generally carboxylate 







Scheme 2. Mechanistic pathways for organometallic C−H activation. 
 
Consequently, base-assisted C–H metalation has been studied in greater details, giving rise to 
several distinct pathways. Among them, CMD (concerted metalation deprotonation) or AMLA 
(ambiphilic metal-ligand activation) and BIES (base-assisted internal electrophilic 
substitution) pathways have been suggested. The term CMD was named by 
Fagnou/Gorelsky,[35] whereas AMLA was disclosed through computational studies by 
MacGregor/Davies,[36] although both mechanism presents similar six-membered transition 
state, where both metalation and deprotonation occur simultaneously. While for BIES 
mechanism[37] which was introduced by Ackermann, electrophilic substitution type C–H 
activation occurs by carboxylate additives. In contrast to CMD/AMLA, the selectivity of BIES 






Scheme 3. Comparison of transition state structures in base-assisted metalation. 
The control of regioselectivity remains an arduous task owing to subtle reactivity difference of 
omnipresent C–H bonds. Nonetheless, in recent years several strategies have evolved to 
address this challenging issue. These include:  a) the substrate’s electronic bias by exploiting 
its inherent more acidic positions. b) Likewise, steric bias forces the activation at the less 
hindered  C–H bond. Unfortunately, these strategies depend on the nature of the substrates, 
thereby minimizing its generality. In this regard, introduction of directing group (DG)[27d, 38] 
with Lewis basic functionalities plays a crucial role for proximity-induced C–H activations 
(Scheme 4). In addition, the elegant use of the functional groups embedded within the 
molecules, as directing groups is an alternative atom-economical approach. Thus, considerable 
efforts have been made towards weakly co-ordinating[39] and removable directing groups.[40]  
 
 
Scheme 4. Selectivity-control in C–H activation. 
Moreover, recently transient directing groups have gained considerable attention as it avoids 






1.2. Transition Metal-Catalyzed C–F/C–H Functionalization 
 
Fluorinated organic compounds have gained considerable attention in pharmaceutical, 
agrochemical and material sciences due to their unique chemical and physical properties.[42] 
The installation of the small, highly electronegative fluorine atom on organic compounds 
significantly enhances their solubility and metabolic stability.[43] Notably, fluoroalkenes are 
considered as important fluorinated molecules due to their enhanced biological properties.[44] 
Therefore, there is a strong demand to get access to the fluorinated building blocks. Among 
various routes to synthesis fluorinated scaffolds, transition metal-catalyzed fluorination 
reactions have emerged as a promising approach.[43a, 45] Alternatively, the selective activation 
of C–F bonds is step-economical route to synthesize highly functionalized fluorinated 
molecules.[42a, 42b] In this context readily available polyfluorinated molecules can be selectively 
derivatized to form the C–C bonds by transition metal-mediated C–F bond activation.[46] 
1.2.1. Precious Transition Metal-Catalyzed C–F Functionalization 
 
An early example of defluorinative coupling of 1,1-difluoroethylene with aryl halides was 
elegantly achieved using palladium as catalyst by Heitz in 1991.[47] In their pioneering 
contribution, an arylpalladium(II) iodide species was formed in the presence of triethylamine 
which underwent insertion into 1,1-difluoroethylene 1 to form β,β‐difluorinated 
phenethylpalladium(II) species (Scheme 5). Thus, the formed palladium(II) species readily 
underwent β‐fluorine elimination to furnish α‐fluorostyrenes 3, synthetically valuable building 
blocks for fluoropolymers. 
 
Scheme 5. Palladium-catalyzed defluorinative coupling through β-fluoro elimination. 
After a decade, in 2005 Ichikawa reported an intramolecular Heck-type 5-endo-trig cyclization 
of oxime derivatives containing 1,1-difluoro-1-alkene motifs 4.[48]  A combination of Pd(PPh3)4 
and PPh3 enabled the facile β-fluorine elimination for the synthesis of 5-fluoro-3H-pyrroles 5 




pentafluorobenzoyloximes 6 for Heck-type of cyclization to form exo-difluoromethylene 7 unit 
via exclusively β-fluorine elimination (Scheme 6b).[49] These elegant findings through fluorine 
elimination set the stage for further developments in the area of transition metal-catalyzed C–
F bond activation. 
 
Scheme 6. Heck-type 5-endo-cyclization. 
Taking inspiration from these studies, insertion of fluoroalkenes into metal species have been 
intensively studied in recent years.[46] Transmetalation of organometallic reagents from main 
group elements to transition metals is the key step, preceding the insertion into the 
fluoroalkenes. It is noteworthy to mention that this type of reactivity is largely restricted to 
organosilicon and organoboron compounds. In an early report in 2008, Murakami showed the 
potential of rhodium catalysis for the formation of arylrhodium(I) species with aryl boronic 
esters 9 which underwent insertion into C–C double bond and subsequently selective β-fluorine 
elimination delivered gem-difluoroalkenes 10 (Scheme 7).[50] 
 
Scheme 7. Rhodium‐catalyzed arylation by β-fluorine elimination. 
Later, Toste described redox-neutral process for the palladium-catalyzed defluorinative 




synthesis monofluoroalkene 13 building blocks (Scheme 8).[51] Notably, these mild reaction 
conditions tolerated various sensitive functional groups to afford monofluorostilbene products 
with excellent diastereoselectivity. 
 
Scheme 8. Palladium-catalyzed defluorinative coupling. 
Recently, the merger of C–F activation with challenging C–H cleavage has become a research 
area of topical interest for the synthesis of highly valuable fluorinated scaffolds. Loh made a 
significant advancement in this research area by achieving C–F/C–H activation using 
Cp*Rh(III) catalyst (Scheme 9).[52] The authors utilized redox-neutral conditions for the α-
fluoroalkenylation with 1,1-difluoro-1-alkenes 11 through chelation-directed rhodium(III)-
catalyzed C–H bond cleavage of (hetero)arenes 14. Notably, in situ generated hydrogen 
fluoride had beneficial effect in the outcome of the reaction possibly due to the hydrogen bond 
involvement in the activation of C–F bond. 
 





In 2017, Li and Wang achieved the synthesis of different types of fluorinated heterocycles by 
directing group governed distinct reactivities (Scheme 10).[53] The authors employed a 
Cp*Rh(III) complex with 2,2-difluorovinyl tosylate 17 as the coupling partner to control the 
selectivity over C–N formation versus β-fluorine elimination, by using N–OMe and N–OPiv 
benzamides 16 and 19. Annulated dihydroisoquinolin-1(2H)-ones 18 bearing a gem-difluorides 
substituent at the C4 position were formed when N–OPiv benzamides were used whereas for 
N–OMe benzamide, mono fluoroalkene 20 was formed by β-fluorine elimination which was 
further treated under acidic condition to afford 4-fluoroisoquinolin-1(2H)-one 21. In addition, 
this reaction protocol tolerated a wide range of functional groups under mild reaction 
conditions. 
 
Scheme 10. Rhodium-catalyzed coupling of benzamides with 2,2-difluorovinyl tosylate 17. 
Shortly thereafter, Wang and Loh presented a unique way to synthesize five membered lactams 
23 using α,α-difluoromethylene alkynes 22 via Cp*Rh(III)-catalyzed two fold C–F bond 
cleavage (Scheme 11).[54] Oxidant-free reaction conditions were employed for the 
defluorinative [4+1] annulation reaction for the synthesis of alkynyl substituted isoindolin-1-
ones 23. A plethora of α,α-difluoromethylene alkynes 22 worked efficiently as one carbon 




methodology presents one of the scarce examples in the literature where sp carbon atom of 
alkyne was used as a one-carbon coupling partner. 
 
Scheme 11. Cp*Rh(III)-catalyzed [4+1] annulation via C−F Bond activation. 
In 2018, an iridium(III)-catalyzed double C–H functionalization of C(sp2)–H and C(sp3)–H 
bonds of anisoles was reported (Scheme 12).[55] A catalytic combination of Cp*Ir(III) complex 
25 and ancillary sulfoxide ligand 22 was employed to enable the sequential cleavage of C–H 
bonds of anisoles 24. The authors proposes a β-fluorine elimination which leads to the 
formation of fluoroallene species and in the following steps, subsequent β-H elimination 
delivered the chromene scaffolds 28. Likewise, a wide array of anisoles 24 and difluoroalkynes 
22 were tested which were efficiently coupled to from the chromene products 28. 
 






1.3. Enantioselective C–H Activation 
The direct activation of inert C–H bonds represents a very attractive, atom- and step-economic 
approach for providing new synthetic transformations.[27, 56] However, enantioselective C–H 
functionalization represents a valuable strategy for the construction of complex chiral 
compounds from simple precursors by selectively activating particular C–H bonds. Thus, over 
the past years transition metal complexes have been identified as powerful catalysts for the 
enantioselective C–H functionalization reactions.[57] In this context, 4d and 5d transition metals 
were mainly employed to enable full selectivity control.[58] With the rising concerns for the 
prices and toxicities of precious transition metals, recent focus has shifted towards Earth-
abundant and cost-effective transition metals[31] for successful execution of stereocontrolled 
organometallic C–H activations.[59] In addition to organometallic C–H activations, outer-
sphere processes have also been realized which do not involve the formation of direct metal-
carbon bond.[60] This type of mechanism is more prominent for metal−carbenoid and −nitrenoid 
insertion reactions (Scheme 13).[61] So, outer-sphere mechanisms are not discussed here. 
 
Scheme 13. Mechanistic classification for enantioselective C–H activations. 
1.3.1. Palladium Catalysis 
Since the pioneering studies by Sokolov in 1977 on the introduction of mono-protected chiral 
amino acids for the enantioselective stoichiometric C–H palladation (Scheme 14),[62] palladium 
has become the most commonly applied transition metal for enantioselective organometallic 
C–H activations. Consequently, a large variety of chiral ligands have evolved for a successful 
outcome of palladium-catalyzed C–H activation reactions, with commonly used phosphorus-






Scheme 14. Enantioselective stoichiometric C–H palladation of ferrocene 29. 
1.3.1.1. Phosphorus-Based Ligands 
In 2009, Cramer achieved enantioselective palladium(0)/palladium(II) C–H functionalization 
in an intramolecular desymmetrization reaction.[64] The authors utilized a TADDOL-derived 
monodentate phosphine 32 ligand to induce high enantioselectivity for intramolecular arylation 
with vinyl triflates 31. This protocol provided access to a wide variety of chiral indane motifs 
33 containing quaternary stereogenic centers with high enantioselectivities (Scheme 15a). 
Later, a phosphoramidite-type of TADDOL based ligand 35 proved viable for the arylation of 






Scheme 15. Palladium-catalyzed enantioselective intramolecular arylation. 
The potential of TADDOL-based ligands was also shown towards the formation of P-
stereogenic phosphinic amides, as independently reported by Duan[66] and Ma.[67] Also, Gu 
reported TADDOL ligand-facilitated asymmetric induction in an atroposelective cyclization 
protocol.[68] 
In addition, SPINOL-derived chiral phosphoric acid 39 was found as the best ligand for the 
palladium-catalyzed atroposelective olefination of arenes 37 (Scheme 16).[69] Later, the same 





Scheme 16. Palladium-catalyzed atroposelective olefination of arene 37. 
Furthermore, the Josiphos-type ligand 42 was utilized in combination with palladium catalysis 
for the intramolecular C−H arylation to syntheses highly enantio-enriched silicon-based ring 
systems 43 (Scheme 17).[71]  
 
Scheme 17. Palladium-catalyzed desymmetrization of 2-(arylsilyl)aryl triflates 41. 
It is noteworthy that a bifunctional phosphine-carboxylate ligand was also applied for 
enantioselective palladium-catalyzed arylation reactions by Baudoin.[72] In 2017, Cramer 
reported C−H alkenylation of ketene aminal phosphate with a phosphine ligand, containing 
both point and axial chirality.[73] 
 
1.3.1.2 Monoprotected Amino Acids as Chiral Ligands 
Since the introduction of mono-protected amino acids (MPAA) by Sokolov as chiral ligands,[62] 
their application in combination with palladium catalysis has significantly propelled this 
emerging research area.[63a] An elegant study by Yu in 2008 demonstrated the potential of 
MPAAs as viable ligands for this class of transformations. The utilization of a bulky menthol-
derived amino acid ligand 45 enabled the desymmetrization of diaryl(2-pyridyl)methane 





Scheme 18. Palladium-catalyzed desymmetrization using MPAA 45. 
Later, Yu achieved desymmetrization of α,α-diphenylacetates[75] and diarylmethylamines[76] by 
merging similar type of MPAA complex with palladium catalysis. In the former case, sodium 
salt 47 was reacted with styrene derivatives 48 under oxygen atmosphere (Scheme 19a). Later, 
the same group extended this approach to diarylmethylamines 51 using molecular iodine as 
both a reagent and an oxidant using leucine derivative 53 as the chiral ligand (Scheme 19b).  
 
Scheme 19. Palladium-catalyzed olefination of α,α-diphenylacetates 47 and iodination of 
diarylmethylamines 51. 
In subsequent studies, MPAAs have emerged as powerful ligands for palladium-catalyzed 
desymmetrization of diarylmethylamines[77] and diarylphosphinamides[78] with arylboronic 
acid pinacol esters, providing the desymmetrized products with high enantioselectivities. 
Enantioselective transformations of ferrocenes via direct C−H activation are a key subject area 
to synthesize planer chiral ferrocenes in a step-economical way (Scheme 20). Consequently, 
building on the great success of MPAAs ligands, enantioselective arylation with arylboronic 
acids[79] 12 as well as olefination of ferrocenes[80] 29 have been feasible by the judicious choice 
of MPAAs ligand. In addition, You developed further transformations towards enantioselective 





Scheme 20. Palladium-catalyzed asymmetric functionalization of ferrocenes 29. 
In 2016, Yu made a contribution towards the development of palladium-catalyzed iodination 
of chiral arylalkylamines as well as β-amino acid and β-amino alcohol derivatives utilizing 
MPAAs as chiral ligands (Scheme 11).[82] This protocol was not restricted to the iodination, 
the same group extended this strategy towards olefins[83] 38 and arylboronic acid pinacol 





Scheme 21. Palladium-catalyzed enantioselective functionalization of arenes using MPAAs. 
Subsequently, synthesis of axially chiral biaryls via kinetic resolution was disclosed by 
palladium-catalyzed C–H iodination using MPAAs.[85] Similar strategy enabled the 
atroposelective olefination of biaryls containing P(O)Ph2 as the directing group.[86] In a recent 
study, Shi employed L-pyroglutamic acid as chiral ligand for the atroposelective synthesis of 
axially chiral styrenes.[87] 
 
1.3.1.3 Chiral Transient Auxiliaries 
Since the contribution by Yu on enantioselective C(sp3)–H activations[88] by transient directing 
group (TDG), novel methods have evolved over the past years for chiral transient directing 
group[41] approaches in synergistic C–H activation. In this context, Shi efficiently employed 
chiral TDGs for the synthesis of axially chiral biaryls. In 2017, Shi reported atroposelective 
olefination of racemic biaryl containing aldehydes 73 in the presence of commercially available 
L-tert-leucine as the chiral TDG using oxygen as the terminal oxidant.[89] Later, this efficient 




38,[89] protected alkynyl bromides 75,[90] allyl acetate derivatives 79[91] and 4-vinyl-1,1-
dioxolan-2-one 77[91] (Scheme 22). 
 
 
Scheme 22. Palladium-catalyzed atroposelective transformations of biaryls using TDG 
strategy. 
Concurrently, related reaction conditions were employed for the synthesis of N–C axially chiral 
scaffolds by Shi[92] and Xie.[93] 
Another powerful approach was demonstrated for the synthesis of axially chiral scaffolds by 
introducing chiral auxiliaries. This strategy was mainly explored by the groups of Colobert and 




were used as chiral auxiliaries for successful olefination,[94] acetoxylating and halogenation,[95] 
as well as arylation[96] reactions (Scheme 23).  
 
Scheme 23. Palladium-catalyzed diastereoselective C–H activation of biaryls 81. 
In 2018, an interesting strategy was put into practice by Yu for the enantioselective remote 
meta-C–H activation using a chiral norbornene as a transient mediator.[97] This concept was 
further applied by Zhou for three-component coupling reactions involving aryl iodides 2, aryl 
bromides 85 and variety of terminating reagents 38 including olefins, alkynes, cyanide, boronic 





Scheme 24. Palladium/chiral norbornene cooperative catalysis towards chiral biaryls. 
1.3.2. Rhodium Catalysis 
1.3.2.1. Ligand-Induced Asymmetric C–H Activation 
Early pioneering studies on rhodium(I)-catalyzed enantioselective C–H activations can be 
traced back to the elegant contributions of Murai[99] and Ellman/Bergman.[100] Murai applied a 
monodentate phosphine ligand for a rhodium(I)-catalyzed enantioselective hydroarylation 
protocol.[99] Later, Ellman/Bergman presented intramolecular imine-directed hydroarylation of 
ketimines 89 (Scheme 25). The key to success was the use of BINOL-based chiral ligands 90 
or 91 to achieve high enantioselectivities for this cyclization protocol. 
 
Scheme 25. Rhodium-catalyzed hydroarylation of ketimine 89. 
This early pioneering studies have set the stage for various enantioselective annulation 
reactions using alkynes and alkenes as coupling partners by the aid of chiral biphosphine 
ligands.[101]  
Considering the high importance of enantioselective hydroarylation reactions, a number of 
reports have been documented in the literature. In a recent study, Matsunaga employed a hybrid 
catalyst, namely a 1:1 mixture of Cp*Rh(III) and (S)-BINSate anion for the addition of 2-
phenylpyridine 93 with α,β-unsaturated ketones 94.[102] Also the scope was further extended to 





Scheme 26. Rhodium-catalyzed C–H activation using chiral anions. 
Subsequently, Matsunaga reported the merger of a chiral carboxylic acid 102 with Cp*Rh(III) 
complex for the synthesis of 1,4-dihydroisoquinolin-3(2H)-one derivatives 103 via a 
desymmetrization process (Scheme 27).[103] 
 




In 2019, a protocol for highly enantioselective arylation of ferrocenes 104 was reported by 
You.[104] The authors employed a TADDOL-based chiral ligand 105 to synthesis planar chiral 
ferrocenes 106 by thioketone directed C–H activation (Scheme 28).  
 
Scheme 28. Rhodium-catalyzed C–H arylation of ferrocenes. 
TADDOL-derived monodentate phosphonite has also been applied by You in atroposelective 
C–H arylation reactions to synthesis highly enantioenriched chiral biaryls.[105]  
 
1.3.2.2. Chiral Cpx-Based Catalysts  
Apart from the use of exogenous chiral ligands with Cp*Rh(III) complexes, another powerful 
approach involves the use of chiral cyclopentadienyl-based (Cpx) complex to gain high levels 
of selectivity control.[106] The application of these complexes was demonstrated by Cramer for  
the annulation of hydroxamic acid derivatives 107 with olefins 94 to provide the annulated 
products 109 with excellent enantioselectivities (Scheme 29a).[107] Using a bulky OTIPS 
substituent on Cpx complex Rh111 enabled the functionalization of hydroxymates 19 with 





Scheme 29. Rhodium-catalyzed enantioselective C–H annulation. 
In subsequent reports, similar chiral Cpx complexes have found application in enantioselective 
intramolecular reactions to synthesize cyclized scaffold.[109] Later, chiral isoindolone 
derivatives 115 were synthesized using diazo compounds 113 via rhodium-catalyzed C–H 
activation (Scheme 30).[110]  
 




Chiral Cpx complex was also effective for enantioselective [3+2] spiroannulation reactions as 
demonstrated by You. Quaternary stereogenic centers 118 were formed under oxidative 
conditions (Scheme 31).[111] 
 
Scheme 31. Rhodium-catalyzed spiroannulations. 
In 2017, Ellman showed the potential of similar type of chiral Cpx complex  Rh121 for 
enantioselective rhodium(III)-catalyzed C–H bond addition to nitroalkenes 120 (Scheme 
32).[112]  
 
Scheme 32. Rhodium-catalyzed enantioselective dual C–H activation. 
Later, a three component reaction involving arene, terminal alkenes, and aminating agent was 
achieved by the same group. The authors utilized the same chiral rhodium complex Rh121 for 
the synthesis of α-methyl branched amines 125 with moderate to good enantioselectivities 
(Scheme 33).[113] 
 
Scheme 33. Rhodium-catalyzed enantioselective three component reaction. 
You also showed the application of chiral Cpx rhodium complexes Rh111 for successful 




studies, a SPINOL-type ligand Rh127 provided  improved enantioselectivities as shown by the 
same group.[115]  
 
Scheme 34. Rhodium-catalyzed atroposelective C–H olefination. 
Later, in 2019, Wang employed the same chiral rhodium(III) complex Rh127 for the synthesis 
atropo-stable indolinone derivatives 130 via dual C–H activation in an oxidative alkyne 
annulation conditions (Scheme 35).[116] 
 
Scheme 35. Rhodium-catalyzed atroposelective synthesis of C–N axially chiral biaryls. 
In addition to the aforementioned reports, successful approaches have been described for the 
atroposelective synthesis of biaryls using chiral Cpx complex with notable contributions from 
Li,[117] as well as Antonchick and Waldmann.[118]  
Despite significant advances, it is noteworthy to mention that the multi-step syntheses of chiral 






1.3.2.3. Other Strategies 
In 2012, Ward and Rovis devised a completely different approach to enantioselective C–H 
activation using rhodium catalysis. Here, a Cp* ligand was linked with biotin derivative that 
binds to streptavidin in a host-guest type interaction typical for enzymes providing environment 
for asymmetric induction. The initial potential of this catalytic system was tested for 
enantioselective annulation of hydroxymates 16 and olefins 94 at room temperature (Scheme 
36).[119] Later, the same group improved the versatility of this catalytic system towards the 
synthesis of  δ-lactams in high yields and enantioselectivity.[120] 
 
Scheme 36. Rhodium-catalyzed C–H activation with artificial metalloenzymes. 
The use of chiral transient directing group was largely limited to palladium catalysis, until 
recently, Wang employed this strategy to rhodium catalysis in their enantioselective synthesis 
of chiral phthalides from simple aldehydes.[121]  
1.3.3. Iridium Catalysis 
Over the past years, owing to unique properties of iridium catalysts, there has been a 
considerable increase in the use of iridium complexes for the development of novel and 
selective enantioselective C–H transformations.[122] 
In 2000, Togni documented an early example of an iridium-catalyzed enantioselective C–H 
hydroarylation of norbornene 132 with benzamide 133.[123] An iridium complex bearing 
cyclopentadienyl (Cp) and chiral ligand (R)-MeO-BIPHEP 134 enabled the intermolecular 
enantioselective hydroarylation to provide the alkylated product 135 in 94% ee, albeit with a 





Scheme 37. Early example of iridium-catalyzed enantioselective hydroarylation of 
norbornene 133. 
In 2008, in a related study Shibata employed [Ir(cod)2]BF4 as the catalyst and (R)-MeO-
BIPHEP 137 as the chiral ligand to achieve a single example of enantioselective C−H addition 
of 2’-methylacetophenone 136 to norbornene 133 with 58% yield and 70% ee (Scheme 38).[124] 
 
Scheme 38. Iridium-catalyzed enantioselective hydroarylation 2’-methylacetophenone 136. 
In 2013, Hartwig disclosed enantioselective C–H additions of heteroarenes to bicycloalkenes 
133 with the cooperation of (S)-DTBM-SEGPHOS 140 as the chiral ligand to provide highly 
enantioenriched alkylated products 141 (Scheme 39).[125] Notably, the reaction occurred 
efficiently with heteroarenes, including indoles, thiophenes, pyrroles and furans, selectively 
reacting on the C–H bonds adjacent to the heteroatoms. Even for unprotected indoles, C2 
alkylation was observed in contrast to its typical reactivity at the C3 position. A broad range of 






Scheme 39. Iridium-catalyzed enantioselective hydroarylation of bicycloalkanes. 
Thereafter, a combination of cationic iridium complex and newly designed sulfur linked 
bis(phosphoramidite) ligand [(R,R)-S-Me-BIPAM] 143 was applied by Yamamoto for amide- 






Scheme 40. Enantioselective additions to norbornenes 133. 
Later, Nishimura observed a similar reactivity in an example of enantioselective C–H 
alkylation of N-sulfonylbenzamides 145 using (R,R)-QuinoxP* as the chiral ligand (Scheme 
41).[127] 
 
Scheme 41. Enantioselective C–H alkylation of N-sulfonylbenzamides 145. 
While early enantioselective transformations were mainly limited to bicycloalkenes as olefin 
coupling partners, recently a broad variety of olefin partners has been employed. Intrigued by 
their previous racemic work on intermolecular C2-alkylation of N-protected indoles with 
terminal alkenes,[128] in 2015 Shibata applied a combination of iridium(I) catalyst and chiral 
diphosphine ligands (S)-SEGPHOS or (S)-Xyl-BINAP to enable the highly enantioselective 
intramolecular version of this protocol (Scheme 42).[129] C3-substituted ketone directed 
intramolecular C2 alkylations were achieved with this catalytic system to furnish highly 





Scheme 42. Enantioselective C−H alkylation of indole derivatives 148. 
The same group reported a catalytic system which set the stage for first iridium-catalyzed 
enantioselective C(sp2)−H alkylation of ferrocene by the aid of 1-isoquinolyl moiety 149 as the 
directing group (Scheme 43).[130] The key to success was represented by the use of a 
combination of iridium(I) complex and an analogue of Carreira’s diene ligand 150 to introduce 
planer chirality in ferrocene.[131] Thus various sensitive functional groups on olefin coupling 
partners 38 were tolerated to afford the alkylated products 151 in good yields and excellent 
enantioselectivitites. 
 




In contrast, efficient branch-selective, highly enantioselective iridium-catalyzed 
hydroarylations of styrenes and α-olefins of anilides were disclosed.[132] Key to success for 
achieving anilide 152 directed enantioselective ortho-C–H activation was the development of 
a chiral bisphosphite ligand 153 to generate tertiary benzylic stereocenters in high 
enantioselectivity and high atom economy (Scheme 44a). Also, the authors extended this 
strategy to hydroheteroarylation of terminal olefins 38 with thiophene 155 using a ferrocene-
based bisphosphonate ligand 156. With this tailored ligand 157, a diverse range of α-olefins 38 
were found as amenable substrates to provide the alkylated thiophenes 157 without 









In line with intramolecular hydroarylations, Rueping and Cavallo, very recently, expanded this 
approach towards oxygen tethered internal olefins 158 through amide and ketone directed C–
H activation (Scheme 45).[133] Here the use of (R,R)-QuinoxP* as chiral ligand proved to be 
crucial to achieve high enantioselectivities with the combination of a cationic iridium(I) 
catalyst. Thus, biologically relevant chiral dihydrobenzofurans 159 were obtained. Notably, 
this protocol also provided access to quaternary stereocenter with high enantioselectivity, albeit 
with lower yield. 
 
Scheme 45. Enantioselective intramolecular C–H alkylation. 
Besides numerous reports on enantioselective C−H alkylations, enantioselective 
hydroarylations of electron rich olefins using iridium complexes have remained elusive until 
very recently.[134] In 2015, Nishimura developed iridium catalyzed hydroarylation of vinyl 
ethers 160 via directed C−H activation. Promising results were obtained after initial screening 
with chiral diene (S,S)-Fc-tfb*, which provided the desired chiral ether 161 with 77% ee 
(Scheme 46a). Later the same group succeeded to achieve highly enantioselective alkylation 
of N-sulfonylbenzamides 145 with vinyl ethers 160 utilizing an iridium complex bearing the 
chiral diene (S,S)-Me-tfb* (Scheme 46b). Moreover, the authors were able to expand this 






Scheme 46. Enantioselective hydroarylation of electron-rich olefins 160. 
On a different note, the Shibata group in 2009 reported for the first time iridium-catalyzed 
enantioselective addition to carbon−heteroatom double bonds.[135] A moderate 
enantioselectivity of 72% ee was observed when a chiral bisphosphine ligand was employed to 
synthesize enantioenriched oxindole derivative. Later, Yamamoto and coworkers were able to 
extend this protocol to high enantioselectivity using a chiral bidentate bis-phosphoramidite 





Scheme 47. Enantioselective intramolecular C–H additions. 
1.3.4. Ruthenium Catalysis 
Over the past decades, versatile and cost-effective ruthenium(II) arene complexes[137] have 
shown enormous success in various C–H activation reactions.[27t, 39, 138] Despite of these major 
advances, enantioselective C–H transformations with comparatively inexpensive ruthenium 
catalysts remains considerably underdeveloped. 
Very recently, Cui and co-workers developed enantioselective ruthenium(II)-catalyzed 
intramolecular C–H hydroarylations of nitrogen-tethered olefin aldehydes 168 (Scheme 
48a).[139] The key to success was represented by the use of a commercially available α-
methylamines 169 as chiral TDG for the synthesis of highly enantioenriched indoline 
derivatives 171. The optimization studies showed that addition of catalytic amounts of 
protected chiral carboxylic acid 170 was beneficial for the outcome of the reaction. Shortly 
after, Wang and coworkers concurrently achieved similar reactivities with the oxygen-tethered 
olefin aldehydes 172 by the aid of an α-chiral amine as the chiral TDG (Scheme 48b).[140] This 
methodology set the stage for the highly efficient synthesis of 2,3-dihydrobenzofurans 173, 





Scheme 48. Enantioselective ruthenium(II)-catalyzed C–H alkylation. 
1.3.5. Nickel Catalysis 
The complexes of nickel have emerged as efficient catalysts for their versatile applicationsin 





1.3.5.1. Intramolecular Reactions 
Over the past years, a significant progress has been observed for the nickel-catalyzed 
enantioselective intramolecular C–H activations. In 2009, Nakao and Hiyama reported a 
racemic protocol for intramolecular C–H alkylation of pyridines with tethered olefins by a 
cooperative nickel/Lewis acid manifold.[143] Later, Cramer achieved preliminary success in 
enantioselective version of this protocol by using a chiral isoquinoline-based N-heterocyclic 
carbene[144] 176 to provide endo-cyclized products 174 in 78.5:21.5 e.r. (Scheme 49a).[145] 
Later, further improvement of this protocol was reported by the same group. A modified 
acenaphthene backbone contained NHC ligand 178, which was developed based on previous 
ligand design by Gawley,[146] was found to be crucial to achieve excellent enantioselectivities 
in the presence of MAD (methylaluminium bis(2,6-di-tert-butyl 4-methylphenoxide) as a 
Lewis acid (Scheme 49b).[147]  Further developments in this direction were reported by Ye, 
where TADDOL-based HASPOs 180 were employed to promote nickel-aluminum bimetallic 
catalysis for highly enantioselective exo-selective intramolecular C–H cyclization of imidazole 
derivatives 181 (Scheme 49c).[148] 
Despite these advances, enantioselective cyclizations were limited to the use of pyrophoric 
organoaluminium reagents as additives[149] which significantly restrict the substrate scope. To 
address this issue, Ackermann realized an aluminum-free reaction conditions for nickel 
catalyzed intramolecular highly enantioselective transformation. The unprecedented use of 
nickel/JoSPOphos[150] manifold enabled the endo-cyclization of imidazoles with unactivated 
alkenes 182 (Scheme 49d).[151] 
 
Later, Cramer employed chiral SIPR ligand 186 with bulky flanking groups for highly 
enantioselective nickel(0)-catalyzed endo-cyclization of indoles and pyrrole 185 (Scheme 
49e).[152] This approach was further extended by Shi to pyridines 188 utilizing a bulky chiral 
NHC ligand 189 in the presence of MAD as Lewis acid (Scheme 49f).[153] Shortly thereafter, 
the same group devised similar strategy in the presence of a bulky chiral NHC ligand to 
synthesis enantioenriched fluorotetralins by achieving endo-selective C–H annulation of 









1.3.5.2. Intermolecular Reactions 
Although numerous studies have been conducted on nickel-catalyzed intramolecular 
enantioselective hydroarylations, enantioselective intermolecular C–H activations remain 
extremely scarce in the literature. Inspired by the previous racemic work on nickel/NHC 
catalyzed three-component coupling by Fukuzawa,[155] an enantioselective version of this 
protocol was reported by Cramer and coworkers using a novel chiral NHC ligand 193 (Scheme 
50).[156] The key to success was the use of flanking N-aryl substituted Grubbs-type chiral 
NHC[157] 193 to provide annulated indanols 194 in a highly enantioselective fashion. 
 
Scheme 50. Enantioselective reductive three-component coupling. 
1.3.6. Cobalt Catalysis 
Over the last few decades, cobalt complexes have turned out to be among most promising 3d 
metals with numerous application to the functionalization of inert C–H bonds.[31, 32d, 32f, 32g, 32j] 
In general, these reactions can be performed by two strategies. (a) So-called low-valent cobalt 
catalysis:[32i] These are commonly performed under reductive conditions, where readily 
available cobalt(II) salt are reduced in situ to form either a cobalt(0) complex or, more 
commonly, a cobalt(I)-complex, which undergoes oxidative addition to promote the 
functionalization. (b) Cobalt(III) catalysis is mainly performed using bench-stable high-valent 
cobalt(III) catalysts with cyclopentadienyl ligands.[32f] Early developments in the field of 
enantioselective cobalt-catalyzed C–H functionalizations have been realized using low-valent 
cobalt chemistry. 
 
1.3.6. 1. Cobalt Catalysis under Reductive Conditions 
In 2014, Yoshikai utilized a combination of CoCl2 as the catalyst and (R,R)-BDPP as the 




alkenylbenzaldehydes 195 to deliver highly enantioenriched indanones 197 (Scheme 51a).[158] 
The authors further extended this protocol to 2-acylbenzaldehydes 198 using a catalytic system 
of CoBr2 and (R,R)-Ph-BPE for the synthesis of phthalides 200 building blocks in high 
enantioselectivity (Scheme 51b). Cobalt-chiral diphosphine catalytic systems provided the 
phthalide and indanone derivatives in good yields and with high enantio-control.  
 
Scheme 51. Enantioselective cobalt-catalyzed intramolecular hydroacylations. 
Later, the same group extended this approach to more challenging trisubstituted alkenes for the 
step-economical synthesis of 2,3-disubstituted indanones 202 (Scheme 52).[159] The authors 




using a catalytic system of CoBr2 and (R,R)-BDPP to provide the corresponding chiral cyclic 
ketones 202 in high yields and enantioselectivities. Notably, the outcome of the reaction was 
only hardly influenced by the E/Z ratio of the starting olefin substrates.  
 
Scheme 52. Hydroacylation of trisubstituted alkenes 201. 
Shortly thereafter, the versatile cobalt catalysis was applied by Dong and coworkers for a 
unique desymmetrization protocol for the intramolecular hydroacylation process to construct 
strained four-membered cyclobutanone derivatives 204 (Scheme 53).[160] The authors were 
able to control the regioselectivity to enable the formation of four-membered cyclobutanone 
204 in preference to the five-membered regioisomers. A cobalt catalyst derived from chiral 
diphosphine ligand (S,S)-BDPP enabled the synthesis of strained cyclobutanones 204 from α-
substituted dienyl aldehydes 203 with quaternary and tertiary stereogenic centers in high yields 
and with high enantioselectivities. 
 




In 2016, Yoshikai unraveled the low-valent cobalt catalyzed enantioselective C–H alkylation 
of indole derivatives 205 with styrenes 48.[161] Imine-directed C–H alkylation was achieved in 
the presence of Co(acac)2 as catalyst and BINOL-derived phosphoramidiateds 206 as chiral 
ligand. Thus, enantioenriched 1,1-diarylethane derivatives were obtained in high yields and 
with high enantioselectivities. 
 
 
Scheme 54. Enantioselective cobalt-catalyzed hydroarylation of styrenes 48. 
1.3.7. Iron Catalysis 
Iron is by far the most naturally abundant transition metal on Earth.  Iron chemistry is promoted 
by low cost and low toxicities as well as a broad array of various oxidation states. This has 
been reflected in the increasing use of iron catalysts in molecular syntheses, pharmaceutical 
and agrochemical industries.[162] This has set the stage for catalytic iron-catalyzed 
organometallic C–H functionalization processes. While the field of iron-catalyzed C–H 
activation is emerging, still the development of enantioselective C–H transformation is highly 
desirable. 
On this note, in 2018 Ackermann succeed to achieve first highly enantioselective iron-
catalyzed organometallic C–H activation (Scheme 55).[163] The authors reported 
enantioselective C–H secondary alkylation of (aza)indoles by the design of a novel bulky meta-




enantiocontrol. A plethora of diversely substituted indoles and azaindoles 208 were tested with 
styrenes and vinylmetallocenes 48 under the optimized reaction conditions. Thus, chiral C2-
alkylated products 210 were obtained in excellent yields and enantioselectivities. 
 
 


















1.4. Transition Metal-Catalyzed Oxidative C–H Activation towards Resource Economy 
Transition metal-catalyzed C−H activation has emerged as viable tool for molecular synthesis 
due to its high atom- and step-economy.[27, 56] In this regard, oxidative C−H transformations 
are particularly attractive as they avoid the use of prefunctionalization. Yet, oxidant economy 
significantly contradicts the sustainable nature of synthetically attractive oxidative C−H 
transformations. Unfortunately, oxidative C−H activations heavily rely on expensive and toxic 
chemical oxidants including hypervalent iodine(III) and copper(II) or silver(I) salts, generating 
stoichiometric amounts of undesired chemical waste. Also, in recent years use of molecular 
oxygen has gained certain attention as terminal oxidant[164] but its use with highly flammable 
organic solvents imposes safety issues.[165] 
1.4.1.1. Palladium-Catalyzed C–H Olefinations with Chemical Oxidants 
 
Mizoroki-Heck couplings have huge impact on synthetic chemistry for C−C bond formation 
reactions.[15b, 166] Given the significantly high importance of olefination reactions, 
Fujiwara−Moritani reaction even offers a better strategy for the introduction of olefins into 
arene C−H bonds as it avoids the preactivation of the substrates.[167] Yet, the use of large excess 
of substrates and lack of site-selectivity have jeopardized the application of Fujiwara−Moritani 
reaction to an extent. Thus, over the past decades directing group assisted C−H activation has 
become an attractive strategy to control the regioselectivity.[27d, 38] Consequently, these 
oxidative transformations are largely depended on the use of chemical oxidants for the 
reoxidation of metal centers. Here few representative examples have been provided to highlight 
the necessity of the expensive and toxic chemical oxidants for successful outcome of the 
palladium-catalyzed olefination reactions. 
In an elegant study by De Vries and Van Leeuwen in 2002, palladium-catalyzed oxidative 
olefinations of anilides 211 were achieved at room temperature (Scheme 56a).[168] 2.0 mol% 
Pd(OAc)2 was employed as catalyst in combination with 3.0 equiv of BQ as terminal oxidant 
to obtain optimal yields for the olefination protocol. 
In a related study, Shi reported palladium-catalyzed ortho-olefination of N,N-
dimethylbenzylamines 213 (Scheme 56b).[169] Among a series of tested chemical oxidants, 





Scheme 56. Palladium-catalyzed ortho-olefination in presence of chemical oxidants. 
Later, Chang disclosed oxidative alkenylation and arylation of pyridine N-oxides 215 in the 
presence of silver based oxidant (Scheme 57).[170]  
 
Scheme 57. Palladium-catalyzed oxidative alkenylation and arylation with silver-based 
oxidants. 
In 2010, ortho-C−H olefination reaction for phenylacetic acids 218 was disclosed using oxygen 





Scheme 58. Oxygen as terminal oxidant in ortho-C−H olefination reaction. 
In 2010, a protocol for palladium-catalyzed C(sp3)−H olefination was documented (Scheme 
59).[172] A superstoichiometric mixture of Cu(OAc)2 and AgOAc as oxidants provided the 
highest yield for this olefination protocol with a fancy directing group. 
 
Scheme 59. Palladium-catalyzed oxidative C(sp3)−H olefination. 
These examples set the stage for the further developments in palladium-catalyzed oxidative 
transformations with chemical oxidants with notable contributions from Gevorgyan,[173] 
Shi,[174] Yu,[175] among others.[27m] 
Despite these advances, the vast majority of C−H olefination reactions required activated or 
electronically-biased olefins, such as acrylates and styrenes. In 2014, Maiti reported C−H 
olefination reactions with unactivated alkenes 223 as coupling partners (Scheme 60).[176] The 
authors disclosed palladium-catalyzed chelation-assisted C−H alkenylation of phenylacetic 
acid derivatives 222 with unbiased aliphatic alkenes 223 by the aid of 8-aminoquinoline as the 
directing group. The key to success was the use of rac-BINAM as the ligand for this oxidative 
alkenylation protocol with 1 equiv of BQ under atmospheric pressure of oxygen as the oxidant.  
 





In addition to the aforementioned reports, oxidative olefinations have also emerged as an 
attractive strategy for the enantioselective transformations including desymmetrization 
reactions and atroposelective transformations which have been comprehensively discussed in 
the previous chapter (cf. chapter 1.3.1.).[41a, 57-58, 63a] 
Other than directing group assisted C−H activation,[27d, 38] ligand-assisted palladium catalyzed 
Fujiwara−Moritani type reaction has recently gained certain momentum.[177] In 1969, in a 
pioneering work palladium-catalyzed Fujiwara−Moritani reaction was reported to form C−C 
bonds under oxidative conditions (Scheme 61a).[167a, 178] Later, Yu’s study disclosed oxidative 
olefinations of electron-deficient arenes in the presence of 2,6-dialkylpyridine ligands. 
Significant contributions have also been made in the ligand-accelerated C−H olefination 
reactions by Yu,[179] Sanford,[180] Stahl.[181] In these studies mainly pyridines 226 or 227 have 
been identified as the best ligands for the Fujiwara−Moritani reactions of simple arenes 
(Scheme 61b). Very recently, Fernández-Ibáñez identified inexpensive bidentate S,O-
ligands[37a, 182] 229 for non-directed C−H olefination reactions of electron-rich and electron-
poor arenes 216 (Scheme 61c).[183] Similarly, these oxidative transformations are also limited 
to the use of superstoichiometric amounts of chemical oxidants which impeded the 





Scheme 61. Non-directed C−H activation under oxidative conditions. 
1.4.1.2. Cobalt-Catalyzed C–H Activations with Chemical Oxidants 
Among the 3d transition metals, bench-stable cobalt(II) salts have gained wide applications 
due to their commercial availability, easy set up and robustness.[32a] Starting from Daugulis’s 
work on C–H/N–H annulation of benzamides 229 with the aid of 8-aminoquinoline as the 
directing group (Scheme 62a),[184] cobalt-catalyzed oxidative C–H/X–H annulation has 
emerged as a versatile step-economical way to synthesis decorated heterocycles.[164d, 185]  
In this context, in 2016 the Ackermann group utilized for the first time molecular oxygen as 






Scheme 62. C–H/N–H annulation of benzamides 231 with internal alkynes 117 under 
oxidative conditions. 
Besides annulation with alkynes 117, alkenes 38/94 and allenes 110/236 have also found 
suitable application in the annulation protocol in the presence of chemical oxidants, with 
notable contributions from Daugulis,[186] Ackermann,[185f] Cheng,[187] Volla/Maiti (Scheme 63 
and 64).[188] 
 





Scheme 64. Cobalt-catalyzed oxidative C–H/N–H annulation with allenes 236 and 110. 
Oxidative cobalt(II)-catalyzed C–H activation was not limited to annulation reactions. Indeed, 
various C–C and C–Het bond forming reactions have been well studied in the literature. 
Balaraman reported the oxidative C–H alkynylation by the aid of 8-aminoquinoline as the 
directing group in the presence of Co(acac)3 as the catalyst and superstoichiometric amounts 
of Ag2CO3 to obtain the alkynylated products 239 (Scheme 65).[189]  
 
Scheme 65. Cobalt(II)-catalyzed oxidative C–H alkynylation. 
Recently, a protocol for the synthesis of the bicyclo[n.1.0] ring system 241 was realized by Shi 
through oxidative multiple C(sp3)−H functionalization strategy in the presence of 
superstoichiometric amounts of Ag2CO3 as the oxidant (Scheme 66).[190] 
 
Scheme 66. Cobalt-catalyzed oxidative C(sp3)−H functionalization. 
Almost at the same time three independent reports were documented for the allylation of 




Jeganmohan,[191] Chatani,[192] and Maiti.[193] Silver based chemical oxidants were employed for 
this oxidative allylation protocol. Jeganmohan used Ag2O as the oxidant, whereas Chatani 
employed Ag2CO3 as the oxidant in the presence of Co(OAc)2.4H2O as the catalyst. Maiti 
observed optimal reactivity using Ag2SO4 as the oxidant in DCE as the solvent. Notably, all 
these studies provided allylic selectivity over styrenyl-type reactivity (Scheme 67). 
 
Scheme 67. Cobalt-catalyzed C−H allylation in the presence of silver based oxidants. 
In addition, versatile cobalt catalysis was discovered as a viable tool to realize C–Het bond 
forming reactions. Song and Niu reported oxidative cobalt-catalyzed C(sp2)−H alkoxylation of 
amides 231 by the aid of a bidentate directing group (Scheme 68).[194]  
 
Scheme 68. Oxidative C(sp2)−H alkoxylation of amides 231. 
An intramolecular dehydrogenative C−H amination was reported by Ge.[195] This protocol 
proved viable for the synthesis of β- and γ-lactams 246 by C(sp3)−H bond activation (Scheme 
69a). A silver based oxidant was found to be the most efficient for this amination protocol. 




N,O-auxiliary, ortho-C−H aminations were feasible with secondary alkyl amines 247 (Scheme 
69b). Here, AgNO3 was found to be the optimal oxidant in this reaction.  
 
Scheme 69. Oxidative cobalt-catalyzed C−H amination. 
1.4.1.3. Representative Examples on Copper-Catalyzed C–H activations with Chemical 
Oxidants 
Building upon elegant studies by Ullmann and Goldberg,[9, 197] copper complexes have been 
widely applied for C−C and C−Het bond forming reactions. In this context, copper-catalyzed 
C−H arylation with aryl halides have been well studied by Daugulis,[198] Miura[199] and 
Ackermann[200] utilizing copper(I) catalysts. Besides aryl halides, diaryliodonium salts have 
been well investigated as arylating agents with copper complexes, with key reports by 
Gaunt,[201] Glorius,[202] Shi[203] and among others. 
Moreover, oxidative C−H/C−H couplings are an attractive strategy, which avoids 
prefunctionalized starting materials. Consequently, several examples have been documented 
on oxidative cross-coupling reactions in the presence of chemical oxidants.[204] In a recent 
example, Shi utilized 2-(pyridin-2-yl) isopropyl amine (PIP) as directing group for oxidative 
coupling between benzamides 249 and thiophenes 60 using AgNO3 as oxidant (Scheme 70).[205]  
 
Scheme 70. Copper-catalyzed oxidative C−H/C−H coupling. 
In the light of oxidative transformations, copper catalyzed alkyne annulations represent a step-




catalyzed annulation between phenols 251 and internal alkynes 58 to synthesize benzofurans 
252 under an atmosphere of oxygen (Scheme 71a).[206] It is noteworthy to mention that ortho-
alkynylation was achieved using PIP as the bidentate directing group and silver-based chemical 
oxidant (Scheme 71b).[207]  
 
Scheme 71. Copper catalyzed oxidative annulation and alkenylation. 
You reported copper-mediated 8-aminoquinloine assisted C−H//N−H annulation to synthesize 
3-methyleneisoindolin-1-ones derivatives 256 (Scheme 72a).[208] Later, a related protocol was 
disclosed using catalytic amounts of CuBr2 and O2 as the sacrificial oxidant (Scheme 72b).[209] 
 
Scheme 72. Copper catalyzed synthesis of isoindolinones. 
This protocol was further extended to challenging C(sp3)−H activations.[210] Here a 
combination of a copper(II) salt and Ag2CO3 was exploited for the alkenylation with alkynyl 





Scheme 73. C(sp3)−H bond activation with alkynyl carboxylic acids. 
Likewise, copper catalysis has also been extensively used in C−Het bond forming reactions. 
Considering the importance of C−N bonds, numerous reports have been documented for 
copper-catalyzed C−H amination reactions using various amination sources.[211] Furthermore, 
oxidative C−H/N−H coupling have been realized between quinoline-N-oxide 215 and cyclic 
amines 247 in the presence of stoichiometric silver(I) oxidant (Scheme 74).[212] 
 
Scheme 74. Copper-catalyzed oxidative C−H amination. 
In 2013, ortho-amination of benzamides 229 have been reported by the Daugulis groups by the 
aid of 8-aminoquinoline as the directing group.[213] This amination protocol required NMO as 
oxidant in the presence of cocatalytic Ag2CO3 as additive to improve the outcome of the 
reaction (Scheme 75a). In a related study, copper-catalyzed C−H aminations have also been 
reported using PIDA as oxidant using picolinamide as the directing group (Scheme 75b).[214] 
 




Furthermore, intramolecular C(sp3)−H amidations have been independently reported by 
Kuninobo/Kanai,[215] Ge[216] and You (Scheme 76).[217] These transformations were also limited 
to the use of chemical oxidants or O2 as the terminal oxidant. 
 
Scheme 76. Intramolecular C(sp3)−H amidations. 
Likewise, copper-catalyzed oxygenation has been well studied under oxidative conditions. 
Goosen employed AgOTf as the oxidant for ortho-alkoxylation of 2-phenyl pyridine 93 






Scheme 77. copper-catalyzed oxidative oxygenation. 
The low cost of copper catalysts has lead to the development of various copper-promoted C−H 
activation reactions. In this context, Ge disclosed copper-promoted C−H oxygenation of 
C(sp3)−H bond directed by bidentate 8-aminoquinoline group (Scheme 78).[220] 
 
Scheme 78. Copper-promoted C−H oxygenation. 
1.4.2. Electrochemical Transition Metal-Catalyzed C–H Activation. 
In modern era there is an increasing demands for renewable energy sources, including the wind 
and solar energies.[221] Thus, the use of electricity is highly desirable for chemical synthesis 
which opens up a new avenue for environmentally-benign strategy towards improved 
molecular synthesis.[222] Moreover, chemical oxidants operate at a fixed potential, whereas 
electricity offers to control the potential and current for the desired transformation, thus 
enabling better selectivities of the reactions[223] with optimal resource-economy.[224] 
 
Building upon pioneering works of Kolbe[225] and Shono,[226] organic electrosynthesis[227] has 
undergone a significant renaissance. Over the few decades there has been significant 
developments in organic electrosynthesis, exploiting the innate reactivity of organic molecules. 
Consequently, electrochemical and metal-free transformations exploiting the inherent 




Yoshida,[230] and Xu,[231]   among others. In this context, the merger of transition metal catalysis 
with electrosynthesis[232] has shown an enormous potential for the activation of strong C−H 
bonds. Thus, electrochemistry holds unique potential towards the development of 
environmentally-benign diverse C−H functionalizations to form C−C or C−Het bonds, using 
electrons as green terminal oxidants in lieu of expensive chemical oxidants.[232] 
1.4.2.1. Palladium Catalyzed Electrochemical C–H Activation 
 
In 2007, Amatore and Jutand documented the merger of palladium-catalyzed C−H activation 
with electrosynthesis. Hence, the authors reported on Fujiwara-Moritani-type[167] C–H 
alkenylation reaction of N-acetylanilines 266 in AcOH as reaction media (Scheme 79).[233] Co-
catalytic amounts of p-benzoquinone were beneficial as redox mediators for this reaction, 
which was regenerated at the anode to recycle the palladium(II) species in the catalytic cycle. 
This early study set the stage for further developments in electrochemical palladium-catalyzed 
C–H activation. 
 
Scheme 79. Electrocatalytic Fujiwara-Moritani reaction. 
In 2009, Kakiuchi exploited electrochemistry for the palladium-catalyzed halogenation of 2-
phenyl pyridine 93 with hydrogen halides.[234] This protocol enabled the incorporation of 
synthetically useful halo groups on the aromatic rings without expensive halogenation reagents 
(Scheme 80). Instead, electricity was solely responsible to form the electrophilic Cl+ species to 





Scheme 80. Electrochemical palladium-catalyzed halogenation of phenylpyridines 93.  
a PdBr2 (2.0 mol %) and 2M HBr(aq) used. 
In a related approach, later the same group extended the C–H halogenation approach to C–H 
iodinations (Scheme 81).[235] Here, the authors utilized elemental iodine as the iodonium source 
to enable the C–H iodinations in MeCN as reaction media. Notably, this iodination protocol 
was also compatible with KI as iodonium source. 
 
Scheme 81. Electrochemical palladium-catalyzed iodination. 
Later, ortho-C−H perfluoroalkoxylation of phenyl pyridines 93 with perfluroalkylated acids 
270 was reported under mild reaction conditions (Scheme 82).[236] This was an early example 





Scheme 82. Palladium-catalyzed electrochemical C–H perfluorooxygenation. 
Until recently, strongly-coordinating phenylpyridines and anilides were substrates of choice in 
the early developments of electrochemical transformations. In this context, Kakuichi later 
succeeded to achieve ortho-selective chlorination of electron-poor benzamides 272 by a 
modified chlorinated bidentate 8-aminoquinoline directing group (Scheme 83).[238] 
 
Scheme 83. Electrochemical bidentate directing group assisted C–H chlorination. 
In 2017, a major contribution was achieved by Mei in electrochemical palladium catalyzed C–
H activation. Thus, Mei reported palladium-catalyzed C(sp3)−H oxygenation of oxime 
derivatives 274 (Scheme 84).[239] It is noteworthy to mention that this protocol offered a broad 






Scheme 84. Palladium-catalyzed C(sp3)–H oxygenation. 
In subsequent efforts, the same group reported efficient palladium-catalyzed oxidative ortho-
C(sp2)−H methylation and benzoylation of oximes 276 with methyltrifluoroborates 277 and 
benzoyl acetic acids 279 as the coupling partners respectively (Scheme 85a and 85b).[240] Also, 
the authors prepared cyclometalated palladacycle which was found to be a competent catalyst 
for the C−H methylation reactions. 
 




In subsequent study, Sanford reported related electrochemical C(sp2)–H and C(sp3)–H 
oxygenations (Scheme 86).[241] A broad range of directing groups was also found amenable in 
this protocol. In addition, this transformation tolerated an array of sensitive functional groups. 
 
Scheme 86. Electrochemical C(sp2)–H and C(sp3)–H oxygenation. 
1.4.2.2. Cobalt-Catalyzed Electrochemical C–H Activation  
Over the past decades C−H electrosynthesis has largely relied on precious 4d and 5d transition 
metals, prominently featuring expensive palladium, rhodium,[242] iridium[243] and ruthenium[244]  
complexes. In recent years, the prices of precious transition metals have increased significantly 
which has led to a growing demand in the use of Earth-abundant and cost-efficient 3d metals 
as viable catalysts for molecular C−H transformations.[232c] 
 
1.4.2.2.1. C−H Oxygenation 
 
Recently, versatile cobalt catalysts have become a powerful tool for oxidative electrochemical 
C−H activations with notable contributions by Ackermann.[32a, 245] In 2017, Ackermann 
reported the first electrochemical cobalt catalyzed C−H oxygenation.[246] To the best of my 
knowledge, this is the first example for electrochemical C−H activation by Earth-abundant 3d 
transition metals. Here, the authors elegantly employed a combination of Cp*-free 
Co(OAc)2.4H2O as the inexpensive catalyst and NaOPiv as base for the electrochemical C−H 
oxygenation of benzamides 231 with aliphatic alcohols 243 enabled by a N,O-bidentate 
directing group (Scheme 87). The key characteristic of this protocol was high levels of 





Scheme 87. Electrochemical cobalt-catalyzed C–H oxygenation. 
 
1.4.2.2.2. C−N Bond Formation 
 
Intrigued by the pioneering C−H oxygenation,[246] the electrooxidative direct C−H amination 
of otherwise inert C−H bonds of aromatic benzamides 231 was reported by Ackermann.[247] 
The reaction was performed in the renewable solvent -valerolactone (GVL) at 40°C in the 
absence of expensive and toxic metal oxidants. It should be duly noted that this was the first 
report for the use of biomass-derived solvent in electrocatalysis.[6, 248] The amination of 
benzamides 231 proceeded with diverse set of secondary amines 247 with H2 as the only 
stoichiometric byproduct, produced by cathodic reduction (Scheme 88). Thereafter, Lei 
reported similar reactivity utilizing 8-AQ as directing group for the C−H amination with cyclic 





Scheme 88. Cobaltacatalyzed electrooxidative C−H amination. 
1.4.2.2.3. C−H Activation for Annulations. 
 
In 2018, an unprecedented electrochemical annulation of C−H and N−H bond with alkynes 
255 was disclosed by Ackermann (Scheme 89).[250] Notably, versatile and robust cobalt 
catalysis enabled the synthesis of isoquinolone motifs 287 by C−H/N−H annulation of 
benzamides 231 in H2O as the reaction medium. A broad range of substrates was tolerated in 
this annulation protocol at room temperature, including benzamides, heterocycles, and alkenes 
bearing pyridine N-oxide as the directing group. 
 
Scheme 89. Electrooxidative C−H/N−H annulation. 
In subsequent reports, Lei extended this approach towards the [4+2] C−H/N−H annulation of 
amides 229 with gaseous ethylene and ethyne (Scheme 90).[251] Here, 8-aminoquinoline was 





Scheme 90. Electrooxidative C−H/N−H annulaiton with ethyne and ethylene. 
In contrast to the previous reports, which were mainly limited to terminal alkynes, Ackermann 
showed the versatility of cobalt catalysis towards internal alkynes 117 for electrooxidative 
C−H/N−H annulations (Scheme 91).[252] A traceless hydrazide directing group enabled the 
annulation process at room temperature. Likewise, a wide range of internal alkynes 117 were 
found as suitable substrates. A key feature of this transformation was represented by the 
electroreductive hydrazide cleavage, using catalytic amounts of SmI2 to remove the 
benzhydrazide in a traceless manner.  
 
Scheme 91. Electrochemical C−H/N−H activation with internal alkynes 117. 
Subsequently, a step-economical annulation was unraveled by Ackermann by the direct use of 




substituted allenes 236 were tolerated and provided the corresponding products 238 with high 
regioselectivity (Scheme 92). 
 
Scheme 92. Cobaltacatalyzed electrochemical C−H activation with allenes. 
In addition to annulations with alkynes 117/255 and allenes 236, Lei and Ackermann 
independently reported the oxidative C−H/N−H carbonylation with gaseous carbon monoxide. 
Lei utilized 8-aminoquinoline as the directing group for the C−H/N−H carbonylation in the 
presence of catalytic amounts of cobalt catalyst.[254] Likewise, the reaction was further 
extended to intermolecular variant in the presence of secondary amines (Scheme 93a). In 
addition to carbon monoxide, Ackermann also showed the versatility of cobalt catalysis with 
synthetically useful isocyanides 296 for C−H/N−H annulation with benzhydrazides 290 














1.4.2.3. Copper Catalyzed Electrochemical C–H Activation 
 
While notable advances have been reported on Earth-abundant cobalt catalysis for sustainable 
electrocatalysis,[31] a recent trend has shifted to other Earth-abundant metalla-electrocatalyzed 
C−H transformations. Recently, Mei exploited the potential of copper catalysis for 
electrochemical C−H amination reactions. It is noteworthy to mention that the authors achieved 
direct C−H aminations of electron-rich anilides 298 at room temperature using electricity as 
green oxidant (Scheme 95a).[256] The optimized electrocatalyst proved broadly applicable and 
showed high functional group tolerance. Shortly thereafter, in a related work, Nicholls and 
coworkers disclosed similar reactivity by the aid of 8-aminoquinoline directing group.[257] The 
authors succeeded in achieving electro-oxidative aminations of amides 229 with amines 247 












Transition metal-catalyzed C−H activation has been continuously evolving as an increasingly 
powerful approach in the emerging field of synthetic chemistry.[27, 56] The development of new 
molecular reactions continuous to be highly desirable in the advent of organic synthesis to 
elevate the productivity at lower cost. Thus, the objective of this thesis was to aim on the 
development of cost-effective and environmentally-benign metal-catalyzed selective C−H 
activation reactions with olefins and alkynes with a major emphasis on the identification of 
resource-economical conditions. In addition, a considerable focus has been placed on the 
mechanistic understandings of these C−H activations. 
Over the past years, C−F functionalization has emerged as a viable tool for the incorporation 
of fluorinated scaffolds into organic molecules.[42a, 42b] Thus we became interested in exploiting 
the potential of inexpensive and versatile manganese catalysis for unprecedented C−F/C−H 
functionalization through β-fluoride elimination (Scheme 95). Particularly, a broad substrate 
scope and mild reaction conditions should be of prime importance for the synthesis of diverse 
fluorinated scaffolds.  
 
 
Scheme 95. Manganese(I)-catalyzed C−F/C−H functionalization. 
Despite enormous advances in the application of ruthenium catalysts in organometallic C−H 
activations,[27t, 39, 138]  challenging C–F functionalization by ruthenium catalysis remained 
elusive. In this context, related studies of hydroarylations were achieved with unactivated 
alkenes and perfluoroalkylalkenes by Ackermann,[258] which set the stage for the merger of 
C−H activation with C−F functionalization. In this regard, our aim was to develop a ligand 
enabled new strategy for a switch in chemoselectivity towards challenging C–F 





Scheme 96. E-selective C–H/C–F functionalization by ruthenium (II) catalysis. 
The fascinating research area of enantioselective C–H activation remains primarily dominated 
by 4d and 5d transition metals.[58] Recent efforts have been directed more towards non-toxic 
Earth-abundant transition metals.[59] Considering the importance of efficient and step-
economical assembly of chiral molecules, novel enantioselective transformations utilizing 
cost-effective transition metals should be developed under sustainable reaction conditions. In 
this context, numerous studies on cobalt(III)-catalyzed C–H activation have been developed 
due to their significant versatility.[31, 32d, 32f, 32g, 32j] Still enantioselective transformations with 
cobalt(III) catalysts have remained elusive and unexplored at the outset of this work. In this 
context, a combination of Cp*Co(III) catalyst with a novel chiral acid was investigated for 
achieving high enantioselectivities in C–H alkylation reactions. Furthermore, detailed 






Scheme 97. Enantioselective cobalt(III)-catalyzed C−H activation enabled by chiral 
carboxylic acid cooperation. 
 
In this regard, we also became interested in the development of new enantioselective 
transformations utilizing cost-effective ruthenium as the catalyst. While organometallic 
ruthenium catalyzed C−H activations are well-investigated,[27t, 39, 138] the enantioselective 
transformations remain underdeveloped. Thus, we decided to explore the versatility of 
ruthenium catalysts for the enantioselective C−H alkylation reactions with the combination of 
a chiral acid, along with detailed mechanistic studies (Scheme 98). 
 
 
Scheme 98. Enantioselective ruthenium(II)-catalyzed C−H alkylation. 
To harness the full potential of C–H activation, metallaelectrocatalysis provides excellent 
resource economy for sustainable organic synthesis.[224] Over the past years, the merger of C–
H activation and electrosynthesis has emerged as a potent strategy, albeit early contributions 
were limited to palladium catalysis.[232] In this context, the use of less toxic and inexpensive 
copper in oxidative electrochemical transformations offers an attractive strategy towards 
improved resource economy using electrons as green oxidant. Thus, inexpensive copper 
catalyst was intended to utilize in electrochemical conditions for oxidative annulation reactions 





Scheme 99. Cupraelectro-catalyzed alkyne annulation. 
In 2017, Ackermann reported the first cobalt-catalyzed electrochemical C–H activation where 
electro-oxidation of the cobalt catalyst is the key step.[246] Since then, electrochemical oxidative 
transformations with Earth-abundant cobalt have gained enormous attention, employing 
electrons as traceless oxidant.[32a, 245] In this context, 4d and 5d transition metal-catalyzed 
electrochemical transformations remained restricted to the use of activated alkenes as coupling 
partners. Thus, within this thesis, a new protocol for electrochemical C–H allylation with 
unactivated alkenes was intended to address utilizing inexpensive and Earth-abundant cobalt 
catalysts. Detailed mechanistic studies were performed to delineate the unique reactivity with 
unbiased olefins (Scheme 100). 
 
 
Scheme 100. Cobalt-catalyzed electrochemical C–H allylation. 
To unleash the full potential of electrocatalysis towards perfect resource economy, 
enantioselective electrosynthesis is highly desirable as a new sustainable tool for the 
construction of chiral molecules.[232] Despite significant advances in electrosynthesis, 




showcasing the challenges in asymmetric electrosynthesis. Consequently, our focus was to 
develop the first enantioselective metallaelectro-catalyzed C–H activation. Thus, our approach 
was directed towards electrochemical atroposelective synthesis of axially-chiral biaryls. In this 
regard, a sustainable protocol for the enantioselective electrochemical C–H activation was 
addressed by the cooperation of transient directing group utilizing palladium as catalyst under 
mild reaction conditions. Furthermore, a major focus of our strategy was the late-stage 
diversification of axially chiral compounds to access target structures of value to asymmetric 
catalysis (Scheme 101). 
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3. Results and Discussion 
3.1. Manganese(I)-Catalyzed (Per)Fluoro-Allylative and Alkenylative C–F/C–H 
Functionalizations 
In recent years, manganese catalysts have gained considerable attention owing to their 
inexpensive nature and low toxicities[32g, 259] with significant numbers of studies for various C–
H additions onto C–C or C–Het multiple bonds and C–H allylations reactions via β-oxygen or 
-carbon elimination.[260] Recently, transition metal mediated β-fluorine elimination has become 
a viable tool for the transformation of C–F bonds.[46] Consequently, the merger of C–F 
activation with challenging C–H cleavages presents a sustainable and atom-economical 
approach to enable the selective synthesis of fluorinated molecules.[52-55] Thus, we were 
interested in the development of catalytic C–F/C–H activations by the aid of inexpensive and 
less toxic manganese catalysis. 
 
Scheme 102. Examples of bioactive fluoroalkenes 
3.1.1. Optimization Studies 
After initial optimization studies by Dr. D. Zell for the allylative C–H/C–F functionalizations 
of indole 315, almost quantitative yield was observed when indole 315a was reacted with 
perfluroalkylalkene 301a in the presence of catalytic amounts of MnBr(CO)5 and 2.0 equiv of 
K2CO3 in dioxane (Table 1, entry 1). It is noteworthy to mention that in the absence of the base, 
the yield of the desired product 316aa was significantly reduced, being suggestive of the 
formation of the corresponding fluoride salt which is possibly the driving force of the reaction 
(entry 2). Moreover, in a recent study the group of Ichikawa showed the potential of Lewis-
acids to enable the activation of inert sp3 C−F bond of the CF3 group through a Friedel–Crafts-
type mechanism.[261] Thus, a series of Lewis acids, including AlCl3, Et2AlCl, BF3·OEt2, TiCl4, 
ZrCl4, and FeCl3 were tested under our optimized reaction conditions (entry 3-8), which, 
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however failed to provide the desired C−F/C−H functionalization product 316aa; highlighting 
the necessity of MnBr(CO)5 as the effective catalyst for this challenging transformation. 
 
Table 1. Optimization for manganese(I)-catalyzed allylative C−F/C−H functionalization.[a] 
 
Entry Variation of the standard conditions 316aa [%][b] 
1 none 97 
2 in the absence of K2CO3 7 
3 AlCl3 in place of [Mn] ---[c] 
4 Et2AlCl in place of [Mn] ---[c] 
5 BF3·OEt2 in place of [Mn] ---[c] 
6 TiCl4 in place of [Mn] ---[c] 
7 ZrCl4 in place of [Mn] ---[c,d] 
8 FeCl3 in place of [Mn] ---[c,d] 
[a] Reaction conditions: 315a (0.50 mmol), 301a (1.00 mmol), [MnBr(CO)5] (10 mol %), 
K2CO3 (0.50 mmol), solvent (0.50 mL), 80 °C, 20 h. [b] isolated yield. [c] Lewis acid (1.0 
equiv). [d] Performed by Mr. V. Müller. 
 
Next, we were interested in the incorporation of the α-fluoroalkenyl motifs in to arenes using 
gem-difluoroalkenes 11 as the coupling partner, which is a very appealing class of synthetic 
intermediates with highly polarized C−C double bonds. A comprehensive optimization study 
with indole 315a reflected the necessity of acetate base for increasing the reactivity to large 
extent, revealing 20 mol % NaOAc as additive to be optimal (Table 2, entry 1-3). Similarly, 
after probing various reaction temperatures, optimal reactivity was observed at 100 °C, while 
higher reaction temperatures were detrimental to the yield of the desired product 317aa (entry 
4-7). Notably, higher concentration of gem-difluoroalkenes improved the reactivity, albeit the 
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Table 2. Optimization for manganese(I)-catalyzed alkenylative C−F/C−H functionalization.[a] 
 
 
Entry NaOAc [mol %] Temperature [°C] Yield [%][b] 
1 30 100 77 
2 10 100 74 
3 20 100 81 
4 20 90 40 
5 20 95 68 
6 20 105 70 
7 20 120 57 
8 20 100 60[c] 
9 20 100 85[d] 
[a] Reaction conditions: 315a (0.50 mmol), 11a (1.00 mmol), [MnBr(CO)5] (10 mol %), K2CO3 
(0.50 mmol), NaOAc (10-30 mol %), 1,4-dioxane (0.50 mL), 20 h. [b] isolated yield. [c] 11a ( 
0.60 mmol). [d] 11a ( 1.50 mmol). 
3.1.2. Substrate Scope and Limitations of C–H/C–F Functionalizations 
With the optimized reaction condition in hand, we next investigated the versatility and 
robustness of allylative C–H/C–F functionalizations (Table 3). Initially, a gram-scale reaction 
was carried out and the desired product 316aa was obtained without any significant loss of 
efficacy (entry 1). Next, various C5-substituted 2-pyridylindoles were tested under the 
optimized reaction condition (entries 2-4). Both electron-rich and electron-deficient indoles 
provided the desired products 316 in excellent yields and with good diastereoselectivities, 
albeit acetate base facilitated the reactivity for the substrate 315d (entry 4). Importantly, 
sterically-hindered C3 substituted indoles also afforded the corresponding desired products in 
good to excellent yields (entries 5-7). To our delight, challenging 7-azaindole 315g, which is a 
key structural motif present in various anticancer drug molecules, was very efficiently 
converted to provide the desired allylative C–H/C–F product 316ga in good yield and with 
good diastereoselectivity, although addition of acetate base and higher concentration of 301a 
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were needed (entry 8). Furthermore, 1-(pyridin-2-yl)-1H-pyrrole (320a), 2-phenylpyridines 
(93a), benzo[h]quinoline (323a) also delivered the desired products in good yields under 
slightly modified reaction conditions (entries 9-11). However, cyano and nitro-substituted 
indoles 315h and 315i remained untouched under the optimized condition (entries 12-13). In 
addition, 1-(pyridin-2-yl)-1H-benzo[d]imidazole (324a) and 9-(pyridin-2-yl)-9H-carbazole 
(326a) did not react under otherwise identical reaction conditions (entries 14-15).  
 
Table 3. Scope of the manganese(I)-catalyzed allylative C–H/C–F functionalization.[a] 
 
























































[a] Reaction conditions: 315 (0.50 mmol), 301a (0.60 mmol), [MnBr(CO)5] (7.5 mol %), 
K2CO3 (0.50 mmol), 1,4-dioxane (0.5 mL), 20 h. [b] Yield of isolated product. [c] Reaction 
carried on 3.0 mmol scale. [d] NaOAc (30 mol %) as additive. [e] 301a (1.0 mmol). [f] 120 °C. 
 
Furthermore, different perfluoroalkyl chain lengths were investigated under the optimized 
reaction conditions (Table 4). 1H,1H,2H-Perfluorohexene (301b) and 1H,1H,2H-
perfluorododecene (301c) reacted efficiently with indole 315a and 2-phenylpyridine 93b to 
furnish the corresponding products 316ab-316ac and 322bc in good yields respectively (entries 
1-3). In the latter case, an elevated reaction temperature and a higher concentration of 301c 
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Table 4. Scope of the manganese(I)-catalyzed C–H/C–F functionalization with 
perfluoroalkylalkene.[a] 
 













[a] Reaction conditions: 315/93 (0.50 mmol), 301 (0.60 mmol), [MnBr(CO)5] (7.5 mol %), 
K2CO3 (0.50 mmol), 1,4-dioxane (0.50 mL), 20 h. [b] Yield of isolated product. [c] NaOAc 
(30 mol %) as additive. [d] 301c (2.0 equiv) [e] 120 °C. 
 
Next, we turned our attention towards direct functionalization of peptides which holds 
significant potential in  biomolecular chemistry for chemoselective ligation of peptide (Table 
5). To our delight, protected amino acids 328a-328b underwent C−F/C−H functionalization 
without racemization of the stereogenic centers, reflecting the mildness and versatility of the 
developed methodology (entries 1-2). In addition, more structurally complex dipeptide 328c 
also delivered the desired product 329ca with high levels of site-selectivity, albeit higher 
catalyst loading was needed to increase the turnover number (entry 3). 
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Table 5. C–H/C–F functionalization with amino acids.[a] 
 










[a] Reaction conditions: 328a (0.50 mmol), 301a (0.60 mmol), [MnBr(CO)5] (10 mol %), 
K2CO3 (0.50 mmol), 1,4-dioxane (0.50 mL), 20 h. [b] Yield of isolated product. [c] NaOAc 
(30 mol %) as additive. [d] 301a (2.0 equiv) [e] 301a (3.0 equiv), [Mn] (20 mol %). 
 
Moreover, on a pleasing note, challenging perfluoroalkenes 303 were found as suitable 
substrates for C−H perfluoroalkenylations (Table 6). Indole 315a and sterically-demanding 
C3-substituted indole 315e provided the desired perfluoroalkenylation products in good yields 
and selectively delivered the E-isomers (entry 1-2). Even more challenging protected amino 
acids 328a-328b were also identified as amenable substrates for the perfluoroalkenylation, 
showcasing the versatility of our method (entries 3-4). However, higher catalyst loading was 
necessary for the pyrazole derivative 332a to afford the desired product 333ab in synthetically 
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useful yield (entry 5). It is noteworthy to mention that all the perfluoroalkenylation products 
were selectively obtained as the E-isomer. 
Table 6. Alkenylative C−F/C−H functionalizations with perfluoroalkenes.[a] 
 
Entry Indole Perfluoroalkenes Product Yield[b] 
1 
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[a] Reaction conditions: 315/328/332 (0.50 mmol), 303 (0.60 mmol), [MnBr(CO)5] (10 mol 
%), K2CO3 (0.50 mmol), 1,4-dioxane (0.50 mL), 20 h. [b] Yield of isolated product. [c] NaOAc 
(30 mol %) as additive. [d] [Mn] (15 mol %). 
3.1.3. Proposed Catalytic Cycle 
Detailed mechanistic studies by Dr. D. Zell revealed a significant amount of H/D exchange at 
C2-position of the reisolated starting material 315a, which is suggestive of a reversible C–H 
bond activation step. In addition KIE experiments by Dr. D. Zell and DFT studies by M. Bursch 
and Prof. S. Grimme supported a facile and reversible BIES-type C–H metalation event.  
Thus, the proposed catalytic cycle initiates via a carbonate-assisted facile BIES C–H activation 
step to form the manganacycle 335 (Scheme 103). Then, fast coordination of 
perfluoroalkylalkene 301a with the  manganacycle 335 and subsequent migratory insertion into 
the manganese-carbon bond forms intermediate 337. Next, rate-determining β-F elimination 
by the carbonate base preferentially forms the Z-configured product 316 as supported from 
DFT-calculations by M. Bursch and regenerates the initially formed bicarbonate complex 334 
and completes the cycle. Formation of the potassium fluoride is possibly the driving force for 
the reaction, as in the absence of carbonate base the reactivity is significantly reduced. 
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3.2. Ruthenium(II)-Catalyzed E-Selective Allylative C−F/C−H Functionalization 
During last two decades ruthenium(II) complexes have been extensively studied in catalytic 
C−H bond activation due to their cost-effectiveness as well as their robust and versatile 
reactivity.[27t, 39, 138] Furthermore, metal-catalyzed hydroarylations reactions[262] are particularly 
attractive because of their perfect atom-economy with significant progress realized by versatile 
ruthenium catalysts.[7] In this context, early contributions were primarily realized with 
relatively unstable and expensive low-valent ruthenium catalysts such as [RuH2(CO)(PPh3)3], 
[RuH2(PPh3)4], [Ru(CO)2(PPh3)3] or [RuH2(H2)2(PCy3)2]. However, recently bench-stable 
[Ru(O2CR)2(p-cymene)] complex has been identified as powerful catalyst for various direct 
C–H bond arylations, hydroarylations and oxidative annulation reactions.[263] Thus far simple 
hydroarylations were reported with unactivated alkenes and perfluoroalkylalkenes by 
ruthenium(II)biscarboxylate catalysts.[258] Despite significant advancement of atom-
economical hydroarylations, ruthenium(II)-catalyzed C–F bond activations remains largely 
underexplored. 
On this note, developments of step-economical protocols for the site-selective installation of 
fluorine-containing moieties into organic molecules are in great demand. Thereby, we were 
interested to achieve challenging ruthenium catalyzed C–F/C–H functionalization-based C–H 
allylations reactions via β-fluorine elimination.  
3.2.1. Optimization Studies 
The optimization study was commenced by probing various reaction conditions for the 
envisioned C–F/C–H functionalization with synthetically useful ketimine 338 (Table 7). Initial 
study under ligand-free conditions did not deliver the desired product 307aa (Table 7, entry 1). 
Subsequently, we tested a set of representative ligands and solvents. Cyclohexane turned out 
to be the optimal solvent for the C–F/C–H functionalization among other typical organic 
solvents (entries 2-9). It is noteworthy to mention that the presence of strong base delivered the 
hydroarylation product selectively under ligand-free conditions which was previously achieved 
by the Ackermann group using a pyridine directing group (entry 10).[258]  Among a variety of 
bases, K3PO4 provided slightly improved yields of the desired ketone 307aa upon one-pot 
hydrolysis (entries 11-16). Subsequently, a variety of electron-rich and electron-deficient 
phosphines were tested in cyclohexane. The best catalytic efficiency was realized in the 
presence of electron-deficient P(4-C6H4F)3 as ligand (entries 17-23), particularly employing 
the trimethoxyphenylketimine 340a as the substrate (entries 26-27). Moreover, higher or lower 
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reaction temperatures failed to improve the yields of the desired product 307aa (entries 24-25). 
Finally, control experiment in the absence of the catalyst showed the necessity of the ruthenium 
catalyst for the envisioned C–F/C–H functionalization (entry 29). The E/Z-diastereo-
selectivities were slightly influenced by the choice of the ligand, generally favoring the E-
diastereomer, while only very minor amounts of the corresponding hydroarylation products 
339aa of less than 2% were observed under the optimized reaction condition.  
 
Table 7. Optimization for the ruthenium(II)-catalyzed allylative C‒F/C‒H functionalization.[a] 
 
Entry Ligand Base Solvent E/Z Yield 307aa:339aa 
1 --- K2CO3 CyH --- --- --- 
2 PPh3 K2CO3 NMP --- --- --- 
3 PPh3 K2CO3 HFIP --- --- --- 
4 PPh3 K2CO3 H2O --- --- --- 
5 PPh3 K2CO3 DME --- --- --- 
6 PPh3 K2CO3 PhMe 2.7 40% 84:16 
7 PPh3 K2CO3 m-xylene 2.0 42% 80:20 
8 PPh3 K2CO3 1,4-dioxane 2.0 45% 80:20 
9 PPh3 K2CO3 CyH 2.5 42% 80:20 
10 --- KOH 1,4-dioxane --- 70% 0:100 
11 PPh3 Cs2CO3 CyH 2.7 35% 80:20 
12 PPh3 KH2PO4 CyH 2.4 38% 85:15 
13 PPh3 KHCO3 CyH --- --- --- 
14 PPh3 Na2CO3 CyH --- --- --- 
15 PPh3 K3PO4 CyH 2.8 53% 84:16 
16 PPh3 K3PO4 PhMe 1.7 38% 87:13 
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[a] Reaction conditions: 338a (0.50 mmol), 301a (0.60 mmol), [RuCl2(p-cymene)]2  (5.0 mol 
%), ligand (20 mol %), base (2.0 equiv), solvent (1.0 mL), 120 °C, 24 h, isolated yields. [b] 
TMP-ketimine 340a. [c] 110 °C. [d] 140 °C. [e] 301a (1.50 mmol). [f] Base (3.0 equiv). [g] 
Without [Ru].  
 
Next, we tested different directing groups for the envisioned allylative C–F/C–H 
functionalization (Table 8). However, no conversion was observed with challenging aldimines 
341a and 343a (entries 1-2). Also, N-(pivaloyloxy)benzamide 16a and o-toluic acid 346a failed 










17 PCy3 K3PO4 CyH 2.0 8% 80:20 
18 dppf K3PO4 CyH --- --- --- 
19 P(Cy)Ph2 K3PO4 CyH 2.7 35% 60:40 
20 P(4-C6H4Cl)3 K3PO4 CyH 2.0 25% 87:13 
21 P(4-C6H4Me)3 K3PO4 CyH 2.3 27% 80:20 
22 P(4-C6H4OMe)3 K3PO4 CyH 3.0 28% 94:6 
23[b] P(4-C6H4F)3 K3PO4 CyH 3.5 65% 98:2 
24[b,c] P(4-C6H4F)3 K3PO4 CyH 5.3 54% 98:2 
25[b,d] P(4-C6H4F)3 K3PO4 CyH 3.7 59% 97:3 
26[e] P(4-C6H4F)3 K3PO4 CyH 3.0 65% 96:4 
27[b,e] P(4-C6H4F)3 K3PO4 CyH 3.5 73% 98:2 
28[f] P(4-C6H4F)3 K3PO4 CyH 3.3 72% 97:3 
29[g] P(4-C6H4F)3 K3PO4 CyH --- --- --- 
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Table 8. Attempted directing groups for allylative C–F/C–H functionalization.[a] 
 
















[a] Reaction conditions: Imine (0.50 mmol), 301a (1.50 mmol), [RuCl2(p-cymene)]2  (5.0 mol 
%), P(4-C6H4F)3  (20 mol %), K3PO4 (2.0 equiv), CyH (1.0 mL), 120 °C, 24 h, isolated yields. 
n.r. = No Reaction. 
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3.2.2. Substrate Scope of C–F/C–H Functionalization 
Diversely substituted valuable ketimines 340 were tested under the optimized catalytic reaction 
conditions (Table 9). Both electron-rich and electron-poor arenes 340 were well tolerated under 
the reaction condition furnishing the desired products 307 in moderate to good yields with 
moderate E/Z ratio. The robust ruthenium(II)catalysis manifold permitted C–F/C–H 
functionalizations in high levels of chemo-, site- and regio-selectivity. Methyl  and ethyl 
substituted ketimines 340a and 340b both furnished the products in good yields under the 
optimized reaction conditions (entries 1-2). Subsequently, various para-substituted ketimines 
340c-340h were tested, providing the corresponding products 307ca-307ha in moderate to 
good yields (entries 3-8). Notably, the robust ruthenium(II)catalysis manifold proved to be 
tolerant of a set of synthetically meaningful electrophilic functional groups, including chloro 
and ester substituents (entries 7-8), which should prove invaluable for further late-stage 
diversification. The site selectivity was largely governed by steric repulsion for the meta-
substituted arene 340i (entry 9). However, the versatile ruthenium(II)catalyst also showed 
limitations. Nitro  and cyano-substituted ketimines 340j and 340k did not furnish the products 
340ja and 340ka respectively, under the optimized reaction condition (entries 10-11). Also, 
heteroarene 348a failed to undergo the C–F/C–H functionalizations (entry 12). 
 
Table 9. Scope of the allylative C–H/C–F functionalizations.[a] 
 
Entry Ketimine Product E/Z 307:339 Yield 
1 
  
78:22 98:2 73% 





75:25 99:1 63% 
3 
  
84:16 92:8 62% 
4 
  
80:20 99:1 53% 
5 
  
75:25 98:2 58% 
6 
  
72:28 97:3 54% 
7 
  
70:30 99:1 48% 
8 
  
83:17 98:2 59% 





74:26 91:9 63% 
10 
  
--- --- n.r. 
11 
  




--- --- n.r. 
[a] Reaction conditions: 340 (0.50 mmol), 301a (1.50 mmol), [RuCl2(p-cymene)]2  (5.0 mol 
%), P(4-C6H4F)3  (20 mol %), K3PO4 (2.0 equiv), CyH (1.0 mL), 120 °C, 24 h, isolated yields. 
 
The versatile ruthenium(II)-catalyzed C–F/C–H functionalization was subsequently tested with 
other perfluoroalkylalkenes 301 (Table 10). Thereby, 1H,1H,2H-perfluoro-1-dodecene 301c 
was likewise smoothly converted into the corresponding products 307 with various substituted 
ketimines 340 in good yields and with good diasteroselectivities (entries 1-7), exploiting the 
removable nature of the ketimine within a user-friendly one-pot procedure. Similarly, a 
considerable variability with respect to the perfluoroalkyl chain length was observed. Likewise, 
1H,1H,2H-perfluoro-1-hexene 301b was tested under the reaction conditions with various 
unsubstituted 340a and para-substituted ketimines 340c-340d, furnishing the corresponding 
products with high levels of chemo-, diastereo-, and position-selectivities (entries 8-10). 
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Table 10. C–F/C–H functionalization with perfluoroalkylalkenes 301.[a] 
 






























73:27 100:0 54% 






















84:16 99:1 52% 
[a] Reaction conditions: 340 (0.50 mmol), 301 (1.50 mmol), [RuCl2(p-cymene)]2  (5.0 mol %), 
P(4-C6H4F)3  (20 mol %), K3PO4 (2.0 equiv), CyH (1.0 mL), 120 °C, 24 h, isolated yields. 
3.2.3. Mechanistic Studies 
Considering the unique selectivity features of the ruthenium(II)-catalyzed C–F/C–H 
functionalization, we became then intrigued to delineating its mode of action.  
 
3.2.3.1. Intermolecular Competition Experiment 
To this end, we performed an intermolecular competition experiment between electron-rich 
and electron-deficient arenes 340c and 340f, which revealed a preferential reactivity in favor 
of the more electron-rich substrate 340c (Scheme 104). This finding is in disagreement with a 
CMD/AMLA-type C–H activation. Instead, a base-assisted internal electrophilic substitution 
(BIES)-type C–H metalation is rather operative for the allylative C–F/C–H functionalization. 




Scheme 104. Competition experiment between electron-rich and electron-deficient arenes. 
3.2.3.2. Deuterium Labeling Experiments 
Subsequently, we performed deuterium labeling experiments to gain insights into the C–H 
ruthenation step (Scheme 105). The ruthenium(II)-catalyzed C–F/C–H functionalization was 
performed in the presence of the isotopically-labeled D2O as co-solvent (Scheme 105). Here, 
we observed a considerable H/D exchange at the ortho-positions of the allylated product [D]n-
307aa and the hydrolyzed starting material [D]n-340a’. 
 
Scheme 105. Deuterium labeling experiments for C–F/C–H functionalization. 
3.2.3.3. KIE Study 
Moreover, to gain further mechanistic understanding of the C–H activation step, independent 
KIE-experiments were performed (Scheme 106). Thus, the substrate 340a and its deuterated 
analogue [D]5-340a were employed for independent kinetic experiments (Scheme 106). We 
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observed a very minor kinetic isotope effect (KIE) of kH/kD = 1.1, suggestive of a facile and 




Scheme 106. Intramolecular KIE by independent experiments. 
3.2.4. Proposed Catalytic Cycle  
Based on our detailed mechanistic studies, the allylative ruthenium(II)-catalyzed C–H/C–F 
functionalization of ketimines 340 is proposed to be initiated by a reversible and facile BIES-
type C−H cleavage to form the ruthenacycle 351 (Scheme 107). In the subsequent step, the 
ruthenacycle 351 is then coordinated by the perfluoroalkylalkene 301a in a fast and reversible 
step. In the following step, a migratory insertion into the ruthenium-carbon bond forms seven-
membered ruthenacycle intermediate 353 in a possibly irreversible process as there was no H/D 
exchange in the perfluoroalkylalkenes 301a. Finally, diastereo-selective base-mediated -F-
elimination delivers the desired product 307, along with a subsequent ligand exchange 
regenerating the catalytically active species 350. 





Scheme 107. Proposed catalytic cycle ruthenium-catalyzed C–F/C–H functionalization. 
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3.3. Enantioselective Cobalt(III)-Catalyzed C–H Activation 
Despite numerous reports on precious 4d and 5d transition metal-catalyzed[57]  enantioselective 
C–H activations,[58] full selectivity control with 3d metal catalysts remains a challenging area 
of research (cf. chapter 1.3.). However, this area has gained major attention during the course 
of this doctoral thesis.[59] 
 
In this context, enantioselective C–H alkylations by 3d transition metals were thus far largely 
achieved with superstoichiometric amounts of reactive Grignard reagent, which jeopardized 
the functional group tolerance of these transformations. It is noteworthy to mention that the 
Yoshikai group achieved the enantioselective cobalt(II)-catalyzed C–H alkylation by the use 
of BINOL-derived phosphoramidites,[161] whereas, the Ackermann group reported the first 
highly enantioselective iron-catalyzed C–H secondary alkylation of (aza)indoles through the 
design of a novel bulky meta-1-adamantyl substituted chiral NHC ligand.[163] But these 
transformations still required the use of superstoichiometric amounts of reactive Grignard 
reagent. 
 
Despite significant advances in the use of cobalt(III) complexes in recent years for various C–
H activation reactions,[264] asymmetric cobalt(III)-catalyzed C–H activation remained 
unexplored at the outset of this work, although very few examples of enantioselective 
cobalt(II)-catalyzed C–H transformations have been reported under reductive conditions (cf. 
chapter 1.3.6.).[59] Furthermore, the Ackermann group reported a racemic highly branch-
selective cobalt(III)-catalyzed C–H alkylation using stoichiometric amounts of Brønsted 
acid.[265] Drawing inspiration from these studies, we were interested in the development of the 
first highly enantioselective cobalt(III)-catalyzed C–H activation. 
3.3.1. Optimization Studies 
After extensive optimization with commonly used chiral carboxylic acids,[63, 266]  initial results 
by Dr. F. Pesciaioli showed the quest for the development of novel chiral acids for the 
challenging enantioselective cobalt(III)-catalyzed C−H alkylation. Here is a brief overview of 
the initial studies from Dr. F. Pesciaioli (Scheme 108). 




Scheme 108. Enantioselective cobalt(III)-catalyzed C−H alkylation performed by Dr. F. 
Pesciaioli. [a] Chiral acid (1.0 equiv). Markovnikov:anti-Markovnikov selectivities in 
parentheses. 
After identifying the novel chiral acid scaffold CA5,[267] further probing of additives and 
diversely substituted novel chiral acid CA5 were performed for achieving high levels of 
enantiocontrol (Table 11). Amberlyst 15 was found to have a beneficial effect for improving 
the catalytic efficacy as well as the enantioselectivity (entry 3). Further modifications to the 
phenyl rings on the chiral acids failed to increase the enantioselectivity (entries 4-5). 
Gratifyingly, by increasing the reaction temperature and prolonging the reaction time to 65 
hours we were able to access the product 355aa in synthetically useful 61% yield and with high 
enantioselectivity (92:8 e.r.) (entry 6). However, a slight decrease in yield was observed when 
a reduced amount of acid additive was employed (entry 7). The use of [Cp*CoI2]2 as the catalyst 
also showed similar reactivity in terms of catalytic efficiency and enantioselectivity (entry 8). 
It is noteworthy to mention that a decrease in yield was observed when the reaction was 
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performed for a shorter reaction time (entry 9), highlighting the need of longer reaction time 
for achieving synthetically useful yields of this challenging transformation. 
 
Table 11. Asymmetric cobalt(III)‐catalyzed C−H alkylation.[a] 
 
Entry Acid Additive Yield [%] 355aa:356aa e.r. 
1 1-AdCO2H --- 32 >19:1 50:50[b] 
2 CA5 --- 16 >19:1 93:7[c] 
3 CA5 Amberlyst 15 22 >19:1 96:4[c] 
4 CA6 Amberlyst 15 25 >19:1 91:9 
5 CA7 Amberlyst 15 7 >19:1 58:42 
6 CA5 Amberlyst 15 61 11:1 92:8[c,e,f] 
7 CA5 Amberlyst 15 56 11:1 92:8[d,e,f] 
8 CA5 Amberlyst 15 60 11:1 92:8[e,f,g] 
9 CA5 Amberlyst 15 48 11:1 92:8[e,f,h] 
[a] Reaction conditions:  354a (0.50 mmol), 223a (1.50 mmol), [Co] (10 mol %), AgSbF6 (20 
mol %), chiral acid (20 mol %), additive (1.50 equiv), DCE (0.50 M), 25 °C, 20 h, conversion 
determined by 1H-NMR with Ph3CH as the internal standard. [b] Acid (1.0 equiv). [c] 
performed by Dr. F. Pesciaioli. [d] Amberlyst 15 (1.0 equiv). [e] DCE (1.0 M), 65 h. [f] 
Isolated yields. [g] [Cp*CoI2]2 (5.0 mol %). [h] 48 h. 




3.3.3. Effect of the N‐Substitution Pattern 
With the optimized reaction conditions in hand, we next examined the effect of substituents on 
the pyridyl group for the enantioselective C–H alkylation (Table 12). Unsubstituted pyridine 
315a provided the product 357aa in nearly identical yield, but with lower enantioselectivity 
(entry 1). The same held true for 4-methyl-substituted pyridine, which provided the product 
359ba in marginally lower yield and with decreased enantioselectivity (entry 2). Thus, 5-
methylpyridine (5-Mepy) was identified as being slightly superior in terms of 
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Table 12. N‐substitution pattern in asymmetric C−H alkylation.[a] 
 
Entry Indole Product M:AM[b] Yield[c] e.r.[d] 
1 
  
82:18 59% 88:12 
2 
  
85:15 50% 87:13[e] 
3 
  
92:8 61% 92:8[e] 
[a] Reaction conditions:  Indole (0.50 mmol), 223a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), 
AgSbF6 (20 mol %), CA5 (20 mol %), Amberlyst 15 (1.50 equiv), DCE (0.50 mL, 1.0 M), 50 
°C, 65 h. [b] All Markovnikov:anti-Markovnikov selectivities determined by 1H-NMR 
spectroscopy. [c] Yield of isolated product. [d] Determined by chiral HPLC analysis. [e] 
Performed by Dr. F. Pesciaioli. 
 
3. Results and Discussion 
 
102 
3.3.4. Substrate Scope and Limitations of Asymmetric C−H Activation 
With the identified best catalyst, we tested the effect of the substitution on indoles 354 (Table 
13). Our robust catalyst provided the desired C2 alkylated products 355 with high branched 
selectivities and with high level of enantiocontrol. Halogens at C5, including sensitive bromide 
and iodide, furnished the desired products 355ba and 355ca in high enantioselectivities (entries 
2-3). Furthermore, the substrate 354d bearing an ester group was also tolerated under our mild 
and Grignard-free condition, delivering the C2 alkylated product 355da in good yield and with 
high levels of enantiocontrol (entry 4). Unfortunately, both cyano- and nitro-motifs 354e and 
354f were however not acceptable under our optimized reaction condition (entries 5-6). In 
addition, azaindole 354g did not react and failed to provide the C2 alkylated product (entry 7).  
Table 13. Asymmetric C−H activation with indoles 354.[a] 
 
Entry Indole Product Yield[b,c] e.r.[d] 
1 
  
61% (92:8) 92:8 
2 
  
66% (94:6) 93:7 
3 
  
65% (96:4) 92:8 















[a] Reaction conditions:  indole (0.50 mmol), 223a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), 
AgSbF6 (20 mol %), CA5 (20 mol %), Amberlyst 15 (1.50 equiv), DCE (0.50 mL, 1.0 M), 50 
°C, 65 h. [b] Yield of isolated product. [c] Markovnikov:anti-Markovnikov selectivities in 
parentheses; determined by 1H-NMR spectroscopy. [d] Determined by chiral HPLC analysis. 
 
Subsequently, we surveyed various unactivated olefins 223 to examine the effect of the 
substitution on the aryl ring (Table 14). Methyl substitution at the para-position furnished the 
desired product 355ab in slightly lower yield and enantioselectivity (entry 1). However, a 
methoxy substituent in the para-position provided the corresponding product 355ac in a similar 
yield and enantioselectivity as compared to compound 355ab (entry 2). Similarly, para-phenyl 
and fluoro gave the desired products 355ad and 355ae respectively in moderate yields and with 
good enantioselectivities (entries 3-4). Electron-rich disubstituted methoxy substituted olefin 
223f was also tolerated, delivering the C2 alkylated product 355af in good yield and with high 
enantioselectivity (entry 5). Chloro (223g) and bromo (223i) groups did not hamper the 
reactivity, highlighting the mildness of our reaction conditions (entries 6 and 8). However, in 
the case of pentafluoro benzene 223h we observed a significant decrease in the 
enantioselectivity (entry 7). Other functionalities were tested, such as acetate, triflate, and ester, 
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which afforded the products 355aj-355al in moderate yields and with good enantioselectivities 
(entries 9-11). However the acetate-substituted phenyl ring (223j) required a higher 
temperature to achieve good conversion (entry 9). At 60 °C, product 355aj was formed in 55% 
isolated yield and 88:12 er. As observed before, at a higher temperature the ratio of linear to 
branched product also increased significantly.[265] Unfortunately, in case of the unactivated 
alkyl substituted alkenes 223n and 223o, we observed the products 355an and 355ao 
respectively in significantly decreased yields and enantioselectivities, reflecting the challenges 
of this transformation (entries 13-14). In addition, 2-substituted hydroxyl group failed to 
deliver the desired product 355ap in synthetically useful yields (entry 15). 
Table 14. Asymmetric C−H activation with alkenes 223.[a] 
 












51% (92:8) 89:11 






52% (94:6) 92:8 
5 
  




41% (93:7) 88:12 
7 
  




49% (86:14) 92:8[e] 
9 
  
55% (75:25) 88:12[f] 
10 
  
42% (96:4) 87:13 
11 
  
56% (86:14) 86:14 


















[a] Reaction conditions:  354 (0.50 mmol), 223 (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), 
AgSbF6 (20 mol %), CA5 (20 mol %), Amberlyst 15 (1.50 equiv), DCE (0.50 mL, 1.0 M), 50 
°C, 65 h. [b] Yield of isolated product. [c] Markovnikov:anti-Markovnikov selectivities in 
parentheses; determined by 1H-NMR spectroscopy. [d] Determined by chiral HPLC analysis. 
[e] Performed by Dr. F. Pesciaioli. [f] at 60 °C. [g] 354b instead of 354a. 
 
Furthermore, we were able to remove the pyridine orienting groups in a traceless fashion to 
generate the free indoles 357 (Table 15). Other than simple indole 355aa, dimethoxy 355da 
and ester substituted C2 alkylated products 355af were also transformed into the free indoles 
357 by hydrogenation without erosion of the enantioselectivities (entries 1-3). Furthermore, 
single crystal X-ray diffraction confirmed that 357da was the (R)-enantiomer, and the other 
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Table 15. Traceless removal of directing group.[a] 
 
 
















[a] Reaction conditions:  (1) 355 (0.20 mmol), MeOTf (0.22 mmol), CH2Cl2 (0.50 mL), 0 °C 
to 25 °C, 6 h.  (2) Pd(OH)2/C (10 wt.-%), HCO2NH4 (2.0 mmol), MeOH (1.0 mL), 60 °C, 6 h. 
[b] Yield of isolated product. [c] Markovnikov:anti-Markovnikov selectivities in parentheses; 
determined by 1H-NMR spectroscopy. [d] Determined by chiral HPLC analysis. 
3.3.5. Mechanistic Studies 
Given the novelty of the chiral acid CA5 and the high levels of enantioselectivity generated in 
this transformation, we were keen to delineate its mode of action. Therefore, detailed 
experimental and computational mechanistic studies were performed in order to gain insights 
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3.3.5.1. Kinetic Reaction Orders 
3.3.5.1.1. Reaction Order with respect to Chiral Acid CA5. 
Initially, we determined the kinetic order of the reaction under the optimized reaction 
conditions with respect to the concentration of the chiral acid CA5 which was equal to n = 
0.904 ± 0.03, indicating a first order dependence on the concentration of chiral acid (Scheme 
109). Next, we tested the order of the chiral acid under modified reaction conditions in the 
absence of the Amberlyst 15 additive. Quite strikingly, we found the order of the chiral acid 
without Amberlyst 15 was equal to n = 2.07 ± 0.14, which corresponds to an order of two. 
These findings suggest that the chiral acid CA5 may form a dimeric species in solution which 
is also in accordance with our non-linear effect study. 
 
 
Scheme 109. Order in chiral acid CA5 with and without Amberlyst 15. 
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3.3.5.2. Non-Linear Effect Studies 
The deviation from the proportionality between the enantiomeric excess of the chiral ligand 
and the enantiomeric induction of the transformation was next investigated. We studied the 
non-linear effect in our enantioselective transformation in two distinct sets of conditions. In the 
first instance, the absence of a non-linear effect (NLE) excludes the formation of a multiligand 
containing catalyst or catalytically competent oligomer in the enantioselective Co(III)-
catalyzed C–H alkylation. Then, the effect of the enantiomeric excess of the chiral acid CA5 
over the enantiomeric induction of the transformation was investigated under Amberlyst 15-
free reaction conditions, which gave a considerable negative non-linear-effect. This arguably 
relates to the existence of a dimeric species in solution. 
 
 
Scheme 110. Non-linear effect studies with and without Amberlyst 15. 
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3.3.5.3. Diffusion NMR Study 
To further investigate the presence of a dimeric chiral acid species in solution, we performed 
detailed diffusion controlled NMR spectroscopy in collaboration with Dr. Michael John 
(Figure 1). As diffusion NMR experiments resolve different compounds depending on their 
size and shape of the molecules, we prepared two NMR samples of chiral acid with and without 
the external acid TFA. Indeed, the diffusion coefficients were different and the ratio of 
diffusion coefficients indicated the formation of dimers in the absence of TFA. These findings 
can be rationalized by a hydrogen bond-stabilized dimeric resting state of the chiral acid which 
are supported by detailed NLE study and kinetic studies (vide supra). 
 
 
Figure 1. Overlay of DOSY spectra (500 MHz, 25 °C, CDCl3) of CA5 (8 mg, 0.017 mmol, in 
700 mL of CDCl3) in the presence (blue) and absence (green) of 0.063 mmol of TFA. The ratio 
of diffusion coefficients (5.5 × 10-10 ± 0.2 × 10-10 m2s-1 / 4.0 × 10-10 ± 0.2 × 10-10 m2s-1 = 
1.375) indicates the formation of dimers in the absence of TFA. DOSY spectra were recorded 
on a Bruker Avance III HD 500 MHz instrument equipped with a Cryoprobe Prodigy. The 
pulse sequence dstebpgp3s was used, and the diffusion delay (d20) and gradient duration (p30) 
were set to 150 and 1 ms, respectively. nHexane was used as internal standard. 
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3.3.5.4. H/D Exchange Experiment 
Next, we performed a H/D exchange experiment with CD3CO2D as the co-solvent to probe the 
C–H activation elementary step (Scheme 111). As a result, a significant deuterium 
incorporation was observed at the C3-position of the product 355ia as well as at the C3- and 
C7 positions in the starting material in accordance with previously reported racemic branched- 
selective cobalt(III)-catalyzed C–H alkylations.[265] Notably, we observed a significant H/D 
scrambling in the C2-position of the re-isolated starting material 355i which clearly suggests a 
facile and reversible C–H metalation step to be involved.  
 
Scheme 111. H/D scrambling experiment for cobalt(III)-catalyzed C–H alkylation. 
3.3.6. Proposed Catalytic Cycle 
To gain deeper mechanistic insight into the enantioselective cobalt(III)-catalyzed C–H 
alkylation by the co-operation of the novel chiral carboxylic acid CA5, detailed DFT-studies 
were performed by Dr. J. C. A. Oliveira. Given that the H/D exchange experiment clearly 
suggested a reversible C–H metalation step to be involved, migratory insertion and proto-
demetalation steps were interrogated by means of computational DFT studies.  




On the basis of our detailed mechanistic studies, we propose a plausible catalytic cycle initiated 
by a reversible and facile C−H metalation to form the intermediate 359 (Scheme 112). Then, 
and following co-ordination of the alkene 223, a reversible migratory insertion into the cobalt-
carbon bond proceeds to form racemic intermediate 361. Afterwards, in line with our DFT-
studies, the turnover-limiting proto-demetalation step proceeds with chiral acid CA5, which 
acts as the proton source in the enantio-determining step. Thus, the (R)-enantiomer of 
intermediate 361 undergoes selective proto-demetalation with C2-symmetric chiral acid CA5 
to generate the enantioenriched product 355. 
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3.4. Ruthenium(II)-Catalyzed Enantioselective C–H Activation 
Ruthenium(II) complexes have been recognized as powerful catalysts for various C–H 
activation reactions, in particular for hydroarylation reactions.[27t, 39, 138] Despite significant 
advancements, ruthenium-catalyzed enantioselective C–H activations remain rare.[268] This can 
be largely attributed to the absence of reactivity of pentamethylcyclopentadienyl ruthenium(II) 
complexes, which significantly jeopardizes the use of chiral Cpx ligands to achieve full 
selectivity control.[269] Furthermore, it is noteworthy that the multi-step syntheses of Cpx-
ligands and pre-coordination to metal catalysts reduce the atom- and step economy to large 
extent.[106]  
 
In light of enantioselective C–H activation, the cooperative combination of chiral carboxylic 
acids (CCAs) with transition metals has become a successful tool for efficient 
enantioinduction.[34a, 58a] While ruthenium-catalyzed enantioselective transformations are 
scarce in literature, in very recent reports, the groups of Cui[139] and Wang[140] independently 
reported ruthenium(II)-catalyzed enantioselective intramolecular hydroarylations by the 
cooperation of a chiral amine as the directing group[41] where the enantio-induction was 
primarily governed by the chiral amine. Intrigued by our previous development of the first 
cobalt(III)-catalyzed enantioselective C–H alkylations by the design of a novel C2-symmetric 
chiral acid,[270] we became interested in devising a new enantioselective strategy for ruthenium-
catalyzed asymmetric C–H activations. Particularly the design of novel chiral carboxylic acids 
was envisioned to control the enantio-determining proto-demetalation step.[63a, 271] 
3.4.1. Optimization Studies 
The optimization studies were initiated by probing the effect of various classes of typical 
Brønsted acids for the enantioselective C2-selective intramolecular C–H alkylation of olefin-
tethered indole 362a (Scheme 113). Over the past years, N-protected amino acids have evolved 
as powerful ligands particularly for palladium-catalyzed enantioselective C–H 
functionalizations.[63a] Thus, we initially started our optimization with this class of ligands in 
the presence of catalytic amounts of [RuCl2(p-cymene)]2 to furnish the desired cyclized indole 
derivative 363a at room temperature. The reaction worked very efficiently with both Boc-  CA2 
and phthaloyl- protected CA8 amino acids, enabling the cyclization with almost quantitative 
yields, albeit very poor levels of enantiocontrol were observed. Furthermore, well-defined 
chiral phosphoric acids CA9[266] which have been broadly used in the enantioselective C–H 
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transformations failed to provide any reactivity, reflecting the quest for the development of 
novel chiral carboxylic acids for organometallic ruthenium-catalyzed enantioselective C–H 
activation strategies. Recently we achieved the highly enantioselective cobalt(III)-catalyzed C–
H activation through the design of a novel C2-symmetric chiral carboxylic acid.[270] Intrigued 
by this result, we surveyed this class of chiral carboxylic acids in the ruthenium-catalyzed 
enantioselective C–H alkylation. We were pleased to observe an excellent yield of the desired 
cyclized product with C2-symmetric chiral acid CA5 with a promising enantioselectivity.  
 
 
Scheme 113. Chiral acid screening for the enantioselective C–H alkylation. 
 
Next, various representative solvents were tested, but fell short in delivering the product 363a 
in improved enantioselectivity (Table 16, entries 1-5). Thus, toluene was found to be the 
optimal solvent (entry 5). Furthermore, we also probed the effect of additives for 
enantioselective ruthenium-catalyzed C–H alkylations (entries 6-9). Nonetheless, in stark 
contrast to our previous report,[270]  Amberlyst 15 did not show a beneficial effect on the 
outcome of the reaction (entry 6). Similar results were obtained for other acid additives which 
provided the desired product 363a in almost quantitative yields, but lower levels of 
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Table 16. Asymmetric ruthenium(II)-catalyzed C–H activation.[a] 
 
 
Entry Additive Solvent Yield [%] e.r.[b] 
1 --- 1,2-DCE 93 76:24 
2 --- o-xylene 55 70:30 
3 --- 1,4-dioxane 52 62:38 
4 --- PhCF3 90 71:29 
5 --- PhMe 92 84:16 
6 Amberlyst 15 PhMe 94 84:16 
7 Amberlite CG50 PhMe 88 77:23 
8 Citric Acid PhMe 95 78:22 
9 MS13X PhMe 90 84:16 
[a] Reaction conditions: 362a (0.25 mmol), [Ru] (10 mol %), AgSbF6 (20 mol %), CA5 (20 
mol %), Additive (1.50 equiv), PhMe (0.50 mL), RT, 12 h, isolated yields. [b] 
Enantioselectivities determined by chiral HPLC. 
 
Thereafter, diversely substituted novel chiral carboxylic acids were newly synthesized and 
probed in the envisioned enantioselective transformations of indoles (Scheme 114). Variation 
in meta-substitution provided the product 363a in lower enantioselectivity for both methyl 
CA10 and trifluoromethyl substituted arenes CA11. Similarly, 3,5-disubstituted methyl CA12 
also failed to improve the enantioselectivity. However, we observed a beneficial effect of para-
phenyl substituted chiral acids in improving the enantioselectivity. Among the tested electron-
rich and electron-deficient chiral scaffolds, para-methyl substituted chiral acid CA14 turned 
out to be superior for achieving high levels of enantiocontrol. Slightly bulkier ethyl-substituted 
CA15 was tested as well but provided inferior results compared to the methyl group. 




Scheme 114. Chiral acid screening for the enantioselective C–H alkylation of indoles 362a. 
 
Next, we tested several variations of our standard conditions (Table 17). Remarkably, the 
reaction also occurred under silver-free reaction conditions using NaSbF6 or NaPF6 as the 
additive, albeit with slightly lower yields (entries 2-3). As previously observed, Amberlyst 15 
did not improve the enantioselectivity, although the reactivity was not influenced (entry 4). 
Next, a series of several other metal catalysts, such as, [OsCl2(p-cymene)]2, [Cp*Co(CO)I2], 
Pd(OAc)2, [Cp*IrCl2]2 and [Cp*RhCl2]2 were tested, which failed to deliver the desired 
tetrahydrocarbazole derivative 363a in considerable enantioselectivity (entry 5-9). Likewise, 
ent-CA14 afforded the (S)-enantiomer of the tetrahydrocarbazole (entry 10). 
 
 
3. Results and Discussion 
 
117 
Table 17. Asymmetric ruthenium(II)-catalyzed C–H activation.[a] 
 
 
Entry Variation of Standard Condition Yield[%] e.r. [b] 
1 none 95 85:15 
2 NaSbF6 instead of AgSbF6 37[c] 77:23 
3 NaPF6 instead of AgSbF6 20[c] 83:17 
4 Amberlyst 15 as additive 94 85:15 
5 [OsCl2(p-cymene)]2 as catalyst --- --- 
6 [Cp*Co(CO)I2] as catalyst <5 n.d. 
7 Pd(OAc)2 as catalyst --- --- 
8 [Cp*IrCl2]2 as catalyst --- --- 
9 [Cp*RhCl2]2 as catalyst 90 58:42 
10 ent-CA14 was used 94 15:85 
[a] Reaction conditions: 362a (0.25 mmol), [Ru] (10 mol %), AgSbF6 (20 mol %), CA14 (20 
mol %), PhMe (0.50 mL), RT, 12 h, isolated yields. [b] Determined by chiral HPLC. [c] 
Conversion determined by 1H-NMR using Ph3CH as the internal standard. n.d. = not 
determined. 
3.4.2. Effect of N-Substitution Pattern 
Subsequently, we surveyed the substitution pattern on the pyridyl directing group for the 
enantioselective C–H alkylation (Table 18). Hence, a similar yield was observed for the 
unsubstituted pyridine 364a, albeit lower enantioselectivity of the cyclized product 365a was 
obtained (entry 1). The 4-methyl-substituted pyridine 366a provided a marginally lower yield 
compared to the 5-methyl substituted substrate 362a as well as a lower enantioselectivity (entry 
2). Thus, 5-methylpyridine (5-Mepy) 362a furnished the desired product 363a with the highest 
enantioselectivity (entry 3). 
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Table 18. Effect of N-substitution pattern on asymmetric C–H alkylation.[a] 
 
 













[a] Reaction conditions: Indole (0.25 mmol), [Ru] (10 mol %), AgSbF6 (20 mol %), CA14 (20 
mol %), PhMe (0.50 mL), RT, 12 h, isolated yields. [b] Determined by chiral HPLC. 
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3.4.3. Substrate Scope of Asymmetric C–H Alkylation 
With the optimized catalyst in hand, various C5 and C6 substituted indoles 362 were tested 
(Table 19). Our approach provided the desired C2-cyclized products 363 in excellent yields 
and with good enantiocontrol independent of varying the sterics and electronics of the 
substituents. Both electron-rich and electron-deficient substrates furnished the desired products 
with good enantioselectivity under exceedingly mild reaction conditions (entries 1-5). 
Remarkably, halogens including fluoride and bromide were well tolerated in the versatile 
ruthenium(II) catalysis, which would prove invaluable for further late-stage diversifications 
(entries 4-5). Thus the desired products 363d-363e were obtained in high yields and moderate 
enantioselectivities. Furthermore, the reaction was also performed on a 1 mmol scale with 
bromo substrate 362e, furnishing the product in an identical yield of 86% with 83:17 e.r. (entry 
5). Additionally, the product 363e was recrystallized from dichloromethane, and analyzed by 
single crystal X-ray diffraction, clearly revealing the (R)-conformation of the stereocenter. The 
other products 363 were assigned by analogy. Thereafter, an extensive study of the scope of 
this enantioselective transformation was studied by Dr. R. Connon and Mr. R. Steinbock.  
Table 19. Asymmetric C–H alkylation with indoles 362.[a] 
 
 



























[a] Reaction conditions: 362 (0.25 mmol), [Ru] (10 mol %), AgSbF6 (20 mol %), CA14 (20 
mol %), PhMe (0.50 mL), RT, 12 h, isolated yields. [b] Determined by chiral HPLC. [c] 
Performed on 1 mmol scale. 
We further became interested to extend this approach to the synthesis of larger rings (Table 
20). Under our optimized reaction conditions, we observed a rather low conversion for the 
formation of seven-membered ring 369, albeit Amberlyst 15 proved to be beneficial here 
(entries 1-2). Further optimization was performed by Mr. R. Steinbock, showcasing that 
prolonged reaction time could provide cyclohepta[b]indole derivative 369 in a synthetically 
useful yield of 51% with a good enantioselectivity of 82:18 e.r. (entry 3). Unfortunately, larger 
than 7-membered rings could not be formed under otherwise identical reaction conditions 
(entry 4). 
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Table 20. Enantioselective C–H alkylation for larger rings.[a] 
 
Entry n Variation of Standard Condition Yield [%] e.r.[b] 
1 1 none 17 82:18 
2 1 Amberlyst 15 as additive 25 82:18[c] 
3 1 Amberlyst 15 as additive and 72 h 51 82:18[c] 
4 2 none --- --- 
[a] General reaction conditions: 368/370 (0.10 mmol), [Ru] (10 mol %), AgSbF6 (20 mol %), 
CA14 (20 mol %), PhMe (0.50 mL), RT, 20 h, isolated yields. [b] Enantioselectivities 
determined by chiral HPLC. [c] Performed by Mr. R. Steinbock. 
3.4.4. Mechanistic Studies 
 
Given the unique selectivity shown by the chiral carboxylic acid CA14 for the intramolecular 
enantioselective C–H alkylation in ruthenium(II)-catalysis, we were interested to unravel its 
mode of action. Therefore, detailed experimental and computational mechanistic studies were 
performed in order to gain insights into the reaction mechanism. 
3.4.4.1. H/D Exchange Experiment 
Initially, a H/D exchange experiment was conducted in toluene with isotopically-labeled D2O 
as the co-solvent to probe the C–H activation step (Scheme 115). Significant H/D exchange 
was observed in the methyl-group in 363a and in the recovered starting material 362a. This 
observation can be rationalized by a facile and reversible C–H ruthenation step. 
 




Scheme 115. H/D exchange experiment of the enantioselective C–H alkylation. 
3.4.4.2. KIE Studies 
Furthermore, the intramolecular kinetic isotope effect (KIE) was determined for the substrate 
362 and isotopically-labelled substrate [D]n-362a, which showed a KIE of kH/kD ≈ 1.1, which 
is in good agreement with the H/D exchange experiment, being suggestive of a fast and non 
rate-determining C–H ruthenation (Scheme 116). 
 
 
Scheme 116. KIE studies of the enantioselective C–H alkylation. 
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3.4.5. Proposed Catalytic Cycle 
 
In addition to these experimental mechanistic studies, detailed DFT-studies were performed by 
Dr. J. C. A. Oliveira to gain mechanistic insights of enantioselective ruthenium(II)-catalyzed 
C–H alkylation. 
 
On the basis of our mechanistic studies, we propose a plausible catalytic cycle to commence 
with a fast C−H activation step, as supported by the H/D exchange experiments and the KIE 
study, to form the intermediate 373 (Scheme 117). Then, the generated ruthenacycle 373 
undergoes a reversible alkene coordination to form 374, followed by a reversible migratory 
insertion into the ruthenium-carbon bond to form racemic intermediate 375. In accordance with 
the computational studies, a process involving the turnover-limiting proto-demetalation step 
proceeds with chiral acid CA14, which acts as the proton source in the enantio-determining 
step. Finally, selective proto-demetalation occurs from the (R)-enantiomer of intermediate 375 
with the chiral carboxylic acid CA14 to regenerate the catalytically active species 372 and 
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3.5. Copper-Catalyzed Alkyne Annulation by C–H Alkynylation 
In the last decade electro-organic synthesis has witnessed a considerable renaissance in order 
to achieve new reactivity towards improved resource economy.[224] While early contributions 
on the synergistic merger of oxidative metal catalysis with electrosynthesis were limited to the 
use of expensive 4d and 5d transition metals, recent trends have shifted towards inexpensive 
3d transition metal catalysis.[232] In this context, copper is one of the most abundant 3d 
transition metals in the Earth’s crust.[31] Consequently, copper catalysts have emerged in the 
past few years as powerful tools for cost-effective C–H activation reactions. Among others, 
copper catalysts have been widely used for C–H arylations, aminations and alkyne annulation 
reactions (cf. chapter 1.4.1.3). However, oxidative copper-catalyzed C–H activations such as 
aminations or alkyne annulations had largely required toxic and expensive sacrificial oxidants, 
which jeopardize the atom-economy of the overall strategy.[31]  
 
Surprisingly, electrochemical copper-catalyzed C–H activation was largely unexplored. Yet 
very recently, Mei reported copper-catalyzed electrochemical aminations with anilides through 
a proposed single electron transfer (SET) mechanism.[256] Subsequently, similar 
electrooxidative aminations were independently reported by Nicholls[257] using 8-
aminoquinoline as the directing group. However, electrochemical copper-catalyzed C–H 
alkynylations[209, 272] have thus far proven elusive. Thus, we became interested in the 
development of copper-catalyzed electro-oxidative alkyne annulation enabled by C−H 
alkynylations of synthetically valuable benzamides to deliver bioactive five-membered 
isoindolones. It is noteworthy that isoindolones are core structural motifs of various 
pharmaceutical drugs and natural products with distinct biological activity. Hence, sustainable 
methods to synthesize highly functionalized isoindolones scaffolds are highly desirable (Figure 
2). 





Figure 2. Examples of biologically important 3-methyleneisoindolin-1-ones derivatives. 
3.5.1. Optimization of the Copper-Catalyzed Electrochemical C–H Annulation 
Initial optimized reaction conditions for the envisioned copper-catalyzed electrochemical C–H 
annulation were obtained by Dr. C. Tian, in that benzamide 229a was reacted with phenyl 
acetylene 255a in an undivided cell set-up in the presence of 5.0 mol % of Cu(OAc)2.H2O, one 
equiv of NaOPiv in DMA at 100 °C with a combination of graphite felt as anode and platinum 
as cathode. A constant current of 6.0 mA was applied to thereby provide the desired alkyne 
annulated product 256aa with 90% yield (Z/E = 13:1) (Scheme 118). 
 
Scheme 118. Copper-catalyzed electrochemical C–H annulation. 
3.5.2. Substrate Scope and Limitations of the Electrochemical Copper-Catalyzed Alkyne 
Annulation 
With the optimized reaction conditions in hand, we tested the versatility of differently 
substituted benzamides 229 for the electrochemical copper-catalyzed C–H cascade annulation 
to test the generality and limitations of this reaction (Table 21). To our delight, sterically 
crowded ortho-substituted benzamides 229b and 229c efficiently provided the desired 
annulated products 256ba and 256ca in good yields, while for bulky ortho-phenyl-substituted 
benzamide 229c, an increased catalyst loading was required to improve the catalytic efficiency 
(entries 2-3). Even para-nitro substituted benzamide 229d was well tolerated by our robust 
catalysis (entry 4). Unfortunately, electron-rich 2-methoxybenzamide 229e failed to show any 
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reactivity (entry 5). In addition, 2-phenyl-N-(quinolin-8-yl)acrylamide 376a and cyclohexene 
benzamide 378a remained untouched (entries 6-7). 
Table 21. Cupraelectro-catalyzed C–H annulation with benzamides 229.[a] 
 
 
































[a] Reaction conditions: 229 (0.25 mmol), 255a (0.50 mmol), Cu(OAc)2.H2O (5.0 mol %), 
NaOPiv (1.0 equiv), DMA (4.0 mL), 100 °C, constant current at 6.0 mA, 6 h, GF anode (10 mm 
× 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 0.25 mm), undivided cell, isolated 
yields. [b] Cu(OAc)2∙H2O (10 mol %).  
 
Likewise, a broad range of ortho-, meta- and para- substituted terminal alkynes 255 was tested 
under our optimized electrochemical reaction conditions to demonstrate the robustness of our 
catalyst (Table 22). In general, electron-rich 4-ethynyltoluene 255b, 4-ethynylanisole 255c and 
2-ethynylanisole 255d were smoothly converted with good yields to the corresponding 
products 256ab-256ad (entries 1-3). Moreover, meta-chlorophenylacetylene 255e was also 
found as an amenable substrate, while electron-poor 4-ethynyltrifluoroluene 255f showed 
slightly lower reactivity (entries 4-5). To our satisfaction, a series of para-substituted halo 
groups was well tolerated, which should prove invaluable for late-stage diversification (entries 
6-7). In addition, ester 255i and cyano-containing alkyne 255j were also chemo-selectively 
converted to deliver the desired isoindolinones 256ai and 256aj in good yields (entries 8-9). 
Electron-rich heterocycle thiophene acetylene 255k was also found to be amenable substrate 
in the cupraelectro-catalyzed annulation manifold, albeit higher catalyst loading was employed 
to improve the conversion (entry 10). A significant drop in reactivity was observed for the 
aliphatic alkyne 255l (entry 11), whereas the robustness of the copper-catalyzed annulation 
allowed excellent efficacy with alkyne bearing Boc-protected amino acid 255m (entry 12). As 
a limitation of the substrate scope, 4-ethynylpyridine 255n and ethynylcyclohexane 255o 
remained unreacted under the optimized reaction conditions, as the remaining starting materials 
were recovered in almost quantitative yields (entries 13-14). 
 
3. Results and Discussion 
 
129 
Table 22. Cupraelectro-catalyzed C–H annulation with terminal alkynes 255.[a] 
 
 






























































[a] Reaction conditions: 229a (0.25 mmol), 255 (0.50 mmol), Cu(OAc)2.H2O (5.0 mol %), 
NaOPiv (1.0 equiv), DMA (4.0 mL), 100 °C, constant current at 6.0 mA, 6 h, GF anode (10 mm 
× 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 0.25 mm), undivided cell, isolated 
yields. [b] Cu(OAc)2∙H2O (10 mol %). [c] Cu(OAc)2∙H2O (20 mol %). 
3.5.3. Proposed Catalytic cycle for Copper-Catalyzed Electrochemical C–H Annulation 
Based on the mechanistic studies from Dr. C. Tian and cyclic voltammetry analysis from Mr. 
A. Scheremetjew, we have proposed a plausible catalytic cycle for the copper-catalyzed 
electrochemical C–H annulation (Scheme 119). First, the catalytic cycle initiates with the 
benzamide co-ordination to form copper(II) intermediate 381, which readily undergoes anodic 
oxidation to form catalytically competent copper(III) carboxylate species 382. Second, the 
catalytically competent species 382 undergoes facile carboxylate assisted C−H activation to 
form 383. Third, ligand exchange with alkyne 255 forms species 384 and subsequent reductive 
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elimination affords the alkenylated arene 386, which undergoes facile base-assisted cyclization 
to form the annulated product 256. 
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3.6. Electrochemical Cobalt-catalyzed C–H Allylation 
In recent years significant momentum was gained by the merger of transition metal-catalyzed 
oxidative C–H activation with electrochemistry, enabling the use of electrons as sustainable 
redox equivalents.[232] Since the pioneering report on cobalt-catalyzed oxidative C–H 
oxygenation by the Ackermann group in 2017,[246] electrochemical cobalt catalyzed C–H 
activation has been well studied by Ackermann and others.[32a, 245] Moreover, electrochemical 
palladium-,[233] rhodium-, [242e, 242f] iridium-[243b] and ruthenium-[244h]catalyzed organometallic 
C–H activations are mainly restricted to activated alkenes, such as styrenes and acrylates. In 
sharp contrast, electrochemical C–H activation with unactivated aliphatic alkenes is 
unexplored. Thus, Lei developed cobalt-catalyzed electrochemical C–H/N–H annulations with 
simple ethylene, delivering solely the cyclized product.[251] Considering that the control of 
chemo-selectivity is an important endeavor in organic synthesis, we became interested to study 
cobalt-catalyzed electrochemical C–H activation with unactivated alkenes.  
 
Direct C–H allylations have really become an important method in terms of step-economy, 
and, consequently, there has been a significant development in ortho-C–H allylations. Over the 
past years, the synthetic community has witnessed a significant advancement in transition 
metal-catalyzed C–H allylations primarily with prefunctionalized coupling partners, such as 
allyl halides or acetates.[273] While very recently unactivated allylic coupling partners have been 
employed for oxidative C–H allylation reactions, this approach largely required 
superstoichiometric amounts of chemical oxidants, which jeopardized its synthetic utility.[191-
193] In this context, it is noteworthy that electrocatalyzed C–H allylations are as of yet unknown. 
Thus we were interested to develop cobaltaelectro-catalyzed C–H allylations of synthetically 
meaningful benzamides and challenging unactivated alkenes. 
 
3.6.1. Optimization of the Electrochemical Cobalt(II)-Catalyzed C–H Allylation 
 
We initiated our optimization for the envisioned cobalt(II)-catalyzed C–H allylation with 
ortho-substituted benzamide 229f as the model substrate (Table 23). We performed our initial 
test reaction with benzamide 229f and unactivated alkene 223o in a user-friendly undivided 
cell set-up under a constant current electrolysis. We were pleased to exclusively observe 
allylated product 242fo with a catalytic amounts of inexpensive Co(OAc)2.4H2O in the 
presence of NaOAc as the additive (entry 1). Next, we tested various carboxylate and carbonate 
additives, among which, NaOPiv was ideal, providing the desired allylated product 242fo in 
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60% yield (entries 1-5). Then, a series of representative solvents was tested (entries 5-10). To 
our delight, biomass-derived renewable -valerolactone (GVL) provided the optimal results 
(entry 5).[6, 248] Among other typical solvents, DCE gave comparable reactivity (entry 6), while 
other solvents showed either low conversion or no reaction at all (entries 7-10). It is noteworthy 
that a deep eutectic solvent system of choline chloride and urea was able to furnish the desired 
product 242fo, albeit in lower yield (entry 11). Furthermore, different reaction temperatures 
were tested, which revealed the optimal reactivity at 100 °C, while higher or lower reaction 
temperatures reduced the yields (entries 12-13). Control experiments highlighted the necessity 
of the cobalt(II)-catalyst and the electricity (entries 14-15). It is noteworthy that ortho-
unsubstituted benzamides afforded the corresponding products in lower yields with a mixture 
of styrenyl and allylic isomers. This revealed the necessity for the ortho-substitution to provide 
exclusively the β-H elimination product from the allylic proton in a unique manner via a 
conformationally-strained 7-membered metallacycle. 
 
Table 23. Optimization studies for electrochemical cobalt(II)-catalyzed C−H allylation.[a] 
 
 
Entry Additive Solvent Yield [%] 
1 NaOAc GVL 12 
2 KOAc GVL 8 
3 Na2CO3 GVL 19 
4 PivOH GVL 49 
5 NaOPiv GVL 60 
6 NaOPiv DCE 58 
7 NaOPiv TFE 28 
8 NaOPiv MeCN 27 
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9 NaOPiv MeOH/H2O --- 
10 NaOPiv tBuOH/H2O --- 
11 NaOPiv Choline chloride/Urea (1:2) 25[b] 
12 NaOPiv GVL 52[c] 
13 NaOPiv GVL 42[d] 
14 NaOPiv GVL ---[e] 
15 NaOPiv GVL 5[f] 
[a] General reaction conditions: 229f (0.50 mmol), 223o (1.50 mmol), Co(OAc)2∙4H2O (10 mol 
%), additive (1.0 equiv), solvent (4.0 mL), nBu4NPF6 (0.50 equiv), 100 °C, constant current at 
4.0 mA, 14 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), undivided cell, isolated yields. [b] In absence of nBu4NPF6. [c] 120 °C. [d]  80 °C.  
[e] In absence of cobalt source. [f]  No electricity. 
3.6.2. Substrate Scope and Limitations of the Electrochemical Cobalt-Catalyzed C–H 
Allylation 
After establishing the optimized reaction conditions, we next tested various N-amide 
substituents in the cobaltaelectro-catalyzed C–H allylation (Table 24). Pyridine-N-oxide 231a 
which worked very efficiently for electrochemical cobalt-catalyzed C–H oxygenation,[246] 
failed to deliver the allylated product 387a (entry 1). In addition, the recently used sulfonamide 
388a for cobalt-catalyzed electrochemical alkyne annulation,[274] proved to be inefficient for 
the desired C–H allylation reaction (entry 2).  
Table 24. Effect of the orienting group on the electrochemical C–H allylation.[a] 
 
 
Entry Benzamide Product Yield [%] 












[a] Reaction conditions:  Benzamide (0.50 mmol), 223o (1.50 mmol), Co(OAc)2∙4H2O (10 mol 
%), NaOPiv (2.0 equiv), nBu4NPF6 (0.50 equiv), GVL (4.0 mL), 100 °C, constant current at 
4.0 mA, 14 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), undivided cell, isolated yields. [b] Performed by W. Li. 
 
With the optimized reaction conditions in hand, we next decided to assess the generality of the 
electrochemical cobalt-catalyzed C–H allylation (Table 25). The mild reaction conditions in 
undivided cell set-up proved viable for sterically-hindered benzamides and various functional 
groups. Initially, the robustness of the ortho-substituted benzamides 229 was explored with 
challenging n-octene, and independent of the steric influence, the desired products 242 were 
formed with excellent allylic selectivity. To our delight, and in contrast to previous work on 
cobaltaelectro-catalyzed C–H oxygenations,[246] which was severely limited to ortho-
substituted benzamides, in this present study larger substituents including methoxy, 
trifluoromethyl and phenyl provided the corresponding products with excellent levels of allylic 
selectivity (entries 2-4). Fortunately, electron-rich and electron-deficient arenes  were smoothly 
converted with high chemo-selectivity. Even sterically-bulky substituents at the 5-position of 
the benzamides 229i and 229j did not affect the selectivity, and only a slight decrease in yields 
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was observed (entries 6-7). In addition, halo-groups were tolerated, delivering the 
corresponding product 242jo which should prove invaluable for further late-stage 
diversifications, highlighting the potential of the cobaltaelectro-catalyzed C–H allylation 
approach. 
 
Table 25. Cobaltaelectro-catalyzed C–H allylation with benzamides 229.[a] 
 
 

























[a] Reaction conditions: 229 (0.50 mmol), 223o (1.50 mmol), Co(OAc)2∙4H2O (10 mol %), 
NaOPiv (2.0 equiv), nBu4NPF6 (0.50 equiv), GVL (4.0 mL), 100 °C, constant current at 
4.0 mA, 14 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), undivided cell, isolated yields. [b] Co(OAc)2∙4H2O (20 mol %). [c] Performed by 
Dr. C. Tian. 
 
Next, we evaluated the viable substrate scope for unactivated alkenes 223 to demonstrate the 
synthetic utility of our transformation (Table 26). Interestingly, a variation in the extended 
alkyl chain length did not influence the efficacy of the electrocatalytic transformation. Under 
the optimized reaction conditions, both 1-decene 223q and 1-nonene 223r delivered the desired 
products 242fq and 242fr, respectively, in good yields (entries 1-2). Likewise, allyl benzene 
223a was exclusively transformed into the desired allylated product 242fa (entry 3). 
Gratifyingly, the cobaltaelectro-catalyzed C–H allylation proved applicable to the 
chemoselective mono-functionalization of diene 223s to deliver allylated benzamide product 
242fs, demonstrating the unique selectivity features of this transformation without 
isomerization of the additional double bond (entry 4). Notably, various sensitive functional 
groups were fully tolerated by the versatile cobalt catalysis. Acetate-containing substrates 223j 
and 223t were efficiently converted to provide the corresponding allylated benzamides 242fj 
and 242ft in good yields (entries 5-6). It is noteworthy that chloro and epoxy groups were fully 
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tolerated, albeit a higher catalyst loading was employed here (entries 7-8). More delightfully, 
challenging the free hydroxyl group 223x on the alkene was also well accepted (entry 9). 
 
Table 26. Cobaltaelectro-catalyzed C–H allylation with unactivated alkenes 223.[a] 
 
 








































[a] Reaction conditions: 229f (0.50 mmol), 223 (1.50 mmol), Co(OAc)2∙4H2O (10 mol %), 
NaOPiv (2.0 equiv), nBu4NPF6 (0.50 equiv), GVL (4.0 mL), 100 °C, constant current at 
4.0 mA, 14 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), undivided cell, isolated yields. [b] Co(OAc)2∙4H2O (20 mol %). 
3.6.3. Mechanistic Studies 
 
After establishing the versatility of the first electrocatalytic C–H allylation, we were intrigued 
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3.6.3.1. Competition Experiments 
To this end, we carried out an intermolecular competition experiment with electronically 
distinct benzamides 229f and 229g, which clearly showed a preference for the electron-rich 
arene 242fo to react inherently faster than the electron-poor analogue 242go (Scheme 120). 
This supports a BIES mechanism. 
 
Scheme 120. Competition experiments for cobaltaelectro-catalyzed C–H allylation. 
3.6.3.2. H/D Exchange Experiment 
In addition, a H/D-exchange experiment was conducted using isotopically-labeled CD3OD as 
the deuterated co-solvent under the optimized reaction condition, which showed no H/D 
crossover either in the product 242fo or in the isolated starting material 229f (Scheme 121). 
This observation suggests an irreversible C–H activation event to be operative for the cobalt-
catalyzed C–H allylation. 
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3.6.3.3. Gas-Chromatographic Head-Space Analysis 
Finally, Dr. C. Tian observed the formation of molecular hydrogen by gas-chromatographic 
head-space analysis, highlighting molecular hydrogen as the sole by-product formed through 
cathodic reduction (Scheme 122). 
 
Scheme 122. Gas-chromatographic head-space analysis. 
 
3.6.3.4. Cyclic Voltammetry Studies 
 
Furthermore, detailed cyclic voltammetry studies were conducted by Dr. C. Tian in acetonitrile 
on the electrochemical cobalt(II)-catalyzed C–H allylation (Figure 3). While the amide 
substrate 229f was oxidized at 1.46 VSCE, interestingly the alkene 223o did not show any 
relevant oxidation event. Finally, the in-situ generated cobalt catalyst showed a lower oxidation 
potential at 1.19 VSCE. This observation strongly supports an initial anodic cobalt(II/III) single-
electron oxidation. 
 




Figure 3. Cyclic voltammetry.  
General condition: DMA, 0.1 M nBu4NPF6, 5 mM HOAc, 5 mM substrates, 100 mV/s. 
 
3.6.4. Proposed Catalytic Cycle 
 
In accordance with recent findings[275] and on the basis of our mechanistic findings, we have 
depicted a plausible catalytic cycle for the cobalt-catalyzed electrochemical C−H allylation 
(Scheme 123). Here electrochemical cobalt(II)-catalyzed C–H allylation is likely initiated by 
anodic cobalt oxidation to generate the cobalt(III) species 391. After generation of the active 
cobalt(III) species 391, the carboxylate-assisted C–H scission occurs by irreversible, BIES-
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type mechanistic pathways to form the 5-membered cobaltacycle 392 as supported by H/D-
exchange experiment and competition experiment. Thus formed cyclometalated cobalt 
complex undergoes alkene co-ordination to afford 393 and subsequent 1,2-migratory insertion 
with the non-activated alkene 223 forms the conformationally strained 7-membered 
metallacycle 394. Next the 7-membered metallacycle 394 undergoes -hydride elimination 
exclusively from the allylic proton, releasing the desired product 242 with allylic selectivity.  
Finally, the cobalt(I) species 395 is oxidized to the active cobalt(III) catalyst 391 by anodic 
oxidation to complete the catalytic cycle. Notably, the cathodic half-reaction formed H2 as the 
sole stoichiometric byproduct, showcasing the sustainability of the electrochemical oxidative 
allylation. 
 




Scheme 123. Proposed catalytic cycle for cobaltaelectro-catalyzed C–H allylation. 
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3.7. Enantioselective Palladaelectro-Catalyzed C–H Activations 
Electrochemical oxidations have been well studied for the last few decades, since they offer an 
attractive approach by the utilization of electric current to obviate the use of toxic and 
expensive reagents. In recent years, significant advances have been realized by the merger of 
electrosynthesis with organometallic C–H activations, using electrons as green redox 
equivalents.[232] Major progresses in electrochemical palladium catalyzed C–H activations have 
been realized by strong N-directing groups.[234-236, 238-239, 240b, 241, 276] Despite these significant 
advances, electrochemical enantioselective C–H activations are thus far unknown.[277] Possibly 
cathodic catalyst reduction as well as electrochemical degradation of the chiral ligands make 
the asymmetric metallaelectro-catalysis an extremely challenging research area. 
Considering the importance of axially-chiral biaryls as key structural motifs in various 
catalysts,[278] ligands[279] and natural products,[280] we were interested in the development of the 
first electrochemical enantioselective synthesis of axially chiral biaryls. It is noteworthy that 
since the early, albeit moderately selective report on rhodium(I)-catalyzed C–H alkylations of 
arylpyridines, atroposelective syntheses of axially-chiral biaryls have become a major research 
area (cf. chapter 1.3.1.).[281] Notably, Shi employed chiral transient directing groups for the 
efficient synthesis of axially-chiral biaryls.[41a] Despite these advances, these transformations 
are often limited to the use of  toxic oxidants. Hence, we became interested in the development 
of an atroposelective synthesis of axially-chiral biaryls with the aid of transient directing 
groups, employing electricity as the redox agent. Furthermore, it should be duly noted that 
transient directing groups had never been used before in electrochemical C–H activation 
reactions. 
3.7.1. Optimization Studies 
 
For the development of the first enantioselective electrochemical metal-catalyzed C–H 
activation, we were interested in the advancement of atroposelective C–H activation of biaryls 
under sustainable electrochemical conditions (Table 27).  We began our investigations by 
evaluating a series of weakly-coordinating transient directing groups for the envisioned 
atroposelective electrocatalyzed C–H olefination of biaryls 73a with n-butyl acrylate 38a. We 
started our optimization with several α-amino acids to access highly enantioenriched axially 
chiral biaryls 74aa with synthetically useful formyl groups (entries 1-5). Thus, we found that 
L-tert-leucine was the best TDG for this atroposelective transformation, delivering the desired 
product with 53% yield and 97% ee (entry 5). Electrolytes always play a significant role in the 
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outcome of electrochemical reactions. Thus, we tested other electrolyte additives, such as 
NaOAc, KOAc, NaOPiv and nBu4NPF6, which provided inferior results as compared to LiOAc 
(entries 6-9). This finding suggested that the additive played an important role for the 
successful outcome of the reaction, thus operating both as an electrolyte and a base for the 
carboxylate-assisted C–H bond cleavage (vide infra). It is noteworthy that AcOH has been 
found as a commonly used solvent for palladium-catalyzed electrochemical C–H activation 
reactions. In line with previous literatures, we observed AcOH indeed to be the optimal solvent, 
possibly playing a crucial role in the in situ formation of the imine species. When we employed 
only TFE as the reaction medium, we did not observe any reactivity whereas a mixture of TFE 
and AcOH provided the product 74aa in moderate yield and with high enantioselectivity 
(entries 10-11). Prolonging the reaction time, delivered the C–H olefinated product in 71% 
yield and 97% ee (entry 12). Notably, the enantioselective metallaelectro-catalysis also 
occurred under an inert atmosphere, albeit with reduced efficiency (entry 14). In stark contrast 
to the use of chemical oxidants,[89] a redox mediator was not required for efficient 
metallaelectro-catalysis, as we observed that commonly used redox mediators such as 
benzoquinone, failed to improve the reactivity to a large extent. Control experiments confirmed 
the necessity of the TDG, the electricity and the palladium catalyst (entries 15-17). 
Table 27. Optimization of the atroposelective electrocatalyzed C–H olefination.[a] 
 
Entry TDG Additive Solvent Yield [%] ee [%][b] 
1 L-valine LiOAc AcOH 35 48[c] 
2 L-Phenylglycene LiOAc AcOH 37 40 
3 L-tryptophan LiOAc AcOH 21 68[c] 
4 H-Asp(OtBu)-OH LiOAc AcOH 55 20 
5 L-tert-leucine LiOAc AcOH 53 97 
6 L-tert-leucine NaOAc AcOH 47 99 
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7 L-tert-leucine KOAc AcOH 45 98 
8 L-tert-leucine NaOPiv AcOH 50 96 
9 L-tert-leucine nBu4NPF6 AcOH 48 99 
10 L-tert-leucine --- TFE --- --- 
11 L-tert-leucine --- TFE/AcOH 46 99 
12 L-tert-leucine LiOAc AcOH 71 97[d] 
13 L-tert-leucine LiOAc AcOH 66 97[d,e] 
14 L-tert-leucine LiOAc AcOH 43 97[d,f] 
15 --- LiOAc AcOH --- --- 
16 L-tert-leucine LiOAc AcOH 25 97[g] 
17 L-tert-leucine LiOAc AcOH --- ---[h] 
[a] Reaction conditions: Undivided cell, 73a (0.20 mmol), 38a (0.60 mmol), [Pd] (10 mol %), 
TDG (20 mol %), additive (2.0 equiv), solvent (4.5 mL), 60 °C, constant current at 1.0 mA, 14 
h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 0.25 mm), 
isolated yields. [b] Enantioselectivities determined by chiral HPLC. [c] Performed by Dr. C. 
Tian.  [d] 20 h. [e] 38a (2.0 equiv). [f] Under N2. [g] Without electricity. [h] No palladium. 
3.7.2. Substrate Scope of Atroposelective Electrocatalyzed C–H Olefination 
 
With the optimized reaction conditions in hand, we explored the generality of the 
enantioselective palladaelectro-catalysis (Table 28). First, electron-rich and electron-deficient 
racemic biaryls 73 were tested. To our delight, all the corresponding axially chiral compounds 
74 were formed with good yields and in excellent enantioselectivities, reflecting very little 









3. Results and Discussion 
 
149 
Table 28. Atroposelective electro-catalyzed C–H olefination of biaryls 73.[a] 
 




























[a] Reaction conditions: Undivided cell, 73 (0.20 mmol), 38a (0.60 mmol), Pd(OAc)2 (10 mol 
%), L-tert-Leucine (20 mol %), LiOAc (2.0 equiv), AcOH (4.5 mL), 60 °C, constant current at 
1.0 mA, 20 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), isolated yields. [b] Enantioselectivities determined by chiral HPLC. [c] Performed 
by J. Hao. 
 
Second, a broad range of alkene coupling partners was investigated under our optimized 
electrochemical conditions (Table 29). α,β-Unsaturated olefins 38 served as particularly 
effective coupling partners in this reaction conditions. Vinyl sulfone 38b and vinyl 
phosphonate 38c were efficiently installed through atroposelective C–H activation in moderate 
to good yields and in excellent enantioselectivities (entries 1-2). Notably, methyl vinyl ketone 
38d was also compatible, delivering the olefinated product 74bd in high enantioselectivity 
(entry 3). To our delight, various sensitive functional groups, like fluoro- (38f), bromo- (38g), 
nitro- (38h) and carbonyl (38i) substituents, on the arene were well tolerated, which should 
prove invaluable for further late stage modifications. In contrast, alkenes containing bromo- 
(38j) or nitro- (38h) groups exhibited lower reactivity to deliver the corresponding products 
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(entries 4-8). Remarkably, acrylamide (38j) was also compatible with our robust catalyst to 
furnish the axially-chiral biaryl 74bj with very high levels of enantio-induction (entry 9). 
Table 29. Atroposelective palladaelectro-catalysis with alkenes 38.[a] 
 












































[a] Reaction conditions: Undivided cell, 73 (0.20 mmol), 38 (0.60 mmol), Pd(OAc)2 (10 mol 
%), L-tert-Leucine (20 mol %), LiOAc (2.0 equiv), AcOH (4.5 mL), 60 °C, constant current at 
1.0 mA, 20 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 15 mm × 
0.25 mm), isolated yields. [b] Enantioselectivities determined by chiral HPLC. 
 
We were pleased to observe that the palladaelectro-catalysis was not only limited to the 
conversion of racemic biaryls 73. Indeed, the electrocatalysis also set the stage for the synthesis 
of N–C axially-chiral motifs[92a, 93] (Table 30). To improve the conversion, a slightly higher 
loading of TDG was employed for the synthesis of axially chiral N–C scaffold 397 and 398. 
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To demonstrate the generality of our transformation, we tested the scope of olefin coupling 
partners with N-aryl pyrrole 396 as the model substrate. Thus, N–C axially-chiral N-aryl 
pyrroles 397 and 398 were obtained under the electrochemical conditions in a site- and highly 
enantio-selective fashion (entry 1). Other than α,β-unsaturated olefins, perfluoroalkylalkenes 
301a and 301c were also compatible to enable unprecedented C–H perfluoroalkenylations 
(entries 2-3). Thus, this protocol provided a highly enantioselective strategy to deliver 
synthetically useful axially-chiral fluorinated heterobiaryls 398aa and 398ac in moderate to 
good yields. Similarly, vinyl phosphonate (38c), vinyl sulfone (38b) and cholesterol derivative 
(38k) were also identified as suitable coupling partners for the synthesis of versatile N–C 
axially chiral scaffolds with high levels of enantio-induction (entries 4-6). 
 
Table 30. Atroposelective palladaelectro-catalyzed C–H olefination of N-aryl pyrroles.[a] 
 
































[a] Reaction conditions: Undivided cell, 396 (0.20 mmol), 38/301 (0.60 mmol), Pd(OAc)2 (10 
mol %), L-tert-Leucine (30 mol %), LiOAc (2.0 equiv), AcOH (4.5 mL), 60 °C, constant 
current at 1.0 mA, 20 h, GF anode (10 mm × 15 mm × 6 mm), Pt-plate cathode (10 mm × 
15 mm × 0.25 mm), isolated yields. [b] Enantioselectivities determined by chiral HPLC. [c] 
Performed by J. Hao. 
3.7.3. Mechanistic Studies 
 
After establishing a broad scope for the first atroposelective pallada-electrocatalyzed C–H 
activation, detailed experimental and computational mechanistic studies were performed to 
gain insights into its mode of action. 
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3.7.3.1. H/D Scrambling and KIE Studies 
 
First, a H/D exchange experiment was conducted using AcOD as the solvent (Scheme 124a). 
We did not observe a H/D scrambling neither in the product 74aa nor in the recovered starting 
material 73a. Second, a KIE was studied by two independent reactions with isotopically labeled 
compound [D]5-73g, which showed a KIE of kH/kD ≈ 1.8 (Scheme 124b). These findings from 
H/D scrambling experiments and KIE experiments suggests the C–H cleavage step is the rate-
determining step.  






Scheme 124. H/D scrambling and KIE studies for the pallada-electrocatalysis. 




3.7.3.2. Non-Linear Effect Studies 
 
To gain insights into the ligand-to-metal ratio in the atroposelective pallada-electrocatalysis, 
the effect of the enantiomeric excess of L-tert-Leucine on the enantiomeric induction of the 
electrochemical transformation was studied (Scheme 125). Here, we did not observe a non-
linear effect (NLE), which excludes a multi-ligand containing catalyst or oligomeric species, 
instead it is indicative of the enantio-determining step involving a metal to ligand ratio of 1:1. 
























ee of the ligand
 
Scheme 125. Non-linear effect studies for the pallada-electrocatalysis. 
3.7.4. Product Diversification 
As previously described axially chiral compounds are very important building blocks,[278-280] 
thus the synthetic value of the palladium-catalyzed electrochemical C–H olefination was 
demonstrated by the late-stage diversification of thus-obtained highly enantiomerically-
enriched biaryls (Scheme 126-128). In this context, straightforward asymmetric synthesis of 
enantiopure helicenes are in high demand.[282] To this end, we performed a kinetic resolution 
on conformationally stable aldehyde 73h under otherwise optimal reaction conditions. The 
desired olefinated product 74ha was obtained with 95% ee. Then, the addition of K2OsO4 and 
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NaIO4 enabled the preparation of dialdeyde 399 in high yield by oxidative double bond 
cleavage. Subsequently, a Wittig reaction and a catalyzed olefin- metathesis provided the 
highly enantioenriched [5]-helicine 401 in overall good yield and in excellent optical yield 
(Scheme 126). Likewise, a similar strategy was followed for the synthesis of chiral [6]-helicine 
starting from conformationally stable aldehyde 73i. Here [6]-helicene 403 was obtained in 
overall high yield and enantioselectivity (Scheme 127). In addition, the recovered starting 
material 73i, after the kinetic resolution, was treated under the optimized reaction conditions 
using D-tert-Leucine as the TDG. Subsequently, the opposite enantiomer of the olefinated 
product 74ia was obtained which can be converted to the opposite enantiomer ent-[6]-helicine 
403 following the same path. Furthermore, the synthetic utility of our method was reflected by 
the synthesis of chiral dicarboxylic acid 404 and chiral BINOL 405 (Scheme 128). Dialdehyde 
402 was treated under Pinnick oxidation conditions, delivering the dicarboxylic acid 404 while 
Baeyer-Villiger-oxidation gave the chiral BINOL 405. These new chiral molecules should find 
various applications as ligands for asymmetric catalysis. 




Scheme 126. Synthesis of enantioenriched [5]-helicine. 




Scheme 127. Synthesis of enantioenriched [6]-helicine. 




Scheme 128. Late-stage diversification to chiral diacid and substituted BINOL. 
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4. Summary and Outlook 
 
The advent of new synthetic strategies has enriched the synthetic organic chemistry to access 
molecules with tremendous complexity. In this context, transition metal-catalyzed C−H 
activation has emerged as a powerful tool for highly step- and atom- economical synthesis that 
avoids laborious prefunctionalizations of starting materials.[27, 56]  In this thesis, the primary 
focus was the development of novel and sustainable methods by direct C−H activation to 
synthesize value-added synthetic targets of biological importance. 
 
In the first project, the unprecedented use of a manganese(I) complex was demonstrated for 
challenging C−F/C−H functionalizations (Scheme 129).[283] Robust reaction conditions and 
ample substrate scope are some of the key characteristics of this approach. This method proved 
to be viable for synthetically meaningful ketimines. Thus, versatile manganese(I)-catalyzed 
C−F/C−H functionalization allowed for the synthesis of diverse fluorinated scaffolds. In 
addition to allylations and alkenylations, we also identified the potential of manganese catalysis 
in C−H perfluoroalkenylation using challenging perfluoroalkenes. It is noteworthy that even 




Scheme 129. Manganese(I)-catalyzed C−F/C−H functionalizations. 
In the second project, the versatility of ruthenium catalysis was shown towards C–F/C–H 
functionalization (Scheme 130).[284] Previously our group reported on the ruthenium-catalyzed 
C–H hydroarylations with unactivated alkenes and perfluoroalkenes. In the present method, by 
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the judicious choice of a tertiary phosphine ligand, a switch in chemoselectivity was observed 
towards challenging C–F functionalization. More pleasingly, ketimines were found as 
amenable substrates for the envisioned C–F/C–H functionalization to synthesis fluorinated 
ketones by a one-pot hydrolysis. This approach allowed for highly chemo- and position-
selective β-fluorine eliminations with a broad range of substituted ketimines and 
perfluoroalkenes. Considering the importance of fluorinated building blocks, these studies are 
expected to inspire related developments in the field of transition metal catalysis. 
 
Scheme 130. E-selective C–H/C–F functionalization by ruthenium(II) catalysis. 
As with fluorinated scaffolds, chiral molecules represent a class of highly desirable building 
blocks. Thus, the next part of the thesis focused on the development of sustainable 
enantioselective transformations using cost-effective transition metals. In the third project, we 
developed a novel chiral carboxylic acid CA5 to realize the first cobalt(III)-catalyzed 
enantioselective C–H activation (Scheme 131).[270] Initial studies with commonly used mono 
protected amino acids and chiral phosphoric acids failed to provide high levels of 
enantiocontrol. In contrast, the design of novel chiral carboxylic acid CA5 enabled the first 
highly enantioselective cobalt(III)-catalyzed C–H alkylation with unactivated alkenes 223 by 
organometallic chelation assisted C–H activation. The mild Grignard-free reaction conditions 
tolerated a wide array of sensitive functional groups on the indoles 354 as well as on the alkene 
coupling partners 223. Moreover, the directing groups were removed in a traceless fashion 
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under hydrogenation conditions without any erosion of the enantiomeric excess. Detailed 
mechanistic studies by kinetic experiments and non-linear effect studies provided evidence for 
dimeric hydrogen bond stabilized resting state of the chiral carboxylic acid. This study on co-
operative cobalt(III)/chiral acid manifold set the stage for subsequent developments in the 
enantioselective cobalt(III)-catalyzed C–H activation, as further reports were documented by 
Matsunaga[271a] and Cramer.[285] 
 
Scheme 131. Enantioselective cobalt(III)-catalyzed C–H alkylation by chiral carboxylic acid 
cooperation. 
Thereafter, we became interested in the development of ruthenium-catalyzed enantioselective 
organometallic C−H activation with the combination of a chiral acid. In contrast to the 
significant advances in the ruthenium catalyzed C−H activation, organometallic 
enantioselective transformations remain largely underdeveloped. In this project we succeeded 
to achieve enantioselective ruthenium-catalyzed organometallic C−H alkylation, employing a 
C2 symmetrical chiral acid CA14 to control the enantio-induction (Scheme 132).[286] Cost-
effective and bench-stable [RuCl2(p-cymene)]2 was successfully employed with a chiral 
carboxylic acid to synthesis enantioenriched tetrahydrocarbazoles and cyclohepta[b]indoles 
derivatives by intramolecular cyclization at room temperature. C2-symmetric chiral acid was 
found to be crucial for enantioselective intramolecular C−H alkylation while other commonly 
used chiral acids failed in this protocol. Detailed kinetic and DFT studies unraveled a reversible 
C−H metalation step and an enantio-determining proto-demetalation step by the chiral acid. 
DFT studies provided support for the presence of weak secondary dispersive interactions to 
control enantio-induction. 





Scheme 132. Enantioselective ruthenium-catalyzed organometallic C−H alkylation 
Resource-economy is another important aspect in molecular syntheses.[224] Consequently, a 
large portion of the doctoral thesis was focused on addressing improved sustainability and 
resource-economy for the activation of inert C–H bonds. Over the past years, early examples 
of electrochemical C−H activations were largely restricted to the use of palladium. In 2017, 
Ackermann realized the first electrochemical 3d transition metal-catalyzed C−H activation 
using inexpensive cobalt as a catalyst for oxygenation reactions,[246] which has set the stage for 
the development of electrochemical transformations with Earth-abundant transition metals.[232] 
In the fifth project, we realized electrochemical copper-catalyzed sequential alkyne annulations 
with benzamides to synthesis isoindolone motifs 256 in the absence of any chemical oxidants 
(Scheme 133).[287] Inexpensive Cu(OAc)2 was employed as the catalyst for the electrooxidative 
alkynylation protocol by the assistance of 8-aminoquinoline as the directing group. 
Furthermore, our reaction conditions were found to be suitable for the decarboxylative C–H/ 
C–C cleavage with alkynyl carboxylic acids. This study showed the unique potential of copper 
catalysts in electrochemical transformations, which is expected to inspire related developments 
in the near future. 




Scheme 133. Copper-catalyzed electrochemical alkyne annulation. 
 
Thus far, all the reported electrochemical transformations with precious 4d and 5d transition 
metals were limited to activated alkenes, such as styrenes and acrylates. In the subsequent 
project, we showed the versatility of oxidative cobalt catalysis in electrocatalytic C−H 
allylations with unbiased olefins (Scheme 134).[288] A key characteristic of our strategy was the 
use of the biomass-derived solvent -valerolactone as the reaction media. Electro-oxidative 
cobalt catalysis provided the chelation-assisted ortho-C−H allylation by the assistance of 8-
aminoquinoline as the directing group, generating molecular hydrogen as the sole 
stoichiometric by-product. A plethora of sensitive functional groups were fully tolerated, 
providing exclusively the allylic selectivity. Competition experiment provided evidence for a 
base-assisted internal electrophilic-type substitution mechanism for the C–H metalation event. 
This turns out to be one of the scarce example for the application of unactivated olefins in 
electrochemical C−H activation reactions.  





Scheme 134. Cobalt-catalyzed electrochemical C−H allylation 
The merger of electrosynthesis with transition metal catalysis provides enormous potential 
towards perfect resource economy. Despite substantial progress, enantioselective 
metallaelectro-catalyzed C–H activation was not realized before. To address the full potential 
of electrochemistry and considering practical importance of chiral building blocks, we 
achieved the first asymmetric metallaelectro-catalyzed C–H activation under exceedingly mild 
reaction conditions (Scheme 135).[289] We employed inexpensive L-tert-leucine as a transient 
directing group to enable electrochemical atroposelective organometallic C–H activation. This 
was the unprecedented report for the application of transient directing group in electrochemical 
transformations. The combination of Pd(OAc)2 and L-tert-leucine provided excellent 
enantioselectivities for the atroposelective olefination reactions to furnish  axially-chiral 
biaryls. On a pleasing note, similar reaction conditions were also effective for the synthesis of 
N−C axially-chiral motifs in excellent enantioselectivities. Detailed kinetic studies shed light 
on the C−H metalation step, being suggestive of the C–H activation as the rate-determining 
step. In addition, DFT studies showed preference for the formation of seven membered ring 
over the five-membered metallacycle to enable the axial chirality. This metallaelectro-
catalyzed enantioselective protocol provided a step-economical strategy to the synthesis of 
highly enantio-enriched BINOLs, dicarboxylic acids and helicenes. Given the topical interest 
in the development of new approach for enantioselective transformations, this sustainable 
protocol paves the path for further developments in this research area. 
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5. Experimental Part 
5.1. General Remarks 
All reactions involving air- and/or moisture-sensitive compounds were conducted under a dry 
nitrogen atmosphere using pre-dried glassware and standard Schlenk techniques. If not 
otherwise noted, yields refer to isolated compounds which were estimated to be >95% pure 
based on 1H-NMR. 
Vacuum 
The following average pressure was measured on the used rotary vane pump RD4 from 
Vacuubrand®: 0.8∙10–1 mbar (uncorrected value). 
Melting Points  
Melting points were measured on a Stuart® Melting Point Apparatus SMP3 from Barloworld 
Scientific. Values are uncorrected. 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 aluminium 
sheets from Merck. Plates were either visualized under irradiation at 254 nm or 365 nm or 
developed by treatment with a potassium permanganate solution followed by careful warming. 
Chromatographic purifications were accomplished by column chromatography on Merck 
Geduran® silica gel, grade 60 (40–63 μm, 70–230 mesh ASTM). 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with two 
sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; 
internal diameter = 20 mm; length = 600 mm; Flush rate = 10.0 mL/min and chloroform 
(HPLC-quality with 0.6% ethanol as stabilizer) was used as the eluent. 
Infrared Spectroscopy  
IR spectra were recorded using a Bruker® Alpha-P ATR spectrometer. Liquid samples were 
measured as film and solid samples neat. Spectra were recorded in the range from 4000 to 400 
cm–1. Analysis of the spectral data was carried out using Opus 6. Absorption is given in wave 
numbers (cm–1). 
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Nuclear Magnetic Resonance Spectroscopy  
NMR spectra were recorded on Mercury Plus 300, VNMRS 300, Inova 500 and 600 from 
Varian®, or Avance 300, Avance III 300 and 400, Avance III HD 400 and 500 from Bruker®. 
Chemical shifts are reported in δ-values in ppm relative to the residual proton peak or carbon 
peak of the deuterated solvent. 
The coupling constants J are reported in hertz (Hz). Analysis of the recorded spectra was 
carried out using MestReNova 10.0 software. 
 1H-NMR 13C-NMR 
CDCl3 7.26 77.16 
CD3CO2D 11.65 179.0 
 
Gas Chromatography  
Monitoring of reaction process via gas chromatography or coupled gas chromatography-mass 
spectrometry was performed using a 7890 GC-system with/without mass detector 5975C 
(Triple-Axis-Detector) or a 7890B GC-system coupled with a 5977A mass detector, both from 
Agilent Technologies®. 
Mass Spectrometry  
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were measured on a 
time-of-flight mass spectrometer AccuTOF from JEOL. Electrospray ionization (ESI) mass 
spectra were recorded on an Io-Trap mass spectrometer LCQ from Finnigan, a quadrupole 
time-of-flight maXis from Bruker Daltonic or on a time-of-flight mass spectrometer microTOF 
from Bruker Daltonic. ESI-HR-MS spectra were recorded on a Bruker Apex IV or Bruker 
Daltonic 7T, Fourier transform ion cyclotron resonance (FTICR) mass spectrometer. The ratios 
of mass to charge (m/z) are indicated, intensities relative to the base peak (I = 100) are written 
in parentheses. 
Chiral HPLC  
Chiral HPLC chromatograms were recorded on an Agilent 1290 Infinity using CHIRALPAK® 
IA-3, IB-3, IC-3, ID-3, IE-3 and IF-3 columns (3.0 μm particle size; ø: 4.6 mm and 250 mm 
length) at ambient temperature. 
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Specific Rotations  
Optical rotations were measured on an Anton Paar MCP 150 polarimeter using a 10 cm cell 
with a Na 589 nm filter. Concentrations are indicated in g/100 mL. 
Solvents  
All solvents for reactions involving air- and/or moisture-sensitive reagents were dried, distilled 
and stored under an inert atmosphere (dry nitrogen) according to the following standard 
procedures. 
1,2-Dichloroethane (DCE) and toluene (PhMe) were dried over CaH2 for 8 h, degassed and 
distilled under reduced pressure. 1,4-Dioxane and di-n-butylether (nBu2O) were dried over Na 
for 8 h, degassed and distilled under reduced pressure.  
CH2Cl2, DMF, THF, Et2O  were obtained from a MBRAUN MB SPS-800 solvent purification 
system.  
Chemicals  
Chemicals obtained from commercial sources with a purity >95% were used as received 
without further purification. 
The following compounds were known from the literature and synthesized according to 
previously known methods: Indoles 315 and 354[290] and 362,[291], ketimines 340[292], 
Benzamides 229[293], Biaryl aldehydes 73.[89] 
The following compounds were kindly synthesized and provided by the persons listed below:  
Karsten Rauch: IMes·HCl, IPr·HCl, [RuCl2(p-cymene)]2, [Cp*RhCl2]2, dry and/or degassed 
solvents (DCE, tAmOH, 1,4-dioxane, PhMe).  
Dr. Daniel Zell: Indole 354e.  
Valentine Müller: gem-Difluorostyrene 11a. 
Dr. Fabio Pesciaioli: Chiral acid CA5.  
Dr. Cong Tian: Benzamide 229d. 
Nikolaos Kaplaneris: Indole 328a-328c, Alkene 38e-38j and 38k, 255m, Ligand CA2 and 
CA8. 
Rongxin Yin: Indole 354b-354c, ketimine 340f.  
Julia Struwe: 2-Phenyl pyridines 93b. 
Becky Bongsuiru Jei: Chiral acid CA13 and CA15.  
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5.2. General Procedures 
5.2.1. General Procedure A: Manganese(I)-Catalyzed Allylative C−H/C–F 
Functionalization  
A suspension of heteroarene 315 (0.50 mmol, 1.00 equiv), 1H,1H,2H-perfluoroalkene 301 
(0.60 mmol, 1.20 equiv), [MnBr(CO)5] (10.3 mg, 7.5 mol %) and K2CO3 (69.1 mg, 
0.50 mmol, 1.00 equiv) in 1,4-dioxane (0.50 mL, 1.00 M) was stirred at 80 °C for 20 h. At 
ambient temperature, the mixture was diluted with EtOAc (3.0 mL) and the solvents were 
removed in vacuo and the remaining residue was purified by column chromatography on silica 
gel to afford the desired products 316. 
5.2.2. General Procedure B: Manganese(I)-Catalyzed C−H/C–F Functionalization of 
Heteroarenes with Perfluoroalkenes 
A suspension of heteroarene 315/328/332 (0.50 mmol, 1.00 equiv), perfluoroalkene 303 
(1.50 mmol, 3.00 equiv), [MnBr(CO)5] (13.7 mg, 10.0 mol %) and K2CO3 (69.0 mg, 
0.50 mmol, 1.00 equiv) in 1,4-dioxane (0.50 mL, 1.00 M) was stirred at 100 °C for 20 h. At 
ambient temperature, the solvent was removed in vacuo and the remaining residue was purified 
by column chromatography on silica gel to afford the desired products 328/331/333. 
5.2.3. General Procedure C: Ruthenium(II)-Catalyzed C–F/C–H Functionalization 
A suspension of ketimine 340 (0.50 mmol, 1.0 equiv), 1H,1H,2H-perfluoroalkene 301 
(1.50 mmol, 3.0 equiv), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), P(4-C6H4F)3 (31.6 mg, 
20 mol %) and K3PO4 (212 mg, 1.0 mmol, 2.0 equiv) in cyclohexane (1.0 mL) was stirred 
under N2 at 120 °C for 24 h in pressure tube. At ambient temperature, the reaction mixture was 
diluted with EtOAc (5.0 mL) and HCl (5.0 mL, 1 M) was added. The mixture was stirred for 3 
h and extracted with EtOAc (3 x 10.0 mL). After removal of the solvents in vacuo, the 
remaining residue was purified by column chromatography on silica gel to afford the desired 
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5.2.4. General Procedure D: Synthesis of the chiral acid CA5-CA7 and CA10-CA14.  
 
To a solution of (S,S)-diphenylethanediamine (212.3 mg, 1.00 mmol) in CH2Cl2 (4.0 mL) was 
added an equimolar amount of glyoxylic acid monohydrate (92.1 mg, 1.00 mmol) under 
vigorous stirring. After 16 h, the solvent was removed to afford (4S,5S)-4,5-
diphenylimidazolidine-2- carboxylic acid 408 (265.3 mg, 99% yield) as a yellow solid.  
To a solution of 408 in THF/H2O (5 mL, 1:1) at 0 °C, NaHCO3 (252 mg, 3.00 mmol) and acyl 
chloride (2.10 mmol, 2.1 equiv) were added, and the reaction was allowed to reach ambient 
temperature. After 16 h, the reaction mixture was diluted with CH2Cl2 (10 mL) and washed 
with HCl (1 M, 10 mL) solution. The aqueous phase was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic phase was washed with brine and dried over Na2SO4 and the solvent 
was removed under vacuum. The crude mixture was purified via flash chromatography (CH2Cl2 
100% to CH2Cl2:CH3OH = 90:10) to afford chiral acids CA5-CA7 and CA10-CA14. 
5.2.5. General Procedure E: Cobalt(III)-Catalyzed Asymmetric C−H Alkylation  
A suspension of indole 354 (0.50 mmol, 1.00 equiv), alkene 223 (1.50 mmol, 3.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %), AgSbF6 (34.4 mg, 100 µmol, 20.0 mol %), 
chiral acid CA5 (48.0 mg, 100 µmol, 20.0 mol %) and Amberlyst 15 (160 mg, 1.50 equiv) in 
DCE (0.5 mL, 1.0 M) were stirred at 50 °C for 65 h. At ambient temperature, the reaction 
mixture was diluted with EtOAc (2.0 mL) and Et3N (0.5 mL) was added. The mixture was 
stirred for 0.5 h and filtered through a short pad of silica and the solvents were removed in 
vacuo. The crude mixture was purified by flash column chromatography on silica gel to afford 
the desired product 355.  
5.2.6. General Procedure F: Synthesis of Racemic Products for Cobalt(III)-Catalyzed 
C−H Alkylation 
A suspension of indole 354 (0.50 mmol, 1.00 equiv), alkene 223 (1.50 mmol, 3.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %), AgSbF6 (34.4 mg, 100 µmol, 20.0 mol %), 
1-AdCO2H (48.0 mg, 100 µmol, 20.0 mol %) in DCE (0.5 mL, 1.0 M) were stirred at 50 °C for 
20 h. At ambient temperature, the reaction mixture was diluted with EtOAc (2.0 mL) and the 
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solvents were removed in vacuo. The crude mixture was purified by flash column 
chromatography on silica gel to afford the racemic product 355.  
5.2.7. General Procedure G: Traceless Removable of Directing Group for Cobalt(III)-
Catalyzed C−H Alkylated Products 
To a solution of 355 (0.2 mmol, 1.00 equiv) in CH2Cl2 (0.5 mL) was added MeOTf (36.1 mg, 
1.10 equiv) dropwise at 0 °C. After 30 min, the mixture was allowed to warm up to 25 °C and 
stirred for 6 h. After removal of the solvent in vacuo, Pd(OH)2/C (7.7 mg, 10 wt.-%) and 
ammonium formate (126 mg, 2.00 mmol, 10.0 equiv) were added. The mixture was diluted 
with MeOH (1.0 mL) and stirred at 60 °C for 6 h. After addition of EtOAc (5.0 mL) at ambient 
temperature, the mixture was filtered through a short pad of celite® and the solvents were 
removed in vacuo. The crude mixture was purified by flash column chromatography on silica 
gel to yield 357. 
5.2.8. General Procedure H: Ruthenium(II)-Catalyzed Asymmetric C−H Alkylation for 
the Synthesis of Tetrahydrocarbazoles 
A suspension of indole 362 (0.25 mmol, 1.00 equiv), [RuCl2(p-cymene)]2 (7.7 mg, 5.0 mol %), 
AgSbF6 (17.2 mg, 20 mol %), chiral acid CA14 (25.2 mg, 20 mol %) in PhMe (0.50 mL) were 
stirred at 25 °C for 12 h. The reaction mixture was diluted with EtOAc (2.0 mL) and the solvent 
was removed in vacuo. The crude mixture was purified by column chromatography on silica 
gel to afford the desired product 363.  
5.2.9. General Procedure I: Synthesis of Racemic Products for Ruthenium(II)-Catalyzed 
C−H Alkylation 
A suspension of indole 362 (0.10 mmol, 1.00 equiv), [RuCl2(p-cymene)]2 (3.1 mg, 5.0 mol %), 
AgSbF6 (6.9 mg, 100 µmol, 20 mol %), 1-AdCO2H (18.0 mg, 1 equiv) in PhMe (0.50 mL) 
were stirred at 50 °C for 12 h. At ambient temperature, the reaction mixture was diluted with 
EtOAc (2.0 mL) and the solvents were removed in vacuo. The crude mixture was purified by 
column chromatography on silica gel to afford the racemic products rac-363. 
5.2.10. General Procedure J: Copper-catalyzed Alkyne Annulation by C–H Alkynylation 
The electrocatalysis was carried out in an undivided cell, with a RVC anode (10 mm × 15 mm 
× 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). Benzamide 229 (0.25 mmol, 
1.0 equiv), alkyne 255 (0.50 mmol, 2.0 equiv), NaOPiv (31 mg, 0.25 mmol, 1.0 equiv) and 
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Cu(OAc)2∙H2O (2.5 mg, 5.0 mol %) were placed in a 10 mL cell and dissolved in DMA (4.0 
mL). Electrocatalysis was performed at 100 °C with a constant current of 6.0 mA maintained 
for 6 h. At ambient temperature, saturated aqueous NaHCO3 (4.0 mL) was added. The RVC 
anode was washed with EtOAc (3 × 10 mL) in an ultrasonic bath. The washings were added to 
the reaction mixture and the combined phases were extracted with EtOAc (4 × 10 mL), then 
dried over Na2SO4. Evaporation of the solvent and subsequent column chromatography on 
silica gel afforded the corresponding products 256. 
5.2.11. General Procedure K: Cobaltaelectro-Catalyzed C–H Allylation 
The electrolysis was carried out in an undivided cell with a GF anode (10 mm × 15 mm × 6 
mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). Co(OAc)2∙4H2O (12.7 mg, 0.05 
mmol, 10 mol %), NaOPiv (124.0 mg, 1.0 mmol, 2.0 equiv), n-Bu4NPF6 (97.0 mg, 0.25 mmol, 
0.50 equiv) and benzamide 229 (0.50 mmol, 1.0 equiv) were dissolved in GVL (4.0 mL) and 
the alkene 223 (1.5 mmol, 3.0 equiv) was added sequentially. At 100 °C, electrolysis was 
conducted with a constant current of 4.0 mA for 14 h. The mixture was transferred to a flask 
and the electrodes were rinsed with acetone (3 × 5.0 mL). Then the combined solvent was 
removed under reduced pressure, the residue was diluted with EtOAc (10 mL) and stirred with 
NaOH (aq) (2 M, 20 mL) for 2 h. The mixture was extracted with water (3 × 20 mL) and 
successively with EtOAc (3 × 20 mL), then the organic layer was dried over Na2SO4. After 
evaporation of the solvent under vacuo, subsequent column chromatography on silica gel (n-
hexane/EtOAc) yielded the desired product 242. 
5.2.12. General Procedure L: Atroposelective Palladaelectro-catalyzed C–H Olefination 
The electrocatalysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm × 
6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). Biaryls 73 or 396 (0.20 mmol, 
1.0 equiv), acrylates 38 (0.60 mmol, 3 equiv), Pd(OAc)2 (4.49 mg, 10 mol %), L-tert-leucine 
(5.24 mg, 20  %) and LiOAc (26.4 mg, 2 equiv) were placed in a 10 mL cell and dissolved in 
AcOH (4.5 mL). Electrocatalysis was performed at 60 °C with a constant current of 1.0 mA 
maintained for 20 h. At ambient temperature, the reaction mixture was diluted with EtOAc. 
The GF anode was washed with EtOAc (3 × 10 mL) in an ultrasonic bath. The combined 
washings were added to the reaction mixture and the solvents were removed in vacuo. The 
crude mixture was purified by column chromatography on silica gel to yield 74 or 397. 
5.2.13. General Procedure M: General Procedure for the Synthesis of Racemic Products  
The racemic compounds were prepared using rac-D/L-valine as the transient directing groups 
instead of L-tert-leucine, following the general procedure L. 
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5.3. Manganese(I)-Catalyzed Allylative C−H/C–F Functionalization 
5.3.1. Characterization Data 
 
 
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole (316aa): The general 
procedure A was followed using 1-(pyridin-2-yl)-1H-indole (315a) (97.1 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (301a) (268 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10:1) yielded 316aa (301 mg, 97%, Z/E = 90:10) as a 
yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (ddd, J = 7.9, 7.6, 
1.9 Hz, 1H), 7.61 (ddd, J = 6.4, 4.9, 1.9 Hz, 1H), 7.41 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.38 
(ddd, J = 7.4, 4.3, 2.6 Hz, 1H), 7.31 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 7.25−7.12 (m, 2H), 6.50 
(dd, J = 0.9, 0.9 Hz, 1H), 6.16 (dt, J = 22.3, 8.1 Hz, 0.10H, E), 5.82 (dt, J = 33.0, 7.5 Hz, 0.90H, 
Z), 3.90 (ddt, J = 7.5, 4.2, 1.8 Hz, 1.80H, Z), 3.84 (ddt, J = 8.1, 4.5, 1.8 Hz, 0.20H, E).  
13C-NMR (125 MHz, CDCl3): δ = 150.8 (Cq), 149.6 (CH), 146.1 (dt, 1JC‒F = 261 Hz, 2JC‒F = 
29.1 Hz, Cq), 138.3 (CH), 137.1 (Cq), 136.1 (Cq), 128.3 (Cq), 122.4 (CH), 122.1 (CH), 121.0 
(CH), 120.5 (CH), 120.0 (CH), 117.0 (dt, 1JC–F = 288 Hz, 2JC–F = 31.3 Hz, Cq), 113.3 (td, 2JC‒F 
= 8.1 Hz, 3JC−F = 4.2 Hz, CH), 112.4 (m, Cq), 110.9 (m, Cq), 110.7 (m, Cq), 110.5 (m, Cq), 108.6 
(m, Cq), 108.3 (m, Cq), 110.1 (CH), 106.7 (CH), 22.7 (d, 3JC‒F = 4.3 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ  = –80.9 (m), –115.0 (m), –117.5 (m), –122.0 (m), –122.8 (m), 
–123.0 (m), –126.3 (m), –130.8 (m).  
IR (ATR): 3061, 1589, 1472, 1455, 1439, 1197, 1107, 736 cm–1.  
MS (ESI) m/z (relative intensity): 643 ([M + Na+], 20), 621 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C23H12F16N2 + H]+ 621.0818, found 621.0809.  
  
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-fluoro-1-(pyridin-2-yl)-1H-indole (316ba): 
The general procedure A was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (315b) 
(106 mg, 0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (301a) (268 mg, 0.60 mmol). 
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Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 316ba (271 mg, 85%, 
Z/E = 90:10) as a white solid. M.p.: 95 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.88 (ddd, J = 7.7, 7.5, 
2.0 Hz, 1H), 7.43 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.32 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 7.27 (dd, 
J = 8.9, 4.4 Hz, 1H), 7.25–7.21 (m, 1H), 6.90 (dt, J = 9.1, 2.6 Hz, 1H), 6.44 (d, J = 0.9 Hz, 1H), 
6.12 (dt, J = 22.2, 8.2 Hz, 0.10H, E), 5.78 (dt, J = 32.6, 7.5 Hz, 0.90H, Z), 3.85 (ddt, J = 7.7, 
3.9, 2.0 Hz, 1.80H, Z), 3.80 (ddt, 7.7, 4.1, 1.9 Hz, 0.20H, E).  
13C-NMR (125 MHz, CDCl3): δ = 158.5 (d, 1JC‒F = 236 Hz, Cq), 150.7 (Cq), 149.8 (CH), 146.2 
(dt, 1JC‒F = 261, 2JC‒F = 29.0 Hz, Cq), 138.6 (CH), 137.7 (Cq), 133.7 (Cq), 128.8 (d, 3JC‒F = 10.3 
Hz, Cq), 122.4 (CH), 120.4 (CH), 117.2 (dt, 1JC–F = 285 Hz, 2JC–F = 33.3 Hz, Cq), 113.7 (m, Cq), 
113.0 (dt, 2JC‒F  = 8.5 Hz, 3JC‒F  = 4.4 Hz, CH), 112.4 (m, Cq), 110.9 (d, 2JC‒F = 9.5 Hz, CH), 
110.5 (d, 2JC‒F = 26.0 Hz, CH), 110.4 (m, Cq), 110.0 (m, Cq), 108.6 (m, Cq), 108.2 (m, Cq), 
105.4 (d, 2JC‒F = 23.7 Hz, CH), 103.5 (d, 3JC‒F = 4.3 Hz, CH), 22.7 (d, 3JC‒F = 4.3 Hz, CH2).  
19F-NMR (470 MHz, CDCl3): δ = –81.0 (m), –117.6 (m), –122.1 (m), –122.9 (m), – 123.0 (m) 
– 123.4 (m), –123.5 (m), – 126.3 (m), –130.5 (m).  
IR (ATR): 1473, 1450, 1439, 1235, 1143, 776, 663 cm–1.  
MS (ESI) m/z (relative intensity): 661 ([M + Na]+, 15), 639 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C23H11F17N2 + H]+ 639.0724, found 639.0731. 
  
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-chloro-1-(pyridin-2-yl)-1H-indole (316ca): 
The general procedure A was followed using 5-chloro-1-(pyridin-2-yl)-1H-indole (315c) 
(114 mg, 0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (301a) (268 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10:1) yielded 316ca (303 mg, 93%, 
Z/E = 90:10) as a white solid. M.p.: 95 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.8, 2.0, 0.8 Hz, 1H), 7.94–7.84 (m, 1H), 7.54 
(d, J = 2.0 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 7.33 (dd, J = 7.7, 4.8 Hz, 1H), 7.25 (d, J = 8.7 
Hz, 1H), 7.10 (dd, J = 8.7, 2.1 Hz, 1H), 6.41 (s, 1H), 6.11 (dt, J = 22.2, 8.3 Hz, 0.10H, E), 5.77 
(dt, J = 32.6, 7.1 Hz, 0.90H, Z), 3.85 (ddt, J = 7.5, 4.2, 2.1 Hz, 1.80H, Z), 3.80 (ddt, J = 7.5, 
4.2, 2.1 Hz, 0.20H, E).  
13C-NMR (100 MHz, CDCl3): δ = 150.5 (Cq), 149.8 (CH), 146.4 (dt, 1JC‒F = 261, 2JC‒F  = 29.1 
Hz, Cq), 138.6 (CH), 137.6 (Cq), 135.6 (Cq), 129.3 (Cq), 126.6 (Cq), 122.6 (d, 2JC‒F = 13.5 Hz, 
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CH), 120.6 (CH), 120.5 (CH), 119.8 (CH), 117.1 (dt, 1JC–F = 285 Hz, 2JC–F = 33.3 Hz, Cq), 113.4 
(m, Cq), 112.9 (dt, 2JC‒F = 8.7 Hz, 3JC‒F  = 4.5 Hz, CH), 111.2 (d, 4JC‒F = 2.8 Hz, CH), 110.6 
(m, Cq), 110.2 (m, Cq), 108.6 (m, Cq), 108.2 (m, Cq), 107.9 (m, Cq), 103.1 (CH), 22.7 (d, 3JC‒F 
= 4.4 Hz, CH2).  
19F-NMR (470 MHz, CDCl3): δ = –80.8 (m), –117.5 (m), –122.0 (m), –122.8 (m), –122.9 (m), 
–123.4 (m), –126.1 (m), –130.2 (m).  
IR (ATR): 3069, 1588, 1471, 1235, 1051, 781, 707, 528 cm–1.  
MS (ESI) m/z (relative intensity): 655 ([M + H]+, 100), 621 (15).  
HR-MS (ESI): m/z calcd. for [C23H11ClF16N2 + H]+  655.0428, found 655.0436. 
 
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-methoxy-1-(pyridin-2-yl)-1H-indole (316da): 
The general procedure A was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (315d) 
(112 mg, 0.50 mmol), 1H,1H,2H-perfluoro-1-decene (301a) (268 mg, 0.60 mmol) and NaOAc 
(12.3 mg, 30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 
316da (292 mg, 90%, Z/E = 88:12) as a colorless oil.  
1H-NMR (400 MHz, CDCl3): δ =  8.60 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 7.86 (ddd, J = 7.7, 7.5, 
2.0 Hz, 1H), 7.44 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.32–7.19 (m, 2H), 7.05 (d, J = 2.5 Hz, 1H), 
6.81 (dd, J = 9.0, 2.5 Hz, 1H), 6.40 (d, J = 1.0 Hz, 1H), 6.13 (dt, J = 22.3, 8.2 Hz, 0.12H, E), 
5.79 (dt, J = 32.8, 7.5 Hz, 0.88H, Z), 3.87 (ddt, J = 7.5, 4.0, 2.3 Hz, 2H), 3.84 (s, 3H).   
13C-NMR (75 MHz, CDCl3): δ = 155.1 (Cq), 151.0 (Cq), 149.8 (CH), 146.0 (dt, 1JC‒F = 261 Hz, 
2JC‒F = 29.0 Hz, Cq), 138.5 (CH), 136.6 (Cq), 132.2 (Cq), 128.9 (Cq), 121.9 (CH), 120.2 (CH), 
116.7 (dt, 1JC–F = 285 Hz, 2JC–F = 33.3 Hz, Cq), 113.3 (dt, 2JC‒F  = 8.4 Hz, 3JC‒F  = 4.5 Hz, CH), 
112.1 (CH), 111.8 (m, Cq), 111.0 (CH), 110.7 (m, Cq), 110.2 (m, Cq), 107.7 (m, Cq), 107.2 (m, 
Cq), 106.6 (m, Cq), 103.6 (CH), 102.4 (CH), 55.8 (CH3), 22.8 (d, J = 4.3 Hz, CH2).  
19F-NMR (376 MHz, CDCl3): δ = −80.9 (m), – 117.5 (m), – 122.0(m), –122.8(m), – 122.9 (m), 
– 123.4 (m), –126.2 (m), –130.9 (m).  
IR (ATR): 1474, 1450, 1438, 1237, 1201, 1146, 907, 729, 649 cm–1.  
MS (ESI) m/z (relative intensity): 673 ([M + Na]+, 20), 651 ([M + H]+, 100), 381 (15).  
HR-MS (ESI): m/z calcd. for [C24H14F16N2O + H]+ 651.0923, found 651.0917. 
 





The general procedure A was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole (315e) 
(104 mg, 0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (301a) (268 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 316ea (285 mg, 90%, 
Z/E = 88:12) as a white solid. M.p.: 65 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.8, 1.9, 0.8 Hz, 1H), 7.86 (ddd, J = 8.1, 7.5, 
2.0 Hz, 1H), 7.58–7.53 (m, 1H), 7.45 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.37–7.31 (m, 1H), 7.28 
(ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.19–7.14 (m, 2H), 5.92 (dt, J = 23.2, 7.5 Hz, 0.12H, E), 5.69 
(dt, J = 33.3, 7.4 Hz, 0.88H, Z), 3.86 (ddt, J = 7.5, 3.9, 2.3 Hz, 2H), 2.32 (s, 3H).   
13C-NMR (125 MHz, CDCl3): δ = 151.2 (Cq), 149.7 (CH), 145.3 (dt, 1JC‒F = 261 Hz, 2JC‒F = 
29.0 Hz, Cq),  138.3 (CH), 136.4 (Cq), 131.2 (Cq), 129.3 (Cq), 122.7 (CH), 121.8 (CH), 120.6 
(CH), 120.4 (CH) 118.7 (CH), 116.6 (dt, 1JC–F = 285 Hz, 2JC–F = 33.3 Hz, Cq), 113.9 (dt, 2JC‒F  
= 8.2 Hz, 3JC‒F  = 4.5 Hz, CH), 112.9 (m, Cq), 111.7 (Cq), 110.6 (m, Cq), 110.5 (m, Cq), 110.3 
(m, Cq), 109.9 (CH), 108.7 (m, Cq), 108.2 (m, Cq), 20.4 (d, 3JC‒F = 4.5 Hz, CH2), 8.6 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –80.8 (m), –117.4 (m), –122.1 (m), –122.8 (m), – 122.8 (m), 
– 123.3 (m), –126.1 (m), –131.7 (m).  
IR (ATR): 3066, 1587, 1472, 1147, 906, 728 cm–1.  
MS (ESI) m/z (relative intensity): 657 ([M + Na]+, 15), 635 ([M + H]+, 100), 633 (20).  
HR-MS (ESI): m/z calcd. for [C24H14F16N2 + H]+  635.0974, found 635.0973.  
  
(Z)-Methyl-2-[(1H,1H,2H-Perfluorodec-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole-3-
yl]acetate (316fa): The general procedure A was followed using methyl 2-(1-(pyridin-2-yl)-
1H-indol-3-yl)acetate (315f) (134 mg, 0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (301a) 
(268 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 
316fa (214 mg, 62%, Z/E = 90:10) as a yellow solid. M.p.: 68 °C.  
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1H-NMR (500 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.87 (ddd, J = 7.7, 7.5, 
1.9 Hz, 1H), 7.65 (ddd, J = 8.1, 3.2, 1.7 Hz, 1H), 7.47 (ddd, J = 7.9, 1.0, 0.8 Hz, 1H), 7.40–
7.27 (m, 2H), 7.26–7.15 (m, 2H),  6.04 (dt, J = 22.8, 7.2 Hz, 0.10H, E), 5.77 (dt, J = 33.4, 7.4 
Hz, 0.90H, Z), 3.94 (ddt, J = 7.4, 4.4, 2.2 Hz, 2H), 3.81 (s, 2H), 3.69 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 171.7 (Cq) , 150.7 (Cq), 149.7 (CH), 145.4 (dt, 1JC‒F = 
260 Hz, 2JC‒F = 29.1 Hz, Cq), 138.4 (CH), 136.4 (Cq), 133.4 (d, 4JC‒F = 2.0 Hz, Cq), 128.1 (Cq), 
122.9 (CH), 122.2 (CH), 121.1 (CH), 120.7 (CH), 118.8 (CH), 116.7 (dt, 1JC–F = 282 Hz, 2JC–F 
= 33.0 Hz, Cq), 113.7 (dt, 2JC‒F = 8.1 Hz, 3JC‒F = 4.3 Hz, CH), 112.6 (m, Cq), 112.3 (m, Cq), 
110.1 (CH), 110.7 (m, Cq), 110.4 (m, Cq), 108.7 (Cq), 108.5 (m, Cq), 108.2 (m, Cq), 52.0 (CH3), 
30.1 (CH2), 20.3 (d, 3JC‒F = 4.2 Hz, CH2).  
19F-NMR (376 MHz, CDCl3): 𝛿 = –80.9 (m), –117.5 (m), –122.1 (m), –122.9 (m), – 123.4 (m), 
–124.1 (m), –126.2 (m), –130.4 (m).  
IR (ATR): 1740, 1472, 1439, 1200, 1108, 733, 663 cm–1.  
MS (ESI) m/z (relative intensity): 693 [M + H+], (100).  
HR-MS (ESI): m/z calcd. for [C26H16F16N2O2 + H]+ 693.1029, found 693.1025. 
  
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-3-bromo-1-(pyridin-2-yl)-1H-indole (319aa): A 
modified general procedure A was followed using 3-bromo-1-(pyrimidin-2-yl)-1H-indole 
(318a) (136 mg, 0.50 mmol), 1H,1H,2H-perfluoro-1-decene (301a) (446 mg, 1.00 mmol), 
[MnBr(CO)5] (13.7 mg, 10 mol %) and NaOAc (12.3 mg, 30 mol %). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 319aa (310 mg, 89%, Z/E = 88:12) as a 
colorless oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.89 (ddd, J = 7.7, 7.7, 
2.0 Hz, 1H), 7.64–7.58 (m, 1H), 7.48–7.42 (m, 1H), 7.37–7.32 (m, 2H), 7.27–7.23 (m, 2H), 
5.96 (dt, J = 22.4, 7.3 Hz, 0.12H, E), 5.68 (dt, J = 32.7, 7.3 Hz, 0.88H, Z), 3.98 (ddt, J = 7.5, 
3.9, 2.0 Hz, 2H).   
13C-NMR (125 MHz, CDCl3): δ = 150.2 (d, 4JC‒F = 2.5 Hz, Cq), 149.8 (CH), 145.7 (dt, 1JC‒F = 
261 Hz, 2JC‒F  = 29.1 Hz, Cq), 138.4 (CH), 135.9 (d, 3JC‒F = 8.8 Hz, Cq), 132.8 (d, 4JC‒F = 
2.0 Hz, Cq), 127.2 (Cq), 123.7 (d, 3JC‒F = 5.7 Hz, CH), 122.5 (d, 2JC‒F = 10.1 Hz, CH), 121.6 
(d, 3JC‒F = 3.8 Hz, CH), 120.4 (CH), 119.2 (CH), 117.2 (dt, 1JC–F = 283 Hz, 2JC–F = 33.0 Hz, 
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Cq), 112.7 (m, Cq), 112.5 (dt, 2JC‒F = 8.5 Hz, 3JC‒F = 4.4 Hz, CH), 110.7 (m, Cq), 110.6 (m, Cq), 
110.2 (CH), 110.1 (m, Cq), 109.8 (m, Cq), 108.4 (m, Cq), 95.0 (Cq), 21.1 (d, 3JC‒F = 4.3 Hz, 
CH2).  
19F-NMR (470 MHz, CDCl3): δ = –80.9 (m), –117.5 (m), –122.0 (m), –122.8 (m), –123.2 (m), 
–123.4 (m), –126.2 (m), –130.1 (m).  
IR (ATR): 1469, 1453, 1235, 1108, 738, 663 cm–1.  
MS (ESI) m/z (relative intensity): 699 ([M(79Br) + H]+, 100), 619 (10).  
HR-MS (ESI): m/z calcd. for [C22H1179BrF16N3 + H]+ 699.9875, found 699.9918. 
  
(Z)-2-(1H,1H,2H-Perfluorohex-2-en-1-yl)-1-(pyridin-2-yl)-1H-7-azaindole (316ga): A 
modified general procedure A was followed using 1-(pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridine 
(315g) (98.0 mg, 0.50 mmol), 1H,1H,2H-perfluoro-1-decene (301a) (446 mg, 1.00 mmol), 
[MnBr(CO)5] (13.7 mg, 10 mol %) and NaOAc (12.3 mg, 30 mol %). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 316ga (254 mg, 82%, Z/E = 80:20) as a 
colorless oil.  
1H-NMR (300 MHz, CDCl3) δ = 8.58 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.28 (dt, J = 4.8, 1.8 Hz, 
1H), 7.95–7.82 (m, 3H), 7.30 (ddd, J = 6.7, 4.9, 2.0 Hz, 1H), 7.12 (ddd, J = 7.8, 4.8, 1.9 Hz, 
1H), 6.42 (dt, J = 2.0, 0.9 Hz, 1H), 6.17 (dt, J = 22.3, 8.2 Hz, 0.20 H, E), 5.83 (dt, J = 32.8, 
7.5 Hz, 0.80H, Z), 4.00 (ddt, J = 7.5, 3.6, 2.0 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 149.8 (Cq), 148.8 (CH, Z), 148.7 (CH, E), 146.5 (dt, 1JC–F = 
262 Hz, 2JC–F = 29.6 Hz, Cq), 143.1 (CH), 138.1 (CH), 137.3 (Cq), 128.1 (CH), 122.1 (CH), 
121.7 (CH), 119.0 (Cq), 117.4 (CH), 116.5 (dt, 1JC–F = 286 Hz, 2JC–F = 32.7 Hz, Cq), 115.2 (Cq), 
113.0 (dt, 2JC–F = 8.7 Hz, 3JC–F = 4.5 Hz, CH), 112.6 (m, Cq), 111.5 (m, Cq), 111.0 (m, Cq), 
110.4 (m, Cq), 107.9 (m, Cq), 106.7 (m, Cq), 101.5 (CH), 23.3 (d, 3JC–F = 4.4 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –81.0 (m), –117.6 (m), –122.1 (m), –122.1 (m), –122.9 (m), 
–123.0 (m), –126.3 (m), –130.4 (m).  
IR (ATR): 3073, 2852, 1590, 1471, 1236, 805, 663 cm-1.  
MS (ESI) m/z (relative intensity): 622 ([M + H]+, 100), 602 (15).  
HR-MS (ESI): m/z calcd. for [C22H11F16N3 + H]+  622.0770, found  622.0769. 
 




(Z)-2-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-1H-pyrrol-1-yl]pyridine (321aa): The 
general procedure A was followed using 2-(1H-pyrrol-1-yl)pyridine (320a) (72.0 mg, 
0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (301a) (268 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 10:1) yielded 321aa (177 mg, 62%, Z/E = 87:13) 
and 321aa’ (59.1 mg, 12%, Z/E = 87:13) as yellow oils.  
1H-NMR (400 MHz, CDCl3): δ = 8.47 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.77 (ddd, J = 8.2, 7.5, 
1.9 Hz, 1H), 7.28 (dt, J = 8.2, 0.9 Hz, 1H), 7.18 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 7.01 (ddd, J = 
3.1, 1.8, 0.5 Hz, 1H), 6.24 (ddd, J = 3.1, 2.6, 0.5 Hz, 1H), 6.16 (dt, J = 22.7, 8.2 Hz, 0.13H, E), 
6.12–6.09 (m, 1H) 5.81 (dt, J = 33.4, 7.5 Hz, 0.87H, Z), 3.88 (ddt, J = 7.5, 3.9, 2.0 Hz, 1.74H, 
Z), 3.83 (ddt, J = 7.5, 4.0, 2.0 Hz, 0.26H, E).  
13C-NMR (100 MHz, CDCl3): δ = 152.5 (Cq), 148.6 (CH), 145.4 (dt, 1JC–F = 260 Hz, 2JC–F = 
30.1 Hz, Cq), 138.5 (CH), 129.1 (Cq), 121.2 (CH), 121.0 (CH), 116.9 (dt, 1JC–F = 285 Hz, 2JC–F 
= 33.3 Hz, Cq), 116.6 (CH), 114.6 (dt, J = 8.3, 4.3 Hz, CH), 112.2 (m, Cq), 111.3 (m, Cq), 111.2 
(m, Cq), 110.9 (m, Cq), 110.7 (CH), 109.7 (CH), 108.6 (m, Cq), 107.8 (Cq), 22.9 (d, 3JC–F = 4.2 
Hz, CH2).  
19F-NMR (376 MHz, CDCl3): δ = –80.8 (m), –117.5 (m), –122.0 (m), –122.8 (m), −123.0 (m), 
– 123.5 (m), –126.2 (m), –132.3 (m).  
IR (ATR): 1523, 1504, 1325, 1182, 992, 754 cm–1.  
MS (ESI) m/z (relative intensity): 593 ([M + Na]+, 20), 571 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C19H10F16N2 + H]+ 571.0661, found 571.0668. 
 
(Z)-2-[2,5-Di-(1H,1H,2H-perfluorodec-2-en-1-yl)-1H-pyrrol-1-yl]pyridine (321aa'):  
1H-NMR (300 MHz, CDCl3): δ = 8.58 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 8.2, 7.5, 
2.0 Hz, 1H), 7.34 (dt, J = 8.2, 0.9 Hz, 1H), 7.23 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.03–5.92 (m, 
2H), 5.80 (dt, J = 22.7, 8.2 Hz, 0.26H, E), 5.61 (dt, J = 33.4, 7.5 Hz, 1.74H, Z), 3.45 (ddt, J = 
7.5, 3.9, 2.0 Hz, 4H).  
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13C-NMR (100 MHz, CDCl3): δ = 150.7 (Cq), 149.8 (CH), 145.7 (dt, 1JC–F = 259 Hz, 2JC–F = 
30.1 Hz, Cq), 138.4 (CH), 129.1 (Cq), 123.1 (CH), 121.9 (CH), 117.4 (dt, 1JC–F = 288 Hz, 2JC–F 
= 33.3 Hz, Cq), 112.6 (dt, J = 8.3, 4.3 Hz, CH), 111.2 (m, Cq), 110.8 (m, Cq), 110.2 (m, Cq), 
109.7 (m, Cq), 108.8 (m, Cq), 108.2 (m, Cq), 107.8 (CH), 21.3 (d, 3JC–F = 4.1 Hz, CH2).  
19F-NMR (376 MHz, CDCl3): δ = –81.2 (m), –117.7 (m), –121.9 (m), –122.2 (m), −123.1 (m), 
– 123.1 (m), –126.4 (m), –131.8 (m).  
IR (ATR): 2960, 2924, 1473, 1235, 1143, 1047, 735, 559 cm–1.  
MS (ESI) m/z (relative intensity): 997 ([M + H]+, 100), 573 (20), 545 (15).  
HR-MS (ESI): m/z calcd. for [C29H12F32N2 + H]+ 997.0562, found: 997.0553 
  
(Z)-2-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)phenyl]pyridine (322aa): A modified 
procedure A was followed using 2-phenylpyridine (93a) (78.0 mg, 0.50 mmol), 1H,1H,2H-
perfluoro-1-decene (301a) (268 mg, 0.60 mmol) and NaOAc (12.3 mg, 30 mol %) at 120 °C. 
Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 322aa (169 mg, 58%, 
Z/E = 86:14) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.74 (dt, J = 7.7, 1.8 Hz, 
1H), 7.48–7.17 (m, 6H), 6.05 (dt, J = 23.1, 8.2 Hz, 0.14H), 5.76 (dt, J = 33.4, 7.7 Hz, 0.86H), 
3.73 (ddt, J = 7.7, 4.0, 2.3 Hz, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 159.3 (Cq), 149.0 (CH), 145.4 (dt, 1JC‒F = 258 Hz, 2JC‒F  = 
29.0 Hz, Cq), 140.3 (Cq), 136.4 (d, 2JC‒F = 7.4 Hz, CH), 135.7 (Cq), 130.0 (d, 2JC‒F = 7.8 Hz, 
CH), 128.7 (d, 3JC‒F = 3.2 Hz, CH), 127.0 (d, 3JC‒F = 4.2 Hz, CH), 123.9 (CH), 123.8 (d, 2JC‒F 
= 10.8 Hz, CH), 121.9 (d, 4JC‒F = 2.2 Hz, CH), 117.0 (dt, 1JC–F = 285 Hz, 2JC–F = 33.3 Hz, Cq), 
115.7 (m, CH), 112.7 (m, Cq), 112.4 (m, Cq), 110.9 (m, Cq), 110.7 (m, Cq), 108.5 (m, Cq), 108.3 
(m, Cq), 27.8 (d, 3JC‒F = 3.5 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –81.0 (m),–117.5 (m), –122.2 (m), –123.0 (m), – 123.5 (m), 
– 124.5 (m), –126.3 (m), –132.7 (m).  
IR (ATR): 1235, 1198, 1105, 748, 663 cm–1.  
MS (ESI) m/z (relative intensity): 582 [M + H]+, (100).  
HR-MS (ESI): m/z calcd. for [C21H11F16N + H]+  582.0709, found 582.0718. 
 




(Z)-10-(1H,1H,2H-Perfluorodec-2-en-1-yl)benzo[h]quinolone (324aa): A modified general 
procedure A was followed using benzo[h]quinolone (323a) (90.0 mg, 0.50 mmol), 1H,1H,2H-
perfluoro-1-decene (301a) (446 mg, 1.00 mmol), [MnBr(CO)5] (13.7 mg, 10 mol %) and 
NaOAc (12.3 mg, 30 mol %) at 120 °C. Isolation by column chromatography (n-
hexane/EtOAc = 10:1) yielded 324aa (163 mg, 54%, Z/E = 96:4) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.97 (ddd, J = 4.3, 1.9, 0.9 Hz, 1H), 8.25–8.09 (m, 1H), 7.85 
(dd, J = 7.3, 1.9 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.64–7.56 (m, 2H), 
7.49 (ddd, J = 8.0, 4.3, 0.6 Hz, 1H), 6.50 (dt, J = 24.3, 8.0 Hz, 0.04H, E), 6.20 (dt, J = 35.0, 
7.4 Hz, 0.96H, Z), 4.80 (ddt, J = 7.4, 3.8, 2.3 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 147.8 (Cq), 147.4 (CH), 145.0 (dt, 1JC‒F = 261 Hz, 2JC‒F  = 
29.1 Hz, Cq), 137.4 (Cq), 135.7 (CH), 135.5 (Cq), 131.2 (CH), 129.2 (Cq), 128.8 (CH), 128.2 
(CH), 127.7 (CH), 127.5 (Cq), 125.8 (CH), 121.0 (CH), 117.6 (CH), 116.9 (dt, 1JC–F = 275 Hz, 
2JC–F = 32.3 Hz, Cq), 113.4 (m, Cq), 111.3 (m, Cq), 110.9 (m, Cq), 110.7 (m, Cq), 108.6 (m, Cq), 
108.0 (m, Cq), 33.0 (d, 3JC‒F = 3.8 Hz, CH2).  
19F-NMR (376 MHz, CDCl3): δ = –80.8 (m), –117.2 (m), –122.0 (m), –122.1 (m), – 122.8 (m), 
–122.9 (m), –126.2 (m), –133.7 (m).  
IR (ATR): 1235, 1200, 1146, 833, 663 cm–1.  
MS (ESI) m/z (relative intensity): 606 ([M + H]+, 100), 582 (20).  
HR-MS (ESI): m/z calcd. for [C23H11F16N + H]+ 606.0709, found 606.0704. 
  
(Z)-2-(1H,1H,2H-Perfluorohex-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole (316ab): The general 
procedure A was followed using 1-(pyridin-2-yl)-1H-indole (315a) (97.1 mg, 0.50 mmol) and 
1H,1H,2H-perfluoro-1-hexene (301b) (148 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 316ab (160 mg, 76%, Z/E = 90:10) as a 
colourless oil.  
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1H-NMR (400 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.93 (ddd, J = 7.6, 7.6, 
2.0 Hz, 1H), 7.72–7.60 (m, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.45–7.32 (m, 2H), 7.25–7.18 (m, 
2H), 6.54 (d, J = 0.9 Hz, 1H), 6.20 (dt, J = 22.5, 8.3 Hz, 0.10H, E), 5.85 (dt, J = 32.9, 7.5 Hz, 
0.90H, Z), 3.93 (ddt, J = 6.9, 3.3, 2.4 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 150.9 (Cq) , 149.7 (CH), 145.9 (dt, 1JC–F = 262 Hz, 2JC–F = 
29.8 Hz, Cq)  138.4 (CH), 137.1 (Cq), 136.1 (Cq), 128.3 (Cq), 122.4 (CH), 122.2 (CH), 121.0 
(CH), 120.5 (CH), 120.4 (CH), 117.9 (dt, 1JC–F = 285 Hz, 2JC–F = 33.0 Hz, Cq), 113.3 (dt, 2JC‒F  
= 8.3 Hz, 3JC‒F  = 4.3 Hz, CH), 110.1 (CH), 109.6 (m, Cq), 107.7 (m, Cq), 103.7 (CH), 22.7 (d, 
3JC–F = 4.3 Hz, CH2).  
19F-NMR (376 MHz, CDCl3):  δ = –80.8 (m), –115.9 (m, E), –118.5 (m, Z), –127.4 (m, Z), –
127.9 (m, E), –131.0 (m).  
IR (ATR): 3059, 1587, 1119, 782, 737 cm–1.  
MS (ESI) m/z (relative intensity): 443 ([M + Na]+, 10), 421 (100).  
HR-MS (ESI): m/z calcd. for [C19H12F8N2 + H]+  421.0946, found  421.0950. 
  
(Z)-2-(1H,1H,2H-Perfluorododec-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole (316ac): The 
general procedure A was followed using 1-(pyridin-2-yl)-1H-indole (315a) (97.1 mg, 
0.50 mmol) and 1H,1H,2H-perfluoro-1-dodecene (301c) (328 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 10:1) yielded 316ac (302 mg, 84%, Z/E = 89:11) 
as a colorless oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 2.0, 0.8 Hz, 1H), 7.87 (ddd, J = 7.7, 7.5, 
2.0 Hz, 1H), 7.63–7.58 (m, 1H), 7.48 (dt, J = 8.0, 1.0 Hz, 1H), 7.40–7.36 (m, 1H), 7.31 (ddd, 
J = 7.5, 4.9, 1.0 Hz, 1H), 7.20–7.15 (m, 2H), 6.50 (d, J = 0.9 Hz, 1H), 6.15 (dt, J = 22.4, 8.2 
Hz, 0.11H, E), 5.81 (dt, J = 32.8, 7.5 Hz, 0.89H, Z), 3.90 (ddt, J = 7.5, 4.0, 2.2 Hz, 1.78H, Z), 
3.85 (ddt, J = 7.5, 4.0, 2.2 Hz, 0.22H, E).  
13C-NMR (125 MHz, CDCl3): δ = 150.8 (Cq), 149.7 (CH), 146.2 (dt, 1JC‒F = 261 Hz, 2JC‒F = 
29.0 Hz, Cq), 138.4 (CH), 137.1 (Cq), 136.1 (d, 4JC‒F = 2.0 Hz, Cq), 128.3 (Cq), 122.4 (CH), 
122.2 (CH), 121.1 (CH), 120.6 (CH), 120.4 (CH), 117.2 (dt, 1JC–F = 290 Hz, 2JC–F = 33.1 Hz, 
Cq), 113.3 (dt, 2JC‒F = 8.5 Hz, 3JC‒F = 4.4 Hz, CH), 112.7 (m, Cq), 110.8 (m, Cq), 110.6 (m, Cq), 
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110.1 (CH), 108.8 (m, Cq), 108.5 (m, Cq), 108.2 (m, Cq), 106.3 (m, Cq), 106.1 (m, Cq), 103.7 
(CH), 22.7 (d, 3JC‒F = 4.3 Hz, CH2).  
19F-NMR (470 MHz, CDCl3): δ = –81.0 (m), –117.6 (m), –121.8 (m), –122.0 (m), –122.0 (m), 
–122.2 (m), –122.9 (m), –123.0 (m), –126.3 (m), –130.9 (m).  
IR (ATR): 1471, 1438, 1200, 1105, 735, 556, 528 cm–1.  
MS (ESI) m/z (relative intensity): 721 ([M + H]+, 100), 621 (10).  
HR-MS (ESI): m/z calcd. for [C25H12F20N2 + H]+  721.0754, found 721.0755. 
 
(Z)-4-Methoxy-2-[2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]pyridine (322bc):  A 
modified general procedure A was followed using 2-(4-methoxyphenyl)pyridine (93b) 
(93.0 mg, 0.50 mmol), 1H,1H,2H-perfluoro-1-dodecene (301c) (546 mg, 1.00 mmol) and 
[MnBr(CO)5] (13.7 mg, 10 mol %) at 120 °C. Isolation by column chromatography (n-
hexane/EtOAc = 10:1) yielded 322bc (201 mg, 57%, Z/E = 92:8) as a pale yellow solid. M.p.: 
55 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.80–7.57 (m, 1H), 7.37–
7.34 (m, 1H), 7.34–7.31 (m, 1H), 7.20 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 6.86 (dd, J = 8.4, 2.6 Hz, 
1H), 6.80 (d, J = 2.6 Hz, 1H), 6.05 (dt, J = 23.0, 8.2 Hz, 0.08H, E), 5.76 (dt, J = 33.4, 7.7 Hz, 
0.92H, Z), 3.82 (s, 3H), 3.72 (ddt, J = 7.4, 3.8, 2.3 Hz, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 159.8 (Cq), 159.1 (Cq), 149.0 (CH), 145.3 (dt, 1JC–F = 258 Hz, 
29.0 Hz, Cq), 137.2 (Cq), 136.4 (CH), 132.9 (Cq), 131.3 (CH), 123.7 (CH), 121.5 (CH), 117.1 
(dt, 1JC–F = 289 Hz, 2JC–F = 33.2 Hz, Cq), 115.7 (Cq), 115.5 (CH), 112.4 (CH), 112.2 (m, Cq), 
110.7 (m, Cq), 110.6 (m, Cq), 110.5 (m, Cq), 108.8 (m, Cq), 108.5 (m, Cq), 108.2 (m, Cq), 55.3 
(CH3), 28.1 (d, 4JC–F = 3.4 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –117.5 (m), –121.7 (m), –121.8 (m), –122.0 (m), 
–122.2 (m), –122.8 (m), –123.0 (m), –126.2 (m), –132.7 (m).  
IR (ATR): 1609, 1467, 1429, 1201, 1147, 1045, 786, 529 cm–1.  
MS (ESI) m/z (relative intensity): 712 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C24H13F20NO + H]+  712.0751, found 712.0756. 
 





ate (329aa): A modified general procedure A was followed using methyl acetyl-1-(pyridin-2-
yl)-L-tryptophanate (328a) (168 mg, 0.50 mmol), 1H,1H,2H-perfluoro-1-decene (301a) 
(446 mg, 1.00 mmol), [MnBr(CO)5] (13.7 mg, 10 mol %) and NaOAc (12.3 mg, 30 mol %). 
Isolation by column chromatography (n-hexane/EtOAc = 1:1) yielded 329aa (317 mg, 83%, 
Z/E = 98:2) as a white solid. M.p.: 118 °C. 
 
Reaction with 328a (ee = 35%): 
 
1H-NMR (500 MHz, CDCl3): δ = 8.64–8.53 (m, 1H), 7.85 (ddd, J = 7.5, 7.5, 1.9 Hz, 1H), 7.58–
7.51 (m, 1H), 7.42 (dt, J = 8.0, 1.0 Hz, 1H), 7.34–7.26 (m, 2H), 7.19–7.11 (m, 2H), 6.26 (d, J 
= 8.0 Hz, 1H), 5.78 (dt, J = 22.7, 7.0 Hz, 0.02H, E), 5.47 (dt, J = 33.1, 7.2 Hz, 0.98H, Z), 4.96 
(ddd, J = 8.0, 6.4, 5.0 Hz, 1H), 4.01–3.77 (m, 2H), 3.66 (s, 3H), 3.42–3.25 (m, 2H), 1.94 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 172.4 (Cq), 169.8 (Cq), 150.6 (Cq), 149.7 (CH), 145.5 (dt, 
1JC‒F = 262 Hz, 2JC‒F = 29.3 Hz, Cq), 138.4 (CH), 136.6 (Cq), 133.6 (Cq), 128.5 (Cq), 122.9 
(CH), 122.3 (CH), 120.9 (CH), 120.6 (CH), 118.6 (CH), 116.9 (dt, 1JC–F = 292 Hz, 2JC–F = 
31.8 Hz, Cq), 113.6 (CH), 112.4 (m, Cq), 112.1 (m, Cq), 110.6 (m, Cq), 110.3 (m, Cq), 110.0 
5. Experimental Part 
 
189 
(CH), 109.9 (Cq), 108.5 (m, Cq), 108.1 (m, Cq), 52.8 (CH), 52.4 (CH3), 26.9 (d, 4JC‒F = 4.1 Hz, 
CH2), 23.0 (CH3), 20.1 (CH2).  
19F-NMR (470 MHz, CDCl3): δ = –80.9 (m), –117.4 (m), –121.0 (m), –121.1 (m), –122.9 (m), 
–123.0 (m), –126.3 (m), –130.2 (m).  
IR (ATR): 1725, 1472, 1439, 1201, 1147, 1106, 908, 707 cm–1.  
MS (ESI) m/z (relative intensity): 786 ([M + Na]+, 20), 764 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C29H21F16N3O3 + H]+ 764.1400, found 764.1392. 
  
(Z)- Benzyl tert-butyloxycarbonyl-1-(pyridin-2-yl)-2-(1H,1H,2H-perfluorodec-2-en-1-yl)-
L-tryptophanate (329ba): A modified general procedure A was followed using benzyl tert-
butyloxycarbonyl-1-(pyridin-2-yl)-L-tryptophanate (328b) (236 mg, 0.50 mmol), 1H,1H,2H-
perfluoro-1-decene (301a) (446 mg, 1.00 mmol), [MnBr(CO)5] (13.7 mg, 10 mol %) and 
NaOAc (12.3 mg, 30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 20:1) 
yielded 329ba (381 mg, 85%, Z/E = 90:10) as a white solid. M.p.: 63 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.85 (ddd, J = 7.7, 7.6, 
1.9 Hz, 1H), 7.68–7.48 (m, 1H), 7.41–7.26 (m, 6H), 7.23–7.11 (m, 4H), 5.84 (dt, J = 23.1, 
8.4 Hz, 0.10H, E), 5.53 (dt, J = 33.0, 7.1 Hz, 0.90H, Z), 5.21 (d, J = 8.3 Hz, 1H), 5.14–4.96 (m, 
2H), 4.80–4.68 (m, 1H), 3.95–3.78 (m, 2H), 3.34 (d, J = 6.0 Hz, 2H), 1.41 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 171.8 (Cq), 154.9 (Cq), 150.6 (Cq), 149.5 (CH), 145.7 (dt, 
1JC‒F = 261 Hz, 2JC‒F  = 29.0 Hz, Cq), 138.2 (CH), 136.6 (Cq), 134.9 (Cq), 133.6 (Cq), 128.2 
(CH), 122.8 (CH), 122.1 (CH), 120.7 (d, 2JC‒F = 39.7 Hz, CH), 118.8 (CH), 113.7 (CH), 110.1 
(Cq), 110.0 (CH), 79.9 (CH2), 67.3 (Cq), 54.2 (CH), 28.2 (CH3), 27.6 (CH2), 20.3 (d, 3JC‒F = 
4.0 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –117.3 (m), –122.1 (m), –122.1 (m), –122.8 (m), 
–123.2 (m), –126.2 (m), –130.2 (m).  
IR (ATR): 1707, 1472, 1238, 1149, 906, 649 cm–1.  
MS (ESI) m/z (relative intensity): 920 ([M + Na]+, 20), 898 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C38H31F16N3O4 + H]+  898.2132, found: 898.2122. 
 





1-(pyridin-2-yl)-1H-indol-3-yl}propanoyl]-L-alaninate (329ca): A modified general 
procedure A was followed using benzyl N-(tert-butoxycarbonyl)-1-(pyridin-2-yl)-L-
tryptophyl-L-alaninate (328c) (54.2 mg, 0.10 mmol), 1H,1H,2H-perfluoro-1-decene (301a) 
(134 mg, 0.30 mmol), NaOAc (2.4 mg, 30 mol %) and [MnBr(CO)5] (5.6 mg, 20 mol %). 
Isolation by column chromatography (n-hexane/EtOAc = 1:1) yielded 329ca (62.0 mg, 64%, 
Z/E = 90:10) as a pale yellow solid. M.p.: 140 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.90 (ddd, J = 7.6, 7.5, 
1.9 Hz, 1H), 7.77–7.64 (m, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.39–7.31 (m, 5H), 7.28 (t, J = 3.8 
Hz, 2H), 7.19 (dd, J = 6.1, 3.1 Hz, 2H), 6.33 (d, J = 7.1 Hz, 1H), 5.89 (dt, J = 22.9, 7.2 Hz, 
0.10H, E), 5.59 (dt, J = 33.2, 7.2 Hz, 0.90H, Z), 5.31 (bs, 1H), 5.05 (d, J = 2.8 Hz, 2H), 4.64–
4.33 (m, 2H), 3.93 (ddt, J = 7.4, 3.8, 2.3 Hz, 2H), 3.47–3.13 (m, 2H), 1.45 (s, 9H), 1.33 (d, J = 
7.1 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 172.0 (Cq), 170.8 (Cq), 155.1 (Cq), 150.8 (Cq), 149.7 (CH), 
145.2 (dt, 1JC‒F = 260 Hz, 2JC‒F = 29.1 Hz, Cq), 138.4 (CH), 136.8 (Cq), 135.3 (Cq), 133.8 (Cq), 
128.6 (CH), 128.4 (CH), 128.2 (Cq), 128.0 (CH), 122.9 (CH), 122.3 (CH), 121.1 (CH), 120.9 
(CH), 118.9 (CH), 117.0 (dt, 1JC‒F = 288 Hz, 2JC‒F = 33.0 Hz, Cq), 113.7 (dt, J = 8.3, 4.3 Hz, 
CH), 113.2 (m, Cq), 112.7 (m, Cq), 111.0 (m, Cq), 110.9 (m, Cq), 110.7 (m, Cq), 110.4 (Cq), 
110.1 (CH), 107.9 (m, Cq), 80.1 (Cq), 67.0 (CH2), 54.9 (CH), 48.3 (CH), 28.2 (CH3), 27.7 
(CH2), 20.2 (d, 3JC‒F = 4.6 Hz, CH2), 18.4 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –80.8 (m), –117.3 (m), –122.0 (m), –122.0 (m), –122.8 (m), 
–122.8 (m), –126.1 (m), –130.5 (m).  
IR (ATR): 3303, 2982, 1658, 1472, 1458, 1238, 1202, 1148 cm–1.  
MS (ESI) m/z (relative intensity):  991 ([M + Na]+, 30), 969 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C41H36F16N4O5 + H]+ 969.2503, found: 969.2497. 




(E)-1-(Pyridin-2-yl)-2-(perfluorodec-2-en-1-yl)-1H-indole (330aa): The general procedure 
B was followed using 1-(pyridin-2-yl)-1H-indole (315a) (58.2 mg, 0.30 mmol) and 
perfluorodec-1-ene (303a) (450 mg, 0.90 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 20:1) yielded 330aa (172 mg, 85%).  
1H-NMR (500 MHz, CDCl3): δ = 8.58 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (ddd, J = 7.7, 5.9, 
1.9 Hz, 1H), 7.71 (dt, J = 7.9, 1.0 Hz, 1H), 7.58 (dd, J = 8.5, 0.9 Hz, 1H), 7.46 (dt, J = 8.0, 1.0 
Hz, 1H), 7.37–7.28 (m, 2H), 7.24 (dt, J = 7.4, 1.0 Hz, 1H), 7.19 (dd, J = 2.1, 1.1 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 150.5 (Cq), 149.4 (CH), 148.9 (ddt, 1JC–F = 255 Hz, 2JC–F = 
41.0 Hz, 3JC–F = 3.2 Hz, Cq), 138.3 (CH), 137.9 (Cq), 137.2 (dtd, 1JC–F = 250 Hz, 2JC–F = 
46.0 Hz, 2JC–F = 29.7 Hz, Cq), 127.4 (Cq), 125.5 (CH), 124.2 (dd, 2JC–F = 23.5 Hz, 3JC–F = 5.3 
Hz, Cq), 122.3 (CH), 122.0 (CH), 122.0 (CH), 120.7 (m, Cq), 119.0 (CH), 116.9 (m, Cq), 113.1 
(m, Cq), 112.7 (m, Cq), 112.3 (m, Cq), 111.4 (dd, 3JC–F = 7.7 Hz, 4JC–F = 5.3 Hz, CH), 110.9 
(CH), 110.3 (m, Cq), 108.5 (m, Cq), 108.2 (m, Cq). 
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –116.7 (m), –122.1 (m), –122.1 (m), –122.2 (m), 
–122.8 (m), –123.7 (m), –126.2 (m), –135.0 (dtt, J = 140, 26.5, 7.2 Hz), –162.9 (dt, J = 140, 
12.6 Hz).  
IR (ATR): 1470, 1441, 1198, 1145, 737, 708 cm–1.  
MS (ESI) m/z (relative intensity): 675 ([M + H]+, 100).  
HR-MS (ESI): m/z calcd. for [C23H9F19N2 + H]+  675.0535, found: 675.0539. 
 
(E)-3-Methyl-1-(pyridin-2-yl)-2-(1,2,3,3-tetrafluoro-3-phenylprop-1-en-1-yl)-1H-indole 
(330eb): The general procedure B was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole 
(315e) (62.4 mg, 0.30 mmol), 3-(pentafluorophenyl)pentafluoroprop-1-ene (303b) (286 mg, 
0.90 mmol) and NaOAc (7.4 mg, 30 mol %). Isolation by column chromatography (n-
hexane/EtOAc = 15:1) yielded 330eb (126 mg, 86%).  
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1H-NMR (500 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 7.5, 
1.9 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.65 (dt, J = 8.4, 0.9 Hz, 1H), 7.41 (dt, J = 8.1, 0.9 Hz, 
1H), 7.34 (ddd, J = 8.4, 7.2, 1.1 Hz, 1H), 7.29–7.21 (m, 2H), 2.41 (dd, J = 3.1, 2.2 Hz, 3H). 
13C-NMR (125 MHz CDCl3): δ = 150.6 (Cq), 149.3 (CH), 145.3 (m, Cq), 145.2 (dt, 1JC‒F 
= 250 Hz, 2JC‒F = 4.6 Hz, Cq), 141.9 (m, Cq), 138.0 (m, Cq), 138.3 (CH), 137.3 (Cq), 136.8 (m, 
Cq), 128.5 (Cq), 125.6 (CH), 121.7 (CH), 121.4 (CH), 121.1 (dd, 2JC‒F = 22.8 Hz, 3JC‒F 
= 3.5 Hz, Cq), 120.9 (Cq), 120.3 (CH), 118.3 (CH), 112.8 (Cq), 111.1 (CH), 108.8 (m, Cq), 9.4 
(d, 4JC‒F = 3.2 Hz, CH3).  
19F-NMR (283 MHz, CDCl3): δ = –93.4 (m), –130.3 (dt, J = 146, 15.4 Hz), –139.4 (m), –148.5 
(m), –159.4 (m), –160.5 (m).  
IR (ATR): 1592, 1580, 1528, 1506, 1282, 1187, 929, 745 cm–1.  
MS (ESI) m/z (relative intensity): 509  ([M + Na]+, 10), 487 ([M + H]+, 100), 467 (15).  
HR-MS (ESI): m/z calcd. for [C23H11F9N2 + H]+ 487.0851, found: 487.0859. 
 
Benzyl (S,E)-2-(tert-butoxycarbonyl)amino)-3-{2-(perfluorodec-2-en-1-yl)-1-(pyridin-2-
yl)-1H-indol-3-yl}propanoate (331bc): A modified general procedure B was followed using 
benzyl tert-butyloxycarbonyl-1-(pyridin-2-yl)-L-tryptophanate (328b) (142 mg, 0.30 mmol), 
perfluorodec-1-ene (303c) (450 mg, 0.90 mmol), [MnBr(CO)5] (12.3 mg, 15 mol %) and 
NaOAc (7.4 mg, 30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 10:1) 
yielded 331bc (135 mg, 57%).  
1H-NMR (400 MHz, CDCl3):  δ = 8.53 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.83 (m, 1H), 7.80–7.73 
(d, J = 8.0 Hz, 1H), 7.65–7.54 (d, J = 8.4 Hz, 1H), 7.39–7.33 (t, J = 7.3 Hz, 2H), 7.31–7.22 (m, 
5H), 7.20–7.12 (m, 2H), 5.16–5.07 (dd, J = 11.3, 5.1 Hz, 2H), 5.05–4.96 (d, J = 12.4 Hz, 1H), 
4.83–4.73 (q, J = 7.3 Hz, 1H), 3.52–3.13 (d, J = 6.6 Hz, 2H), 1.54–1.15 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 155.0 (Cq), 150.1 (Cq), 149.5 (CH), 147.9 (dd, 
1JC‒F = 257 Hz, 2JC‒F  = 44.5 Hz, Cq), 138.4 (CH), 137.9 (m, Cq), 137.4 (Cq), 135.1 (CH), 128.5 
(CH), 128.2 (CH), 128.0 (CH), 127.7 (CH), 125.9 (CH), 122.2 (CH), 121.9 (Cq), 120.7 (Cq), 
119.1 (m, Cq), 118.7 (CH), 117.0 (dt, 1JC‒F = 287 Hz, 2JC‒F  = 33.9 Hz, Cq), 113.4 (m, Cq), 112.8 
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(m, Cq), 111.2 (CH), 110.9 (m, Cq), 110.7 (m, Cq), 110.4 (m, Cq), 108.8 (m, Cq), 108.3 (m, Cq), 
79.9 (CH2), 67.2 (Cq), 53.8 (CH), 28.4 (CH2), 27.6 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = –80.8 (m), –116.7 (m), –121.8 (m), –121.9 (m), –122.1 (m), 
–122.7 (m), –123.3 (m), –121.1 (m), –126.8 (dt, J = 146, 23.6 Hz), –160.3 (dt, J = 146, 12.3 
Hz).  
IR (ATR): 3362, 2957, 1587, 1569, 1450, 1383, 1212, 996 cm–1.  
MS (ESI) m/z (relative intensity): 974 ([M + Na]+, 70), 952 ([M + H]+, 100), 896 (20).  
HR-MS (ESI): m/z calcd. for [C38H28F19N3O4 + H]+ 952.1849, found: 952.1833. 
 
(E)-Methyl acetyl-1-(pyridin-2-yl)-2-[3-(pentafluorophenyl)tetrafluoroprop-1-en-1-yl]-L-
tryptophanate (331ab): The general procedure B was followed using methyl acetyl-1-
(pyridin-2-yl)-L-tryptophanate (328a) (101 mg, 0.30 mmol), 3-
(pentafluorophenyl)pentafluoroprop-1-ene (303b) (178 mg, 0.60 mmol) and NaOAc (7.4 mg, 
30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 1:1) yielded 331ab (148 
mg, 48%) as a yellow solid. M.p.: 122 oC.  
1H-NMR (400 MHz, CDCl3): δ = 8.50 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.85 (ddd, J = 7.7, 7.5, 
1.9 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.32 
(d, J = 7.4 Hz, 1H), 7.30–7.27 (m, 1H), 7.27–7.20 (m, 1H), 6.11 (d, J = 8.0 Hz, 1H), 4.98 (dt, 
J = 8.0, 6.0 Hz, 1H), 3.62 (s, 3H), 3.35 (d, J = 6.0 Hz, 2H), 1.92 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 171.9 (Cq), 169.7 (Cq), 150.2 (Cq), 149.4 (CH), 146.2 (m, 
Cq), 143.7 (m, Cq), 141.8 (m, Cq), 139.1 (m, Cq), 138.4 (CH), 137.3 (d, 4JC–F = 2.0 Hz, Cq), 
136.6 (Cq), 127.7 (d, 4JC–F = 1.7 Hz, Cq), 125.8 (CH), 122.5 (Cq), 122.2 (CH), 121.9 (CH), 
120.5 (CH), 118.9 (CH), 118.7 (m, Cq), 112.7 (m, Cq), 111.3 (CH), 100.0 (m, Cq), 52.4 (CH3), 
52.4 (CH), 27.7 (CH2), 22.9 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –94.0 (m), –128.5 (dt, J = 146, 16.7 Hz), –139.4 (m), –148.2 
(m), –157.9 (dt, J = 146, 18.5 Hz), –160.1 (m).  
IR (ATR): 3285, 2957, 1744, 1657, 1527, 1506, 1371, 993, 741 cm–1.  
MS (ESI) m/z (relative intensity): 638 ([M + Na]+, (20), 616 ([M + H]+, 100), 596 (10).  
HR-MS (ESI): m/z calcd. for [C28H18F9N3O3 + H]+  616.1265, found  616.1277. 





(333ab): A modified general procedure B was followed using 1-(4-methoxyphenyl)-1H-
pyrazole (332a) (52.2 mg, 0.30 mmol), 3-(pentafluorophenyl)pentafluoroprop-1-ene (303b) 
(286 mg, 0.90 mmol) and NaOAc (7.4 mg, 30 mol %). Isolation by column chromatography 
(n-hexane/EtOAc = 15:1) yielded 333ab (96.3 mg, 68%).  
1H-NMR (400 MHz, CDCl3): δ = 7.58 (d, J = 1.8 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.43 (d, J 
= 8.5 Hz, 1H), 7.09 (ddd, J = 8.5, 2.8, 2.4 Hz, 1H), 7.07 (dd, J = 2.8, 1.3 Hz, 1H), 6.35 (dd, J 
= 2.4, 1.8 Hz, 1H), 3.86 (s, 3H).  
13C-NMR (125 MHz CDCl3): δ = 158.7 (Cq), 149.4 (dt, 1JC‒F = 255 Hz, 2JC‒F = 45.0 Hz, 3JC‒F 
= 7.3 Hz, Cq), 146.0 (m, Cq), 144.1 (m, Cq), 142.9 (m, Cq), 140.8 (CH), 138.1 (m, Cq), 132.6 
(Cq), 129.5 (CH), 126.9 (CH), 123.1 (dd, 2JC‒F = 22.8 Hz, 3JC‒F = 4.2 Hz, Cq), 117.8 (CH), 115.5 
(CH), 112.7 (m, Cq), 108.5 (m, Cq), 107.0 (CH), 55.8 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = –94.2 (m), –132.8 (dt, J = 141, 16.3 Hz), –139.1 (m), –148.6 
(m), –160.3 (m), –162.4 (m).  
IR (ATR): 2946, 1524, 1505, 1326, 1182, 1043, 993, 755 cm–1.  
MS (ESI) m/z (relative intensity): 475 ([M + Na]+, 20), 453 ([M + H]+, 100), 433 (10).  
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5.3.2. Removal of Directing Group 
 
Methyl trifluoromethanesulfonate (98.4 mg, 66 µL, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 317ab (157 mg, 0.50 mmol, 1.00 equiv) in CH2Cl2 (7.5 mL) at 0 °C, 
and the resulting solution was stirred for 12 h at 25 °C. After removal of the solvent, PhSNa 
(330 mg, 2.50 mmol, 5.00 equiv) and MeOH (5.0 mL) were added and the resulting mixture 
was stirred at 100 °C for 24 h with a reflux condenser. The solvents were removed, and the 
resulting residue was neutralized using HCl (1.0 M) and extracted with CH2Cl2 (4 × 20 mL). 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. The remaining residue was purified by column chromatography on silica gel (n-
hexane/EtOAc: 20:1) to afford the desired product 409 (71.4 mg, 60%) as a white solid. 
 
(Z)-2-(1-Fluoro-2-phenylvinyl)-1H-indole (409): M.p.: 135 °C.  
1H-NMR (400 MHz, CDCl3): 𝛿 = 8.31 (bs, 1H), 7.63–7.58 (m, 3H), 7.40–7.34 (m, 3H), 7.29–
7.21 (m, 2H), 7.13 (ddd, J = 7.9, 7.5, 0.9 Hz, 1H), 6.84 (d, J = 1.7 Hz, 1H), 6.50 (d, J = 20.8 
Hz, 0.10H, E), 6.23 (d, J = 39.9 Hz, 0.90H, Z).  
13C-NMR (100 MHz, CDCl3): 𝛿 = 151.5 (d, J = 253 Hz, Cq), 136.5 (CH), 133.2 (d, 3JC–F = 
3.3 Hz, Cq), 130.7 (d, 2JC–F = 31.3 Hz, Cq), 128.8 (d, 4JC–F = 7.5 Hz, CH), 128.7 (CH), 128.5 
(Cq), 127.5 (Cq), 123.4 (CH), 121.0 (CH), 120.7 (CH), 111.1 (CH), 105.6 (d, 2JC–F = 8.8 Hz, 
CH), 101.5 (d, 3JC–F = 3.8 Hz, CH).  
19F-NMR (376 MHz, CDCl3): 𝛿 = –109.4 (d, J = 20.8 Hz, E), –118.3 (d, J = 39.9 Hz, Z).  
IR (ATR): 3425, 3052, 1653, 1446, 1024, 944, 589 cm–1.  
MS (ESI) m/z (relative intensity): 238 ([M + H]+, 80), 163 (100).  
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5.4. Ruthenium(II)-catalyzed C–F/C–H functionalization 
5.4.1. Characterization Data 
 
(E)-1-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307aa): The general 
procedure C was followed using N-(3,4,5-trimethoxyphenyl)-1-phenylethan-1-imine (340a) 
(143 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) (669 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 307aa (199 mg, 73%, 
E/Z = 78:22, 307aa/339aa = 98:2) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.4, 1.4 Hz, 1H), 7.49 (ddd, J = 7.6, 7.4, 1.4 Hz, 
1H), 7.39 (ddd, J = 7.6, 7.5, 1.4 Hz, 1H), 7.28 (dd, J = 7.5, 1.4 Hz, 1H), 6.18 (dt, J = 23.1, 8.4 
Hz, 0.78H, E), 5.95 (dt, J = 33.7, 7.8 Hz, 0.22H, Z), 3.84 (ddt, J = 8.3, 4.1, 2.3 Hz, 2H), 3.20–
3.10 (m, 0.04H, 339aa), 2.64 (s, 2.34H, E), 2.63 (s, 0.66H, Z).  
13C-NMR (75 MHz, CDCl3): δ = 201.1 (Cq), 144.4 (dt, 1JC‒F = 257.1 Hz, 2JC‒F = 29.1 Hz, Cq), 
138.3 (Cq), 136.6 (Cq), 132.4 (CH), 131.2 (CH), 130.2 (CH), 127.1 (CH), 120.8 (dt, 1JC‒F = 
288.3 Hz, 2JC‒F = 34.2 Hz, Cq), 119.0 (d, 2JC‒F = 16.8 Hz, CH), 115.2 (m, Cq), 113.6 (m, Cq), 
111.1 (m, Cq), 110.6 (m, Cq), 108.2 (m, Cq), 106.6 (m, Cq), 29.2 (CH3), 28.4 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –122.1 (m), –122.8 
(m), –123.4 (m), –124.0 (m), –126.2 (m), –132.4 (m).  
IR (ATR): 1690, 1357, 1226, 1199, 1143, 1116, 759, 732 cm–1.  
MS (ESI) m/z (relative intensity): 569 ([M + Na]+, 100), 547 ([M + H]+, 45), 381 (15).  
HR-MS (ESI): m/z calcd. for [C18H10F16O + H]+ 547.0549, found 547.0554. 
  
(E)-1-[2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]propan-1-one (307ba): The general 
procedure C was followed using N-(3,4,5-trimethoxyphenyl)-1-phenylpropan-1-imine (340b) 
(150 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) (669 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 307ba (176 mg, 63%, 
E/Z = 75:25, 307ba/339ba = 99:1) as a yellow oil.  
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1H-NMR (500 MHz, CDCl3): δ = 7.72 (dd, J = 8.0, 1.4 Hz, 1H), 7.43 (ddd, J = 7.7, 7.5, 1.4 Hz, 
1H), 7.33 (ddd, J = 8.0, 7.5, 1.4 Hz, 1H), 7.22 (dd, J = 7.7, 1.4 Hz, 1H), 6.15 (dt, J = 23.1, 8.4 
Hz, 0.75H, E), 5.93 (dt, J = 33.7, 7.8 Hz, 0.25H, Z), 3.75 (ddt, J = 7.4, 4.1, 2.0 Hz, 2H), 3.10‒
3.00 (m, 0.02H, 339ba), 2.94 (q, J = 7.2 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 204.4 (Cq), 143.9 (dt, 1JC‒F = 256.2 Hz, 2JC‒F = 27.3 Hz, Cq), 
137.8 (Cq), 137.1 (Cq), 131.9 (CH), 131.1 (CH), 129.0 (CH), 127.0 (CH), 119.0 (d, 2JC‒F = 
8.2 Hz, CH), 117.2 (dt, 1JC‒F = 287.7 Hz, 2JC‒F = 31.3 Hz, Cq), 113.4 (m, Cq), 112.9 (m, Cq), 
112.0 (m, Cq), 110.7 (m, Cq), 110.4 (m, Cq), 108.5 (m, Cq), 34.4 (CH2), 28.3 (m, CH2), 8.2 
(CH3).  
19F-NMR (471 MHz, CDCl3): δ = ‒80.9 (m), ‒114.4 (m, E), ‒117.4 (m, Z), ‒122.0 (m), ‒122.8 
(m), ‒123.3 (m), ‒123.9 (m), ‒126.2 (m), ‒132.5 (m).  
IR (ATR): 1709, 1340, 1291, 1259, 1143, 1121, 721, 700 cm–1.  
MS (ESI) m/z (relative intensity): 583 ([M + Na]+, 100), 561 ([M + H]+, 10).  
HR-MS (ESI): m/z calcd. for [C19H12F16O + H]+ 561.0705, found 561.0708. 
  
(E)-1-[4-Methyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307ca): The 
general procedure C was followed using 1-(4-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340c) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) 
(669 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ca (174 mg, 62%, E/Z = 84:16, 307ca/339ca = 92:8) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 7.71 (d, J = 8.0 Hz, 1H), 7.15 (dd, J = 8.0, 1.4 Hz, 1H), 7.05 
(d, J = 1.4 Hz, 1H), 6.14 (dt, J = 23.3, 8.3 Hz, 0.84H, E), 5.91 (dt, J = 32.5, 8.3 Hz, 0.16H, Z), 
3.80 (ddt, J = 7.5, 4.0, 2.2 Hz, 2H), 3.20–3.03 (m, 0.16H, 339ca), 2.58 (s, 2.52H, E), 2.57 (s, 
0.48H, Z), 2.36 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 200.5 (Cq), 143.9 (dt, 1JC‒F = 260.3 Hz, 2JC‒F = 27.5 Hz, Cq), 
143.2 (Cq), 138.6 (Cq), 133.7 (Cq), 132.1 (CH), 130.7 (CH), 127.6 (CH), 119.1 (d, 2JC‒F = 
18.3 Hz, CH), 117.1 (dt, 1JC‒F = 289.1 Hz, 2JC‒F = 33.8 Hz, Cq), 113.2 (m, Cq), 112.1 (m, Cq), 
111.0 (m, Cq), 110.7 (m, Cq), 109.7 (m, Cq), 108.6 (m, Cq), 29.1 (CH3), 28.5 (m, CH2), 21.3 
(CH3).  
19F-NMR (471 MHz, CDCl3): δ = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –122.0 (m), –122.8 
(m), –123.4 (m), –124.4 (m), –126.3 (m), –132.8 (m).  
5. Experimental Part 
 
198 
IR (ATR): 1695, 1395, 1243, 1200, 1155, 1103, 749, 710 cm–1.  
MS (ESI) m/z (relative intensity): 583 ([M + Na]+, 100), 561 ([M + H]+, 20).  
HR-MS (ESI): m/z calcd. for [C19H12F16O + H]+ 561.0705, found 561.0708.  
  
(E)-1-[4-Phenyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307da): The 
general procedure C was followed using 1-([1,1'-biphenyl]-4-yl)-N-(3,4,5-
trimethoxyphenyl)ethan-1-imine (340d) (188 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-
ene (301a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
25/1) yielded 307da (165 mg, 53%, E/Z = 80:20, 307da/339da = 99:1) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 8.1 Hz, 1H), 7.72‒7.52 (m, 3H), 7.54‒7.35 (m, 
4H), 6.21 (dt, J = 23.0, 8.2, 0.7 Hz, 0.80H, E), 5.98 (dt, J = 33.7, 10.5, 1.2 Hz, 0.20H, Z), 3.91 
(ddt, J = 6.1, 4.2, 2.1 Hz, 2H), 3.41–3.06 (m, 0.02H, 339da), 2.64 (s, 2.40H, E), 2.63 (s, 0.60H, 
Z).  
13C-NMR (125 MHz, CDCl3): δ = 200.1 (Cq), 144.9 (Cq), 144.3 (dt, 1JC‒F = 251 Hz, 2JC‒F = 
29.4 Hz, Cq), 139.1 (Cq), 138.8 (Cq), 134.8 (Cq), 130.8 (CH), 129.9 (CH), 128.7 (CH), 128.1 
(CH), 129.0 (CH), 126.9 (CH), 125.3 (CH), 118.7 (d, 2JC‒F = 8.9 Hz, CH), 116.8 (dt, 1JC‒F = 
288.5 Hz, 2JC‒F = 32.3 Hz, Cq), 112.7 (m, Cq), 111.8 (m, Cq), 110.8 (m, Cq), 110.5 (m, Cq), 
110.5 (m, Cq), 108.4 (m, Cq), 29.0 (CH3), 28.6 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = ‒80.8 (m), ‒114.4 (m, E), ‒117.4 (m, Z), ‒121.9 (m), ‒122.7 
(m), ‒123.0 (m), ‒123.3 (m), ‒123.7 (m), ‒126.1 (m), ‒132.5 (m).  
IR (ATR): 1693, 1452, 1257, 1233, 1143, 1057, 961, 749 cm–1.  
MS (ESI) m/z (relative intensity): 645 ([M + Na]+, 100), 623 ([M + H]+, 30).  
HR-MS (ESI): m/z calcd. for [C24H14F16O + H]+ 623.0862, found 623.0867. 
  
(E)-1-[4-Methoxy-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307ea): The 
general procedure C was followed using 1-(4-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340e) (158 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) 
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(669 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ea (167 mg, 58%, E/Z = 75:25, 307ea/339ea = 98:2) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 8.7 Hz, 1H), 6.82 (dd, J = 8.7, 2.7 Hz, 1H), 6.72 
(d, J = 2.7 Hz, 1H), 6.17 (dt, J = 23.5, 8.8 Hz, 0.75H, E), 5.92 (dt, J = 33.9, 7.8 Hz, 0.25H, Z), 
3.86 (ddt, J = 7.0, 4.1, 1.6 Hz, 2H), 3.83 (s, 3H), 3.20‒3.00 (m, 0.04H, 339ea) 2.56 (s, 2.25H, 
E), 2.55 (s, 0.75H, Z).  
13C-NMR (125 MHz, CDCl3): δ = 199.1 (Cq), 162.5 (Cq), 144.1 (dt, 1JC‒F = 256.2 Hz, 2JC‒F = 
27.3 Hz, Cq), 141.5 (Cq), 133.1 (CH), 128.8 (Cq), 118.8 (d, 2JC‒F = 8.9 Hz, CH), 117.5 (dt, 1JC‒
F = 287 Hz, 2JC‒F = 31.3 Hz, Cq), 117.0 (CH), 116.5 (CH), 112.8 (m, Cq), 112.6 (m, Cq), 111.6 
(CH), 110.9 (m, Cq), 110.7 (m, Cq), 110.2 (m, Cq), 55.3 (CH3), 29.0 (m, CH2), 28.8 (CH3).  
19F-NMR (471 MHz, CDCl3): δ = ‒80.7 (m), ‒114.3 (m, E), ‒117.3 (m, Z), ‒121.9 (m), ‒122.9 
(m), ‒123.3 (m), ‒124.0 (m), ‒126.1 (m), ‒132.5 (m).  
IR (ATR): 1686, 1604, 1585, 1235, 1199, 1144, 1106, 733, 706 cm–1.  
MS (ESI) m/z (relative intensity): 599 ([M + Na]+, 100), 577 ([M + H]+, 30).  
HR-MS (ESI): m/z calcd. for [C19H12F16O2 + H]+ 577.0655, found 577.0653. 
 
(E)-1-[4-Trifluoromethyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one 
(307fa): The general procedure C was followed using 1-[4-trifluoromethyl-N-(3,4,5-
trimethoxyphenyl)-1-phenyl]ethan-1-one (340f) (177 mg, 0.50 mmol) and 1H,1H,2H-
perfluorodec-1-ene (301a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 25/1) yielded 307fa (166 mg, 54%, E/Z = 72:28, 307fa/339fa = 97:3) as a 
yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 8.1 Hz, 1H), 7.65 (dd, J = 8.1, 1.4 Hz, 1H), 7.53 
(d, 1.4 Hz, 1H), 6.10 (dt, J = 22.6, 8.5 Hz, 0.72H, E), 5.87 (dt, J = 33.5, 7.5 Hz, 0.28H, Z), 3.86 
(ddt, J = 7.0, 4.0, 2.0 Hz, 2H), 3.30–3.20 (m, 0.06H, 339fa), 2.66 (s, 2.16H, E), 2.65 (s, 0.84H, 
Z).  
13C-NMR (75 MHz, CDCl3): δ = 200.4 (Cq), 145.3 (dt, 1JC‒F = 261.2 Hz, 2JC‒F = 29.5 Hz, Cq), 
139.7 (Cq), 138.8 (Cq), 133.7 (q, 2JC‒F = 33.0 Hz, Cq), 130.0 (CH), 127.8 (q, 3JC‒F = 3.8 Hz, 
CH), 125.0 (d, 1JC‒F = 273.3 Hz, Cq), 124.0 (q, 3JC‒F = 3.7 Hz, CH), 118.0 (dt, 1JC‒F = 376.1 Hz, 
2JC‒F = 22.3 Hz, Cq), 117.7 (d, 2JC‒F = 7.8 Hz, CH), 114.0 (m, Cq), 111.5 (m, Cq), 110.8 (m, 
Cq), 110.2 (m, Cq), 108.0 (m, Cq), 107.5 (m, Cq), 29.3 (CH3), 28.1 (m, CH2).   
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19F-NMR (282 MHz, CDCl3): δ = ‒63.6 (m), ‒81.0 (m), ‒114.7 (m), ‒117.7 (m), ‒122.1 (m), 
‒122.9 (m), ‒123.2 (m), ‒123.4 (m), ‒126.4 (m), ‒130.7 (m).  
IR (ATR): 1719, 1311, 1263, 1223, 1140, 1100, 720, 700 cm–1.  
MS (ESI) m/z (relative intensity): 637 ([M + Na]+, 100), 615 ([M + H]+, 40).  
HR-MS (ESI): m/z calcd. for [C19H9F19O + Na]+ 637.0242, found 637.0241. 
  
(E)-Methyl-4-acetyl-3-(1H,1H,2H-perfluorodec-2-en-1-yl)benzoate (307ga): The general 
procedure C was followed using methyl-4-(1-((3,4,5-trimethoxyphenyl)imino)ethyl)benzoate 
(340g) (172 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) (669 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 307ga (145 mg, 48%, 
E/Z = 70:30, 307ga/339ga = 99:1) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.00 (d, J = 7.7 Hz, 1H), 7.90 (dd, J = 7.7, 1.9 Hz, 1H), 7.79 
(d, J = 1.9 Hz, 1H), 6.10 (dt, J = 22.8, 8.7, 0.70H, E), 5.87 (dt, J = 33.4, 7.7 Hz, 0.30H, Z), 3.92 
(s, 3H), 3.81 (ddt, J = 7.4, 4.5, 2.1 Hz, 2H), 3.30‒3.20 (m, 0.02H, 339ga), 2.61 (s, 2.10H, E), 
2.60 (s, 0.90H, Z). 
13C-NMR (125 MHz, CDCl3): δ = 200.9 (Cq), 165.7 (Cq), 144.5 (dt, 1JC‒F = 256.2 Hz, 2JC‒F = 
27.9 Hz, Cq), 140.3 (Cq), 138.1 (Cq), 133.1 (Cq), 132.3 (CH), 129.6 (CH), 128.2 (CH), 118.0 
(d, 2JC‒F = 8.1 Hz, CH), 115.0 (dt, 1JC‒F = 281 Hz, 2JC‒F = 31.3 Hz, Cq), 112.6 (m, Cq), 111.6 
(m, Cq), 110.9 (m, Cq), 110.6 (m, Cq), 110.4 (m, Cq), 108.5 (m, Cq), 52.4 (CH3), 29.5 (CH3), 
28.1 (m, CH2).  
19F-NMR (471 MHz, CDCl3): δ = ‒80.8 (m), ‒114.5 (m, E), ‒117.4 (m, Z), ‒121.9 (m), ‒122.7 
(m), ‒122.9 (m), ‒123.3 (m), ‒126.1 (m), ‒131.1 (m).  
IR (ATR): 1725, 1663, 1222, 1205, 1156, 1100, 701 cm–1.  
MS (ESI) m/z (relative intensity): 627 ([M + Na]+, 100), 605 ([M + H]+, 10).  
HR-MS (ESI): m/z calcd. for [C20H12F16O3 + H]+ 605.0604, found 605.0601. 




(E)-1-[4-Chloro-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307ha): The 
general procedure C was followed using 1-(4-chlorophenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340h) (160 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) 
(669 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ha (171 mg, 59%, E/Z = 83:17, 307ha/339ha = 98:2) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.76 (dd, J = 8.4, 1.9 Hz, 1H), 7.37 (dd, J = 8.4, 2.1 Hz, 1H), 
7.29 (dd, 2.1, 1.9 Hz, 1H), 6.16 (dt, 22.3, 8.7 Hz, 0.83H, E), 5.92 (dt, J = 33.4, 7.7 Hz, 0.17H, 
Z), 3.80 (ddt, J = 7.8, 4.1, 2.0 Hz, 2H), 3.20–3.10 (m, 0.04H, 339ha) 2.62 (s, 2.49H, E), 2.61 
(s, 0.51H, Z).  
13C-NMR (75 MHz, CDCl3): δ = 199.8 (Cq), 145.1 (dt, 1JC‒F = 275 Hz, 2JC‒F = 28.5 Hz, Cq), 
140.4 (Cq), 138.5 (Cq), 134.7 (CH), 131.6 (CH), 131.2 (CH), 127.2 (Cq), 118.2 (dt, 1JC‒F = 
285.2 Hz, 2JC‒F = 35.3 Hz, Cq), 118.0 (d, 2JC‒F = 7.2 Hz, CH), 115.2 (m, Cq), 114.5 (m, Cq), 
114.3 (m, Cq), 112.4 (m, Cq), 111.5 (m, Cq), 111.1 (m, Cq), 29.1 (CH3), 28.2 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.8 (m), –114.5 (m, E), –117.5 (m, Z), –122.0 (m), –122.7 
(m), –123.0 (m), –123.3 (m), –126.2 (m), –131.2 (m).  
IR (ATR): 1695, 1345, 1279, 1259, 1153, 1102, 741, 721 cm–1.  
MS (ESI) m/z (relative intensity): 603 ([M + Na]+, 100), 581 ([M + H]+, 55).  
HR-MS (ESI): m/z calcd. for [C18H935ClF16O + H]+ 581.0159, found 581.0163. 
  
(E)-1-[5-Methyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (307ia): The 
general procedure C was followed using 1-(3-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340i) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (301a) 
(669 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ia (176 mg, 63%, E/Z = 74:26, 307ia/339ia = 91:9) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 2.7 Hz, 1H), 7.32 (dd, 8.4, 2.7 Hz, 1H), 7.17 (dd, 
J = 8.4 Hz, 2.7 Hz, 1H), 6.17 (dt, J = 23.2, 8.7 Hz, 0.74H, E), 5.94 (dt, J = 33.8, 7.8 Hz, 0.26H, 
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Z), 3.79 (ddt, J = 7.4, 4.2, 2.2 Hz, 2H), 3.22–2.97 (m, 0.18H, 339ia), 2.62 (s, 2.22H, E), 2.61 
(s, 0.78H, Z) 2.42 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 201.2 (Cq), 144.1 (dt, 1JC‒F = 258.1 Hz, 2JC‒F = 28.3 Hz, Cq), 
136.8 (Cq), 136.5 (Cq), 135.1 (Cq), 133.0 (CH), 131.1 (CH), 130.7 (CH), 119.9 (dt, 1JC‒F = 
288.2 Hz, 2JC‒F = 34.1 Hz, Cq), 119.2 (d, 2JC‒F = 17.5 Hz, CH), 115.2 (m, Cq), 112.1 (m, Cq), 
111.6 (m, Cq), 110.7 (m, Cq), 108.6 (m, Cq), 108.2 (m, Cq), 29.1 (CH3), 27.9 (m, CH2), 20.8 
(CH3).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.4 (m, E), –117.5 (m, Z), –122.0 (m), –122.8 
(m), –123.4 (m), –124.3 (m), –126.2 (m), –132.7 (m).  
IR (ATR): 1679, 1607, 1582, 1251, 1185, 1134, 1106, 733, 716 cm–1.  
MS (ESI) m/z (relative intensity): 583 ([M + Na]+, 100), 561 ([M + H]+, 40).  
HR-MS (ESI): m/z calcd. for [C19H12F16O + H]+ 561.0705, found 561.0710. 
  
(E)-1-[4-Methyl-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307ac): The 
general procedure C was followed using 1-(4-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340a) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-ene 
(301c) (820 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) 
yielded 307ac (210 mg, 64%, E/Z = 83:17, 307ac/339ac = 94:6) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 8.0 Hz, 1H), 7.18 (dd, J = 8.0, 1.9 Hz, 1H), 7.08 
(d, J = 1.9 Hz, 1H), 6.20 (dt, J = 25.3, 8.1 Hz, 0.83H, E), 5.95 (dt, J = 33.9, 4.4 Hz, 0.17H, Z), 
3.84 (ddt, J = 7.3, 4.1, 2.1 Hz, 2H), 3.21–3.03 (m, 0.12H, 339ac), 2.61 (s, 2.49H, E), 2.60 (s, 
0.51H, Z), 2.40 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 200.4 (Cq), 144.6 (dt, 1JC‒F = 255.1 Hz, 2JC‒F = 25.3 Hz, Cq), 
143.2 (Cq), 138.6 (Cq), 133.6 (Cq), 132.0 (CH), 130.7 (CH), 127.6 (CH), 119.7 (dt, 1JC‒F = 
275.3 Hz, 2JC‒F = 37.3 Hz, Cq), 119.1 (d, 2JC‒F = 9.8 Hz, CH), 115.1 (m, Cq), 111.6 (m, Cq), 
110.8 (m, Cq), 110.7 (m, Cq), 110.1 (m, Cq), 108.6 (m, Cq), 107.5 (m, Cq), 107.1 (m, Cq), 29.0 
(CH3), 28.4 (m, CH2), 21.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –121.9 (m), –122.8 
(m), –123.0 (m), –123.1 (m), –123.4 (m), –124.4 (m), –126.3 (m), –132.8 (m).  
IR (ATR): 1700, 1355, 1249, 1210, 1195, 1100, 730, 695 cm–1.  
MS (ESI) m/z (relative intensity): 683 ([M + Na]+, 100), 661 ([M + H]+, 30).  
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HR-MS (ESI): m/z calcd. for [C21H12F20O + H]+ 661.0642, found 661.0641. 
 
(E)-1-[4-Methyl-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307cc): The 
general procedure C was followed using 1-(4-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340c) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-ene (301c) 
(820 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307cc (210 mg, 64%, E/Z = 83:17, 307cc/339cc = 94:6) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 8.0 Hz, 1H), 7.18 (dd, J = 8.0, 1.9 Hz, 1H), 7.08 
(d, J = 1.9 Hz, 1H), 6.20 (dt, J = 25.3, 8.1 Hz, 0.83H, E), 5.95 (dt, J = 33.9, 4.4 Hz, 0.17H, Z), 
3.84 (ddt, J = 7.3, 4.1, 2.1 Hz, 2H), 3.21–3.03 (m, 0.12H, 339cc), 2.61 (s, 2.49H, E), 2.60 (s, 
0.51H, Z), 2.40 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 200.4 (Cq), 144.6 (dt, 1JC‒F = 255.1 Hz, 2JC‒F = 25.3 Hz, Cq), 
143.2 (Cq), 138.6 (Cq), 133.6 (Cq), 132.0 (CH), 130.7 (CH), 127.6 (CH), 119.7 (dt, 1JC‒F = 
275.3 Hz, 2JC‒F = 37.3 Hz, Cq), 119.1 (d, 2JC‒F = 9.8 Hz, CH), 115.1 (m, Cq), 111.6 (m, Cq), 
110.8 (m, Cq), 110.7 (m, Cq), 110.1 (m, Cq), 108.6 (m, Cq), 107.5 (m, Cq), 107.1 (m, Cq), 29.0 
(CH3), 28.4 (m, CH2), 21.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –121.9 (m), –122.8 
(m), –123.0 (m), –123.1 (m), –123.4 (m), –124.4 (m), –126.3 (m), –132.8 (m).  
IR (ATR): 1700, 1355, 1249, 1210, 1195, 1100, 730, 695 cm–1.  
MS (ESI) m/z (relative intensity): 683 ([M + Na]+, 100), 661 ([M + H]+, 30).  
HR-MS (ESI): m/z calcd. for [C21H12F20O + H]+ 661.0642, found 661.0641. 
  
(E)-1-[4-Methoxy-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307ec): 
The general procedure C was followed using 1-[4-methoxy-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340e) (160 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-ene (301c) 
(820 mg, 1.50 mmol) Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ec (203 mg, 60%, E/Z = 82:18, 307ec/339ec = 98:2) as a yellow solid. M.p.: 52 °C.  
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1H-NMR (500 MHz, CDCl3): δ = 7.81 (d, J = 8.5 Hz, 1H), 6.81 (dd, J = 8.5, 2.7 Hz, 1H), 6.71 
(d, J = 2.7 Hz, 1H), 6.16 (dt, J = 27.5, 7.8 Hz, 0.82H, E), 5.92 (dt, J = 32.7, 7.5 Hz, 0.18H, Z), 
3.85 (ddt, J = 7.3, 3.6, 1.6 Hz, 2H), 3.82 (s, 3H), 3.20‒3.00 (m, 0.04H, 339ec), 2.55 (s, 2.46H, 
E), 2.54 (s, 0.54H, Z).  
13C-NMR (125 MHz, CDCl3): δ = 199.1 (Cq), 162.4 (Cq), 144.0 (dt, 1JC‒F = 235.3 Hz, 2JC‒F = 
28.1 Hz, Cq), 141.4 (Cq), 133.0 (CH), 128.7 (Cq), 118.7 (d, 2JC‒F = 8.5 Hz, CH), 117.5 (dt, 1JC‒
F = 273.2 Hz, 2JC‒F = 30.9 Hz, Cq), 117.0 (CH), 112.7 (m, Cq), 112.6 (m, Cq), 112.5 (m, Cq), 
111.5 (CH), 111.4 (m, Cq), 110.8 (m, Cq), 110.6 (m, Cq), 110.1 (m, Cq), 108.4 (m, Cq), 55.2 
(CH3), 28.9 (m, CH2), 28.7 (CH3).   
19F-NMR (282 MHz, CDCl3): δ = –80.8 (m), –114.3 (m, E) , –117.4 (m, Z), –121.8 (m), –122.7 
(m), –123.0 (m), –123.1 (m), –123.3 (m), –124.0 (m), –126.1 (m), –132.5 (m).  
IR (ATR): 1720, 1450, 1335, 1229, 1209, 1104, 720, 607 cm–1.  
MS (ESI) m/z (relative intensity): 699 ([M + Na]+, 100), 677 (80).  
HR-MS (ESI): m/z calcd. for [C21H12F20O2 + H]+ 677.0591, found 677.0584. 
  
(E)-1-[5-Methyl-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307ic): The 
general procedure C was followed using 1-(3-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340i) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-ene (301c) 
(820 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
307ic (201 mg, 61%, E/Z = 73:27, 307ic/339ic = 87:13) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 2.5 Hz, 1H), 7.31 (dd, 8.0, 2.5 Hz, 1H), 7.16 (d, 
J = 8.0 Hz, 1H), 6.18 (dt, J = 25.4, 6.3, 0.73H, E), 5.93 (dt, J = 33.4, 4.2 Hz, 0.27H, Z), 3.79 
(ddt, J = 7.7, 4.2, 2.2 Hz, 2H), 3.22–2.97 (m, 0.27H, 339ic), 2.62 (s, 2.19H, E), 2.61 (s, 0.81H, 
Z), 2.42 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 201.2 (Cq), 144.2 (dt, 1JC‒F = 255.3 Hz, 2JC‒F = 28.1 Hz, Cq), 
136.8 (Cq), 136.6 (Cq), 135.1 (Cq), 133.0 (CH), 131.1 (CH), 130.7 (CH), 119.6 (dt, 1JC‒F = 
288.2 Hz, 2JC‒F = 34.1 Hz, Cq), 119.2 (d, 2JC‒F = 7.5 Hz, CH), 115.1 (m, Cq), 112.1 (m, Cq), 
111.6 (m, Cq), 111.2 (m, Cq), 110.7 (m, Cq), 110.1 (m, Cq), 108.1 (m, Cq), 107.5 (m, Cq), 29.2 
(CH3), 27.9 (m, CH2), 20.9 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –121.9 (m), –122.8 
(m), –123.0 (m), –123.1 (m), –123.4 (m), –124.4 (m), –126.3 (m), –132.8 (m).  
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IR (ATR): 1712, 1355, 1243, 1223, 1155, 1130, 725, 695 cm–1.  
MS (ESI) m/z (relative intensity): 683 ([M + Na]+, 100), 661 ([M + H]+, 20).  
HR-MS (ESI): m/z calcd. for [C21H12F20O + H]+ 661.0642, found 661.0639. 
 
(E)-1-[4-Phenyl-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307dc): The 
general procedure C was followed using 1-([1,1'-biphenyl]-4-yl)-N-(3,5-dimethoxy-4-
methylphenyl)ethan-1-imine (340d) (188 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-
ene (301c) (820 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
25/1) yielded 307dc (202 mg, 56%, E/Z = 82:18, 307dc/339dc = 98:2) as a yellow solid. M.p.: 
67 °C .  
1H-NMR (300 MHz, CDCl3): δ = 7.92 (d, J = 8.1 Hz, 1H), 7.66–7.58 (m, 3H), 7.55–7.43(m, 
4H), 6.25 (dt, J = 23.5, 8.2 Hz, 0.82H, E), 6.02 (dt, J = 33.7, 7.8 Hz, 0.18H, Z), 3.90 (ddt, J = 
8.5, 4.1, 2.0 Hz, 2H), 3.27–3.15 (m, 0.02H, 339dc), 2.68 (s, 2.46H, E), 2.67 (s, 0.54H, Z).  
13C-NMR (75 MHz, CDCl3): δ = 200.5 (Cq), 145.2 (dt, 1JC‒F = 251.3 Hz, 2JC‒F = 29.4 Hz, Cq), 
144.4 (Cq), 139.4 (Cq), 139.1 (Cq), 134.9 (Cq), 131.1 (CH), 130.2 (CH), 130.0 (CH), 128.9 
(CH), 128.3 (CH), 127.2 (CH), 125.6 (CH), 119.0 (d, 2JC‒F = 8.1 Hz, CH), 118.1 (dt, 1JC‒F = 
288.2 Hz, 2JC‒F = 32.3 Hz, Cq), 115.2 (m, Cq), 114.4 (m, Cq), 114.1 (m, Cq), 111.6 (m, Cq), 
110.8 (m, Cq), 110.1 (m, Cq), 107.6 (m, Cq), 107.1 (m, Cq), 29.1 (CH3), 28.7 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = ‒80.8 (m), ‒114.4 (m, E), ‒117.4 (m, Z), ‒121.9 (m), ‒122.7 
(m), ‒123.0 (m), ‒123.3 (m), ‒123.4 (m), ‒123.7 (m), ‒126.1 (m), ‒132.5 (m).  
IR (ATR): 1693, 1370, 1265, 1230, 1179, 1121, 710, 630 cm–1.  
MS (ESI) m/z (relative intensity): 745 ([M + Na]+, 100), 740 (30), 723 ([M + H]+, 20).  
HR-MS (ESI): m/z calcd. for [C26H14F20O + H]+ 723.0798, found 723.0786. 
 
(E)-1-[4-Trifluoromethyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one 
(307fc): The general procedure C was followed using 1-[4-trifluoromethyl-N-(3,4,5-
trimethoxyphenyl)-1-phenyl]ethan-1-one (340f) (177 mg, 0.50 mmol) and 1H,1H,2H-
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perfluorododec-1-ene (301c) (820 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 25/1) yielded 307fc (193 mg, 54%, E/Z = 73:27) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.87 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.0, 1.4 Hz, 1H), 7.52 
(d, J = 1.4 Hz, 1H), 6.10 (dt, J = 25.6, 8.5 Hz, 0.73H, E), 5.87 (dt, J = 33.4, 7.8 Hz, 0.27H, Z), 
3.86 (ddt, J = 7.5, 4.0, 2.0 Hz, 2H), 2.65 (s, 2.19H, E), 2.64 (s, 0.81H, Z).  
13C-NMR (100 MHz, CDCl3): δ = 200.4 (Cq), 145.1 (dt, 1JC‒F = 261.2 Hz, 2JC‒F = 29.5 Hz, Cq), 
139.9 (Cq), 138.9 (CH), 133.9 (q, 2JC‒F = 33.1 Hz, Cq), 130.0 (CH), 127.9 (q, 3JC‒F = 3.8 Hz, 
CH), 125.0 (d, 1JC‒F = 273.5 Hz, Cq), 124.1 (d, 2JC‒F = 7.3 Hz, Cq), 117.5 (dt, 1JC‒F = 275.2 Hz, 
2JC‒F = 22.3 Hz, Cq), 116.9 (d, 2JC‒F = 7.8 Hz, CH), 114.1 (m, Cq), 113.2 (m, Cq), 111.6 (m, 
Cq), 110.8 (m, Cq), 110.5 (m, Cq), 110.2 (m, Cq), 108.7 (m, Cq), 108.6 (m, Cq), 29.4 (CH3), 28.1 
(m, CH2).  
19F-NMR (376 MHz, CDCl3): δ = ‒63.6 (m), ‒81.0 (m), ‒114.6 (m, E), ‒117.6 (m, Z), ‒121.9 
(m), ‒122.0 (m), ‒122.3 (m), ‒122.5 (m), ‒123.2 (m), ‒123.4 (m), ‒126.3 (m), ‒130.7 (m).  
IR (ATR): 1712, 1412, 1238, 1212, 1155, 1114, 711, 601 cm–1.  
MS (ESI) m/z (relative intensity): 737 ([M + Na]+, 100), 722 (20).  
HR-MS (ESI): m/z calcd. for [C21H9F23O + Na]+ 737.0178, found 737.0170. 
 
(E)-1-[4-Chloro-2-(1H,1H,2H-perfluorododec-2-en-1-yl)phenyl]ethan-1-one (307ha): The 
general procedure C was followed using 1-(4-chlorophenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340h) (160 mg, 0.50 mmol) and 1H,1H,2H-perfluorododec-1-ene 
(301c) (820 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) 
yielded 307ha (204 mg, 60%, E/Z = 76:24, 307ha/339ha = 99:1) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 8.4 Hz, 1H), 7.37 (dd, J = 8.4, 1.6 Hz, 1H), 7.22 
(d, 1.6 Hz, 1H), 6.14 (dt, J = 24.7, 8.7 Hz, 0.76H, E), 5.92 (dt, J = 35.4, 7.8 Hz, 0.24H, Z), 3.86 
(ddt, J = 7.8, 4.1, 2.0 Hz, 2H), 3.26–3.03 (m, 0.02H, 339ha), 2.62 (s, 2.28H, E), 2.61 (s, 0.72H, 
Z).   
13C-NMR (75 MHz, CDCl3): δ = 199.7 (Cq), 144.5 (dt, 1JC‒F = 259.1 Hz, 2JC‒F = 28.4 Hz, Cq), 
140.1 (Cq), 138.5 (Cq), 134.7 (Cq), 131.5 (CH), 131.2 (CH), 127.2 (CH), 118.3 (dt, 1JC‒F = 
288.3 Hz, 2JC‒F = 32.3 Hz, Cq), 118.0 (d, 2JC‒F = 8.9 Hz, CH), 114.5 (Cq), 113.3 (Cq), 112.1 
(Cq), 111.5 (Cq), 111.1 (Cq), 110.5 (Cq), 108.0 (Cq), 107.1 (Cq), 29.1 (CH3), 28.1 (m, CH2).  
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19F-NMR (282 MHz, CDCl3): δ = ‒80.9 (m), ‒114.5 (m, E), ‒117.5 (m, Z), ‒122.0 (m), ‒122.8 
(m), ‒123.1 (m), ‒123.3 (m), ‒123.4 (m), ‒123.8 (m), ‒126.2 (m), ‒132.4 (m). 
IR (ATR): 1699, 1379, 1269, 1232, 1181, 1123, 711, 630 cm–1.  
MS (ESI) m/z (relative intensity): 703 ([M + Na]+, 100), 698 (10), 685 (20).  
HR-MS (ESI): m/z calcd. for [C20H9ClF20O + Na]+ 702.9915, found 702.9905. 
  
(E)-1-[2-(1H,1H,2H-Perfluorohex-2-en-1-yl)phenyl]ethan-1-one (307ab): The general 
procedure C was followed using N-(3,4,5-trimethoxyphenyl)-1-phenylethan-1-imine (340a) 
(143 mg, 0.50 mmol) and 1H,1H,2H-perfluorohex-2-en-1-yl (301b) (370 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 307ab (83 mg, 48%, E/Z 
= 89:11, 307ab/339ab = 91:9) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.82 (dd, J = 7.5, 1.6 Hz, 1H), 7.50 (ddd, J = 7.7, 7.5, 1.6 Hz, 
1H), 7.39 (ddd, J = 7.7, 7.6, 1.6 Hz, 1H), 7.27 (dd, 7.6, 1.6 Hz, 1H), 6.18 (dt, J = 23.1, 8.3 Hz, 
0.89H, E), 5.95 (dt, J = 33.8, 7.8 Hz, 0.11H, Z), 3.80 (ddt, J = 7.8, 4.0, 2.0 Hz, 2H), 3.20–3.10 
(m, 0.18H, 339ab), 2.64 (s, 2.67H, E), 2.64 (s, 0.33H, Z).  
13C-NMR (75 MHz, CDCl3): δ = 201.1 (Cq), 141.5 (dt, 1JC‒F = 259.2 Hz, 2JC‒F = 28.4 Hz, Cq), 
138.2 (Cq), 136.6 (Cq), 132.4 (CH), 131.2 (CH), 130.2 (CH), 127.1 (CH), 119.3 (dt, 1JC‒F = 
288.1 Hz, 2JC‒F = 32.3 Hz, Cq), 118.3 (d, 2JC‒F = 8.9 Hz, CH), 115.8 (m, Cq), 111.1 (m, Cq), 
29.3 (CH3), 28.3 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = ‒80.7 (m), ‒115.4 (m, E), ‒118.5 (m, Z), ‒124.1 (m, E), ‒
127.8 (m, Z), ‒132.6 (m).  
IR (ATR): 1709, 1425, 1255, 1232, 1189, 1104, 781, 651 cm–1.  
MS (ESI) m/z (relative intensity): 381 ([M + Na]+, 100), 369 (80).  
HR-MS (ESI): m/z calcd. for [C14H10F8O + Na]+ 369.0496, found 369.0497. 
 
(E)-1-[4-Methyl-2-(1H,1H,2H-perfluorohex-2-en-1-yl)phenyl]ethan-1-one (307cb): The 
general procedure C was followed using 1-(4-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-
phenylethan-1-imine (340c) (150 mg, 0.50 mmol) and 1H,1H,2H-perfluorohex-2-en-1-yl 
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(301b) (370 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) 
yielded 307cb (88 mg, 49%, E/Z = 81:19, 307cb/339cb = 99:1) as a yellow oil.    
1H-NMR (300 MHz, CDCl3): δ = 7.75 (dd, J = 1.8 Hz, 0.8 Hz, 1H), 7.19 (dd, J = 8.0, 1.8 Hz, 
1H), 7.17 (dd, 8.0, 0.8 Hz, 1H), 6.18 (dt, J = 23.3, 8.3 Hz, 0.81H, E), 5.95 (dt, J = 32.9, 7.8 Hz, 
0.19H, Z), 3.83 (ddt, J = 8.4, 4.8, 2.2 Hz, 2H), 3.30‒3.15 (m, 0.02H, 339cb), 2.62 (s, 2.43H, 
E), 2.61 (s, 0.57H, Z), 2.40 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 200.5 (Cq), 144.2 (dt, 1JC‒F = 259.1 Hz, 2JC‒F = 28.4 Hz, Cq), 
143.2 (Cq), 138.6 (Cq), 133.6 (Cq), 132.1 (CH), 130.7 (CH), 127.6 (CH), 119.1 (dt, 1JC‒F = 
288.3 Hz, 2JC‒F = 32.3 Hz, Cq), 118.3 (d, 2JC‒F = 8.7 Hz, CH), 112.8 (m, Cq), 108.3 (m, Cq), 
29.0 (CH3), 28.4 (m, CH2) , 21.3 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = ‒80.7 (m), ‒115.4 (m, E), ‒118.4 (m, Z), ‒124.5 (m, E), ‒
127.8 (m, Z), ‒133.0 (m).  
IR (ATR): 1720, 1470, 1267, 1232, 1189, 1131, 711, 630 cm–1.  
MS (ESI) m/z (relative intensity): 383 ([M + Na]+, 100), 333 (10).  
HR-MS (ESI): m/z calcd. for [C15H12F8O + H]+ 361.0833, found 361.0828. 
 
(E)-1-[4-Phenyl-2-(1H,1H,2H-perfluorohex-2-en-1-yl)phenyl]ethan-1-one (307db): The 
general procedure C was followed using 1-([1,1'-biphenyl]-4-yl)-N-(3,5-dimethoxy-4-
methylphenyl)ethan-1-imine (340d) (188 mg, 0.50 mmol) and 1H,1H,2H-Perfluorohex-2-en-
1-yl (301b) (370 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
25/1) yielded 307db (110 mg, 52%, E/Z = 84:16, 307db/339db = 99:1) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.90 (d, J = 8.1 Hz, 1H), 7.60–7.55 (m, 3H), 7.52–7.40 (m, 
4H), 6.23 (dt, J = 23.1, 8.4 Hz, 0.84H, E), 6.00 (dt, J = 33.7, 7.8 Hz, 0.16H, Z), 3.87 (ddt, J = 
8.3, 4.2, 2.1 Hz, 2H), 3.23–3.12 (m, 0.02H, 339db), 2.65 (s, 2.52H, E), 2.66 (s, 0.48H, Z).  
13C-NMR (75 MHz, CDCl3): δ = 200.5 (Cq), 145.2 (dt, 1JC‒F = 259.9 Hz, 2JC‒F = 28.4 Hz, Cq), 
144.5 (Cq), 139.4 (Cq), 139.0 (Cq), 134.9 (Cq), 131.1 (CH), 130.2 (CH), 129.9 (CH), 129.0 
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(CH), 128.4 (CH), 127.1 (CH), 125.6 (CH), 119.0 (d, 2JC‒F = 7.8 Hz, CH), 117.4 (dt, 1JC‒F = 
288.1 Hz, 2JC‒F = 32.3 Hz, Cq), 111.5 (m, Cq), 108.8 (m, Cq), 29.2 (CH3), 28.6 (m, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.6 (m), –115.3 (m, E), –118.4 (m, Z), –124.0 (m, E), –
127.7 (m, Z), –132.4 (m).  
IR (ATR): 1711, 1410, 1237, 1212, 1199, 1111, 701, 600 cm–1.  
MS (ESI) m/z (relative intensity): 445 ([M + Na]+, 100), 423 ([M + H]+, 20).  




A suspension of ketimine 340a (0.50 mmol, 1.0 equiv), 1H,1H,2H-perfluoroalkene 301a 
(1.50 mmol, 3.0 equiv), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), NaOAc (12.3 mg, 
30 mol %)  and K2CO3 (104 mg, 0.75 mmol, 1.50 equiv) in 1,4-dioxane (0.50 mL, 1 M) was 
stirred under nitrogen at 120 °C for 16 h. At ambient temperature, the reaction mixture was 
diluted with EtOAc (5.0 mL) and HCl (5.0 mL, 1 M) was added. The mixture was stirred for 3 
h and extracted with EtOAc (3 x 10 mL). After removal of the solvents in vacuo, the remaining 
residue was purified by column chromatography on silica gel to afford the desired product 
339aa. 
1H-NMR (300 MHz, CDCl3): δ = 7.76 (dd, J = 7.8, 1.6 Hz, 1H), 7.44 (ddd, J = 7.7, 7.5, 1.6 Hz, 
1H), 7.33 (ddd, J = 7.8, 7.5, 1.6 Hz, 1H), 7.28 (dd, J = 7.7, 1.6 Hz, 1H), 3.38–2.77 (m, 2H), 
2.59 (s, 3H), 2.56–2.24 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 201.0 (Cq), 140.0 (Cq), 137.0 (Cq), 132.2 (CH), 131.8 (CH), 
130.1 (CH), 126.8 (CH), 121.0–108.2 (m, –C8F17), 32.7 (t, 2JC‒F = 22 Hz, CH2), 29.2 (CH3), 
25.7 (t, 3JC‒F = 5 Hz, CH2).  
19F-NMR (282 MHz, CDCl3): δ = –80.9 (m), –114.6 (m), –121.7 (m), –122.0 (m), –122.8 (m), 
–123.5 (m), –126.1 (m), –126.3 (m).  
IR (ATR): 1701, 1419, 1257, 1233, 1155, 1121, 711, 610 cm–1.  
MS (ESI) m/z (relative intensity): 589 ([M + Na]+, 100), 584 (10), 569 (40).  
HR-MS (ESI): m/z calcd. for [C18H11F17O + Na]+ 589.0431, found 589.0432. 
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5.4.2. Mechanistic Studies 
 
5.4.2.1. Intermolecular competition experiment 
 
1-(4-methylphenyl)-N-(3,4,5-trimethoxyphenyl)-1-phenylethan-1-imine (340c) (150 mg, 0.50 
mmol), 1-[4-trifluoromethyl-N-(3,4,5-trimethoxyphenyl)-1-phenyl]ethan-1-one (340f) (177 
mg, 0.50 mmol), 1H,1H,2H-perfluoroalkene (301a) (446 mg, 1.0 mmol), [RuCl2(p-cymene)]2  
(15.3 mg, 5.0 mol %), P(4-C6H4F)3 (31.6 mg, 20 mol %) and K3PO4 (212 mg, 1.0 mmol) were 
stirred in cyclohexane (1.0 mL) at 120 °C for 16 h. At ambient temperature, the reaction 
mixture was diluted with EtOAc (10.0 mL), and HCl (5 mL, 1 M) was added. The mixture was 
stirred for 3 h and extracted with EtOAc (3 x 10.0 mL). After removal of the solvents in vacuo, 
307fa and 307ca were isolated together by column chromatography on silica gel. The ratio of 
307fa and 307ca was determined by means of 1H-NMR spectroscopy which corresponds to 
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5.4.2.2. H/D Exchange Experiments 
 
Ketimine 340a (143 mg, 0.50 mmol), 1H,1H,2H-perfluoroalkene (301a) (669 mg, 1.50 mmol), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), P(4-C6H4F)3 (31.6 mg, 20.0 mol %) and K3PO4 
(212 mg, 1.0 mmol) were stirred in cyclohexane (1.0 mL) and D2O (5 equiv) at 120 °C for 
16 h. At ambient temperature, the reaction mixture was diluted with EtOAc (5.0 mL) and HCl 
(5.0 mL, 1 M) was added. The mixture was stirred for 3 h and extracted with EtOAc (3 x 
10.0 mL). After removal of the solvents in vacuo, purification by flash column chromatography 
on silica gel yielded [D]n-340a (21%) and [D]n-307aa (52%). 
 
 




5.4.2.3. Intermolecular KIE by Independent Experiments 
 
Two parallel reactions with 340a and [D]5-340a were performed to determine the 
corresponding KIE value. 340a (143 mg, 0.50 mmol) or [D]5-340a (145 mg, 0.50 mmol), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), P(4-C6H4F)3 (31.6 mg, 20.0 mol %), 1,3,5-
trimethoxybenzene (84 mg, 0.50 mmol) and K3PO4 (212 mg, 1.0 mmol) were stirred in 
cyclohexane (1.0 mL) at 120 °C. A periodic aliquot (0.02 mL) was removed by syringe and 
analyzed by 1H-NMR spectroscopy to provide the following conversions: 
 
 





Table 31. Conversion-time table for determination of the KIE. 
Time (min) 70 85 100 115 130 
307aa 1.2 3.1 5.3 7.5 10.4 
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5.5. Enantioselective Cobalt(III)-catalyzed C–H activation 
5.5.1. Analytical Data of Novel Chiral Acids 
 
(4S,5S)-1,3-Dibenzoyl-4,5-diphenylimidazolidine-2-carboxylic acid  (CA5): General 
procedure D was followed using benzoyl chloride (295 mg, 2.10 mmol) to afford (4S,5S)-1,3-
dibenzoyl-4,5-diphenylimidazolidine-2-carboxylic acid CA5 (309.4 mg, 65% yield) as a white 
solid.  
1H-NMR (600 MHz, CD3CO2D):  = 7.74–7.06 (m, 19H), 7.15−6.84 (m, 2H), 5.50 (s, 1H), 
5.24 (s, 1H).  
13C-NMR (125 MHz, CD3CO2D): (one  carbon resonance is missing due to overlap):  = 173.2 
(Cq), 172.6 (Cq), 171.5 (Cq), 141.0 (Cq), 139.1 (Cq), 135.7 (Cq), 134.7 (Cq), 131.7 (CH), 131.5 
(CH), 129.9 (CH), 129.7 (CH), 129.2 (CH), 129.1 (CH), 129.1 (CH), 127.8 (CH), 127.7 (CH), 
127.2 (CH), 126.7 (CH), 73.9 (CH), 72.8 (CH), 71.0 (CH).  
IR (ATR): 3060, 1645, 1602, 1495, 1447, 1388, 867, 754, 698, 551 cm-1.  
[α]D20: −76.0 (c = 1.00, CHCl3).  
MS (ESI) m/z (relative intensity): 499 (80) [M + Na]+, 477 (100) [M + H]+, 425 (20).  
HR-MS (ESI): m/z calcd. for [C30H24N2O4 + H]+ 477.1807 found 477.1809.  
  
(4S,5S)-1,3-Bis(3-methylbenzoyl)-4,5-diphenylimidazolidine-2-carboxylic acid (CA6): 
General procedure D was followed using m-tolouyl chloride (323 mg, 2.10 mmol) to afford 
(4S,5S)-1,3-bis(3-methylbenzoyl)-4,5-diphenylimidazolidine-2-carboxylic acid  CA6  (352.8 
mg, 70% yield) as a white solid.  
1H-NMR (500 MHz, CD3CO2D): δ = 7.49–7.19 (m, 9H), 7.18–7.03 (m, 8H), 7.02–6.88 (m, 
2H), 5.49 (s, 1H), 5.22 (s, 1H), 2.20 (s, 3H), 2.13 (s, 3H).  
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13C-NMR (125 MHz, CD3CO2D): (one  carbon resonance is missing due to overlap): δ = 173.7 
(Cq), 172.9 (Cq), 171.6 (Cq), 141.3 (Cq), 139.5 (Cq), 139.4 (Cq), 139.3 (Cq), 139.2 (Cq), 135.8 
(Cq), 135.4 (CH), 134.8 (CH), 132.5 (CH), 132.3 (CH), 131.4 (CH), 130.0 (CH), 129.8 (CH), 
129.4 (CH), 129.3 (CH), 129.2 (CH), 129.1 (CH), 128.5 (CH), 128.2 (CH), 127.4 (CH), 126.9 
(CH), 125.0 (CH), 124.8 (CH), 73.8 (CH), 72.8 (CH), 70.8 (CH), 21.2 (CH3), 21.1 (CH3). 
 IR (ATR): 3030, 1642, 1585, 1495, 1384, 1211, 1092, 749, 698, 663 cm-1.  
[α]D20: −67.8 (c = 1.10, CHCl3).  
MS (ESI) m/z (relative intensity): 527 (80) [M + Na]+, 505 (100) [M + H]+, 341 (20).  
HR-MS (ESI): m/z calcd. for [C32H28N2O4 + H]+ 505.2122 found 505.2119. 
  
(4S,5S)-1,3-Di(1-naphthoyl)-4,5-diphenylimidazolidine-2-carboxylic acid (CA7): General 
procedure D was followed using 1-naphthoyl chloride (399 mg, 2.10 mmol) to afford (4S,5S)-
1,3-bis(3-methylbenzoyl)-4,5-diphenylimidazolidine-2-carboxylic acid  CA7  (392.1 mg, 68% 
yield) as a white solid.  
1H-NMR (400 MHz, CDCl3+ 1% TFA): δ = 9.00–8.40 (m, 5H), 8.00–7.53 (m, 3H), 7.52–7.40 
(m, 1H), 7.39–7.26 (m, 3H), 7.20–6.89 (m, 9H), 6.76–6.57 (m, 2H), 6.56–6.24 (m, 2H), 4.91 
(s, 1H), 4.71 (s, 1H).   
13C-NMR (125 MHz, CD3CO2D): (four carbon resonance is missing due to overlap): δ = 172.6 
(Cq), 172.3 (Cq), 172.1 (Cq), 140.5 (CH), 139.0 (Cq), 138.9 (Cq), 135.1 (CH), 134.9 (Cq), 134.0 
(Cq), 133.9 (Cq), 133.1 (Cq), 132.6 (Cq), 132.6 (Cq), 132.3 (CH), 131.0 (CH), 129.6 (CH), 129.2 
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(CH), 129.0 (CH), 128.8 (CH), 127.9 (CH), 127.5 (CH), 127.3 (CH), 127.2 (CH), 126.7 (CH), 
126.7 (CH), 125.6 (CH), 125.4 (CH), 75.3 (CH), 73.9 (CH), 71.9 (CH).  
IR (ATR): 3054, 1637, 1508, 1457, 1299, 778, 750, 697, 655 cm–1.  
[α]D20: –94.9 (c = 1.18, CHCl3).  
MS (ESI) m/z: 599 [M + Na]+.  
HR-MS (ESI): m/z calcd. for [C38H28N2O4 + H]+ 577.2122 found 577.2112. 
 
(4S,5S)-4,5-Diphenyl-1,3-bis[3-(trifluoromethyl)benzoyl]imidazolidine-2-carboxylic acid 
(CA11): General procedure D was followed using 3-(trifluoromethyl)benzoyl chloride (436.8 
mg, 2.10 mmol) to afford CA11 (367.1 mg, 60% yield) as a white solid. M.p.: >200 °C.  
1H-NMR (600 MHz, CD3CO2D): δ = 7.62–7.48 (m, 5H), 7.42–7.34 (m, 2H), 7.29–7.13 (m, 
9H), 7.11–6.99 (m, 2H), 6.98–6.83 (m, 1H), 5.35 (s, 1H), 5.17 (bs, 1H).  
13C-NMR (100 MHz, CD3CO2D) (one carbon resonances are missing due to overlap): δ = 171.7 
(Cq), 171.6 (Cq), 170.9 (Cq), 140.0 (Cq), 138.7 (Cq), 137.0 (Cq), 136.1 (Cq), 131.5 (q, 2JC–F = 
32.4 Hz, Cq), 131.4 (q, 2JC–F = 32.4 Hz, Cq), 131.4 (CH), 130.3 (CH), 130.2 (CH), 130.1 (CH), 
129.9 (CH), 129.5 (CH), 128.2 (CH), 128.2 (CH), 128.0 (CH), 127.6 (CH), 127.4 (CH), 124.9 
(CH), 124.9 (CH), 124.7 (q, 1JC–F = 271.8 Hz, Cq), 124.6 (q, 1JC–F = 271.8 Hz, Cq), 74.5 (CH), 
73.3 (CH), 71.6 (CH).  
19F-NMR (377 MHz, CD3CO2D): δ = −63.7 (m), −63.8 (m).  
IR (ATR): 3066, 3033, 1651, 1456, 1386, 1326, 1280, 1121, 1072, 750, 699 cm-1.  
[α]D
20: −49.2 (c = 1.00, CHCl3). MS (ESI) m/z (relative intensity): 1247 (20) [2M+Na]+, 635 
(100) [M+Na]+, 613 (15) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C32H2219F6N2O4+Na]+ 635.1376 found 635.1361.  





(CA12): General procedure D was followed using 3,5-dimethylbenzoyl chloride (352.8 mg, 
2.10 mmol) to afford CA12 (329.0 mg, 62% yield) as a white solid. M.p.: 180–186 °C.   
1H-NMR (400 MHz, CD3CO2D): δ = 7.46–7.27 (m, 8H), 7.25–7.08 (m, 2H), 7.04–6.67 (m, 
7H), 5.51 (s, 1H), 5.24 (bs, 1H), 2.19 (s, 6H), 2.14 (s, 6H).  
13C-NMR (100 MHz, CD3CO2D) (two carbon resonances are missing due to overlap): δ = 172.9 
(Cq), 171.9 (Cq), 170.3 (Cq), 140.2 (Cq), 138.5 (Cq), 138.1 (Cq), 138.1 (Cq), 134.6 (Cq), 133.7 
(Cq), 132.2 (CH), 132.0 (CH), 128.9 (CH), 128.6 (CH), 128.1 (CH), 128.0 (CH), 126.4 (CH), 
125.8 (CH), 124.6 (CH), 124.5 (CH), 72.6 (CH), 71.7 (CH), 69.6 (CH), 20.0 (CH3), 20.0 (CH3).  
IR (ATR): 3030, 2920, 1651, 1602, 1455, 1390, 1345, 858, 753, 698, 664 cm-1.  
[α]D
20: −97.7 (c = 1.00, CHCl3).  
MS (ESI) m/z (relative intensity): 1087 (10) [2M+Na]+, 533 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C34H32N2O4+H]+ 533.2435 found 533.2436. 
 
(4S,5S)-1,3-Bis(4-methylbenzoyl)-4,5-diphenylimidazolidine-2-carboxylic acid  (CA14): 
General procedure D was followed using 4-methylbenzoyl chloride (323.0 mg, 2.10 mmol) to 
afford (4S,5S)-1,3-dibenzoyl-4,5-diphenylimidazolidine-2-carboxylic acid CA14 (352.0 mg, 
70% yield) as a white solid. M.p.: 168–175 °C.  
1H-NMR (400 MHz, CD3CO2D): δ = 7.49 (d, J = 7.4 Hz, 2H), 7.45–7.40 (m, 2H), 7.39–7.35 
(m, 1H), 7.35–7.21 (m, 7H), 7.21–7.12 (m, 2H), 7.13–6.91 (m, 5H), 5.59 (s, 1H), 5.32 (bs, 1H), 
2.30 (s, 3H), 2.27 (s, 3H).  
13C-NMR (100 MHz, CD3CO2D): δ = 173.8 (Cq), 173.0 (Cq), 171.4 (Cq), 142.8 (Cq), 142.4 
(Cq), 141.4 (Cq), 139.3 (Cq), 132.9 (Cq), 131.8 (Cq), 130.1 (CH), 130.0 (CH), 129.9 (CH), 129.9 
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(CH), 129.3 (CH), 129.2 (CH), 128.2 (CH), 128.1 (CH), 127.3 (CH), 126.7 (CH), 73.4 (CH), 
72.7 (CH), 70.9 (CH), 21.4 (CH3), 21.4 (CH3).  
IR (ATR): 3061, 3008, 1635, 1455, 1377, 1388, 1211, 1182, 828, 752, 697 cm-1.  
[α]D
20: −57.4 (c = 1.00, CHCl3).  
MS (ESI) m/z (relative intensity): 1031 (10) [2M+Na]+, 527 (100) [M+Na]+, 505 (20) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C32H28N2O4+Na]+ 527.1941 found 527.1929. 
5.5.2. Characterization Data of the Alkylated Products 
 
 
(R)-2-(1-Phenylpropan-2-yl)-1-(pyridin-2-yl)-1H-indole (357aa): The general procedure E 
was followed using 1-(pyridin-2-yl)-1H-indole (315a) (97.1 mg, 0.50 mmol) and allylbenzene 
(223a) (177 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc = 30:1) 
yielded 357aa (92 mg, 59%, M/AM = 82:18) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.74 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.89 (ddd, J = 7.7, 2.0 
Hz, 1H), 7.70–7.60 (m, 1H), 7.38 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.33 (dd, J = 8.4, 1.2 Hz, 1H), 
7.28 (d, J = 3.2 Hz, 1H), 7.24–7.12 (m, 5H), 6.99–6.92 (m, 2H), 6.58 (d, J = 0.9 Hz, 1H), 3.68–
3.49 (m, 0.82H, M), 3.05 (dd, J = 13.3, 5.3 Hz, 1H), 2.95 (t, J = 7.7 Hz, 0.36H, AM), 2.60 (dd, 
J = 13.3, 7.5 Hz, 1H), 1.28 (d, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 151.6 (Cq), 149.7 (CH), 146.5 (Cq), 140.3 (Cq), 138.4 (CH), 
137.3 (Cq), 129.1 (CH), 128.3 (Cq), 128.1 (CH), 125.9 (CH), 122.3 (CH), 121.8 (CH), 121.7 
(CH), 120.6 (CH), 120.1 (CH), 109.9 (CH), 100.5 (CH), 43.9 (CH2), 32.9 (CH), 19.4 (CH3).  
IR (ATR): 3025, 2965, 1595, 1585, 1468, 1452, 741 cm–1.  
MS (EI) m/z (relative intensity): 312 (20) [M]+, 221 (35), 207 (100).  
HR-MS (EI+): m/z calcd. For [C22H20N2]+ 312.1626, found 312.1621.  
[α]D20: +16.0 (c = 1.00, CHCl3).  
HPLC  separation (Chiralpak® IB-3, n-hexane/EtOAc  90:10, 1.0 mL/min, detection at 280 
nm): tr (major) = 7.9 min, tr (minor) = 9.5 min, tr (AM) = 10.2 min, 88:12 e.r.  




(R)-1-(5-Methylpyridin-2-yl)-2-(1-phenylpropan-2-yl)-1H-indole (355aa): The general 
procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) (104.1 mg, 
0.50 mmol) and allylbenzene (223a) (177 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355aa (99.4 mg, 61%, M/AM = 92:8) as a 
yellow oil.  
1H-NMR (300 MHz, CDCl3):  = 8.54 (dd, J = 2.4, 0.8 Hz, 1H), 7.69−7.60 (m, 2H), 7.28−7.20 
(m, 3H), 7.20−7.09 (m, 4H), 7.04−6.89 (m, 2H), 6.54 (d, J = 0.8 Hz, 1H), 3.72−3.43 (m, 0.92H, 
M), 3.07 (dd, J = 13.3, 5.2 Hz, 1H), 2.90 (t, J = 7.5 Hz, 0.16H, AM), 2.61 (dd, J = 13.4, 9.0 
Hz, 1H), 2.46 (s, 3H), 1.26 (d, J = 6.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3):  = 149.7 (CH), 149.0 (Cq), 146.3 (Cq), 140.2 (Cq), 138.7 (CH), 
137.3 (Cq), 131.9 (Cq), 128.9 (CH), 128.3 (Cq), 127.9 (CH), 125.8 (CH), 121.4 (CH), 121.1 
(CH), 120.3 (CH), 119.9 (CH), 109.9 (CH), 99.9 (CH), 43.7 (CH2), 32.9 (CH), 19.5 (CH3), 
18.1 (CH3). 
IR (ATR): 2925, 1596, 1482, 1455, 1396, 1346, 1314, 785, 748, 699 cm–1.  
MS (ESI) m/z (relative intensity): 349 (20) [M + Na]+, 327 (100) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C23H22N2 + H]+ 327.1859 found 327.1856.  
[α]D20: +9.2 (c = 0.90, CHCl3).  
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 95:5, 0.75 mL/min, detection at 273 nm): 
tr (major) = 8.9 min, tr (minor) = 10.0 min, tr (AM) = 10.7 min, 92:8 e.r.  
 
(R)-5-Bromo-1-(5-methylpyridin-2-yl)-2-(1-phenylpropan-2-yl)-1H-indole (355ba): The 
general procedure E was followed using 5-bromo-1-(5-methylpyridin-2-yl)-1H-indole (354b) 
(143 mg, 0.50 mmol) and allylbenzene (223a) (177 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355ba (133.3 mg, 66%, M/AM = 94:6) as 
a yellow oil.  
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1H-NMR (300 MHz, CDCl3): δ = 8.50 (dd, J = 2.5, 0.8 Hz, 1H), 7.71 (ddd, J = 7.5, 7.2, 2.5 Hz, 
1H), 7.64 (ddd, J = 7.2, 2.5, 0.8 Hz, 1H), 7.21–7.12 (m, 4H), 7.10–7.00 (m, 2H), 6.95–6.88 (m, 
2H), 6.44 (d, J = 0.8 Hz, 1H), 3.53–3.36 (m, 0.94H, M), 3.00 (dd, J = 13.3, 5.5 Hz, 1H), 2.83 
(t, J = 7.7 Hz, 0.12H, AM), 2.59 (dd, J = 13.3, 8.7 Hz, 1H), 2.44 (s, 3H), 1.23 (d, J = 6.9 Hz, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 149.8 (CH), 148.5 (Cq), 147.6 (Cq), 139.9 (Cq), 138.9 (CH), 
136.0 (Cq), 132.3 (Cq), 130.0 (Cq), 128.9 (CH), 128.0 (CH), 125.9 (CH), 124.1 (CH), 122.3 
(CH), 121.0 (CH), 113.4 (Cq), 111.4 (CH), 99.4 (CH), 43.6 (CH2), 32.9 (CH), 19.6 (CH3), 18.1 
(CH3).  
IR (ATR): 2964, 1595, 1575, 1481, 1450, 747 cm–1.  
MS (ESI) m/z (relative intensity): 405 (100) [M + H, 79Br]+, 327 (20), 289 (10).  
HR-MS (ESI): m/z calcd. for [C23H2179BrN2 + H]+ 405.0957, found 405.0961.  
[α]D20: −12.0 (c = 1.00, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  99:1, 1.00 mL/min, detection at 273 
nm): tr (major) = 17.3 min, tr (minor) = 20.2 min, tr (AM) = 24.0 min, 93:7 e.r. 
 
(R)-5-Iodo-1-(5-methylpyridin-2-yl)-2-(1-phenylpropan-2-yl)-1H-indole (355ca): The 
general procedure E was followed using 5-iodo-1-(5-methylpyridin-2-yl)-1H-indole (354c) 
(167.1 mg, 0.50 mmol) and allylbenzene (223a) (177 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355ca (146.9 mg, 65%, M/AM = 96:4) as a 
yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.49 (dd, J = 2.4, 0.9 Hz, 1H), 7.91 (dd, J = 1.6, 0.9 Hz, 1H), 
7.63 (ddd, J = 8.0, 2.4, 0.9 Hz, 1H), 7.34 (dd, J = 8.6, 1.6 Hz, 1H), 7.21–7.11 (m, 3H), 7.06 (d, 
J = 8.0 Hz, 1H), 6.94 (d, J = 8.6 Hz, 1H), 6.92–6.86 (m, 2H), 6.41 (d, J = 0.8 Hz, 1H), 3.50–
3.36 (m, 0.96H, M), 2.98 (dd, J = 13.4, 5.5 Hz, 1H), 2.80 (t, J = 7.9 Hz, 0.08H, AM), 2.58 (dd, 
J = 13.4, 8.6 Hz, 1H), 2.44 (s, 3H), 1.21 (d, J = 6.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 149.9 (CH), 148.5 (Cq), 147.3 (Cq), 139.9 (Cq), 139.0 (CH), 
136.5 (Cq), 132.4 (Cq), 130.8 (Cq), 129.7 (CH), 129.0 (CH), 128.7 (CH), 128.1 (CH), 125.9 
(CH), 121.1 (CH), 112.0 (CH), 99.1 (CH), 83.8 (Cq), 43.6 (CH2), 32.8 (CH), 19.5 (CH3), 18.1 
(CH3).  
5. Experimental Part 
 
221 
IR (ATR): 3024, 1594, 1495, 1481, 1453, 790, 748 cm–1.  
MS (ESI) m/z (relative intensity): 475 (100) [M + Na]+, 453 (70) [M + H]+, 397 (10).  
HR-MS (ESI): m/z calcd. for [C23H21IN2 + Na]+ 475.0646, found 475.0642.  
[α]D20:  –23.3 (c = 1.03, CHCl3).  
HPLC separation (Chiralpak® ID-3, n-hexane/i-PrOH  98:2, 0.75 mL/min, detection at 273 
nm): tr (major) = 16.6 min, tr (minor) = 19.4 min, tr (AM) = 23.3 min, 92:8 e.r. 
 
(R)-Methyl 1-(5-methylpyridin-2-yl)-2-(1-phenylpropan-2-yl)-1H-indole-6-carboxylate 
(355da): The general procedure E was followed using methyl 1-(5-methylpyridin-2-yl)-1H-
indole-5-carboxylate (354d) (192.1 mg, 0.50 mmol) and allylbenzene (223a) (177 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 355da 
(140.2 mg, 73%, M/AM = 94:6) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.51 (dd, J = 2.4, 0.7 Hz, 1H), 7.88 (dd, J = 1.5, 0.7 Hz, 1H), 
7.85–7.77 (m, 1H), 7.67 (ddd, J = 8.0, 2.4, 0.7 Hz, 1H), 7.59 (dd, J = 8.0, 0.7 Hz, 1H), 7.20–
7.06 (m, 4H), 6.97–6.84 (m, 2H), 6.54 (d, J = 0.7 Hz, 1H), 3.86 (s, 3H), 3.52–3.35 (m, 0.94H, 
M), 3.02 (dd, J = 13.3, 5.5 Hz, 1H), 2.85 (t, J = 7.7 Hz, 0.12H, AM), 2.61 (dd, J = 13.3, 8.7 
Hz, 1H), 2.45 (s, 3H), 1.24 (d, J = 6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 150.1 (Cq), 150.0 (CH), 148.4 (Cq), 139.9 (Cq), 
139.1 (CH), 136.8 (Cq), 132.7 (Cq), 132.1 (Cq), 129.0 (CH), 128.1 (CH), 126.1 (CH), 123.1 
(Cq), 121.6 (CH), 121.4 (CH), 119.5 (CH), 112.2 (CH), 100.2 (CH), 51.8 (CH3), 43.6 (CH2), 
33.0 (CH), 19.5 (CH3), 18.1 (CH3).  
IR (ATR): 3026, 1710, 1614, 1534, 1444, 1288, 743 cm–1.  
MS (ESI) m/z (relative intensity): 407 (30) [M + Na]+, 385 (100) [M + H]+, 269 (10).  
HR-MS (ESI): m/z calcd. for [C25H24N2O2 + Na]+ 407.1729, found 407.1730.  
[α]D20:  +12.0 (c = 0.67, CHCl3).  
HPLC  separation (Chiralpak® IA-3, n-hexane/i-PrOH  99:1, 1.0 mL/min, detection at 273 nm): 
tr (major) = 25.1 min, tr (minor) = 27.5 min, tr (AM) = 42.9 min, 92:8 e.r. 




(R)-1-(5-Methylpyridin-2-yl)-2-[1-(p-tolyl)propan-2-yl]-1H-indole (355ab): The general 
procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) (104.1 mg, 
0.50 mmol) and 1-allyl-4-methylbenzene (223b) (198.3 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355ab (78.2 mg, 46%, M/AM = 97:3) as a 
yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.51 (dd, J = 2.5, 0.8 Hz, 1H), 7.65 (ddd, J = 8.0, 2.5, 0.8 Hz, 
1H), 7.61–7.57 (m, 1H), 7.23–7.17 (m, 2H), 7.14–7.09 (m, 2H), 6.99 (d, J = 7.8 Hz, 2H), 6.83 
(d, J = 7.8 Hz, 2H), 6.50 (d, J = 0.8 Hz, 1H), 3.58–3.38 (m, 0.97H, M), 2.99 (dd, J = 13.4, 5.1 
Hz, 1H), 2.86 (t, J = 7.6 Hz, 0.06H, AM), 2.60 (dd, J = 13.4, 7.8 Hz, 1H), 2.44 (s, 3H), 2.28 (s, 
3H), 1.21 (d, J = 6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 149.8 (CH), 149.2 (Cq), 146.6 (Cq), 138.8 (CH), 137.4 (Cq), 
137.2 (Cq), 135.2 (Cq), 132.0 (Cq), 128.9 (CH), 128.7 (CH), 128.4 (Cq), 121.4 (CH), 121.2 
(CH), 120.3 (CH), 120.0 (CH), 109.9 (CH), 99.9 (CH), 43.2 (CH2), 32.8 (CH), 20.9 (CH3), 
19.3 (CH3), 18.1 (CH3).  
IR (ATR): 3014, 1596, 1482, 1456, 899, 802, 737 cm–1.  
MS (ESI) m/z (relative intensity): 363 (20) [M + Na]+, 341 (100) [M + H]+, 251 (10).  
HR-MS (ESI): m/z calcd. for [C24H24N2 + Na]+ 363.1830, found 363.1832.  
[α]D20:  +11.5  (c  =  1.04, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  99:1, 0.50 mL/min, detection at 273 
nm): tr (major) = 31.6 min, tr (minor) = 34.0 min, tr (AM) = 38.9 min, 90:10 e.r. 
 
(R)-2-[1-(4-Methoxyphenyl)propan-2-yl]-1-(5-methylpyridin-2-yl)-1H-indole (355ac): 
The general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol), 1-allyl-4-methoxybenzene (223c) (222 mg, 1.50 mmol). Isolation by 
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column chromatography (n-hexane/EtOAc = 10:1) yielded 355ac (108.6 mg, 61%, M/AM = 
92:8) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.51 (dd, J = 2.5, 0.8 Hz, 1H), 7.68 (ddd, J = 7.9, 7.5, 2.1 Hz, 
1H) 7.66–7.55 (m, 1H), 7.23–7.09 (m, 4H), 6.85 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.7 Hz, 2H), 
6.49 (d, J = 0.8 Hz, 1H), 3.75 (s, 3H), 3.55–3.35 (m, 0.92H, M), 2.96 (dd, J = 13.5, 5.2 Hz, 
1H), 2.84 (t, J = 7.6 Hz, 0.16H, AM), 2.53 (dd, J = 13.5, 8.8 Hz, 1H), 2.45 (s, 3H), 1.22 (d, J 
= 6.9 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 157.7 (Cq), 149.7 (CH), 149.1 (Cq), 146.4 (Cq), 138.7 (CH), 
137.3 (Cq), 132.3 (Cq), 131.9 (Cq), 129.8 (CH), 128.3 (Cq), 121.4 (CH), 121.1 (CH), 120.2 
(CH), 120.0 (CH), 113.4 (CH), 109.9 (CH), 99.9 (CH), 55.2 (CH3), 42.8 (CH2), 33.0 (CH), 
19.5 (CH3), 18.1 (CH3).  
IR (ATR): 2961, 1688, 1511, 1483, 1456, 811, 747 cm–1.  
MS (ESI) m/z (relative intensity): 379 (20) [M + Na]+, 357 (100) [M + H]+, 211 (10).  
HR-MS (ESI): m/z calcd. for [C24H24N2O + Na]+ 357.1959, found 357.1961.  
[α]D20:  +5.0 (c = 0.80, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  98:2, 0.75 mL/min, detection at 273 
nm): tr (major) = 25.6 min, tr (minor) = 29.7 min, tr (AM) = 35.4 min, 91:9 e.r. 
 
(R)-2-[1-{(1,1'-Biphenyl)-4-yl}propan-2-yl]-1-(5-methylpyridin-2-yl)-1H-indole (355ad): 
The general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol), 4-allyl-1,1'-biphenyl (223d) (291.2 mg, 1.50 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 20:1) yielded 355ad (102.6 mg, 51%, M/AM = 
92:8) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.53 (dd, J = 2.2, 0.9 Hz, 1H), 7.69–7.60 (m, 2H), 7.59–7.54 
(m, 2H), 7.45–7.40 (m, 4H), 7.36–7.30 (m, 1H), 7.24–7.21 (m, 1H), 7.18 (d, J = 8.1 Hz, 1H), 
7.14 (ddd, J = 7.2, 5.0, 1.7 Hz, 2H), 7.03–6.98 (m, 2H), 6.55 (d, J = 0.8 Hz, 1H), 3.63–3.50 (m, 
0.92H, M), 3.07 (dd, J = 13.4, 5.4 Hz, 1H), 2.90 (t, J = 7.9 Hz, 0.16H, AM), 2.65 (dd, J = 13.4, 
8.7 Hz, 1H), 2.45 (s, 3H), 1.29 (d, J = 6.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 149.8 (CH), 149.1 (Cq), 146.4 (Cq), 140.9 (Cq), 139.4 (Cq), 
138.8 (CH), 138.7 (Cq), 137.4 (Cq), 132.0 (Cq), 129.4 (CH), 128.7 (CH), 128.4 (Cq), 127.0 
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(CH), 126.8 (CH), 126.7 (CH), 121.5 (CH), 121.2 (CH), 120.4 (CH), 120.0 (CH), 109.9 (CH), 
100.0 (CH), 43.4 (CH2), 32.8 (CH), 19.5 (CH3), 18.1 (CH3).  
IR (ATR): 3025, 1596, 1482, 1470, 1455, 748, 697 cm–1.  
MS (ESI) m/z (relative intensity): 425 (15) [M + Na]+, 403 (100) [M + H]+, 381 (10).  
HR-MS (ESI): m/z calcd. for [C29H26N2 + Na]+ 425.1987, found 425.1988.  
[α]D20:  +20.0  (c = 0.80, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  98:2, 1.0 mL/min, detection at 273 nm): 
tr (major) = 16.1 min, tr (minor) = 17.7 min, tr (AM) = 22.0 min, 89:11 e.r. 
 
(R)-2-[1-(4-Fluorophenyl)propan-2-yl]-1-(5-methylpyridin-2-yl)-1H-indole (355ae): The 
general procedure A was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol) and 1-allyl-4-fluorobenzene (223e) (204.2 mg, 1.50 mmol). Isolation 
by column chromatography (n-hexane/EtOAc = 20:1) yielded 355ae (89.5 mg, 52%, M/AM = 
94:6) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.51 (dd, J = 2.4, 0.8 Hz, 1H), 7.65 (ddd, J = 8.0, 7.4, 2.4 Hz, 
1H), 7.62–7.58 (m, 1H), 7.22 (dd, J = 2.6, 0.8 Hz, 1H), 7.18 (dd, J = 8.0, 0.7 Hz, 1H), 7.15–
7.10 (m, 2H), 6.88 (d, J = 3.8 Hz, 2H), 6.86 (d, J = 3.8 Hz, 2H), 6.49 (d, J = 0.9 Hz, 1H), 3.54–
3.44 (m, 0.94H, M), 2.99 (dd, J = 13.5, 5.5 Hz, 1H), 2.89–2.80 (t, J = 7.9 Hz, 0.12H, AM), 
2.59 (dd, J = 13.5, 8.5 Hz, 1H), 2.44 (s, 3H), 1.24 (d, J = 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 161.4 (d, 1JC–F = 244.2 Hz, Cq), 149.8 (CH), 149.1 (Cq), 
146.1 (Cq), 138.8 (CH), 137.3 (Cq), 135.8 (Cq), 132.0 (Cq), 130.4 (d, 3JC–F = 8.2 Hz, CH), 128.3 
(Cq), 121.5 (CH), 121.1 (CH), 120.4 (CH), 120.0 (CH), 114.7 (d, 2JC–F = 24.2 Hz, CH), 109.9 
(CH), 100.1 (CH), 42.8 (CH2), 32.8 (CH), 19.4 (CH3), 18.0 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –117.5 (m, 1F).  
IR (ATR): 2965, 1597, 1508, 1482, 1456, 1218, 747 cm–1.  
MS (ESI) m/z (relative intensity): 367 (15) [M + Na]+, 345 (100) [M + H]+, 211 (10).  
HR-MS (ESI): m/z calcd. for [C23H21FN2 + Na]+ 367.1578, found 367.1581.  
[α]D20:  +11.2 (c = 1.07, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 99:1, 1.0 mL/min, detection at 273 nm): 
tr (minor) = 13.3 min, tr (major) = 14.4 min, tr (AM) = 18.3 min, 8:92 e.r. 





(355af): The general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole 
(354a) (104.1 mg, 0.50 mmol), 4-allyl-1,2-dimethoxybenzene (223f) (267.2 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc = 5:1) yielded 355af (121.7 mg, 63%, 
M/AM = 91:9) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.48 (dd, J = 2.6, 0.8 Hz, 0.91H, M), 8.46 (dd, J = 2.6, 0.8 
Hz, 0.09H, AM), 7.62 (ddd, J = 8.0, 2.6, 0.8 Hz, 1H), 7.60–7.54 (m, 1H), 7.21–7.15 (m, 1H), 
7.14–7.06 (m, 3H), 6.65 (d, J = 8.0 Hz, 1H), 6.51–6.43 (m, 2H), 6.29 (d, J = 1.9 Hz, 1H), 3.81 
(s, 3H), 3.62 (s, 3H), 3.53–3.43 (m, 1H), 2.87 (dd, J = 13.4, 5.7 Hz, 1H), 2.53 (dd, J = 13.4, 6.9 
Hz, 1H), 2.42 (s, 3H), 1.27 (d, J = 6.9 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 149.6 (CH), 149.1 (Cq), 148.3 (Cq), 147.1 (Cq), 146.2 (Cq), 
138.7 (CH), 137.3 (Cq), 132.7 (Cq), 131.9 (Cq), 128.3 (Cq), 121.4 (CH), 121.2 (CH), 120.9 
(CH), 120.3 (CH), 119.9 (CH), 111.9 (CH), 110.7 (CH), 109.8 (CH), 100.1 (CH), 55.8 (CH3), 
55.4 (CH3), 43.5 (CH2), 32.9 (CH), 19.3 (CH3), 18.0 (CH3). 
IR (ATR): 2933, 1590, 1515, 1442, 1410, 817, 787 cm–1.  
MS (ESI) m/z (relative intensity): 409 (15) [M + Na]+, 387 (100) [M + H]+, 211 (10). HR-MS 
(ESI): m/z calcd. for [C25H26N2O2 + Na]+ 409.1888, found 409.1886. 
[α]D20:  +20.0 (c = 1.00, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1.00 mL/min, detection at 273 
nm): tr (major) = 10.4 min, tr (minor) = 11.4 min, tr (AM) = 14.4 min, 92:8 e.r. 
 
(R)-2-[1-(4-Chlorophenyl)propan-2-yl]-1-(5-methylpyridin-2-yl)-1H-indole (355ag): The 
general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol), 1-allyl-4-chlorobenzene (223g) (228 mg, 1.50 mmol). Isolation by 
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column chromatography (n-hexane/EtOAc = 20:1) yielded 355ag (73.8 mg, 41%, M/AM = 
93:7) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.49 (dd, J = 2.4, 0.8 Hz, 1H), 7.65 (ddd, J = 8.0, 2.4, 0.7 Hz, 
1H), 7.60–7.57 (m, 1H), 7.22–7.18 (m, 1H), 7.18–7.14 (m, 1H), 7.14–7.09 (m, 4H), 6.83 (d, J 
= 8.1 Hz, 2H), 6.48 (d, J = 0.8 Hz, 1H), 3.57–3.41 (m, 0.93H, M), 2.96 (dd, J = 13.4, 5.7 Hz, 
1H), 2.80 (t, J = 8.4 Hz, 0.14H, AM), 2.58 (dd, J = 13.4, 8.3 Hz, 1H), 2.44 (s, 3H), 1.23 (d, J 
= 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 149.8 (CH), 149.1 (Cq), 145.9 (Cq), 138.8 (CH), 138.6 (Cq), 
137.3 (Cq), 132.0 (Cq), 131.6 (Cq), 130.3 (CH), 128.3 (Cq), 128.1 (CH), 121.6 (CH), 121.1 
(CH), 120.4 (CH), 120.0 (CH), 110.0 (CH), 100.2 (CH), 43.1 (CH2), 32.7 (CH), 19.5 (CH3), 
18.1 (CH3).  
IR (ATR): 2965, 1687, 1483, 1456, 1216, 839, 738 cm–1.  
MS (ESI) m/z (relative intensity): 383 (15) [M + Na, 35Cl]+, 361 (100) [M + H, 35Cl]+, 211 (10), 
173 (5).  
HR-MS (ESI): m/z calcd. for [C23H2135ClN2 + Na]+ 383.1284, found 383.1285.  
[α]D20:  +8.0 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 0.75 mL/min, detection at 273 nm): 
tr (minor) = 11.6 min, tr (major) = 12.3 min, tr (AM) = 14.4 min, 12:88 e.r. 
 
(R)-1-(5-methylpyridin-2-yl)-2-[1-(perfluorophenyl)propan-2-yl]-1H-indole (355ah): The 
general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol), 1-allyl-2,3,4,5,6-pentafluorobenzene (223h) (312.2 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc = 20:1) yielded 355ah (114.4 mg, 55%, 
M/AM = 96:4) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.47 (dd, J = 2.4, 0.8 Hz, 1H), 7.68 (ddd, J = 8.0, 7.5, 2.4 Hz, 
1H), 7.62–7.55 (m, 1H), 7.27–7.22 (m, 1H), 7.22–7.17 (m, 1H), 7.14–7.07 (m, 2H), 6.54 (d, J 
= 0.8 Hz, 1H), 3.68–3.50 (m, 0.96H, M), 3.03 (dd, J = 13.6, 6.1 Hz, 1H), 2.88 (t, J = 7.9 Hz, 
0.08H, AM), 2.78 (dd, J = 13.6, 8.8 Hz, 1H), 2.45 (s, 3H), 1.28 (d, J = 7.0 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 150.0 (CH), 148.8 (Cq), 145.2 (dm, 1JC–F = 243.2 Hz, Cq), 
144.8 (Cq), 139.9 (dm, 1JC–F = 253.2 Hz, Cq), 138.8 (CH), 137.4 (Cq), 137.2 (dm, 1JC–F = 251.2 
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Hz, Cq), 132.2 (Cq), 128.2 (Cq), 121.9 (CH), 120.8 (CH), 120.5 (CH), 120.2 (CH), 113.2 (t, 2JC–
F = 24.2, Cq), 110.0 (CH), 100.2 (CH), 30.6 (CH), 30.1 (CH2), 19.5 (CH3), 18.0 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –142.7 (m, 2F), –157.4 (m, 1F), –163.0 (m, 2F).  
IR (ATR): 2974, 1596, 1519, 1502, 1146, 971, 789 cm–1.  
MS (ESI) m/z (relative intensity): 439 (15) [M + Na]+, 417 (100) [M + H]+, 211 (10).  
HR-MS (ESI): m/z calcd. for [C23H17F5N2 + H]+ 417.1380, found 417.1385.  
[α]D20: +4.0 (c = 1.00, CHCl3).  
HPLC  separation (Chiralpak® IA-3, n-hexane/i-PrOH  95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 6.5 min, tr (minor) = 7.9 min, tr (AM) = 17.6 min, 83:17 e.r. 
 
(R)-2-Methoxy-5-(2-(1-(5-methylpyridin-2-yl)-1H-indol-2-yl)propyl)phenyl acetate 
(355aj): A modified general procedure E was followed using 5-bromo-1-(5-methylpyridin-2-
yl)-1H-indole (354a) (104.1 mg, 0.50 mmol), 5-allyl-2-methoxyphenyl acetate (223j) 
(309.2 mg, 1.50 mmol) at 60 oC. Isolation by column chromatography (n-hexane/EtOAc = 5:1) 
yielded 355aj (113.9 mg, 55%, M/AM = 75:25) as a yellow oil.  
Major isomer (M): 1H-NMR (500 MHz, CDCl3): δ = 8.46 (dd, J = 2.4, 0.8 Hz, 1H), 7.64–7.60 
(m, 1H), 7.60–7.55 (m, 1H), 7.15 (dd, J = 7.2, 0.8 Hz, 1H), 7.13–7.10 (m, 1H), 7.09–7.08 (m, 
1H), 7.03 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.52 (d, J = 0.8 Hz, 1H), 6.45–6.41 (m, 
1H), 6.34 (d, J = 1.9 Hz, 1H), 3.51 (s, 3H), 3.49–3.41 (m, 1H), 2.91–2.80 (m, 1H), 2.72–2.54 
(m, 1H), 2.40 (s, 3H), 2.27 (s, 3H), 1.31 (d, J = 6.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 150.4 (CH), 149.6 (CH), 148.9 (Cq), 146.0 (Cq), 
140.9 (Cq), 139.1 (Cq), 138.9 (CH), 137.8 (Cq), 137.2 (Cq), 131.9 (Cq), 128.3 (Cq), 122.0 (CH), 
121.5 (CH), 121.1 (CH), 120.3 (CH), 119.9 (CH), 112.9 (CH), 109.9 (CH), 99.9 (CH), 55.4 
(CH3), 44.2 (CH2), 32.9 (CH), 20.6 (CH3), 19.7 (CH3), 18.0 (CH3).  
Minor isomer (AM): (one carbon signal less due to overlapping with major isomer) 1H-NMR 
(500 MHz, CDCl3): δ = 8.43 (dd, J = 2.4, 0.8 Hz, 1H), 7.65 (dd, J = 2.4, 0.8 Hz, 1H), 7.56–
7.55 (m, 1H), 7.28–7.25 (m, 1H), 7.25–7.24 (m, 1H), 7.08–7.06 (m, 2H), 6.88 (d, J = 8.0 Hz, 
1H), 6.68 (d, J = 1.9 Hz, 1H), 6.65 (dd, J = 8.0, 1.9 Hz, 1H), 6.46 (d, J = 1.9 Hz, 1H), 3.76 (s, 
3H), 2.93–2.82 (m, 2H), 2.68–2.55 (m, 2H), 2.41 (s, 3H), 2.29 (s, 3H), 1.86 (ddd, J = 15.3, 8.3, 
7.0 Hz, 2H).  
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13C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 150.6 (Cq), 149.8 (CH), 148.9 (Cq), 146.0 (Cq), 
141.0 (Cq), 138.8 (CH), 137.6 (Cq), 137.3 (Cq), 131.8 (Cq), 128.4 (Cq), 122.3 (CH), 120.5 (CH), 
120.4 (CH), 120.4 (CH), 119.8 (CH), 112.5 (CH), 110.0 (CH), 101.9 (CH), 99.9 (CH), 55.7 
(CH3), 35.2 (CH2), 30.1 (CH2), 26.8 (CH2), 17.8 (CH3).  
IR (ATR): 3011, 1762, 1598, 1482, 1456, 1197, 1034, 749 cm–1.  
MS (ESI) m/z (relative intensity): 437 (10) [M + Na]+, 415 (100) [M + H]+, 275 (10).  
HR-MS (ESI): m/z calcd. for [C26H26N2O3 + H]+ 415.2010, found 415.2016.  
[α]D20:  +3.9 (c = 1.02, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  90:10, 1.0 mL/min, detection at 273 
nm): tr (minor) = 15.5 min, tr (major) = 16.5 min, tr (AM) = 32.8 min, 12:88 e.r. 
 
(R)-4-[2-{1-(5-Methylpyridin-2-yl)-1H-indol-2-yl}propyl]phenyl 
trifluoromethanesulfonate (355ak): The general procedure E was followed using 1-(5-
methylpyridin-2-yl)-1H-indole (354a) (104.1 mg, 0.50 mmol), ethyl 4-allylphenyl 
trifluoromethanesulfonate (223k) (399.2 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355ak (99.5 mg, 42%, M/AM = 96:4) as a 
yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.48 (dd, J = 2.4, 0.8 Hz, 1H), 7.65 (ddd, J = 8.0, 2.4, 0.8 Hz, 
1H), 7.60–7.57 (m, 1H), 7.21–7.16 (m, 1H), 7.14–7.09 (m, 3H), 7.05 (d, J = 8.7 Hz, 2H), 6.97 
(d, J = 8.7 Hz, 2H), 6.48 (d, J = 0.8 Hz, 1H), 3.59–3.40 (m, 0.96H, M), 3.02 (dd, J = 13.4, 5.9 
Hz, 1H), 2.85 (t, J = 7.5 Hz, 0.08H, AM), 2.65 (dd, J = 13.4, 8.2 Hz, 1H), 2.44 (s, 3H), 1.25 
(d, J = 7.0 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 149.8 (CH), 148.9 (Cq), 147.8 (Cq), 145.6 (Cq), 140.9 (Cq), 
138.9 (CH), 137.3 (Cq), 132.1 (Cq), 130.7 (CH), 128.3 (Cq), 121.7 (CH), 121.0 (CH), 120.8 
(CH), 120.5 (CH), 120.1 (CH), 119.2 (q, 1JC–F = 319.1 Hz, Cq), 109.9 (CH), 100.3 (CH), 43.2 
(CH2), 32.7 (CH), 19.6 (CH3), 18.0 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –73.0 (m, 1F).  
IR (ATR): 2967, 1596, 1483, 1456, 1208, 888, 710 cm–1.  
MS (ESI) m/z (relative intensity): 497 (10) [M + Na]+, 475 (100) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C24H21F3N2O3S + Na]+ 497.1119, found 497.1117.  
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[α]D20:  +4.4  (c  =  0.90, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  99:1, 0.75 mL/min, detection at 273 
nm): tr (minor) = 21.0 min, tr (major) = 23.2 min, tr (AM) = 32.6 min, 13:87 e.r. 
 
(R)-Ethyl 4-[2-{1-(5-methylpyridin-2-yl)-1H-indol-2-yl}propyl]benzoate (355al): The 
general procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) 
(104.1 mg, 0.50 mmol), ethyl 4-allylbenzoate (223l) (286.5 mg, 1.50 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 10:1) yielded 355al (111.7 mg, 56%, M/AM = 
86:14) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.54 (dd, J = 2.4, 0.8 Hz, 1H), 7.93–7.84 (m, 2H), 7.74–7.55 
(m, 2H), 7.27–7.12 (m, 4H), 7.08–6.98 (m, 2H), 6.53 (d, J = 0.8 Hz, 1H), 4.39 (q, J = 7.1 Hz, 
2H), 3.66–3.49 (m, 0.86H, M), 3.10 (dd, J = 13.4, 5.5 Hz, 1H), 2.89 (t, J = 7.6 Hz, 0.28H, AM), 
2.70 (dd, J = 13.4, 6.5 Hz, 1H), 2.48 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.27 (d, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 149.9 (CH), 149.1 (Cq), 145.9 (Cq), 145.7 (Cq), 
138.9 (CH), 137.4 (Cq), 132.2 (Cq), 129.4 (CH), 129.1 (CH), 128.4 (Cq), 128.3 (Cq), 121.7 
(CH), 121.1 (CH), 120.5 (CH), 120.1 (CH), 110.0 (CH), 100.3 (CH), 60.8 (CH2), 43.8 (CH2), 
32.7 (CH), 19.5 (CH3), 18.1 (CH3), 14.4 (CH3).  
IR (ATR): 2976, 1722, 1609, 1483, 1275, 844 cm–1.  
MS (ESI) m/z (relative intensity): 421 (30) [M + Na]+, 399 (100) [M + H]+, 381 (5), 211 (10).  
HR-MS (ESI): m/z calcd. for [C26H26N2O2 + Na]+ 421.1887, found 421.1886.  
[α]D20:  +3.6 (c = 1.10, CHCl3).  
HPLC  separation (Chiralpak® IB-3, n-hexane/EtOAc  90:10, 1.0 mL/min, detection at 280 
nm): tr (major) = 9.9 min, tr (minor) = 12.1 min, tr (AM) = 17.3 min, 86:14 e.r. 
 
(R)-2-(1-([1,1'-Biphenyl]-4-yl)propan-2-yl)-5-bromo-1-(5-methylpyridin-2-yl)-1H-indole 
(355bm): The general procedure E was followed using 5-bromo-1-(5-methylpyridin-2-yl)-1H-
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indole (354b) (143 mg, 0.50 mmol), 4-allyl-1,1'-biphenyl (223m) (291.2 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc = 20:1) yielded 355bm (127.2 mg, 
53%, M/AM = 92:8) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.54 (dd, J = 2.4, 0.9 Hz, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.66 
(ddd, J = 8.31, 2.4, 0.9 Hz, 1H), 7.60–7.54 (m, 2H), 7.50–7.45 (m, 4H), 7.40–7.35 (m, 1H), 
7.21 (dd, J = 8.7, 1.9 Hz, 1H), 7.15–7.04 (m, 2H), 7.03–6.95 (m, 2H), 6.49 (s, 1H), 3.61–3.44 
(m, 0.92H, M), 3.04 (dd, J = 13.3, 5.7 Hz, 1H), 2.89 (t, J = 7.9 Hz, 0.16H, AM) 2.68 (dd, J = 
13.3, 8.4 Hz, 1H), 2.48 (s, 3H), 1.30 (d, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3):  δ =145.0 (CH), 148.7 (Cq), 147.7 (Cq), 141.0 (Cq), 139.2 (Cq), 
139.0 (CH), 138.9 (Cq), 136.1 (Cq), 132.5 (Cq), 130.1 (CH), 129.5 (CH), 128.8 (CH), 127.1 
(Cq), 126.9 (CH), 126.8 (CH), 124.3 (CH), 122.5 (CH), 121.2 (CH), 113.6 (Cq), 111.5 (CH), 
99.6 (CH), 43.4 (CH2), 32.9 (CH), 19.7 (CH3), 18.1 (CH3).  
IR (ATR): 3026, 1595, 1482, 1207, 1034, 791, 697 cm–1.  
MS (ESI) m/z (relative intensity): 503 (10) [M + Na, 79Br]+, 481 (100) [M + H,79Br]+, 403 (10).  
HR-MS (ESI): m/z calcd. for [C29H2579BrN2 + Na]+ 503.1098, found 503.1093.  
[α]D20:  –8.9 (c = 0.90, CHCl3).  
HPLC  separation (Chiralpak® ID-3, n-hexane/i-PrOH  98:2, 1.0 mL/min, detection at 273 nm): 
tr (major) = 17.1 min, tr (minor) = 19.5 min, tr (AM) = 25.8 min, 89:11 e.r. 
 
(R)-1-(5-Methylpyridin-2-yl)-2-(4-phenylbutan-2-yl)-1H-indole (355an): The general 
procedure E was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) (104.1 mg, 
0.50 mmol), 4-Phenyl-1-butene (223n) (198 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 30:1) yielded 355an (57.8 mg, 34%, M/AM = 80:20) as 
a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.45 (d, J = 2.4 Hz, 1H), 7.71–7.64 (m, 1H), 7.64–7.59 (m, 
1H), 7.28 (d, J = 3.3 Hz, 1H), 7.27–7.23 (m, 2H), 7.23–7.20 (m, 1H), 7.20–7.16 (m, 1H), 7.16–
7.11 (m, 2H), 7.09–7.04 (m, 2H), 6.52 (s, 1H), 3.31–3.11 (m, 0.90H, M), 2.87 (t, J = 4.0 Hz, 
0.10H, AM), 2.59 (t, J = 7.6 Hz, 2H), 2.47 (s, 3H), 2.10–1.94 (m, 1H), 1.83–1.70 (m, 1H), 1.33 
(d, J = 6.9 Hz, 3H).  
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13C-NMR (100 MHz, CDCl3): δ = 150.0 (CH), 149.1 (Cq), 146.9 (Cq), 142.3 (Cq), 138.8 (CH), 
137.5 (Cq), 132.0 (Cq), 128.5 (Cq), 128.4 (CH), 128.2 (CH), 125.5 (CH), 121.4 (CH), 121.2 
(CH), 120.4 (CH), 120.0 (CH), 110.1 (CH), 99.7 (CH), 38.8 (CH), 33.4 (CH2), 30.3 (CH2), 
20.6 (CH3), 18.1 (CH3).  
IR (ATR): 2955, 1593, 1481, 1435, 1399, 1366, 1324, 765, 758, 670 cm–1.  
MS (ESI) m/z (relative intensity): 363 (80) [M + H]+, 341(15) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C24H24N2 + H]+ 341.2012 found 341.2011.  
[α]D20: +16.0 (c = 1.25, CHCl3)  
HPLC separation (Chiralpak® IF-3, n-hexane/EtOAc 95:5, 1.00 mL/min, detection at 273 nm): 
tr (major) = 8.1 min, tr (minor) = 7.5 min, tr (AM) = 7.8 min, 68:32 e.r. 
 
(R)-1-(5-Methylpyridin-2-yl)-2-(octan-2-yl)-1H-indole (355ao): The general procedure E 
was followed using 1-(5-methylpyridin-2-yl)-1H-indole (354a) (104.1 mg, 0.50 mmol), 1-
octene (223o) (168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc = 
30:1) yielded 355ao (59.2 mg, 37%, M/AM = 90:10) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.52 (d, J = 2.5 Hz, 1H), 7.72 (dd, J = 8.1, 2.5, 1H), 7.64–
7.56 (m, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.26–7.18 (m, 1H), 7.18–7.04 (m, 2H), 6.46 (s, 1H), 
3.23–3.08 (m, 0.90H, M), 2.82 (t, J = 7.6 Hz, 0.10H, AM) 2.47 (s, 3H), 1.73–1.52 (m, 1H), 
1.50–1.06 (m, 12H), 0.87 (t, J = 6.9 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 149.9 (CH), 149.2 (Cq), 147.5 (Cq), 138.7 (CH), 137.4 (Cq), 
131.9 (Cq), 128.4 (Cq), 121.3 (CH), 121.2 (CH), 120.2 (CH), 119.8 (CH), 109.9 (CH), 99.3 
(CH), 37.0 (CH2), 31.6 (CH2), 30.7 (CH), 29.2 (CH2), 27.0 (CH2), 22.6 (CH2), 20.5 (CH3), 18.0 
(CH3), 14.0 (CH3).  
IR (ATR): 2935, 1591, 1472, 1465, 1366, 1321, 1310, 787, 741, 689 cm–1.  
MS (ESI) m/z (relative intensity): 321 (100) [M + H]+, 342 (15) [M + Na]+.  
HR-MS (ESI): m/z calcd. for [C22H28N2 + H]+ 321.2325 found 321.2328.  
[α]D20: +25.0 (c = 0.8, CHCl3).  
HPLC separation (Chiralpak® IF-3, n-hexane/EtOAc 90:10, 1.00 mL/min, detection at 280 
nm): tr (major) = 6.3 min, tr (minor) = 5.5 min, tr (AM) = 7.8 min, 72:28 e.r.  
5. Experimental Part 
 
232 
5.5.3. Removable of the Directing Group 
 
(R)-2-(1-Phenylpropan-2-yl)-1H-indole (357aa): The general procedure G was followed 
using (R)-1-(5-Methylpyridin-2-yl)-2-(1-phenylpropan-2-yl)-1H-indole (355aa) (65.2 mg, 
0.20 mmol, e.r. 92:8). Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 
357aa (40.4 mg, 86%, M/AM = 92:8) as a brown solid. M. P.:  75–78 °C.  
1H-NMR (600 MHz, CDCl3): δ = 7.65 (s, 1H), 7.60 (dd, J = 7.7, 1.2 Hz, 1H), 7.34–7.29 (m, 
2H), 7.27 (dd, J = 7.8, 1.7 Hz, 2H), 7.19–7.15 (m, 3H), 7.16–7.10 (m, 1H), 6.25 (d, J = 0.8 Hz, 
0.92H, M), 6.23 (d, J = 0.8 Hz, 0.08H, M), 3.21 (m, 1H), 3.06 (dd, J = 13.3, 6.6 Hz, 1H), 2.90 
(dd, J = 13.3, 7.6 Hz, 1H), 1.38 (d, J = 6.9 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 143.9 (Cq), 139.9 (Cq), 135.5 (Cq), 128.9 (CH), 128.4 (Cq), 
128.2 (CH), 126.1 (CH), 120.9 (CH), 119.9 (CH), 119.5 (CH), 110.3 (CH), 98.2 (CH), 43.8 
(CH2), 35.2 (CH), 19.9 (CH3).  
IR (ATR): 3399, 3025, 1676, 1454, 1301, 1029, 748 cm–1. 
MS (ESI) m/z (relative intensity): 258 (30) [M + Na]+, 236 (100) [M + H]+, 209 (5), 201 (10).  
HR-MS (ESI): m/z calcd. for [C17H17N+ H]+ 236.1430, found 236.1434.  
[α]D20:  –30.0  (c = 0.80, CHCl3).  
HPLC  separation (Chiralpak® IA-3, n-hexane/i-PrOH  99:1, 0.75 mL/min, detection at 273 
nm): tr (major) = 23.9 min, tr (minor) = 26.2 min, tr (AM) = 36.9 min, 92:8 e.r. 
 
(R)-Methyl 2-(1-phenylpropan-2-yl)-1H-indole-6-carboxylate (357da): The general 
procedure G was followed using (R)-methyl 1-(5-methylpyridin-2-yl)-2-(1-phenylpropan-2-
yl)-1H-indole-6-carboxylate (355da) (76.8 mg, 0.20 mmol, e.r. 92:8). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 357da (46.5 mg, 79%, M/AM = 94:6) as a 
yellow solid. M. P.: 145–149 oC.  
1H-NMR (500 MHz, CDCl3): δ = 8.24 (s, 1H), 8.04 (dd, J = 1.6, 0.8 Hz, 1H), 7.77 (dd, J = 8.4, 
1.6 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.30–7.16 (m, 3H), 7.12–7.02 (m, 2H), 6.31 (dd, J = 2.1, 
1.0 Hz, 1H), 3.91 (s, 3H), 3.23 (m, 0.94H, M), 3.03 (dd, J = 13.4, 7.1 Hz, 1H), 2.89 (dd, J = 
13.4, 7.5 Hz, 1H), 2.79 (t, J = 7.6 Hz, 0.12H, AM), 1.37 (d, J = 6.9 Hz, 3H).  
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13C-NMR (125 MHz, CDCl3): δ = 168.5 (Cq), 148.1 (Cq), 139.8 (Cq), 134.9 (Cq), 132.4 (Cq), 
129.1 (CH), 128.4 (CH), 126.4 (CH), 122.5 (Cq), 120.8 (CH), 119.4 (CH), 112.9 (CH), 98.9 
(CH), 52.0 (CH3), 43.7 (CH2), 35.4 (CH), 19.7 (CH3).  
IR (ATR): 3342, 3025, 1687, 1619, 1546, 1314, 743 cm–1.  
MS (ESI) m/z (relative intensity): 316 (30) [M + Na]+, 294 (100) [M + H]+, 117 (5).  
HR-MS (ESI): m/z calcd. for [C19H19NO2+ H]+ 294.1484, found 294.1489.  
[α]D20:  –72.9 (c = 0.93, CHCl3).  
HPLC  separation (Chiralpak® IF-3, n-hexane/i-PrOH  95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 14.1 min, tr (minor) = 16.0 min, tr (AM) = 23.9 min, 92:8 e.r. 
 
(R)-2-(1-(3,4-Dimethoxyphenyl)propan-2-yl)-1H-indole (357af): The general procedure G 
was followed using (R)-2-(1-(3,4-dimethoxyphenyl)propan-2-yl)-1-(5-methylpyridin-2-yl)-
1H-indole (355af) (77.2 mg, 0.20 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 5:1) yielded 357af (48.4 mg, 82%, M/AM = 92:8) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 7.73 (s, 1H), 7.57–7.47 (m, 1H), 7.27–7.18 (m, 1H), 7.08 
(dd, J = 8.1, 1.4 Hz, 2H), 6.76 (d, J = 8.1 Hz, 1H), 6.66 (dd, J = 8.1, 2.0 Hz, 1H), 6.49 (d, J = 
2.0 Hz, 1H), 6.26 (dd, J = 2.1, 0.9 Hz, 1H), 3.85 (s, 3H), 3.65 (s, 3H), 3.15 (m, 0.91H, M), 2.93 
(dd, J = 13.5, 7.2 Hz, 1H), 2.83 (dd, J = 13.5, 7.0 Hz, 1H), 2.76 (t, J = 7.5 Hz, 0.18H, AM), 
1.36 (d, J = 6.9 Hz, 3H). 13C-NMR (125 MHz, CDCl3): δ = 148.6 (Cq), 147.4 (Cq), 144.0 (Cq), 
135.5 (Cq), 132.5 (Cq), 128.4 (Cq), 121.0 (CH), 121.0 (CH), 119.8 (CH), 119.5 (CH), 112.1 
(CH), 110.9 (CH), 110.3 (CH), 98.3 (CH), 55.8 (CH3), 55.6 (CH3), 43.5 (CH2), 35.3 (CH), 19.7 
(CH3).  
IR (ATR): 3368, 3004, 1589, 1305, 1140, 1026, 784 cm–1.  
MS (ESI) m/z (relative intensity): 318 (100) [M + Na]+, 295 (30) [M + H]+, 209 (5).  
HR-MS (ESI): m/z calcd. for [C19H21NO2 + H]+ 296.1641, found 296.1645.  
[α]D20:  − 88.4 (c = 0.95, CHCl3).  
HPLC separation (Chiralpak® IF-3, n-hexane/i-PrOH  98:2, 1.0 mL/min, detection at 273 nm): 
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5.5.4. Mechanistic Studies 
5.5.4.1. H/D-exchange for the asymmetric C−H alkylation 
 
 
The representative procedure E was followed using 354i (121 mg, 0.50 mmol, 1 equiv), 
allylbenzene (223a) (177 mg, 1.50 mmol, 1.50 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %) 
and AgSbF6 (34.4 mg, 20.0 mol %) in DCE (0.4 mL) and CD3CO2D (0.1 mL) for 20 h. At 
ambient temperature, the reaction mixture was diluted with EtOAc (2.0 mL) and Et3N (0.5 mL) 
was added. The mixture was stirred for 0.5 h and filtered through a short pad of silica and the 
solvents were removed in vacuo. The crude mixture was purified by flash column 
chromatography on silica gel to afford the desired product [D]n-355ia (12 mg, 7%) and [D]n-
355i (106 mg, 88% reis.) as yellow oils. 
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5.5.4.2. Kinetic Studies 
5.3.4.2.1. Determination of the reaction order with respect to the concentration of CA5: 
The reaction order was examined using the initial rate method. Five parallel independent 
reactions of 354h (56.6 mg, 0.25 mmol), 223a (88.5 mg, 0.75 mmol), [Cp*Co(CO)I2] (11.9 
mg, 25.0 μmol), AgSbF6 (17.2 mg, 50 μmol), Amberlyst 15 (80 mg, 0.38 mmol) and CA5 
(0.0375, 0.0435, 0.05, 0.05625, 0.0625 mmol) were heated at 50 °C in DCE (0.50 mL). After 
cooling to ambient temperature, 19F-NMR conversions were measured by using 1-
fluorononane as the internal standard. 
Table 32. Reaction order in CA5 for the asymmetric C–H alkylation 
Entry c / mol L-1 k / mol L-1 min-1 ln(c / mol L-1) ln(k / mol L-1 min-1) 
1 0.075 0.0357 -2.59027 -3.3326 
2 0.0875 0.0404 -2.43612 -3.20893 
3 0.10 0.0468 -2.30259 -3.06187 
4 0.1125 0.0512 -2.1848 -2.97202 
5 0.125 0.0483 -2.07944 -2.88062 
 
5.5.4.2.2. Determination of the reaction order with respect to the concentration of CA5 
without Amberlyst 15: 
The reaction order was examined using the change of the vibration between the range of 1497-
1478 cm−1 with the React-IR. A solution of 354a (104.1 mg, 0.50 mmol), 223a (177 mg, 1.50 
mmol), [Cp*Co(CO)I2] (23.8 mg, 50.0 μmol), AgSbF6 (34.5 mg, 100 μmol) and CA5 (0.0875, 
0.1, 0.1125, 0.125, 0.15 mmol) were heated at 50 °C in DCE (0.50 mL) and a  diamond probe 
connected to a Mettler Toledo ReactIR. Every three minutes during 2 h an IR spectrum was 
recorded. The slope for the vibration between the range of 14971478 cm−1 was determined 
during the interval between 3 min and 30 min. 
Table 33. Reaction order in CA5 for the asymmetric C–H alkylation without Amberlyst 15. 
Entry c / mol L-1 k / mol L-1 min-1 ln(c / mol L-1) ln(k / mol L-1 min-1) 
1 0.058 0.045 -2.84158 -3,10109 
2 0.067 0.0633 -2.70805 -2,75987 
3 0.075 0.0722 -2.59026 -2,62832 
4 0.083 0.0909 -2.48490 -2,398 
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5 0.1 0.1431 -2.30258 -1,94421 
 
5.5.4.3. Nonlinear Effect Study 
5.3.4.3.1. Nonlinear effect study in presence of Amberlyst 15 
Six parallel independent reactions of 354a (56.6 mg, 0.25 mmol), 223a (88.6 mg, 0.75 mmol), 
[Cp*Co(CO)I2] (11.9 mg, 25.0 μmol), AgSbF6 (17.2 mg, 50 μmol), Amberlyst 15 (80 mg, 0.38 
mmol) and CA5 (10−100% ee, 24.0 mg, 50.0 μmol) were heated at 50 °C in DCE (0.50 mL) 
for 65 h. At ambient temperature, the reaction mixture was diluted with EtOAc (2 mL) and 
Et3N (0.50 mL) was added. The mixture was stirred for 0.5 h and filtered through a short pad 
of silica and the solvents were removed in vacuo. The crude mixture was purified by flash 
column chromatography on silica gel to afford the desired product 355aa. The enantiomeric 
excess was determined by HPLC with chiral stationary phase. 
Table 34. Nonlinear effect study for the asymmetric C–H alkylation. 
Entry ee of the chiral acid [CA5] ee of the product [355aa] 
1 0 0 
2 10 9.3 
3 30 25.7 
4 50 41.4 
5 70 56.1 
6 90 74.4 
7 100 84.0 
 
5.5.4.3.2. Nonlinear effect study in absence of Amberlyst 15 
Six parallel independent reactions of 354a (56.6 mg, 0.25 mmol), 223a (88.6 mg, 0.75 mmol), 
[Cp*Co(CO)I2] (11.9 mg, 25.0 μmol), AgSbF6 (17.2 mg, 50.0 μmol) and CA5 (10−100% ee, 
24.0 mg, 50.0 μmol) were heated at 50 °C in DCE (0.50 mL) for 65 h. At ambient temperature, 
the reaction mixture was diluted with EtOAc (2 mL) and the solvents were removed in vacuo. 
The crude mixture was purified by flash column chromatography on silica gel to afford the 
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Table 35. Nonlinear effect study for the asymmetric C−H alkylation without Amberlyst 15. 
Entry ee of the chiral acid [CA5] ee of the product [355aa] 
1 0 0 
2 10 2.5 
3 30 14.7 
4 50 26.8 
5 70 44.1 
6 90 68.6 
7 100 84.0 
 
5.5.4.4. DOSY Experiment: 
 
Comparison of two NMR Samples: 
1) 8 mg chiral acid CA5 in 700 L of CDCl3 + 1 L of n-hexane. 
2) 8 mg chiral acid CA5 in 700 L of CDCl3 + 5 L of TFA + 1 L of n-hexane. 
 




Figure 4. Overlay of DOSY spectra (500 MHz, 25 °C, CDCl3) of CA5 (8 mg, 0.017 mmol, in 
700 mL of CDCl3) in the presence (blue) and absence (green) of 0.063 mmol of TFA. The ratio 
of diffusion coefficients (5.5 × 10-10 ± 0.2 × 10-10 m2s-1 / 4.0 × 10-10 ± 0.2 × 10-10 m2s-1 = 1.375) 
indicates formation of dimers in the absence of TFA. DOSY spectra were recorded on a Bruker 
Avance III HD 500 MHz instrument equipped with a Cryoprobe Prodigy. The pulse sequence 
dstebpgp3s was used, and the diffusion delay (d20) and gradient duration (p30) were set to 150 
and 1 ms, respectively. nHexane was used as internal standard. 
5.6. Ruthenium(II)-Catalyzed Enantioselective C–H Activation 
5.6.1. Characterization Data 
 
(R)-1-Methyl-9-(pyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole (365a): The general 
procedure H was followed using 3-(pent-4-en-1-yl)-1-(pyridin-2-yl)-1H-indole (364a) 
5. Experimental Part 
 
240 
(65.5 mg, 0.25 mmol). Isolation by column chromatography (n-hexane/EtOAc = 20:1) yielded 
365a (57.7 mg, 88%) as a yellow solid. M.p.: 77–82 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 
2.0 Hz, 1H), 7.52–7.49 (m, 1H), 7.45 (dd, J = 8.0, 0.9 Hz, 1H), 7.40–7.37 (m, 1H), 7.26 (ddd, 
J = 7.4, 4.9, 0.9 Hz, 1H), 7.16–7.10 (m, 2H), 3.57–3.47 (m, 1H), 2.84–2.67 (m, 2H), 2.16–2.05 
(m, 1H), 1.98–1.81 (m, 2H), 1.69–1.58 (m, 1H), 0.83 (d, J = 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 152.1 (Cq), 149.5 (CH), 140.2 (Cq), 138.2 (CH), 136.8 (Cq), 
128.3 (Cq), 121.8 (CH), 121.4 (CH), 120.2 (CH), 120.2 (CH), 118.1 (CH), 112.6 (Cq), 109.8 
(CH), 31.9 (CH2), 27.2 (CH), 21.5 (CH2), 20.3 (CH3), 19.9 (CH2).  
IR (ATR): 2959, 2929, 1584, 1471, 1437, 1372, 738 cm–1.  
MS (ESI) m/z (relative intensity): 285 (25) [M+Na]+, 263 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C18H18N2+H]+ 263.1543 found 263.1542. 
[α]D
20: –70.5 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® IF-3, n-hexane/EtOAc 95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 11.7 min, tr (minor) = 10.5 min, 76:24 e.r.  
 
(R)-1-Methyl-9-(4-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole (367a): The 
general procedure H was followed using 1-(4-methylpyridin-2-yl)-3-(pent-4-en-1-yl)-1H-
indole (366a) (69.0 mg, 0.25 mmol). Isolation by column chromatography (n-hexane/EtOAc = 
20:1) yielded 367a (62.0 mg, 90%) as a colourless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.47 (d, J = 5.1 Hz, 1H), 7.53–7.46 (m, 1H), 7.40–7.34 (m, 
1H), 7.27 (d, J = 1.5 Hz, 1H), 7.16–7.09 (m, 3H), 3.59–3.45 (m, 1H), 2.86–2.67 (m, 2H), 2.47 
(s, 3H), 2.17–2.05 (m, 1H), 1.98–1.80 (m, 2H), 1.68–1.58 (m, 1H), 0.84 (d, J = 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 152.0 (Cq), 149.9 (Cq), 149.0 (CH), 140.2 (Cq), 136.9 (Cq), 
128.3 (Cq), 122.6 (CH), 121.7 (CH), 120.9 (CH), 120.1 (CH), 118.1 (CH), 112.5 (Cq), 109.8 
(CH), 31.8 (CH2), 27.2 (CH), 21.5 (CH2), 21.2 (CH3), 20.3 (CH3), 19.9 (CH2).  
IR (ATR): 2930, 1601, 1478, 1454, 1224, 824, 736 cm–1.  
MS (ESI) m/z (relative intensity): 299 (10) [M+Na]+, 277 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C19H20N2+Na]+ 299.1519 found 299.1519.  
[α]D
20: –82.2 (c = 1.0, CHCl3).   
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HPLC separation (Chiralpak® IB-3, n-hexane/EtOAc 95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 13.9 min, tr (minor) = 9.5 min, 81:19 e.r. 
 
(R)-1-Methyl-9-(5-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole (363a): The 
general procedure H was followed using 1-(5-methylpyridin-2-yl)-3-(pent-4-en-1-yl)-1H-
indole (362a) (69.0 mg, 0.25 mmol). Isolation by column chromatography (n-hexane/EtOAc = 
20:1) yielded 363a (65.7 mg, 95%) as a colourless oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.45 (d, J = 2.4, 0.8 Hz, 1H), 7.68 (ddd, J = 8.1, 2.4, 0.8 Hz, 
1H), 7.54–7.47 (m, 1H), 7.38–7.32 (m, 2H), 7.16–7.09 (m, 2H), 3.60–3.40 (m, 1H), 2.86–2.66 
(m, 2H), 2.43 (s, 3H), 2.17–2.05 (m, 1H), 2.00–1.80 (m, 2H), 1.71–1.59 (m, 1H), 0.85 (d, J = 
6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 149.7 (CH), 149.7 (Cq), 140.2 (Cq), 138.8 (CH), 137.0 (Cq), 
131.1 (Cq), 128.1 (Cq), 121.7 (CH), 120.0 (CH), 119.8 (CH), 118.0 (CH), 112.1 (Cq), 109.7 
(CH), 31.8 (CH2), 27.1 (CH), 21.5 (CH2), 20.3 (CH3), 19.9 (CH2), 18.0 (CH3).  
IR (ATR): 2928, 1570, 1483, 1385, 1224, 1028, 833, 737 cm–1.  
MS (ESI) m/z (relative intensity): 299 (10) [M+Na]+, 277 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C19H20N2+H]+ 277.1699 found 277.1700. 
[α]D
20: –95.3 (c = 1.0, CHCl3). HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 
mL/min, detection at 273 nm): tr (major) = 7.5 min, tr (minor) = 5.8 min, 85:15 e.r. 
 
(R)-6-Methoxy-1-methyl-9-(5-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole 
(363b): The general procedure H was followed using 5-methoxy-1-(5-methylpyridin-2-yl)-3-
(pent-4-en-1-yl)-1H-indole (362b) (76.5 mg, 0.25 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 363b (68.0 mg, 89%) as a yellow oil.  
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1H-NMR (400 MHz, CDCl3): δ = 8.43 (d, J = 2.3 Hz, 1H), 7.65 (dd, J = 8.1, 2.3 Hz, 1H), 7.31 
(d, J = 8.1 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 2.5 Hz, 1H), 6.77 (dd, J = 8.8, 2.5 
Hz, 1H), 3.87 (s, 3H), 3.55–3.40 (m, 1H), 2.80–2.64 (m, 2H), 2.41 (s, 3H), 2.20–2.02 (m, 1H), 
2.01–1.80 (m, 2H), 1.68–1.56 (m, 1H), 0.84 (d, J = 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 154.5 (Cq), 149.8 (Cq), 149.6 (CH), 140.9 (Cq), 138.8 (CH), 
132.1 (Cq), 130.9 (Cq), 128.6 (Cq), 119.5 (CH), 111.9 (Cq), 111.0 (CH), 110.6 (CH), 100.6 
(CH), 56.0 (CH3), 31.8 (CH2), 27.2 (CH), 21.5 (CH2), 20.3 (CH3), 19.9 (CH2), 18.0 (CH3). 
IR (ATR): 2930, 1596, 1483, 1440, 1388, 1156, 820 cm–1.  
MS (ESI) m/z (relative intensity): 329 (25) [M+Na]+, 307 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C20H22N2O+H]+ 307.1805 found 307.1808. 
[α]D
20: –51.6 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 13.6 min, tr (minor) = 8.6 min, 85:15 e.r.  
 
(R)-7-Methoxy-1-methyl-9-(5-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole 
(363c): The general procedure H was followed using 6-methoxy-1-(5-methylpyridin-2-yl)-3-
(pent-4-en-1-yl)-1H-indole (362c) (76.5 mg, 0.25 mmol). Isolation by column chromatography 
(n-hexane/EtOAc = 10:1) yielded 363c (72.0 mg, 95%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.46 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.1, 2.4 Hz, 1H), 7.37 
(d, J = 8.5 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.79 (dd, J = 8.5, 2.3 
Hz, 1H), 3.79 (s, 3H), 3.46–3.34 (m, 1H), 2.83–2.60 (m, 2H), 2.43 (s, 3H), 2.15–2.00 (m, 1H), 
1.95–1.80 (m, 2H), 1.69–1.56 (m, 1H), 0.82 (d, J = 6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ  = 156.4 (Cq), 149.8 (Cq), 149.8 (CH), 139.0 (Cq), 138.9 (CH), 
137.8 (Cq), 131.1 (Cq), 122.6 (Cq), 119.7 (CH), 118.5 (CH), 112.1 (Cq), 109.0 (CH), 94.7 (CH), 
55.9 (CH3), 31.8 (CH2), 27.2 (CH), 21.5 (CH2), 20.4 (CH3), 20.0 (CH2), 18.1 (CH3). 
IR (ATR): 2930, 1596, 1475, 1406, 1227, 1203, 1025, 796 cm–1.  
MS (ESI) m/z (relative intensity): 329 (10) [M+Na]+, 307 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C20H22N2O+Na]+ 329.1624 found 329.1622. 
[α]D
20: –65.1 (c = 1.0, CHCl3).   
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HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 13.8 min, tr (minor) = 9.6 min, 84:16 e.r.  
 
(R)-7-Fluoro-1-methyl-9-(5-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole (363d): 
The general procedure H was followed using 6-fluoro-1-(5-methylpyridin-2-yl)-3-(pent-4-en-
1-yl)-1H-indole (362d) (73.5 mg, 0.25 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 30:1) yielded 363d (49 mg, 66%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.47 (d, J = 2.3 Hz, 1H), 7.71 (dd, J = 8.1, 2.3 Hz, 1H), 7.41 
(dd, J = 8.5, 5.4 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.07 (dd, J = 9.5, 2.3 Hz, 1H), 6.90 (ddd, J 
= 9.5, 8.5, 2.3 Hz, 1H), 3.55–3.38 (m, 1H), 2.84–2.66 (m, 2H), 2.45 (s, 3H), 2.16–2.05 (m, 1H), 
2.00–1.81 (m, 2H), 1.69–1.59 (m, 1H), 0.85 (d, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.1 (d, 1JC–F = 234.1 Hz, Cq), 149.9 (CH), 149.4 (Cq), 140.5 
(d, 4JC–F = 3.4 Hz, Cq), 139.0 (CH), 137.1 (d, 3JC–F = 12.2 Hz, Cq), 131.5 (Cq), 124.6 (Cq), 119.6 
(CH), 118.5 (d, 3JC–F = 9.9 Hz, CH), 112.1 (Cq), 108.1 (d, 2JC–F  = 24.1 Hz, CH), 97.0 (d, 2JC–F 
= 27.2 Hz, CH), 31.7 (CH2), 27.2 (CH), 21.4 (CH2), 20.3 (CH3), 19.9 (CH2), 18.1 (CH3).   
19F-NMR (377 MHz, CDCl3): δ = –121.5.  
IR (ATR): 2929, 1596, 1473, 1484, 1387, 1142, 825, 797 cm–1.  
MS (ESI) m/z (relative intensity): 295 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C19H1919FN2+H]+ 295.1605 found 295.1612. 
[α]D
20: –78.6 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 7.2 min, tr (minor) = 5.3 min, 86:14 e.r.  
 
(R)-6-Bromo-1-methyl-9-(5-methylpyridin-2-yl)-2,3,4,9-tetrahydro-1H-carbazole (363e): 
The general procedure H was followed using 5-bromo-1-(5-methylpyridin-2-yl)-3-(pent-4-en-
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1-yl)-1H-indole (362e) (88.5 mg, 0.25 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 15:1) yielded 363e (78.0 mg, 88%) as a yellow solid. M.p.: 110–115 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.44 (d, J = 2.4 Hz, 1H), 7.68 (dd, J = 8.2, 2.4 Hz, 1H), 7.60 
(d, J = 1.3 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.23–7.10 (m, 2H), 3.52–3.34 (m, 1H), 2.81–2.59 
(m, 2H), 2.43 (s, 3H), 2.15–2.01 (m, 1H), 1.97–1.80 (m, 2H), 1.74–1.55 (m, 1H), 0.83 (d, J = 
6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 149.9 (CH), 149.3 (Cq), 141.6 (Cq), 139.0 (CH), 135.7 (Cq), 
131.7 (Cq), 129.9 (Cq), 124.3 (CH), 120.7 (CH), 119.8 (CH), 113.2 (Cq), 111.7 (Cq), 111.3 
(CH), 31.6 (CH2), 27.1 (CH), 21.3 (CH2), 20.2 (CH3), 19.8 (CH2), 18.1 (CH3).  
IR (ATR): 2929, 1572, 1483, 1455, 1402, 1027, 792 cm–1.  
MS (ESI) m/z (relative intensity): 377 (25) [M+Na]+, 355 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C19H1979BrN2+Na]+ 377.0624 found 377.0620.  
[α]D
20: –50.5 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 8.6 min, tr (minor) = 5.7 min, 82:18 e.r.  
1 mmol scale reaction: A modified procedure H was followed using 5-bromo-1-(5-
methylpyridin-2-yl)-3-(pent-4-en-1-yl)-1H-indole (362e) (354.0 mg, 1.0 mmol), [RuCl2(p-
cymene)]2 (30.6 mg, 5.0 mol %), AgSbF6 (68.8 mg, 20 mol %) and chiral acid CA14 (100.4 
mg, 20 mol %) in PhMe (2.0 mL) at 25 °C for 36 h. The reaction mixture was diluted with 
EtOAc (5.0 mL) and the solvent was removed in vacuo. The crude mixture was purified by 
flash column chromatography (n-hexane/EtOAc = 15:1) on silica gel to afford the desired 
product 363e. (304.2 mg, 86%) as a yellow soild. HPLC separation (Chiralpak® ID-3, n-
hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): tr (major) = 8.5 min, tr (minor) = 5.7 
min, 83:17 e.r.  
 
(R)-6-Methyl-5-(5-methylpyridin-2-yl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole 
(369a): The general procedure H was followed using 3-(hex-5-en-1-yl)-1-(5-methylpyridin-2-
yl)-1H-indole (368a) (29.0 mg, 0.10 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 30:1) yielded 369a (5.0 mg, 17%) as a yellow oil.  
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1H-NMR (600 MHz, CDCl3): δ = 8.45 (dd, J = 2.5, 0.8 Hz, 1H), 7.67–7.61 (m, 1H), 7.51–7.44 
(m, 1H), 7.22 (d, J = 7.0 Hz, 1H), 7.10 (dd, J = 8.0, 0.8 Hz, 1H), 7.07 (ddd, J = 8.0, 7.0, 1.2 
Hz, 1H), 7.03 (ddd, J = 8.0, 7.0, 1.2 Hz, 1H), 3.26–3.18 (m, 1H), 3.06 (ddd, J = 15.4, 5.8, 2.6 
Hz, 1H), 2.67 (ddd, J = 15.4, 12.4, 2.6 Hz, 1H), 2.40 (s, 3H), 2.06–1.99 (m, 1H), 1.96–1.87 (m, 
2H), 1.84–1.74 (m, 2H), 1.56–1.50 (m, 1H), 1.17 (d, J = 7.2 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 150.0 (CH), 149.5 (Cq), 143.1 (Cq), 138.7 (CH), 136.3 (Cq), 
131.8 (Cq), 128.8 (Cq), 121.6 (CH), 121.2 (CH), 119.8 (CH), 117.7 (CH), 114.6 (Cq), 110.0 
(CH), 33.2 (CH2), 30.5 (CH), 28.7 (CH2), 25.4 (CH2), 24.1 (CH2), 18.4 (CH3), 18.1 (CH3).  
IR (ATR): 2920, 1596, 1570, 1483, 1459, 1384, 1201, 738 cm–1.  
MS (ESI) m/z (relative intensity): 313 (10) [M+Na]+, 291 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C20H22N2+H]+ 291.1856 found 291.1858. 
[α]D
20: –7.4 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 7.6 min, tr (minor) = 6.0 min, 82:18 e.r.  
5.6.2. Mechanistic Studies 
 
5.6.2.1. H/D Exchange Experiment 
 
 
The representative procedure H was followed using 362a (69.0 mg, 0.25 mmol, 1 equiv), 
[RuCl2(p-cymene)]2 (7.7 mg, 5.0 mol %), AgSbF6 (17.2 mg, 20 mol %), CA14 (25.2 mg, 20 
mol %) in PhMe (0.50 mL) and D2O (0.10 mL) at 25 °C for 12 h. At ambient temperature, the 
reaction mixture was diluted with EtOAc (2.0 mL) and the solvents was removed in vacuo. 
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The crude mixture was purified by flash column chromatography on silica gel to afford the 
desired product [D]n-363a (48.0 mg, 71%) and [D]n-362a (17.0 mg, 24%) as yellow oils. 
 
Figure 5. 1H-NMR of reisolated [D]n-362 from the deuteration study.  
 
Figure 6. 1H-NMR of [D]n-363 from the deuteration study.  
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5.6.2.2. Intramolecular Competition KIE Experiment 
 
The representative procedure A was followed using 362a (53.8 mg, 0.195 mmol, 1 equiv), 
[D]n-362a (69.3 mg, 0.25 mmol, 1 equiv)], [RuCl2(p-cymene)]2 (13.7 mg, 10 mol %), AgSbF6 
(30.5 mg, 20 mol %) and CA14 (44.8 mg, 20 mol %) in PhMe (1.5 mL) at 25 °C for 1.5 h. The 
reaction mixture was diluted with EtOAc (5.0 mL) and the solvent was removed in vacuo. The 
crude mixture was purified by flash column chromatography on silica gel to afford the desired 
product 363a (21.0 mg, 17%) and [D]n-362a (98.0 mg, 80%) as yellow oils. The kinetic isotope 
effect of this reaction was determined to be kH/kD ≈ 52/48 ≈ 1.1 as estimated by 1H-NMR 
spectroscopy, based on the recovered starting material. 
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5.7. Copper-catalyzed Alkyne Annulation by C–H Alkynylation 
5.7.1. Characterization Data 
 
(Z)-3-Benzylidene-2-(quinolin-8-yl) isoindolin-1-one (256aa): The general procedure J was 
followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255a (51 mg, 0.50 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 256aa 
(78.7 mg, 90%, E/Z = 1:13) as a white solid. M. p.: 210–215 °C.  
Resonances are reported for (Z)-256aa. 1H-NMR (300 MHz, CDCl3):  = 8.85 (dd, J = 4.2, 1.7 
Hz, 1H), 8.02–7.94 (m, 2H), 7.88 (d, J = 7.7 Hz, 1H), 7.68 (td, J = 7.5, 1.2 Hz, 1H), 7.61–7.53 
(m, 2H), 7.48 (dd, J = 7.4, 1.5 Hz, 1H), 7.34–7.27 (m, 2H), 6.81 (s, 0.93H, Z), 6.71–6.64 (m, 
1H), 6.60–6.48 (m, 4H), 6.02 (s, 0.07H, E).  
13C-NMR (125 MHz, CDCl3):  = 167.9 (Cq), 150.2 (CH), 144.3 (Cq), 138.6 (Cq), 136.0 (Cq), 
135.6 (CH), 134.1 (Cq), 133.4 (Cq), 132.1 (CH), 129.9 (CH), 128.9 (CH), 128.7 (Cq), 128.2 
(Cq), 128.2 (CH), 128.0 (CH), 126.2 (CH), 125.9 (CH), 125.5 (CH), 123.8 (CH), 121.1 (CH), 
119.5 (CH), 107.2 (CH).  
IR (ATR): 3061, 1704, 1596, 1472, 1377, 1221, 1024, 716 cm−1.  
MS (ESI) m/z (relative intensity): 371 (10) [M+Na]+, 349 (60) [M+H]+.  
HR-MS (ESI) m/z calcd for C24H17N2O [M+H]+: 349.1335, found: 349.1324. The analytical 
data correspond with those reported in the literature.[208]   
 
(Z)-3-Benzylidene-7-bromo-2-(quinolin-8-yl)isoindolin-1-one (256ba): The general 
procedure J was followed using benzamide 229b (82 mg, 0.25 mmol) and alkyne 255a (51 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 
yielded 256ba (69.2 mg, 65%, E/Z = 1:10) as a yellow solid. M. p.: 200–205 °C.  
Resonances are reported for (Z)-256ba.  
1H-NMR (400 MHz, CDCl3): δ = 8.83 (dd, J = 4.2, 1.7 Hz, 1H), 8.02–7.93 (m, 2H), 7.90–7.85 
(m, 1H), 7.67 (dd, J = 7.8, 1.2 Hz, 1H), 7.56 (dd, J = 7.5, 1.2 Hz, 2H), 7.46 (dd, J = 7.4, 1.4 
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Hz, 1H), 7.31–7.26 (m, 2H), 6.79 (s, 0.90H, Z), 6.70–6.61 (m, 1H), 6.60–6.43 (m, 3H), 6.00 (s, 
0.10H, E). 
13C-NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 150.3 (CH), 144.4 (Cq), 138.7 (Cq), 136.1 (Cq), 
135.7 (CH), 135.5 (Cq), 135.3 (Cq), 134.2 (Cq), 133.6 (Cq), 132.2 (CH), 130.0 (CH), 129.1 
(CH), 128.8 (Cq), 128.1 (CH), 126.3 (CH), 126.0 (CH), 125.6 (CH), 123.9 (CH), 121.2 (CH), 
119.6 (CH), 107.3 (CH).  
IR (ATR): 3048, 1714, 1650, 1500, 1473, 1070, 757, 693 cm−1.  
MS (ESI) m/z (relative intensity): 449 (30) [M(79Br)+Na]+, 427 (100) [M(79Br)+H]+.  
HR-MS (ESI): m/z calcd for C24H1679BrN2O [M+H]+: 427.0441, found: 427.0448.   
 
(Z)-3-Benzylidene-7-phenyl-2-(quinolin-8-yl)isoindolin-1-one (256ca): The general 
procedure J was followed using benzamide 229c (81 mg, 0.25 mmol) and alkyne 255a (51 mg, 
0.50 mmol) with Cu(OAc)2∙H2O (5.0 mg, 10 mol %). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 2/1) yielded 256ca (54.3 mg, 51%, E/Z = 1:3) as a yellow oil.  
Resonances reported for (Z)-256ca: 1H-NMR (400 MHz, CDCl3): δ = 8.82 (dd, J = 4.2, 1.6 Hz, 
1H), 7.95–7.86 (m, 2H), 7.71 (d, J = 7.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.61 (d, J = 1.2 Hz, 
1H), 7.54 (d, J = 1.3 Hz, 1H), 7.48 (dd, J = 7.5, 1.0 Hz, 2H), 7.43–7.39 (m, 2H), 7.38–7.35 (m, 
2H), 7.26 (d, J = 1.7 Hz, 1H), 6.83 (s, 1H), 6.64 (t, J = 7.3 Hz, 1H), 6.60–6.55 (m, 2H), 6.51 
(d, J = 7.5 Hz, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 167.2 (Cq), 150.2 (CH), 144.3 (Cq), 141.1 (Cq), 139.7 (Cq), 
137.2 (Cq), 135.6 (Cq), 135.6 (CH), 134.2 (Cq), 133.6 (Cq), 131.7 (CH), 131.1 (CH), 130.2 
(CH), 129.7 (CH), 129.4 (CH), 128.7 (Cq), 128.4 (CH), 128.1 (CH), 127.5 (CH), 126.1 (CH), 
125.8 (CH), 125.5 (CH), 124.0 (Cq), 121.0 (CH), 118.6 (CH), 106.7 (CH).  
Resonances reported for (E)-256ca: 1H-NMR (400 MHz, CDCl3): δ = 8.92 (dd, J = 4.2, 1.6 Hz, 
1H), 8.20 (dd, J = 8.3, 1.6 Hz, 1H), 7.95–7.89 (m, 1H), 7.81 (dd, J = 7.3, 1.4 Hz, 1H), 7.66 (d, 
J = 7.8 Hz, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.58 (t, J = 1.4 Hz, 1H), 7.51–7.45 (m, 1H), 7.43–
7.38 (m, 1H), 7.38–7.35 (m, 2H), 7.35–7.32 (m, 4H), 7.32–7.27 (m, 3H), 7.24 (s, 1H), 6.01 (s, 
1H).  
13C-NMR (125 MHz, CDCl3) (two carbon peak less due to overlap): δ = 166.1 (Cq), 151.1 
(CH), 144.9 (Cq), 141.0 (Cq), 138.1 (Cq), 137.4 (Cq), 136.6 (Cq), 136.1 (CH), 135.5 (Cq), 132.8 
5. Experimental Part 
 
251 
(Cq), 131.5 (CH), 131.3 (CH), 129.7 (CH), 129.4 (Cq), 129.2 (CH), 128.1 (CH), 127.7 (CH), 
127.6 (CH), 127.5 (CH), 127.4 (CH), 126.2 (CH), 122.2 (CH), 121.7 (CH), 111.5 (CH).  
IR (ATR): 3055, 1719, 1595, 1473, 1377, 825, 759 cm−1.  
MS (ESI) m/z (relative intensity): 447 (10) [M+Na]+, 425 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C30H20N2ONa [M+Na] +: 447.1468, found: 447.1473.  
 
(Z)-3-Benzylidene-5-nitro-2-(quinolin-8-yl) isoindolin-1-one (256da): The general 
procedure J was followed using benzamide 229d (73 mg, 0.25 mmol) and alkyne 255a (51 mg, 
0.50 mmol) with Cu(OAc)2∙H2O (5.0 mg, 10 mol %). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 256da (57 mg, 58%, E/Z = 1:3) as a yellow oil.  
Resonances reported for (Z)-256da. 1H-NMR (400 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 1.6 
Hz, 1H), 8.78 (d, J = 1.8 Hz, 1H), 8.44 (dd, J = 8.3, 1.9 Hz, 1H), 8.17 (d, J = 8.3 Hz, 1H), 8.01 
(dd, J = 8.3, 1.6 Hz, 1H), 7.65 (dd, J = 8.2, 1.4 Hz, 1H), 7.53 (dd, J = 7.4, 1.3 Hz, 1H), 7.38–
7.31 (m, 2H), 6.99 (s, 1H), 6.74 (dd, J = 8.9, 5.3 Hz, 1H), 6.59 (dd, J = 7.1, 6.4 Hz, 4H).  
13C-NMR (100 MHz, CDCl3): δ = 166.0 (Cq), 150.8 (Cq), 150.5 (CH), 144.0 (Cq), 139.5 (Cq), 
135.9 (CH), 134.6 (Cq), 133.5 (Cq), 132.7 (Cq), 132.5 (Cq), 130.0 (CH), 129.9 (CH), 129.7 (Cq), 
128.1 (CH), 126.7 (CH), 126.5 (CH), 125.7 (CH), 125.2 (CH), 124.0 (CH), 121.5 (CH), 115.6 
(CH), 110.4 (CH).  
Resonances reported for (E)-256da. 1H-NMR (400 MHz, CDCl3): δ = 8.94 (dd, J = 4.2, 1.6 
Hz, 1H), 8.41–8.34 (m, 2H), 8.30 (dd, J = 8.3, 1.7 Hz, 1H), 8.15 (d, J = 8.1 Hz, 2H), 8.05 (dd, 
J = 8.3, 1.4 Hz, 1H), 7.90 (dd, J = 7.3, 1.4 Hz, 1H), 7.76 (dd, J = 8.2, 7.3 Hz, 1H), 7.50 (dd, J 
= 8.4, 4.3 Hz, 1H), 7.42 (dd, J = 6.6, 2.5 Hz, 4H), 6.23 (s, 1H).  
13C-NMR (100 MHz, CDCl3) (two peaks overlap): δ = 164.9 (Cq), 151.4 (CH), 150.3 (Cq), 
144.6 (Cq), 137.3 (Cq), 136.4 (CH), 136.2 (Cq), 134.8 (Cq), 134.1 (Cq), 132.1 (Cq), 131.2 (CH), 
129.3 (CH), 128.9 (CH), 128.7 (CH), 126.4 (CH), 124.8 (CH), 124.3 (CH), 122.1 (CH), 119.0 
(CH), 115.0 (CH).  
IR (ATR): 2955, 1712, 1645, 1596, 1342, 1180, 827, 790 cm−1.  
MS (ESI) m/z (relative intensity): 416 (20) [M+Na]+, 394 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C24H16N3O3 [M+H]+: 394.1186, found: 394.1188. 




(Z)-3-(4-Methybenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ab): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255b (58 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 
yielded 256ab (69.7 mg, 77%, E/Z = 1:6) as a yellow oil.  
Resonances reported for (Z)-256ab. 1H-NMR (400 MHz, CDCl3): δ = 8.82 (d, J = 3.2 Hz, 1H), 
7.97 (d, J = 7.2 Hz, 2H), 7.86 (d, J = 7.8 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.61–7.55 (m, 1H), 
7.52 (dd, J = 7.5, 0.8 Hz, 1H), 7.45 (dd, J = 7.4, 1.2 Hz, 1H), 7.33–7.24 (m, 2H), 6.77 (s, 1H), 
6.41 (d, J = 7.8 Hz, 2H), 6.30 (d, J = 7.8 Hz, 2H), 2.00 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 150.3 (CH), 144.4 (Cq), 138.7 (Cq), 135.8 (Cq), 
135.8 (CH), 135.6 (Cq), 134.3 (Cq), 132.1 (CH), 130.5 (Cq), 130.0 (CH), 129.1 (CH), 128.9 
(CH), 128.8 (Cq), 128.2 (Cq), 128.0 (CH), 126.9 (CH), 125.6 (CH), 123.9 (CH), 121.2 (CH), 
119.6 (CH), 107.5 (CH), 20.8 (CH3).  
Resonances reported for (E)-256ab. 1H-NMR (400 MHz, CDCl3): δ = 8.91 (dd, J = 4.2, 1.5 
Hz, 1H), 8.22 (dd, J = 8.1, 1.3 Hz, 1H), 7.99–7.93 (m, 2H), 7.82 (dd, J = 7.3, 1.2 Hz, 1H), 
7.71–7.68 (m, 1H), 7.52–7.51 (m, 1H), 7.50–7.47 (m, 1H), 7.43–7.36 (m, 2H), 7.25 (d, J = 3.7 
Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 5.98 (s, 1H), 2.35 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 167.0 (Cq), 151.2 (CH), 145.0 (Cq), 138.5 (Cq), 137.4 (Cq), 
136.2 (CH), 135.6 (Cq), 132.9 (Cq), 132.2 (Cq), 131.6 (CH), 131.4 (CH), 130.4 (Cq), 129.6 (Cq), 
129.4 (CH), 129.2 (CH), 128.0 (CH), 126.9 (CH), 126.3 (CH), 123.7 (CH), 123.3 (CH), 121.8 
(CH), 112.3 (CH), 21.3 (CH3).  
IR (ATR): 2922, 1718, 1630, 1565, 1255, 1203, 891, 724 cm−1.  
MS (ESI) m/z (relative intensity): 385 (10) [M+Na]+, 363 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C25H19N2O [M+H]+: 363.1495, found: 363.1492. The analytical 
data correspond with those reported in the literature.[208]   
 
 




(Z)-3-(4-Methoxybenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ac): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255c (66 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) 
yielded 256ac (68.1 mg, 72%, E/Z = 1:1.4) as a white solid. M. p.: 185–190 °C.  
Resonances reported for (Z)-256ac. 1H-NMR (400 MHz, CDCl3): δ = 8.83 (dd, J = 4.2, 1.7 Hz, 
1H), 8.00–7.92 (m, 2H), 7.85 (dd, J = 7.8, 1.5 Hz, 1H), 7.72–7.58 (m, 2H), 7.57–7.49 (m, 1H), 
7.49–7.43 (m, 1H), 7.34–7.26 (m, 2H), 6.75 (s, 1H), 6.50–6.43 (m, 2H), 6.10–6.02 (m, 2H), 
3.81 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 157.7 (Cq), 150.3 (CH), 144.5 (Cq), 138.8 (Cq), 
135.7 (CH), 135.5 (Cq), 134.4 (Cq), 132.1 (CH), 130.7 (CH), 129.6 (Cq), 129.4 (CH), 128.9 
(Cq), 128.8 (CH), 128.2 (CH), 126.0 (Cq), 125.7 (CH), 123.9 (CH), 121.2 (CH), 119.5 (CH), 
111.9 (CH), 107.2 (CH), 55.1 (CH3).  
Resonances reported for (E)-256ac.  1H-NMR (400 MHz, CDCl3): δ = 8.90 (dd, J = 4.2, 1.7 
Hz, 1H), 8.22 (dd, J = 8.2, 1.7 Hz, 1H), 8.00–7.92 (m, 2H), 7.82 (dd, J = 7.3, 1.5 Hz, 1H), 
7.72–7.58 (m, 1H), 7.57–7.49 (m, 1H), 7.49–7.43 (m, 1H), 7.43–7.36 (m, 2H), 7.34–7.26 (m, 
2H), 6.91–6.84 (m, 2H), 5.96 (s, 1H), 3.54 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 166.9 (Cq), 159.1 (Cq), 151.2 (CH), 145.0 (Cq), 138.3 (Cq), 
136.2 (CH), 135.6 (Cq), 133.0 (Cq), 131.6 (CH), 131.4 (CH), 129.9 (CH), 129.2 (CH), 128.2 
(CH), 128.2 (Cq), 127.5 (Cq), 123.7 (CH), 123.1 (CH), 121.8 (CH), 127.5 (Cq), 126.3 (CH), 
113.9 (CH), 112.0 (CH), 55.3 (CH3).  
IR (ATR): 3022, 1712, 1610, 1555, 1243, 1103, 791, 754 cm−1.  
MS (ESI) m/z (relative intensity): 401 (10) [M+Na]+, 379 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C25H19N2O2 [M+H]+: 379.1441, found: 379.1458. The analytical 
data correspond with those reported in the literature.[208]   
 




(Z)-3-(2-Methoxybenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ad): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255d (66 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) 
yielded 256ad (62.0 mg, 66%, E/Z = 1:4) as a white solid. M. p.: 172–180 °C.  
Resonances are reported for (Z)-256ad. 1H-NMR (300 MHz, CDCl3): δ = 8.88 (dd, J = 4.1, 1.5 
Hz, 1H), 8.06–7.96 (m, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.58 (d, J = 7.4 
Hz, 2H), 7.51 (dd, J = 7.4, 1.3 Hz, 1H), 7.34–7.28 (m, 2H), 6.79 (s, 1H), 6.70 (dd, J = 7.8, 1.8 
Hz, 1H), 6.33 (t, J = 7.6 Hz, 2H), 5.95 (t, J = 7.6 Hz, 1H), 3.61 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 167.9 (Cq), 155.9 (Cq), 150.0 (CH), 144.4 (Cq), 138.5 (Cq), 
136.1 (Cq), 135.6 (CH), 133.9 (Cq), 131.9 (CH), 129.8 (CH), 129.7 (CH), 128.7 (CH), 128.5 
(Cq), 128.21 (Cq), 128.1 (CH), 127.7 (CH), 125.2 (CH), 123.6 (CH), 122.3 (Cq), 120.8 (CH), 
119.8 (CH), 118.3 (CH), 108.6 (CH), 103.6 (CH), 54.9 (CH3).  
Resonances are reported for (E)-256ad. 1H-NMR (300 MHz, CDCl3): δ = 8.95 (dd, J = 4.2, 1.5 
Hz, 1H), 8.25 (dd, J = 8.4, 1.6 Hz, 1H), 8.00 (dd, J = 8.4, 1.2 Hz, 2H), 7.96–7.88 (m, 1H), 7.69 
(dd, J = 7.6, 1.1 Hz, 1H), 7.61–7.55 (m, 1H), 7.54–7.49 (m, 1H), 7.44 (dd, J = 7.5, 1.2 Hz, 2H), 
7.37–7.28 (m, 2H), 7.03–6.94 (m, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.02 (s, 1H), 3.72 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 166.8 (Cq), 157.3 (Cq), 150.9 (CH), 144.9 (Cq), 138.2 (Cq), 
136.0 (CH), 132.9 (Cq), 131.5 (CH), 131.2 (CH), 131.1 (CH), 130.3 (Cq), 129.4 (Cq), 129.3 
(CH), 129.1 (CH), 129.0 (CH), 126.2 (CH), 123.9 (Cq), 123.5 (CH), 123.1 (CH), 122.3 (Cq), 
121.6 (CH), 120.1 (CH), 110.6 (CH), 108.7 (CH), 55.4 (CH3).  
IR (ATR): 3048, 1709, 1595, 1398, 1243, 791 cm−1.  
MS (ESI) m/z (relative intensity): 401 (25) [M+Na]+, 379 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C25H18N2O2Na [M+Na]+: 401.1260, found: 401.1262. The 
analytical data correspond with those reported in the literature.[208] 




(Z)-3-(3-Chlorobenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ae): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255e (68 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 
yielded 256ae (66.6 mg, 70%, E/Z = 1:4) as a white solid. M. p.: 170–177 °C.  
Resonances are reported for (Z)-256ae.  1H-NMR (400 MHz, CDCl3): δ = 8.84 (dd, J = 4.2, 
1.7 Hz, 1H), 7.99–7.95 (m, 2H), 7.84 (dd, J = 7.6, 1.2 Hz, 1H), 7.69–7.64 (m, 1H), 7.60 (dd, J 
= 8.3, 1.4 Hz, 1H), 7.56 (dd, J = 7.5, 0.9 Hz, 1H), 7.46 (dd, J = 7.5, 1.4 Hz, 1H), 7.35–7.29 (m, 
2H), 7.26 (dd, J = 1.4, 0.4 Hz, 1H), 6.66 (s, 1H), 6.63 (dd, J = 7.6, 1.6 Hz, 1H), 6.50–6.47 (m, 
1H), 6.46–6.44 (m, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 150.5 (CH), 144.2 (Cq), 138.4 (Cq), 137.0 (Cq), 
135.9 (CH), 135.4 (Cq), 133.9 (Cq), 132.4 (Cq), 132.3 (CH), 129.2 (CH), 129.3 (CH), 129.0 
(Cq), 128.6 (CH), 128.4 (CH), 128.3 (Cq), 127.4 (CH), 126.3 (CH), 126.0 (CH), 125.7 (CH), 
124.0 (CH), 121.4 (CH), 119.7 (CH), 105.3 (CH).  
Resonances are reported for (E)-256ae.  1H-NMR (400 MHz, CDCl3): δ = 8.90 (dd, J = 4.2, 
1.7 Hz, 1H), 8.22 (dd, J = 8.3, 1.7 Hz, 1H), 8.01 (d, J = 1.7 Hz, 2H), 7.81 (dd, J = 7.3, 1.4 Hz, 
1H), 7.71–7.64 (m, 1H), 7.51 (dd, J = 7.5, 1.4 Hz, 1H), 7.43–7.39 (m, 1H), 7.35 (dd, J = 2.3, 
1.8 Hz, 2H), 6.52 (d, J = 7.6 Hz, 1H), 6.55–6.50 (m, 3H), 5.89 (s, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 166.9 (Cq), 151.2 (CH), 144.9 (Cq), 139.6 (Cq), 137.2 (Cq), 
136.2 (CH), 135.2 (Cq), 134.3 (Cq), 132.6 (Cq), 131.9 (CH), 131.3 (CH), 130.5 (Cq), 129.8 
(CH), 129.7 (CH), 129.7 (CH), 129.5 (Cq), 129.4 (CH), 127.6 (CH), 127.6 (CH), 126.3 (CH), 
123.9 (CH), 123.1 (CH), 121.9 (CH), 110.1 (CH).  
IR (ATR): 3058, 1716, 1652, 1593, 1500, 1397, 827, 757 cm−1.  
MS (ESI) m/z (relative intensity): 405 (10) [M+Na]+, 383 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C24H1535ClN2ONa [M+Na]+: 405.0765, found: 405.0762. 
 




(Z)-2-(Quinolin-8-yl)-3-(4-(trifluoromethyl) benzylidene) isoindolin-1-one (256af) 
The general procedure J was followed using benzamide 229a (73 mg, 0.25 mmol) and alkyne 
255f (85 mg, 0.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 2/1) yielded 256af (62.6 mg, 60%, E/Z = 1:20) as a yellow oil.  
Resonances are reported for (Z)-256af: 1H-NMR (400 MHz, CDCl3): δ = 8.82 (dd, J = 4.2, 1.7 
Hz, 1H), 8.03 (dd, J = 7.6, 1.0 Hz, 1H), 7.95 (dd, J = 8.3, 1.7 Hz, 1H), 7.91 (dd, J = 7.8, 1.0 
Hz, 1H), 7.73 (dd, J = 7.6, 1.2 Hz, 1H), 7.62 (dd, J = 7.8, 1.2 Hz, 2H), 7.56 (dd, J = 7.6, 1.4 
Hz, 1H), 7.37 (dd, J = 8.3, 7.6 Hz, 1H), 7.31 (dd, J = 8.3, 4.2 Hz, 1H), 6.80–6.72 (m, 3H), 
6.68–6.61 (m, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 150.4 (CH), 144.1 (Cq), 138.3 (Cq), 137.5 (Cq), 
137.4 (Cq), 135.9 (CH), 133.9 (Cq), 132.5 (CH), 130.2 (CH), 129.5 (CH), 128.9 (Cq), 128.7 
(CH), 128.4 (Cq), 128.2 (CH), 127.7 (q, 2JC–F = 34.2 Hz, Cq), 125.8 (CH), 124.1 (CH), 123.4 
(q, 1JC–F = 270 Hz, Cq), 122.8 (q, 3J C–F = 3.4 Hz, CH), 121.4 (CH), 119.8 (CH), 105.2 (CH).  
19F-NMR (375 MHz, CDCl3): δ = –63.1 (m).  
IR (ATR): 3022, 1711, 1609, 1511, 1221, 827, 798, 728 cm−1.  
MS (ESI) m/z (relative intensity): 417 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C25H16F3N2O [M+H]+: 417.1209, found: 417.1218. 
 
(Z)-3-(4-Fluorobenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ag): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255g (60 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 
yielded 256ag (66.9 mg, 73%, E/Z = 1:6) as a yellow oil.  
Resonances are reported for (Z)-256ag: 1H-NMR (400 MHz, CDCl3): δ = 8.83 (dd, J = 4.2, 1.7 
Hz, 1H), 8.03–7.97 (m, 2H), 7.87 (dd, J = 7.8, 0.9 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.64 (dd, 
J = 8.3, 1.4 Hz, 1H), 7.56 (dd, J = 7.4, 0.9 Hz, 1H), 7.49 (dd, J = 7.4, 1.4 Hz, 1H), 7.38–7.28 
(m, 2H), 6.71 (s, 1H), 6.57–6.47 (m, 2H), 6.26–6.18 (m, 2H).  
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13C-NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 161.0 (d, 1JC–F = 240 Hz, Cq), 150.4 (CH), 144.3 
(Cq), 138.5 (Cq), 136.4 (Cq), 135.8 (CH), 134.1 (Cq), 132.3 (CH), 130.1 (CH), 129.7 (d, 3JC–F = 
8.1 Hz, CH), 129.5 (d, 4JC–F = 2.9 Hz, Cq), 129.2 (CH), 128.8 (Cq), 128.4 (CH), 128.3 (Cq), 
125.7 (CH), 123.9 (CH), 121.3 (CH), 119.6 (CH), 113.1 (d, 2JC–F = 22.9 Hz, CH), 106.0 (CH).  
19F-NMR (375 MHz, CDCl3): δ = –115.6 (m).  
Resonances are reported for (E)-256ag: 1H-NMR (400 MHz, CDCl3): δ = 8.90 (dd, J = 4.2, 1.7 
Hz, 1H), 8.22 (dd, J = 8.4, 1.7 Hz, 1H), 7.96–7.94 (m, 2H), 7.82 (dd, J = 7.4, 1.5 Hz, 1H), 
7.51–7.49 (m, 1H), 7.44–7.42 (m, 1H), 7.42–7.39 (m, 3H), 7.38–7.28 (m, 2H), 7.08–6.98 (m, 
2H), 5.92 (s, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 167.0 (Cq), 161.5 (d, 1JC–F = 247.5 Hz, Cq), 151.2 (CH), 
144.9 (Cq), 139.1 (Cq), 136.2 (CH), 135.3 (Cq), 132.8 (Cq), 131.8 (CH), 131.4 (CH), 131.2 (d, 
3JC–F = 8.0 Hz, CH), 131.2 (Cq), 130.5 (Cq), 129.5 (d, 4JC–F = 2.9 Hz, Cq), 129.6 (CH), 126.3 
(CH), 123.9 (CH), 123.8 (CH), 123.1 (CH), 121.8 (CH), 115.5 (d, 2JC–F = 21.5 Hz, CH), 1107 
(CH).  
19F-NMR (375 MHz, CDCl3): δ = –113.9 (m).  
IR (ATR): 3048, 1715, 1655, 1596, 1397, 1227, 829 cm−1.  
MS (ESI) m/z (relative intensity): 389 (15) [M+Na]+, 367 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C24H16N2O [M+H]+: 367.1241, found: 367.1253. The analytical 
data correspond with those reported in the literature.[210]  
 
(Z)-3-(4-Bromobenzylidene)-2-(quinolin-8-yl) isoindolin-1-one (256ah): The general 
procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255h (91 mg, 
0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1) 
yielded 256ah (76.7 mg, 72%, E/Z = 1:4) as a yellow oil.  
Resonances are reported for (Z)-256ah: 1H-NMR (400 MHz, CDCl3): δ = 8.80 (dd, J = 4.2, 1.7 
Hz, 1H), 8.05–7.97 (m, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.70–7.63 (m, 2H), 7.55 (dd, J = 7.4, 0.9 
Hz, 1H), 7.49 (dd, J = 7.4, 1.4 Hz, 1H), 7.37–7.27 (m, 2H), 6.66 (s, 1H), 6.59 (d, J = 8.3 Hz, 
2H), 6.37 (d, J = 8.3 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 150.4 (CH), 144.3 (Cq), 138.4 (Cq), 136.8 (Cq), 
135.8 (CH), 134.1 (Cq), 132.4 (Cq), 132.3 (CH), 131.6 (CH), 131.2 (CH), 130.1 (CH), 129.5 
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(CH), 129.1 (CH), 128.9 (Cq), 128.5 (CH), 128.3 (Cq), 124.0 (CH), 121.4 (CH), 120.0 (Cq), 
119.7 (CH), 105.7 (CH).  
Resonances are reported for (E)-256ah: 1H-NMR (400 MHz, CDCl3): δ = 8.95 (d, J = 4.3 Hz, 
1H), 8.27 (dd, J = 8.4, 1.6 Hz, 1H), 8.06 (d, J = 1.6 Hz, 1H), 7.91–7.83 (m, 1H), 7.73 (d, J = 
1.3 Hz, 2H), 7.51–7.49 (m, 2H), 7.48–7.44 (m, 2H), 7.30–7.26 (m, 4H), 5.87 (s, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 166.9 (Cq), 151.2 (CH), 144.9 (Cq), 139.2 (Cq), 136.3 (CH), 
135.2 (Cq), 134.3 (Cq), 134.2 (CH), 132.7 (Cq), 131.9 (CH), 131.4 (CH), 130.5 (Cq), 129.6 
(CH), 129.6 (Cq), 129.5 (CH), 129.3 (CH), 126.3 (CH), 123.9 (CH), 123.1 (CH), 121.9 (CH), 
121.6 (Cq), 110.4 (CH).  
IR (ATR): 3049, 1713, 1595, 1472, 1302, 827, 759, 718 cm−1.  
MS (ESI) m/z (relative intensity): 449 (10) [M(79Br)+Na]+, 427 (100) [M(79Br)+H]+.  
HR-MS (ESI): m/z calcd for C24H1579BrN2ONa [M+Na]+: 449.0260, found: 449.0270. 
 
(Z)-Methyl 4-[{3-oxo-2-(quinolin-8-yl)isoindolin-1-ylidene} methyl)benzoate (256ai): The 
general procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255i 
(80 mg, 0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
2/1) yielded 256ai (71.7 mg, 70%, E/Z = 1:7) as a yellow solid. M. p.: 185–190 °C.  
Resonances are reported for (Z)-256ai.  1H-NMR (400 MHz, CDCl3): δ = 8.81 (dd, J = 4.2, 1.7 
Hz, 1H), 7.97 (dd, J = 7.6, 1.2 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.67 
(t, J = 7.4 Hz, 1H), 7.59–7.53 (m, 2H), 7.48 (d, J = 7.4, 1H), 7.31–7.25 (m, 2H), 7.21–7.15 (m, 
2H), 6.73 (s, 1H), 6.62–6.54 (m, 2H), 3.79 (3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 166.6 (Cq), 150.4 (CH), 144.2 (Cq), 138.6 (Cq), 
138.4 (Cq), 137.2 (Cq), 135.8 (CH), 134.0 (Cq), 132.4 (CH), 130.0 (CH), 129.4 (CH), 128.8 
(Cq), 128.5 (CH), 128.3 (Cq), 128.1 (CH), 127.4 (CH), 127.3 (Cq), 125.7 (CH), 124.0 (CH), 
121.4 (CH), 119.7 (CH), 105.7 (CH), 51.9 (CH3).  
Resonances are reported for (E)-256ai: 1H-NMR (400 MHz, CDCl3): δ = 8.90 (dd, J = 4.2, 1.7 
Hz, 1H), 8.23 (dd, J = 8.3, 1.7 Hz, 1H), 8.02–7.99 (m, 2H), 7.82 (dd, J = 7.3, 1.4 Hz, 1H), 7.67 
(t, J = 7.4 Hz, 1H), 7.51 (dd, J = 7.4, 1.0 Hz, 1H), 7.46–7.42 (m, 3H), 7.41–7.37 (m, 1H), 7.31–
7.25 (m, 2H), 7.21–7.15 (m, 2H), 5.96 (s, 1H), 3.81 (3H). 
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13C-NMR (100 MHz, CDCl3): δ = 167.0 (Cq), 166.7 (Cq), 151.3 (CH), 144.9 (Cq), 140.4 (Cq), 
139.8 (Cq), 136.3 (CH), 135.2 (Cq), 132.6 (Cq), 131.9 (CH), 131.4 (CH), 130.5 (Cq), 129.8 
(CH), 129.7 (CH), 129.6 (CH), 129.5 (CH), 129.1 (Cq), 127.3 (Cq), 126.3 (CH), 123.9 (CH), 
123.2 (CH), 121.9 (CH), 110.6 (CH), 52.1 (CH3).  
IR (ATR): 3050, 1712, 1604, 1472, 1276, 1107, 791, 732 cm−1.  
MS (ESI) m/z (relative intensity): 429 (10) [M+Na]+, 407 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C26H19N2O3 [M+H]+: 407.1390, found: 407.1397.   
 
(Z)-4-[{3-Oxo-2-(quinolin-8-yl) isoindolin-1-ylidene} methyl] benzonitrile (256aj): The 
general procedure J was followed using benzamide 229a (62 mg, 0.25 mmol) and alkyne 255j 
(64 mg, 0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
1/1) yielded 256aj (61.5 mg, 66%, E/Z = 1:6) as a white solid. M. p.: 235–242 °C.  
Resonances are reported for (Z)-256aj. 1H-NMR (400 MHz, CDCl3): δ = 8.83 (dd, J = 4.2, 1.7 
Hz, 1H), 8.06–7.97 (m, 2H), 7.89 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.67 (dd, J = 
8.2, 1.4 Hz, 1H), 7.65–7.59 (m, 1H), 7.54 (d, J = 6.5 Hz, 1H), 7.41–7.30 (m, 2H), 6.80 (d, J = 
8.2 Hz, 2H), 6.71 (s, 1H), 6.66 (d, J = 8.2 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 150.5 (CH), 144.1 (Cq), 138.8 (Cq), 138.2 (Cq), 
138.0 (Cq), 136.0 (CH), 133.9 (Cq), 132.6 (CH), 130.1 (CH), 129.8 (CH), 128.9 (Cq), 128.8 
(CH), 128.7 (CH), 128.3 (Cq), 125.8 (CH), 124.1 (CH), 121.6 (CH), 119.9 (CH), 118.7 (Cq), 
109.5 (CH), 109.2 (Cq), 104.6 (CH).  
Resonances are reported for (E)-256aj.1H-NMR (400 MHz, CDCl3): δ = 8.93 (dd, J = 4.2, 1.7 
Hz, 1H), 8.27 (dd, J = 8.3, 1.7 Hz, 1H), 8.05–8.02 (m, 2H), 7.85 (dd, J = 7.3, 1.4 Hz, 1H), 7.72 
(dd, J = 7.5, 1.1 Hz, 1H), 7.66–7.59 (m, 2H), 7.58–7.55 (m, 1H), 7.52–7.42 (m, 5H), 5.93 (s, 
1H).  
13C-NMR (100 MHz, CDCl3): δ = 166.9 (Cq), 151.3 (CH), 144.9 (Cq), 140.6 (Cq), 140.4 (Cq), 
138.8 (Cq), 136.4 (CH), 136.0 (CH), 134.9 (Cq), 132.5 (Cq), 132.2 (CH), 132.1 (CH), 131.4 
(CH), 130.6 (Cq), 130.3 (CH), 130.2 (CH), 129.8 (CH), 129.6 (Cq), 126.4 (CH), 123.0 (CH), 
122.0 (CH), 118.8 (CH), 111.0 (Cq).  
IR (ATR): 3047, 1704, 1650, 1597, 1470, 1144, 754 cm−1.  
MS (ESI) m/z (relative intensity): 396 (20) [M+Na]+, 374 (100) [M+H]+.  
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HR-MS (ESI): m/z calcd for C25H16N3O [M+H]+: 374.1288, found: 374.1295. The analytical 
data correspond with those reported in the literature.[208]   
 
(Z)-2-(Quinolin-8-yl)-3-(thiophen-3-ylmethylene) isoindolin-1-one (256ak): The general 
procedure J was followed using benzamide 229a (73 mg, 0.25 mmol) and alkyne 255k (54 mg, 
0.50 mmol) with Cu(OAc)2∙H2O (5.0 mg, 10 mol %). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 2/1) yielded 256ak (66 mg, 75%, E/Z = 1:3) as a yellow solid. 
M. p.: 170–175 °C.  
Resonances reported for (Z)-256ak: 1H-NMR (300 MHz, CDCl3): δ = 8.83 (dd, J = 4.1, 1.8 
Hz, 1H), 8.04 (dd, J = 8.4, 1.7 Hz, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.68 
(dd, J = 8.0, 5.8 Hz, 2H), 7.56–7.52 (m, 2H), 7.39 (d, J = 7.9 Hz, 1H), 7.37–7.28 (m, 1H), 6.65 
(s, 1H), 6.54 (dd, J = 5.0, 3.0 Hz, 1H), 6.20 (d, J = 4.3 Hz, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 150.5 (CH), 144.6 (Cq), 138.6 (Cq), 136.2 (Cq), 
135.9 (CH), 134.2 (Cq), 133.8 (Cq), 132.2 (CH), 129.8 (CH), 129.0 (CH), 128.9 (Cq), 128.5 
(CH), 128.2 (Cq), 127.9 (CH), 125.8 (CH), 123.9 (CH), 123.0 (CH), 122.8 (CH), 121.4 (CH), 
119.5 (CH), 101.8 (CH).  
Resonances reported for (E)-256ak: 1H-NMR (300 MHz, CDCl3): δ = 8.91 (dd, J = 4.1, 1.8 
Hz, 1H), 8.23 (dd, J = 8.4, 1.7 Hz, 1H), 7.96 (d, J = 7.7 Hz, 2H), 7.84 (d, J = 7.9 Hz, 1H), 7.73–
7.61 (m, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.49–7.42 (m, 2H), 7.37–7.27 (m, 2H), 7.07 (d, J = 5.0 
Hz, 1H), 5.85 (s, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 166.9 (Cq), 151.3 (CH), 145.0 (Cq), 139.2 (Cq), 136.3 (CH), 
135.5 (Cq), 134.2 (Cq), 132.8 (Cq), 131.8 (CH), 131.4 (CH), 130.3 (Cq), 129.6 (Cq). 129.5 (CH), 
129.4 (CH), 128.9 (CH), 126.3 (CH), 125.7 (CH), 124.0 (CH), 123.8 (CH), 123.2 (CH), 121.8 
(CH), 106.2 (CH).  
IR (ATR): 3021, 1709, 1501, 1473, 1397, 827, 789 cm−1.  
MS (ESI) m/z (relative intensity): 377 (10) [M+Na]+, 355 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C22H15N2OS [M+H]+: 355.0900, found: 355.0902.   




(Z)-Ethyl 2-(3-oxo-2-(quinolin-8-yl) isoindolin-1-ylidene)acetate (256al): The general 
procedure J was followed using benzamide 229a (73 mg, 0.25 mmol) and alkyne 255l (49 mg, 
0.50 mmol) with Cu(OAc)2∙H2O (10.0 mg, 20 mol %). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/3) yielded 256al (36.2 mg, 42%, E/Z = 1:5) as a yellow oil.  
Resonances are reported for (Z)-256al: 1H-NMR (400 MHz, CDCl3): δ = 8.88 (dd, J = 4.4, 1.7 
Hz, 1H), 8.24 (dd, J = 8.3, 1.7 Hz, 1H), 7.99 (dd, J = 7.5, 1.0 Hz, 1H), 7.94 (dd, J = 8.3, 1.4 
Hz, 1H), 7.83 (dd, J = 7.3, 1.0 Hz, 1H), 7.78 (dd, J = 7.3, 1.4 Hz, 1H), 7.74–7.64 (m, 3H), 7.43 
(dd, J = 8.3, 4.2 Hz, 1H), 5.98 (s, 1H), 3.45 (dq, J = 10.9, 7.1 Hz, 1H), 3.26 (dq, J = 10.9, 7.1 
Hz, 1H), 0.72 (t, J = 7.1, 0.7 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.4 (Cq), 164.3 (Cq), 150.6 (CH), 144.9 (Cq), 144.0 (Cq), 
138.0 (Cq), 136.2 (CH), 134.5 (Cq), 132.9 (CH), 130.9 (CH), 129.4 (CH), 128.9 (Cq), 128.7 
(CH), 128.2 (Cq), 126.1 (CH), 124.3 (CH), 121.5 (CH), 120.4 (CH), 95.5 (CH), 60.1 (CH2), 
13.6 (CH3).  
Resonances are reported for (E)-256al: 1H-NMR (400 MHz, CDCl3): δ = 9.23 (dd, J = 7.9, 0.9 
Hz, 1H), 8.90 (d, J = 1.6 Hz, 1H), 8.30–8.26 (m, 1H), 8.07–8.00 (m, 2H), 7.75 (dd, J = 6.5, 1.1 
Hz, 3H), 7.73–7.62 (m, 1H), 7.48 (dd, J = 8.3, 4.2 Hz, 1H), 5.25 (s, 1H), 4.18 (qd, J = 7.1, 3.8 
Hz, 2H), 1.24 (t, J = 7.0 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 167.6 (Cq), 166.1 (Cq), 151.5 (CH), 150.8 (Cq), 144.7 (Cq), 
136.3 (CH), 134.3 (Cq), 133.3 (CH), 131.9 (Cq), 131.4 (CH), 131.3 (CH), 130.3 (Cq), 130.0 
(CH), 129.6 (Cq), 128.4 (CH), 126.4 (CH), 123.7 (CH), 122.1 (CH), 100.2 (CH), 60.3 (CH2), 
14.2 (CH3).  
IR (ATR): 3010, 1705, 1601, 1533, 1290, 855, 770, 728 cm−1.  
MS (ESI) m/z (relative intensity): 345 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C21H17N2O3 [M+H]+: 345.1234, found: 345.1232.   




(S,Z)-tert-Butyl-(1-oxo-1-((3-((3-oxo-2-(quinolin-8-yl) isoindolin-1-ylidene) methyl) 
phenyl) amino)-3-phenylpropan-2-yl) carbamate (256am): The general procedure J was 
followed using benzamide 229a (73 mg, 0.25 mmol) and alkyne 255m (182 mg, 0.50 mmol) 
with Cu(OAc)2∙H2O (5.0 mg, 10 mol %). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 2/1) yielded 256am (106.7 mg, 70%, E/Z = 1:6) as a yellow oil.  
Resonances are reported for (Z)-256am: 1H-NMR (400 MHz, CDCl3): δ = 8.78 (dd, J = 4.0, 
1.1 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.86–7.78 (m, 2H), 7.69–7.61 (m, 1H), 7.54 (t, J = 7.5 
Hz, 1H), 7.48–7.43 (m, 1H), 7.38 (d, J = 7.1 Hz, 1H), 7.32–7.27 (m, 3H), 7.24–7.14 (m, 5H), 
6.85 (d, J = 8.0 Hz, 1H), 6.68 (s, 1H), 6.52–6.40 (m, 2H), 6.26 (dd, J = 12.6, 7.6 Hz, 1H), 5.06 
(s, 1H), 4.31 (s, 1H), 3.14–2.92 (m, 2H), 1.43 (s, 9H).  
13C-NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 167.8 (Cq), 167.1 (Cq), 149.4 (CH), 143.3 (Cq), 
137.6 (Cq), 135.5 (CH), 135.5 (Cq), 134.9 (CH), 134.8 (CH), 134.7 (Cq), 133.3 (Cq), 133.1 (Cq), 
131.3 (CH), 129.0 (Cq), 128.4 (Cq), 128.3 (CH), 128.2 (CH), 128.0 (CH), 127.4 (CH), 127.3 
(Cq), 126.0 (CH), 124.8 (CH), 124.7 (CH), 123.4 (CH), 123.0 (CH), 120.3 (CH), 120.2 (CH), 
118.9 (CH), 118.7 (CH), 105.6 (CH), 79.7 (Cq), 55.5 (CH), 37.1 (CH2), 27.3 (CH3).  
Resonances are reported for (E)-256am:  1H-NMR (400 MHz, CDCl3): δ = 8.88 (dd, J = 4.0, 
1.1 Hz, 1H), 8.21 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.4 Hz, 2H), 7.89–7.75 (m, 2H), 7.65 (t, J = 
7.4 Hz, 1H), 7.50 (d, J = 1.1 Hz, 1H), 7.43–7.36 (m, 3H), 7.35 – 7.24 (m, 2H), 7.22 – 7.14 (m, 
2H), 7.11 (d, J = 6.9 Hz, 2H), 7.07–6.98 (m, 3H), 5.90 (s, 1H), 5.13 (s, 1H), 4.42 (s, 1H), 3.15–
2.91 (m, 2H), 1.36 (s, 9H).  
13C-NMR (100 MHz, CDCl3): δ = 168.7 (Cq), 166.1 (Cq), 154.8 (CH), 150.3 (CH), 144.0 (Cq), 
138.1 (Cq), 136.6 (Cq), 135.7 (CH), 135.6 (CH), 135.3 (Cq), 135.1 (Cq), 134.3 (Cq), 133.3 (Cq), 
131.8 (CH), 130.9 (CH), 130.4 (Cq), 129.4 (CH), 128.5 (CH), 128.5 (Cq), 127.8 (CH), 126.2 
(Cq), 125.9 (CH), 125.4 (CH), 124.6 (CH), 122.8 (CH), 122.5 (CH), 120.9 (CH), 119.9 (CH), 
118.2 (CH), 116.9 (CH), 116.8 (CH), 110.6 (CH), 79.7 (Cq), 55.5 (CH), 37.3 (CH2), 27.3 (CH3).  
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IR (ATR): 3022, 1721, 1652, 1542, 1244, 872, 791, 711 cm−1.  
MS (ESI) m/z (relative intensity): 633 (10) [M+Na]+, 611 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C38H34N4O4Na [M+Na]+: 633.2472, found: 633.2475. 
5.8. Electrochemical Cobalt-catalyzed C–H Allylation 
5.8.1. Characterization Data 
 
(E)-2-Methyl-6-(oct-2-en-1-yl)-N-(quinolin-8-yl)benzamide (242fo): The general procedure 
K was followed using 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 0.50 mmol) 
and n-octene (223o) (168.0 mg, 1.5 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 10:1) yielded 242fo (112.0 mg, 60%) as a colourless oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.90 (s, 1H), 8.98 (dd, J = 7.4, 1.7 Hz, 1H), 8.72 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.57 (m, 1H), 7.54 (dd, J = 8.3, 1.7 Hz, 1H), 
7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (dd, J = 7.4, 1.7 Hz, 1H), 7.16–7.07 (m, 2H), 5.54 (dtt, J = 
14.7, 6.6, 1.4 Hz, 1H), 5.40 (dtt, J = 14.7, 6.6, 1.4 Hz, 1H), 3.43 (d, J = 6.6 Hz, 2H), 2.42 (s, 
3H), 1.88–1.73 (m, 2H), 1.18–1.06 (m, 6H), 0.77 (t, J = 6.2 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.7 (Cq), 148.2 (CH), 138.5 (Cq), 137.8 (Cq), 137.7 (Cq), 
136.3 (CH), 134.7 (Cq), 134.4 (Cq), 132.5 (CH), 129.1 (CH), 128.1 (CH), 128.1 (CH), 128.0 
(Cq), 127.4 (CH), 127.0 (CH), 121.9 (CH), 121.6 (CH), 116.8 (CH), 36.7 (CH2), 32.4 (CH2), 
31.4 (CH2), 28.9 (CH2), 22.4 (CH2), 19.5 (CH3), 14.0 (CH3).  
IR (ATR): 2947, 1675, 1582, 1429, 1296, 970, 800, 710 cm–1.  
MS (ESI) m/z (relative intensity): 395 (20) [M+Na]+, 373 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C25H28N2O+Na]+ 395.2094 found 395.2087.  
The analytical data correspond with those reported in the literature.[193] 
 




(E)-2-Methoxy-6-(oct-2-en-1-yl)-N-(quinolin-8-yl)benzamide (242eo): A modified general 
procedure K was followed using 2-methoxy-N-(quinolin-8-yl)benzamide (229e) (140.0 mg, 
0.50 mmol) and n-octene (223o) (168.0 mg, 1.5 mmol) with Co(OAc)2∙4H2O (25.4 mg, 0.1 
mmol, 20 mol %). Isolation by column chromatography (n-hexane/EtOAc = 5:1) yielded 242eo 
(106.5 mg, 55%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 10.04 (s, 1H), 8.99 (dd, J = 7.5, 1.5 Hz, 1H), 8.72 (dd, J = 
4.2, 1.5 Hz, 1H), 8.14 (dd, J = 8.3, 1.5 Hz, 1H), 7.58 (dd, J = 8.3, 7.5 Hz, 1H), 7.51 (dd, J = 
8.3, 1.5 Hz, 1H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.32 (dd, J = 8.3, 7.5 Hz, 1H), 6.90 (dd, J = 
7.7, 1.0 Hz, 1H), 6.84 (dd, J = 8.4, 0.9 Hz, 1H), 5.55 (dtt, J = 15.2, 6.6, 1.2 Hz, 1H), 5.42 (dtt, 
J = 15.2, 6.6, 1.2 Hz, 1H), 3.82 (s, 3H), 3.49–3.41 (m, 2H), 1.87–1.76 (m, 2H), 1.18–1.04 (m, 
6H), 0.76 (t, J = 6.4 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 166.3 (Cq), 156.4 (Cq), 148.0 (CH), 140.3 (Cq), 138.5 (Cq), 
136.2 (CH), 134.8 (Cq), 132.5 (CH), 130.2 (CH), 128.0 (Cq), 127.9 (CH), 127.4 (CH), 126.9 
(Cq), 122.0 (CH), 121.6 (CH), 121.5 (CH), 116.7 (CH), 108.8 (CH), 55.8 (CH3), 36.4 (CH2), 
32.3 (CH2), 31.3 (CH2), 28.8 (CH2), 22.4 (CH2), 14.0 (CH3).  
IR (ATR): 2922, 1656, 1590, 1492, 1322, 998, 850, 730 cm–1.  
MS (ESI) m/z (relative intensity): 411 (80) [M+Na]+, 389 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C25H28N2O2+Na]+ 411.2043 found 411.2040.  
The analytical data correspond with those reported in the literature.[193] 
 
(E)-2-(Oct-2-en-1-yl)-N-(quinolin-8-yl)-6-(trifluoromethyl)benzamide (242go): The 
general procedure K was followed using N-(quinolin-8-yl)-2-(trifluoromethyl)benzamide 
(229g) (158.4 mg, 0.50 mmol) and n-octene (223o) (168.0 mg, 1.5 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 20:1) yielded 242go (110.3 mg, 52%) as a yellow oil.  
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1H-NMR (400 MHz, CDCl3): δ = 9.98 (s, 1H), 8.95 (dd, J = 7.1, 1.7 Hz, 1H), 8.71 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.64–7.56 (m, 3H), 7.55–7.48 (m, 2H), 7.42 (dd, J 
= 8.3, 4.2 Hz, 1H), 5.59–5.49 (m, 1H), 5.48–5.38 (m, 1H), 3.49 (d, J = 6.8 Hz, 2H), 1.86–1.78 
(m, 2H), 1.20–1.07 (m, 6H), 0.79 (t, J = 6.2 Hz, 3H).  
13C-NMR (100 MHz, CDCl3) (one resonance is missing due to overlap): δ = 165.5 (Cq), 148.3 
(CH), 139.9 (Cq), 138.4 (Cq), 136.3 (CH), 135.1 (q, 3JC–F = 1.9 Hz, Cq), 134.1 (Cq), 133.4 (CH), 
129.3 (CH), 128.0 (Cq), 127.4 (CH), 127.4 (q, 2JC–F = 30.1 Hz, Cq), 127.1 (CH), 124.0 (q, 3JC–
F = 4.7 Hz, CH), 123.8 (q, 1JC–F = 270.4, Cq), 122.2 (CH), 121.7 (CH), 116.9 (CH), 36.3 (CH2), 
32.3 (CH2), 31.3 (CH2), 28.7 (CH2), 22.4 (CH2), 14.0 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –58.8.  
IR (ATR): 3328, 1720, 1670, 1532, 1422, 1350, 980, 720, cm–1.  
MS (ESI) m/z (relative intensity): 449 (70) [M+Na]+, 427 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C25H25N2OF3+Na]+ 449.1811 found 449.1804.  
The analytical data correspond with those reported in the literature.[192] 
 
(E)-3-(Oct-2-en-1-yl)-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (242co): The 
general procedure K was followed using N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide 
(229c) (162.0 mg, 0.50 mmol) and n-octene (223o) (168.0 mg, 1.5 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 10:1) yielded 242co (119.1 mg, 55%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.66 (s, 1H), 8.80 (dd, J = 7.4, 1.8 Hz, 1H), 8.63 (dd, J = 4.2, 
1.8 Hz, 1H), 8.09 (dd, J = 8.3, 1.8 Hz, 1H), 7.59–7.45 (m, 5H), 7.40–7.34 (m, 3H), 7.24 (d, J 
= 7.7 Hz, 2H), 7.18–7.07 (m, 1H), 5.73–5.58 (m, 1H), 5.56–5.40 (m, 1H), 3.61 (d, J = 6.7 Hz, 
2H), 1.95–1.75 (m, 2H), 1.27–1.05 (m, 6H), 0.80 (t, J = 6.6 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 147.9 (CH), 140.4 (Cq), 139.8 (Cq), 139.0 (Cq), 
138.4 (Cq), 136.6 (Cq), 136.0 (CH), 134.4 (Cq), 132.6 (CH), 129.3 (CH), 128.8 (CH), 128.7 
(CH), 128.2 (CH), 128.0 (CH), 128.0 (CH), 127.8 (Cq), 127.3 (CH), 127.3 (CH), 121.6 (CH), 
121.4 (CH), 116.5 (CH), 36.8 (CH2), 32.4 (CH2), 31.4 (CH2), 28.9 (CH2), 22.4 (CH2), 14.0 
(CH3).  
IR (ATR): 2955, 1678, 1522, 1502, 1472, 1290, 932, cm–1.  
MS (ESI) m/z (relative intensity): 457 (30) [M+Na]+, 435 (100) [M+H]+.  
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HR-MS (ESI): m/z calcd. for [C30H30N2O+Na]+ 457.2256 found 457.2252.  
The analytical data correspond with those reported in the literature.[192] 
 
(E)-2,3-Dimethyl-6-(oct-2-en-1-yl)-N-(quinolin-8-yl)benzamide (242ho): The general 
procedure K was followed using 2,3-dimethyl-N-(quinolin-8-yl)benzamide (229h) (138.1 mg, 
0.50 mmol) and n-octene (223o) (168.0 mg, 1.5 mmol). Isolation by column chromatography 
(n-hexane/EtOAc = 30:1) yielded 242ho (114.0 mg, 59%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 9.90 (s, 1H), 9.00 (dd, J = 7.3, 1.7 Hz, 1H), 8.70 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.60 (dd, J = 8.3, 7.2 Hz, 1H), 7.54 (dd, J = 8.3, 
1.7 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 
5.53 (dtt, J = 15.2, 6.2, 1.2 Hz, 1H), 5.38 (dtt, J = 15.2, 6.2, 1.2 Hz, 1H), 3.40 (d, J = 6.2 Hz, 
2H), 2.31 (s, 3H), 2.29 (s, 3H), 1.85–1.72 (m, 2H), 1.20–1.06 (m, 6H), 0.78 (t, J = 6.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 169.1 (Cq), 148.0 (CH), 138.4 (Cq), 137.9 (Cq), 136.2 (CH), 
135.1 (Cq), 134.8 (Cq), 134.4 (Cq), 132.8 (Cq), 132.1 (CH), 130.4 (CH), 128.2 (CH), 128.0 (Cq), 
127.3 (CH), 126.7 (CH), 121.7 (CH), 121.5 (CH), 116.7 (CH), 36.6 (CH2), 32.4 (CH2), 31.4 
(CH2), 28.9 (CH2), 22.5 (CH2), 20.0 (CH3), 16.7 (CH3), 14.1 (CH3).  
IR (ATR): 2045, 1710, 1668, 1552, 1473, 1224, 1175, 865, cm–1.  
MS (ESI) m/z (relative intensity): 409 (90) [M+Na]+, 387 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C26H30N2O+Na]+ 409.2250 found 409.2251.  
The analytical data correspond with those reported in the literature.[192] 
 
(E)-2-(Dec-2-en-1-yl)-6-methyl-N-(quinolin-8-yl)benzamide (242fq): The general 
procedure K was followed using 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 
0.50 mmol) and n-decene (223q) (210.1 mg, 1.5 mmol). Isolation by column chromatography 
(n-hexane/EtOAc = 10:1) yielded 242fq (124.0 mg, 62%) as a yellow oil.  
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1H-NMR (600 MHz, CDCl3): δ = 9.92 (s, 1H), 8.99 (dd, J = 7.5, 1.3 Hz, 1H), 8.71 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.58 (m, 1H), 7.54 (dd, J = 8.3, 1.4 Hz, 1H), 
7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.27 (dd, J = 7.7, 1.4 Hz, 1H), 7.17–7.10 (m, 2H), 5.56 (dtt, J = 
16.5, 6.7, 1.3 Hz, 1H), 5.41 (dtt, J = 16.5, 6.7, 1.3 Hz, 1H), 3.45 (d, J = 6.7 Hz, 2H), 2.43 (s, 
3H), 1.87–1.77 (m, 2H), 1.25–1.20 (m, 2H), 1.17–1.07 (m, 8H), 0.84 (t, J = 7.3 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.5 (Cq), 148.1 (CH), 138.4 (Cq), 137.6 (Cq), 137.6 (Cq), 
136.2 (CH), 134.5 (Cq), 134.3 (Cq), 132.3 (CH), 129.0 (CH), 128.0 (CH), 127.9 (CH), 127.9 
(Cq), 127.3 (CH), 126.9 (CH), 121.8 (CH), 121.5 (CH), 116.7 (CH), 36.7 (CH2), 32.4 (CH2), 
31.8 (CH2), 29.2 (CH2), 29.1 (CH2), 29.1 (CH2), 22.7 (CH2), 19.5 (CH3), 14.1 (CH3).  
IR (ATR): 2977, 1688, 1533, 1405, 1299, 973, 850, 719 cm–1.  
MS (ESI) m/z (relative intensity): 423 (40) [M+Na]+, 401 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C27H32N2O+H]+ 401.2587 found 401.2589.  
The analytical data correspond with those reported in the literature.[193] 
 
(E)-2-Methyl-6-(non-2-en-1-yl)-N-(quinolin-8-yl)benzamide (242fr): The general 
procedure K was followed using 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 0.50 
mmol) and n-nonene (223r) (189.0 mg, 1.5 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 10:1) yielded 242fr (124.1 mg, 64%) as a yellow oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.93 (s, 1H), 9.01 (dd, J = 7.6, 1.4 Hz, 1H), 8.72 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.60 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.55 (dd, J = 8.3, 
1.4 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.28 (dd, J = 7.7, 1.4 Hz, 1H), 7.15 (dd, J = 7.8, 
1.2 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 5.57 (dtt, J = 14.9, 6.7, 1.5 Hz, 1H), 5.41 (dtt, J = 14.9, 
6.6, 1.5 Hz, 1H), 3.46 (dd, J = 6.8, 1.5 Hz, 2H), 2.44 (s, 3H), 1.88–1.79 (m, 2H), 1.22–1.07 (m, 
8H), 0.82 (t, J = 7.3 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.5 (Cq), 148.0 (CH), 138.4 (Cq), 137.6 (Cq), 137.6 (Cq), 
136.1 (CH), 134.5 (Cq), 134.3 (Cq), 132.3 (CH), 128.9 (CH), 128.0 (CH), 127.9 (CH), 127.9 
(Cq), 127.3 (CH), 126.9 (CH), 121.8 (CH), 121.5 (CH), 116.7 (CH), 36.7 (CH2), 32.4 (CH2), 
31.6 (CH2), 29.1 (CH2), 28.8 (CH2), 22.6 (CH2), 19.5 (CH3), 14.1 (CH3).  
IR (ATR): 2912, 1666, 1545, 1492, 1287, 890, 811, 765 cm–1.  
MS (ESI) m/z (relative intensity): 409 (20) [M+Na]+, 387 (100) [M+H]+.  
5. Experimental Part 
 
268 
HR-MS (ESI): m/z calcd. for [C26H30N2O+Na]+ 409.2250 found 409.2248.  
The analytical data correspond with those reported in the literature.[193] 
 
(E)-2-Cinnamyl-6-methyl-N-(quinolin-8-yl)benzamide (242fa): The general procedure K 
was followed using 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 0.50 mmol) and 
allylbenzene (223a) (177.0 mg, 1.5 mmol). Isolation by column chromatography (n-
hexane/EtOAc = 10:1) yielded 242fa (100.1 mg, 53%) as a yellow oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.98 (s, 1H), 9.02 (dd, J = 7.9, 1.3 Hz, 1H), 8.48 (dd, J = 4.3, 
1.7 Hz, 1H), 8.10 (dd, J = 8.3, 1.7 Hz, 1H), 7.60 (dd, J = 7.9, 1.3 Hz, 1H), 7.53 (dd, J = 8.3, 
1.3 Hz, 1H), 7.34–7.29 (m, 2H), 7.22–7.20 (m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 7.14–7.10 (m, 
2H), 7.10–7.07 (m, 3H), 6.41–6.27 (m, 2H), 3.66 (d, J = 6.5 Hz, 2H), 2.47 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.4 (Cq), 148.0 (CH), 138.2 (Cq), 137.8 (Cq), 137.1 (Cq), 
136.6 (Cq), 136.0 (CH), 134.8 (Cq), 134.2 (Cq), 131.2 (CH), 129.1 (CH), 128.5 (CH), 128.3 
(CH), 128.0 (CH), 127.8 (Cq), 127.2 (CH), 127.2 (CH), 126.7 (CH), 125.9 (CH), 121.9 (CH), 
121.5 (CH), 116.6 (CH), 37.1 (CH2), 19.5 (CH3).  
IR (ATR): 2952, 1671, 1570, 1477, 1223, 899, 801, 734 cm–1.  
MS (ESI) m/z (relative intensity): 401 (30) [M+Na]+, 379 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C26H22N2O+H]+ 379.1805 found 379.1804.  




(E)-2-Methyl-6-(octa-2,7-dien-1-yl)-N-(quinolin-8-yl)benzamide (242fs): A modified 
procedure K was followed using 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 
0.50 mmol) and 1,7-octadiene (223s) (167.0 mg, 1.5 mmol) with Co(OAc)2∙4H2O (25.4 mg, 
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0.1 mmol, 20 mol %). Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 
242fs (98.0 mg, 53%) as a yellow oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.92 (s, 1H), 8.99 (dd, J = 7.6, 1.4 Hz, 1H), 8.71 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.62–7.58 (m, 1H), 7.55 (dd, J = 8.3, 1.4 Hz, 1H), 
7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.15–7.11 (m, 2H), 5.65 (dtt, J = 16.9, 
10.2, 6.7 Hz, 1H), 5.58 (dtt, J = 15.0, 6.7, 1.4 Hz, 1H), 5.40 (dtt, J = 15.0, 6.7, 1.4 Hz, 1H), 
5.03–4.74 (m, 2H), 3.45 (dd, J = 6.7, 1.4 Hz, 2H), 2.43 (s, 3H), 1.95–1.77 (m, 4H), 1.30–1.24 
(m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 168.5 (Cq), 148.1 (CH), 138.6 (CH), 138.4 (Cq), 137.6 (Cq), 
137.5 (Cq), 136.2 (CH), 134.6 (Cq), 134.3 (Cq), 131.8 (CH), 129.0 (CH), 128.4 (CH), 128.0 
(CH), 127.9 (Cq), 127.3 (CH), 126.9 (CH), 121.8 (CH), 121.5 (CH), 116.7 (CH), 114.2 (CH2), 
36.7 (CH2), 33.2 (CH2), 31.8 (CH2), 28.4 (CH2), 19.5 (CH3).  
IR (ATR): 2910, 1651, 1561, 1432, 1297, 907, 809, 720 cm–1.  
MS (ESI) m/z (relative intensity): 393 (25) [M+Na]+, 371 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C25H26N2O+Na]+ 393.1937 found 393.1931.  
The analytical data correspond with those reported in the literature.[193] 
 
(E)-2-Methoxy-4-{3-[3-methyl-2-(quinolin-8-ylcarbamoyl)phenyl]prop-1-en-1-yl}phenyl 
acetate (242fj): A modified general procedure K was used with 2-methyl-N-(quinolin-8-
yl)benzamide (229f) (131.1 mg, 0.50 mmol) and eugenol acetate (223j) (309.1 mg, 1.5 mmol). 
After electrolysis, the mixture was transferred to a flask and the electrodes were rinsed with 
acetone (3 × 5.0 mL). Then the combined solvent was removed under reduced pressure and 
subsequent column chromatography on silica gel (n-hexane/EtOAc = 5:1) yielded 242fj (132.1 
mg, 57%) as a yellow oil.   
1H-NMR (400 MHz, CDCl3): δ = 9.93 (s, 1H), 8.97 (dd, J = 7.5, 1.5 Hz, 1H), 8.39 (dd, J = 4.2, 
1.7 Hz, 1H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.58 (dd, J = 8.3, 7.5 Hz, 1H), 7.52 (dd, J = 8.3, 
1.5 Hz, 1H), 7.37–7.32 (m, 1H), 7.32–7.28 (m, 1H), 7.20–7.14 (m, 2H), 6.74 (d, J = 8.0 Hz, 
1H), 6.63–6.55 (m, 2H), 6.34–6.15 (m, 2H), 3.65 (s, 3H), 3.62 (d, J = 5.6 Hz, 2H), 2.44 (s, 3H), 
2.27 (s, 3H).  
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13C-NMR (100 MHz, CDCl3): δ = 169.0 (Cq), 168.5 (Cq), 150.7 (Cq), 148.3 (CH), 138.6 (Cq), 
138.3 (Cq), 138.0 (Cq), 136.5 (Cq), 136.3 (Cq), 136.0 (CH), 135.0 (Cq), 134.3 (Cq), 130.6 (CH), 
129.2 (CH), 128.9 (CH), 128.5 (CH), 127.9 (Cq), 127.4 (CH), 127.2 (CH), 122.3 (CH), 122.0 
(CH), 121.7 (CH), 118.5 (CH), 116.7 (CH), 109.6 (CH), 55.6 (CH3), 37.1 (CH2), 20.7 (CH3), 
19.5 (CH3).  
IR (ATR): 2940, 1682, 1577, 1321, 1277, 960, 808, 659 cm–1.  
MS (ESI) m/z (relative intensity): 489 (100) [M+Na]+, 467 (90) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C29H26N2O4+Na]+ 489.1785 found 489.1777.  
  
(E)-6-[3-Methyl-2-(quinolin-8-ylcarbamoyl)phenyl]hex-4-en-1-yl acetate (242ft): A 
modified general procedure K was used with 2-methyl-N-(quinolin-8-yl)benzamide (229f) 
(131.1 mg, 0.50 mmol) and hex-5-en-1-yl acetate (223t) (177.0 mg, 1.5 mmol). After 
electrolysis, the mixture was transferred to a flask and the electrodes were rinsed with acetone 
(3 × 5.0 mL). Then the combined solvent was removed under reduced pressure and subsequent 
column chromatography on silica gel (n-hexane/EtOAc = 3:1) yielded 242ft (104.0 mg, 52%) 
as a yellow oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.90 (s, 1H), 8.97 (dd, J = 7.5, 1.4 Hz, 1H), 8.71 (dd, J = 4.2, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.60–7.57 (m, 1H), 7.54 (dd, J = 8.3, 1.4 Hz, 1H), 
7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.13–7.10 (m, 2H), 5.60 (dtt, J = 15.0, 
6.7, 1.5 Hz, 1H), 5.37 (dtt, J = 15.0, 6.7, 1.5 Hz, 1H), 3.89 (t, J = 6.7 Hz, 2H), 3.47–3.41 (m, 
2H), 2.42 (s, 3H), 1.96 (s, 3H), 1.92–1.87 (m, 2H), 1.53–1.47 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 170.8 (Cq), 168.4 (Cq), 148.1 (CH), 138.4 (Cq), 137.6 (Cq), 
137.2 (Cq), 136.2 (CH), 134.6 (Cq), 134.2 (Cq), 130.5 (CH), 129.2 (CH), 129.0 (CH), 128.0 
(CH), 127.9 (Cq), 127.3 (CH), 126.9 (CH), 121.8 (CH), 121.5 (CH), 116.7 (CH), 63.9 (CH2), 
36.6 (CH2), 28.7 (CH2), 28.1 (CH2), 21.0 (CH3), 19.5 (CH3).  
IR (ATR): 3011, 1650, 1555, 1423, 1276, 903, 801, 689 cm–1.  
MS (ESI) m/z (relative intensity): 425 (70) [M+Na]+, 403 (90) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C25H26N2O3+Na]+ 425.1836 found 425.1829.  
The analytical data correspond with those reported in the literature.[192] 




(E)-2-(6-Chlorohex-2-en-1-yl)-6-methyl-N-(quinolin-8-yl)benzamide (242fu): A modified 
general procedure K was used with 2-methyl-N-(quinolin-8-yl)benzamide (229f) (131.1 mg, 
0.50 mmol) and 6-chlorohexene (223u) (177.0 mg, 1.5 mmol) with Co(OAc)2∙4H2O (25.4 mg, 
0.1 mmol, 20 mol %). After electrolysis, the mixture was transferred to a flask and the 
electrodes were rinsed with acetone (3 × 5.0 mL). Then the combined solvent was removed 
under reduced pressure and subsequent column chromatography on silica gel (n-hexane/EtOAc 
= 5:1) yielded 242fu (119.0 mg, 63%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.94 (s, 1H), 9.02 (dd, J = 7.4, 1.7 Hz, 1H), 8.77 (dd, J = 4.2, 
1.7 Hz, 1H), 8.21 (dd, J = 8.3, 1.7 Hz, 1H), 7.64 (dd, J = 7.4,  1.6 Hz, 1H), 7.60 (dd, J = 8.3, 
1.6 Hz, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 7.34–7.30 (m, 1H), 7.20–7.10 (m, 2H), 5.67 (dtt, J 
= 15.0, 6.7, 1.5 Hz, 1H), 5.38 (dtt, J = 15.0, 6.7, 1.5 Hz, 1H), 3.48 (d, J = 6.7 Hz, 2H), 3.42-
3.33 (m, 2H), 2.47 (s, 3H), 2.07–1.97 (m, 2H), 1.70–1.62 (m, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 168.6 (Cq), 148.3 (CH), 138.5 (Cq), 137.7 (Cq), 137.3 (Cq), 
136.4 (CH), 134.8 (Cq), 134.4 (Cq), 130.0 (CH), 129.9 (CH), 129.2 (CH), 128.2 (CH), 128.0 
(Cq), 127.4 (CH), 127.1 (CH), 122.0 (CH), 121.7 (CH), 116.8 (CH), 44.4 (CH2), 36.7 (CH2), 
31.9 (CH2), 29.5 (CH2), 19.5 (CH3).  
IR (ATR): 2937, 1645, 1502, 1444, 1238, 780 cm–1.  
MS (ESI) m/z (relative intensity): 401 (100) [M+Na]+, 379 (90) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C23H23N2O35Cl+Na]+ 401.1391 found 401.1394.  
 
(E)-2-Methyl-6-[8-(oxiran-2-yl)oct-2-en-1-yl]-N-(quinolin-8-yl)benzamide (242fv): A 
modified general procedure K was used with 2-methyl-N-(quinolin-8-yl)benzamide (229f) 
(131.1 mg, 0.50 mmol) and 1,2-epoxy-9-decene (223v) (232.0 mg, 1.5 mmol) with 
Co(OAc)2∙4H2O (25.4 mg, 0.1 mmol, 20 mol %). After electrolysis, the mixture was transferred 
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to a flask and the electrodes were rinsed with acetone (3 × 5.0 mL). Then the combined solvent 
was removed under reduced pressure and subsequent column chromatography on silica gel (n-
hexane/EtOAc = 4:1) yielded 242fv (118.0 mg, 57%) as a yellow oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.89 (s, 1H), 8.97 (dd, J = 7.5, 1.4 Hz, 1H), 8.71 (dd, J = 4.2, 
1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.57 (m, 1H), 7.55 (dd, J = 8.3, 1.4 Hz, 1H), 
7.43 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.13–7.08 (m, 2H), 5.55 (dtt, J = 15.0, 
6.7, 1.4 Hz, 1H), 5.38 (dtt, J = 15.0, 6.7, 1.4 Hz, 1H), 3.46–3.41 (m, 2H), 2.82 (tdd, J = 5.7, 
4.0, 2.7 Hz, 1H), 2.69 (dd, J = 5.1, 4.0 Hz, 1H), 2.42 (s, 3H), 2.40 (dd, J = 5.1, 2.7 Hz, 1H), 
1.82 (d, J = 6.5 Hz, 2H), 1.43–1.38 (m, 2H), 1.34–1.22 (m, 2H), 1.20–1.14 (m, 4H).  
13C-NMR (150 MHz, CDCl3): δ = 168.6 (Cq), 148.2 (CH), 138.5 (Cq), 137.7 (Cq), 136.3 (CH), 
134.7 (Cq), 134.4 (Cq), 132.1 (CH), 129.1 (CH), 128.4 (CH), 128.1 (CH), 128.0 (Cq), 127.4 
(CH), 127.0 (CH), 121.9 (CH), 121.6 (CH), 116.8 (CH), 52.3 (CH), 47.1 (CH2), 36.7 (CH2), 
32.4 (CH2), 32.2 (CH2), 29.0 (CH2), 28.9 (CH2), 25.7 (CH2), 19.5 (CH3).  
IR (ATR): 2921, 1688, 1566, 1430, 1154, 903, 810, 737 cm–1.  
MS (ESI) m/z (relative intensity): 437 (50) [M+Na]+, 415 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C27H30N2O2+Na]+ 437.2199 found 437.2196.  
The analytical data correspond with those reported in the literature.[193] 
  
(E)-2-(10-Hydroxydec-2-en-1-yl)-6-methyl-N-(quinolin-8-yl)benzamide (242fx): A 
modified general procedure K was used with 2-methyl-N-(quinolin-8-yl)benzamide (229f) 
(131.1 mg, 0.50 mmol) and 9-decenol (223x) (234.0 mg, 1.5 mmol). After electrolysis, the 
mixture was transferred to a flask and the electrodes were rinsed with acetone (3 × 5.0 mL). 
Then the combined solvent was removed under reduced pressure and subsequent column 
chromatography on silica gel (n-hexane/EtOAc = 2:1) yielded 242fx (114.0 mg, 55%) as a 
yellow oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.92 (s, 1H), 8.98 (dd, J = 7.5, 1.4 Hz, 1H), 8.70 (dd, J = 4.2, 
1.7 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.56 (m, 1H), 7.53 (dd, J = 8.3, 1.4 Hz, 1H), 
7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (t, 1H), 7.14–7.08 (m, 2H), 5.58–5.51 (m, 1H), 5.43–5.33 
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(m, 1H), 3.58–3.50 (m, 2H), 3.43 (d, J = 6.9 Hz, 2H), 2.42 (s, 3H), 1.83–1.78 (m, 2H), 1.49–
1.42 (m, 2H), 1.24–1.18 (m, 2H), 1.16–1.07 (m, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 168.5 (Cq), 148.0 (CH), 138.3 (Cq), 137.6 (Cq), 137.5 (Cq), 
136.1 (CH), 134.5 (Cq), 134.2 (Cq), 132.2 (CH), 128.9 (CH), 128.0 (CH), 127.9 (CH), 127.9 
(CH), 127.2 (CH), 126.9 (Cq), 121.8 (CH), 121.5 (CH), 116.7 (CH), 62.8 (CH2), 36.7 (CH2), 
32.7 (CH2), 32.3 (CH2), 29.1 (CH2), 29.1 (CH2), 29.0 (CH2), 25.6 (CH2), 19.5 (CH3).  
IR (ATR): 2923, 1670, 1535, 1437, 1255, 987, 850, 719 cm–1.  
MS (ESI) m/z (relative intensity): 439 (70) [M+Na]+, 417 (100) [M+H]+.  
HR-MS (ESI): m/z calcd. for [C27H32N2O2+H]+ 417.2537 found 417.2535. 
5.8.2. Mechanistic Studies 




The electrocatalysis was carried out in an undivided cell with a GF anode (10 mm × 15 mm × 
6 mm) and a Pt cathode (10 mm × 15 mm × 0.25 mm). Benzamide 229f (157.2 mg, 
0.60 mmol), and benzamide 229g (189.6 mg, 0.60 mmol), n-octene 223o (22.4 mg, 
0.20 mmol), NaOPiv (49.6 mg, 0.40 mmol), nBu4NPF6 (97.0 mg, 0.25 mmol), and 
Co(OAc)2∙4H2O (5.0 mg, 10 mol %) were placed in a 10 mL cell and dissolved in GVL (4.0 
mL). Electrocatalysis was proformed at 100 °C with a constant current of 4.0 mA maintained 
for 10 h. At ambient temperature, the mixture was transferred to a flask and the electrodes were 
rinsed with acetone (3 × 5.0 mL). Then, the solvent was removed under reduced pressure and 
the residue was stirred with NaOH (aq) (2 M, 15 mL) for 2 h. The mixture was extracted with 
H2O (3 × 20 mL) and successively with EtOAc (3 × 20 mL) then the organic layer was dried 
over Na2SO4. After evaporation of the solvent under vacuo, the crude mixture was filtered 
through very short silica column. After evaporation of the solvent, dibromomethane (43.5 mg, 
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0.25 mmol, 1.25 equiv) was added as an internal standard. The ratio of 242fo and 242go was 











5.8.2.2. H/D Exchange Experiment 




The electrocatalysis was carried out in an undivided cell with a GF anode (10 mm × 15 mm × 
6 mm) and a Pt cathode (10 mm × 15 mm × 0.25 mm). Benzamide 229f (131.1 mg, 
0.50 mmol), n-octene 223o (168.4 mg, 1.5 mmol), NaOPiv (124.0 mg, 1.0 mmol), nBu4NPF6 
(97.0 mg, 0.25 mmol) and Co(OAc)2∙4H2O (12.7 mg, 10 mol %) were placed in a 10 mL cell 
and dissolved in GVL (3.6 mL) and CD3OD (0.40 mL). Electrocatalysis was performed at 80 
°C with a constant current of 4.0 mA maintained for 7 h. At ambient temperature, the mixture 
was transferred to a flask and the electrodes were rinsed with acetone (3 × 5.0 mL). Then, the 
combined solvent was removed under reduced pressure, the residue diluted with EtOAc (10 
mL) and stirred with NaOH (aq) (2 M, 20 mL). The mixture was extracted with H2O (3 × 20 
mL) and successively with EtOAc (3 × 20 mL) then the organic layer was dried over Na2SO4. 
After evaporation of the solvent under vacuo subsequently column chromatography on silica 
gel (n-hexane/EtOAc = 10:1) yielded [D]n-229f (89.0 mg, 68%) as a yellow solid and [D]n-
242fo (46.6 mg, 25%) as a colorless oil. The D-incorporation was estimated by 1H-NMR 
spectroscopy. 





5. Experimental Part 
 
277 
5.9 Enantioselective Palladaelectro-Catalyzed C–H Activations by Transient Directing 
Groups 
5.9.1. Characterization Data 
 
(E)-Butyl 3-(1-(2-formylphenyl)naphthalen-2-yl)acrylate (74aa): The general procedure L 
was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46.4 mg, 0.20 mmol) and n-butyl 
acrylate (38a) (76.9 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc 
= 5:1) yielded 74aa (51.1 mg, 71%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 9.49 (s, 1H), 8.19 (dd, J = 7.6, 0.8 Hz, 1H), 7.97 (d, J = 8.8 
Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.78 (td, J = 8.8, 1.5 Hz, 1H), 7.69 
(t, J = 7.4  Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.48–7.34 (m, 3H), 7.28 (d, J = 8.4 Hz, 1H), 6.50 
(d, J = 16.0 Hz, 1H) , 4.13 (t, J = 6.5 Hz, 2H), 1.64–1.60 (m, 2H), 1.38–1.33 (m, 2H), 0.93 (t, 
J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 191.3 (CH), 166.6 (Cq), 142.0 (CH), 141.3 (Cq), 136.7 (Cq), 
135.3 (Cq), 134.1 (CH), 133.8 (Cq), 133.3 (Cq), 132.0 (CH), 131.2 (Cq), 129.1 (CH), 128.9 
(CH), 128.2 (CH), 127.8 (CH), 127.3 (CH), 127.3 (CH), 127.0 (CH), 122.7 (CH), 120.2 (CH), 
64.4 (CH2), 30.6 (CH2), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 2959, 1697, 1630, 1597, 1389, 1297, 1269, 1176, 818 cm–1.  
MS (ESI) m/z (relative intensity): 381 (100) [M + Na]+, 359 (30) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C24H22O3 + Na]+ 381.1461 found 381.1468. 
[α]D
20: –35.9 (c = 1.1, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 17.1 min, tr (minor) = 11.2 min, 97% ee.  
The analytical data correspond with those reported in the literature.[89] 
 
(E)-Butyl 3-(2'-formyl-6-methyl-[1,1'-biphenyl]-2-yl)acrylate (74ba) 
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The general procedure L was followed using 2'-methyl-[1,1'-biphenyl]-2-carbaldehyde (73b) 
(39.3 mg, 0.20 mmol) and and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 6:1) yielded 74ba (42.6 mg, 66%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.61 (s, 1H), 8.06 (dd, J = 7.8, 1.4 Hz, 1H), 7.69 (td, J = 7.5, 
1.4 Hz, 1H), 7.64–7.52 (m, 2H), 7.41–7.29 (m, 2H), 7.25–7.17 (m, 2H), 6.27 (d, J = 15.9 Hz, 
1H), 4.06 (t, J = 6.6 Hz, 2H), 2.00 (s, 3H), 1.64–1.46 (m, 2H), 1.39–1.20 (m, 2H), 0.89 (t, J = 
7.4 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 191.5 (CH), 166.5 (Cq), 142.7 (Cq), 142.4 (CH), 138.1 (Cq), 
137.3 (Cq), 134.3 (CH), 134.1 (Cq), 134.0 (Cq), 131.5 (CH), 130.9 (CH), 128.5 (CH), 128.5 
(CH), 128.0 (CH), 123.9 (CH), 119.9 (CH), 64.3 (CH2), 30.6 (CH2), 20.8 (CH3), 19.1 (CH2), 
13.7 (CH3). 
IR (ATR): 2959, 1596, 1711, 1695, 1311, 1245, 1014, 785, 748, 699 cm–1.  
MS (ESI) m/z (relative intensity): 345 (100) [M + Na]+, 323 (5) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C21H22O3 + Na]+ 345.1461 found 345.1466. 
[α]D
20: –35.9 (c = 1.1, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 98:2, 1.0 mL/min, detection at 273 nm): 
tr (major) = 11.3 min, tr (minor) = 10.2 min, 95% ee.  
The analytical data correspond with those reported in the literature.[89] 
 
 (E)-Butyl 3-(6-ethyl-5'-fluoro-2'-formyl-[1,1'-biphenyl]-2-yl)acrylate (74ca): The general 
procedure L was followed using 2'-ethyl-5-fluoro-[1,1'-biphenyl]-2-carbaldehyde (73c) 
(45.4 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 5:1) yielded 74ca (50.3 mg, 71%, E/Z = 98:2) as a yellow 
oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.53 (s, 1H), 8.12 (dd, J = 8.7, 5.9 Hz, 1H), 7.61 (dd, J = 7.7, 
1.4 Hz, 1H), 7.50–7.35 (m, 2H), 7.34–7.23 (m, 1H), 7.19 (d, J = 16.0 Hz, 1H), 6.98 (dd, J = 
8.8, 2.6 Hz, 1H), 6.31 (d, J = 16.0 Hz, 0.98H, E), 5.78 (d, J = 12.0 Hz, 0.02H, Z), 4.10 (t, J = 
6.6 Hz, 2H), 2.35 (qd, J = 7.4, 3.5 Hz, 2H), 1.66–1.52 (m, 2H), 1.41–1.25 (m, 2H), 1.06 (t, J = 
7.5 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H).  
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13C-NMR (100 MHz, CDCl3): δ = 189.8 (CH), 166.4 (Cq), 166.0 (d, 1JC–F = 260.1 Hz, Cq), 
145.3 (d, 3JC–F = 8.5 Hz, Cq), 143.1 (Cq), 142.0 (CH), 136.0 (Cq), 133.9 (Cq), 131.1 (d, 4JC–F = 
2.7 Hz, Cq), 130.7 (d, 2JC–F = 10.2 Hz, CH) 130.1 (CH), 129.1 (CH), 123.9 (CH), 120.4 (CH), 
118.2 (d, 2JC–F = 20.2 Hz, CH), 116.2 (CH), 64.4 (CH2), 30.6 (CH2), 26.6 (CH2), 19.1 (CH2), 
14.9 (CH3), 13.7 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –102.4.  
IR (ATR): 2963, 1713, 1635, 1604, 1580, 1272, 1222, 1183, 799 cm–1.  
MS (ESI) m/z (relative intensity): 377 (100) [M + Na]+, 355 (5) [M + H]+. 
 HR-MS (ESI): m/z calcd. for [C22H23FO3 + Na]+ 377.1523 found 377.1528. 
[α]D
20: –1.2 (c = 1.2, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 98:2, 1 mL/min, detection at 273 nm): 
tr (major) = 10.0 min, tr (minor) = 8.8 min, 95% ee. 
 
 
(E)-Butyl 3-(1-(6-formylbenzo[d][1,3]dioxol-5-yl)naphthalen-2-yl)acrylate (74da): The 
general procedure L was followed using 6-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-
carbaldehyde (73d) (55.2 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc = 4:1) yielded 74da (43.4 mg, 54%, 
E/Z = 97:3) as a yellow oil.   
1H-NMR (400 MHz, CDCl3): δ = 9.34 (s, 0.03H, Z), 9.23 (s, 0.97H, E), 7.95 (d, J = 8.7 Hz, 
1H), 7.91 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.59 (s, 1H), 7.58–7.50 (m, 2H), 7.47–
7.41 (m, 1H), 7.38 (d, J = 8.5 Hz, 1H), 6.77 (s, 1H), 6.51 (d, J = 16.0 Hz, 1H), 6.20 (d, J = 3.3 
Hz, 2H), 4.16 (t, J = 6.6 Hz, 2H), 1.76–1.57 (m, 2H), 1.46–1.34 (m, 2H), 0.96 (t, J = 7.4 Hz, 
3H).   
13C-NMR (100 MHz, CDCl3): δ = 189.6 (CH), 166.7 (Cq), 152.7 (Cq), 148.7 (Cq), 142.0 (CH), 
138.5 (CH), 136.2 (Cq), 133.8 (Cq), 133.5 (Cq), 131.5 (Cq), 130.5 (Cq), 129.2 (Cq), 128.2 (CH), 
127.4 (CH), 127.4 (CH), 127.0 (CH), 122.6 (CH), 120.3 (CH), 111.3 (CH), 106.4 (CH), 102.4 
(CH2), 64.5 (CH2), 30.7 (CH2), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 2927, 1712, 1683, 1480, 1259, 1177, 1036, 819 cm–1.  
MS (ESI) m/z (relative intensity): 425 (100) [M + Na]+, 403 (30) [M + H]+.  
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HR-MS (ESI): m/z calcd. for [C25H22O5 + Na]+ 425.1359 found 425.1363. 
[α]D
20: +4.0 (c = 0.35, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 16.4 min, tr (minor) = 11.7 min, 99% ee. 
 
 
(E)-Butyl 3-(1-(2-formyl-4,5-dimethoxyphenyl)naphthalen-2-yl)acrylate (74ea): The 
general procedure L was followed using 4,5-dimethoxy-2-(naphthalen-1-yl)benzaldehyde 
(73e) (58.4 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 3:1) yielded 74ea (50.3 mg, 60%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.30 (s, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 8.1 Hz, 
1H), 7.85 (d, J = 8.7 Hz, 1H), 7.65 (s, 1H), 7.57–7.47 (m, 2H), 7.43 (dd, J = 8.1, 6.6 Hz, 1H), 
7.36 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 6.50 (d, J = 15.9 Hz, 1H), 4.14 (t, J = 6.6 Hz, 2H), 4.07 
(s, 3H), 3.93 (s, 3H), 1.69–1.57 (m, 2H), 1.40–1.33 (h, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 
3H).  
13C-NMR (100 MHz, CDCl3): δ = 190.1 (CH), 166.6 (Cq), 153.9 (Cq), 149.4 (Cq), 142.1 (CH), 
136.4 (Cq), 136.4 (Cq), 133.8 (Cq), 133.65 (Cq), 131.5 (Cq), 129.1 (CH), 128.8 (Cq), 128.1 (CH), 
127.4 (CH), 127.3 (CH), 127.1 (CH), 122.6 (CH), 120.2 (CH), 113.5 (CH), 108.5 (CH), 64.4 
(CH2), 56.4 (CH3), 56.2 (CH3), 30.7 (CH2), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 2958, 1708, 1680, 1595, 1272, 1092, 752 cm–1.  
MS (ESI) m/z (relative intensity): 441 (100) [M + Na]+, 419 (5) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C26H26O5 + Na]+ 441.1672 found 441.1676.  
[α]D
20: +23.7 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 24.1 min, tr (minor) = 21.9 min, 98% ee.  
The analytical data correspond with those reported in the literature.[89] 
 




(E)-Butyl 3-(1-(2-formyl-4-(trifluoromethyl)phenyl)naphthalen-2-yl)acrylate (74fa): The 
general procedure L was followed using 2-(naphthalen-1-yl)-5-(trifluoromethyl)benzaldehyde 
(73f) (60.2 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 5:1) yielded 74fa (51.4 mg, 60%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 9.45 (s, 1H), 8.45–8.37 (m, 1H), 8.02–7.95 (m, 2H), 7.94–
7.89 (m, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.58–7.47 (m, 2H), 7.41 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 
7.33 (d, J = 15.9 Hz, 1H), 7.16 (dd, J = 8.5, 0.9 Hz, 1H), 6.48 (d, J = 15.9 Hz, 1H), 4.09 (t, J = 
6.9 Hz, 2H), 1.65–1.51 (m, 2H), 1.39–1.25 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 189.7 (CH), 166.3 (Cq), 144.7 (Cq), 141.1 (CH), 135.6 (Cq), 
134.8 (Cq), 133.7 (Cq), 132.9 (CH), 131.7 (Cq), 131.4 (d, 2JC-F = 33.8 Hz, Cq), 131.2 (Cq), 130.3 
(q, 3JC-F = 3.2 Hz, CH), 129.7 (CH), 128.4 (CH), 127.8 (CH), 127.6 (CH), 126.4 (CH), 124.9 
(q, 3JC-F = 3.7 Hz, CH), 123.9 (q, 1JC-F = 278.2 Hz, Cq) 122.7 (CH), 121.0 (CH), 64.5 (CH2), 
30.6 (CH2), 19.1 (CH2), 13.6 (CH3).  
19F-NMR (375 MHz, CDCl3): δ = –62.9. 
IR (ATR): 2961, 1701, 1615, 1330, 1173, 1131, 750, 710 cm–1.  
MS (ESI) m/z (relative intensity): 449 (100) [M + Na]+, 427 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C25H21F3O3 + Na]+ 449.1335 found 449.1336. 
[α]D
20: -8.1 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 11.5 min, tr (minor) = 8.0 min, 97% ee.  
The analytical data correspond with those reported in the literature.1 
 
 
(E)-2-(2-(2-(Phenylsulfonyl)vinyl)naphthalen-1-yl)benzaldehyde (74ab): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46.4 mg, 0.20 mmol) 
and (vinylsulfonyl)benzene (38b) (100.8 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 1:1) yielded 74ab (41.4 mg, 52%) as a yellow oil.  
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1H-NMR (400 MHz, CDCl3): δ = 9.44 (s, 1H), 8.18 (dd, J = 7.7, 1.4 Hz, 1H), 7.96–7.88 (m, 
2H), 7.84–7.76 (m, 3H), 7.73 (d, J = 7.6, 1.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.65–7.60 (m, 
1H), 7.59–7.52 (m, 3H), 7.44 (dd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.41–7.33 (m, 2H), 7.31 (d, J = 8.5 
Hz, 1H), 6.86 (d, J = 15.6 Hz, 1H).  
13C-NMR (100 MHz, CDCl3): (two carbon less due to overlap) δ = 190.9 (CH), 140.4 (Cq), 
140.2 (Cq), 140.1 (CH), 137.7 (Cq), 135.2 (Cq), 134.2 (CH), 134.1 (Cq), 133.5 (CH), 133.1 (Cq), 
131.9 (CH), 129.6 (CH), 129.4 (CH), 129.3 (Cq), 128.3 (CH), 128.2 (CH), 127.8 (CH), 127.7 
(CH), 127.6 (CH), 127.1 (CH), 122.8 (CH).  
IR (ATR): 2924, 1696, 1607, 1303, 1084, 786, 742, 680 cm–1.  
MS (ESI) m/z (relative intensity): 421 (100) [M + Na]+, 399 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C25H18O3S + Na]+ 421.0869 found 421.0870.  
[α]D
20: +20.1 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 80:20, 1 mL/min, detection at 273 nm): 
tr (major) = 20.0 min, tr (minor) = 12.9 min, 98% ee. 
 
 
(E)-Diethyl (2-(1-(2-formylphenyl)naphthalen-2-yl)vinyl)phosphonate (74ac): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46.4 mg, 0.20 mmol) 
and diethyl vinylphosphonate (38c) (98.4 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 1:9) yielded 74ac (53.6 mg, 68%) as a yellow oil.   
1H-NMR (400 MHz, CDCl3): δ = 9.43 (s, 1H), 8.12 (dd, J = 7.8, 1.5 Hz, 1H), 7.93 (d, J = 8.7 
Hz, 1H), 7.88 (dd, J = 8.2, 1.2 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.75–7.69 (m, 1H), 7.66–7.59 
(m, 1H), 7.50 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.37 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.31 (ddd, J 
= 7.5, 1.2, 0.6 Hz, 1H), 7.25–7.21 (m, 1H), 7.20-7.05 (m, 1H), 6.29 (t, J = 17.7 Hz, 1H), 4.04–
3.86 (m, 4H), 1.20 (dt, J = 15.2, 7.1 Hz, 6H).  
13C-NMR (100 MHz, CDCl3): δ = 191.2 (CH), 145.4 (d, J = 7.1 Hz, CH), 141.2 (Cq), 136.0 
(Cq), 135.2 (Cq), 134.0 (CH), 133.7 (Cq), 133.2 (Cq), 131.9 (CH), 131.6 (d, J = 1.8 Hz, Cq), 
129.1 (CH), 128.9 (CH), 128.1 (CH), 127.7 (CH), 127.3 (CH), 126.9 (CH), 122.5 (CH), 117.7 
(CH), 115.8 (CH), 61.9 (d, J = 5.4 Hz, CH2), 61.8 (d, J = 5.4 Hz, CH2), 16.3 (d, J = 4.1 Hz, 
CH3), 16.2 (d, J = 4.1 Hz, CH3). 
31P-NMR (160 MHz, CDCl3): δ = 18.2. 
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IR (ATR): 2981, 1697, 1595, 1247, 1049, 1023, 965, 770 cm–1.  
MS (ESI) m/z (relative intensity): 417 (100) [M + Na]+, 395 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C23H23O4P + Na]+ 417.1226 found 417.1232.  
[α]D
20: -6.8 (c = 1.2, CHCl3).   
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 31.0 min, tr (minor) = 28.7 min, 99% ee.  
 
(E)-2'-methyl-6'-(3-oxobut-1-en-1-yl)-[1,1'-biphenyl]-2-carbaldehyde (74bd): The general 
procedure L was followed using 2'-methyl-[1,1'-biphenyl]-2-carbaldehyde (73b) (39.3 mg, 
0.20 mmol) and but-3-en-2-one (38d) (42.1 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 7:1) yielded 74bd (33.8 mg, 64%, E/Z = 96:4) as a 
colourless oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.63 (s, 1H), 8.08 (dd, J = 7.8, 1.5, 1H), 7.71 (td, J = 7.5, 1.5 
Hz, 1H), 7.65–7.55 (m, 2H), 7.41–7.32 (m, 2H), 7.23 (ddd, J = 7.6, 1.3, 0.6 Hz, 1H), 7.03 (d, 
J = 16.2 Hz, 1H), 6.53 (d, J = 16.0 Hz, 0.96H, E), 6.44 (d, J = 12.0 Hz, 0.04H, Z), 2.07 (s, 3H), 
2.02 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 198.0 (Cq), 191.4 (CH), 142.6 (Cq), 141.3 (CH), 138.3 (Cq), 
137.3 (Cq), 134.2 (CH), 134.2 (Cq), 134.0 (Cq), 131.8 (CH), 130.9 (CH), 128.8 (CH), 128.6 
(CH), 128.6 (CH), 128.0 (CH), 124.0 (CH), 27.1 (CH3), 20.8 (CH3).  
IR (ATR): 2945, 1696, 1632, 1445, 1376, 1316, 750, 701 cm–1.  
MS (ESI) m/z (relative intensity): 287 (100) [M + Na]+, 265 (30) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C18H16O2 + Na]+ 287.1043 found 287.1045.  
[α]D
20: -26.7 (c = 1.1, CHCl3).   
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 15.8 min, tr (minor) = 11.6 min, 98% ee.  
 
(E)-4-methoxyphenyl -3-(1-(2-formylphenyl)naphthalen-2-yl)acrylate (74ae): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46.4 mg, 0.20 mmol) 
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and 4-methoxyphenyl acrylate (38e) (106.9 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 4:1) yielded 74ae (55.5 mg, 68%, E/Z = 97:3) as a yellow 
oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.55 (s, 0.03H, Z), 9.53 (s, 0.97H, E), 8.19 (dd, J = 7.9, 1.4 
Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.99–7.89 (m, 2H), 7.83–7.73 (m, 1H), 7.73–7.51 (m, 3H), 
7.51–7.40 (m, 2H), 7.34–7.22 (m, 2H), 6.80 (dd, J = 8.3, 2.5 Hz, 1H), 6.75–6.65 (m, 3H), 3.81 
(s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 191.2 (CH), 164.8 (Cq), 160.4 (Cq), 151.6 (Cq), 144.0 (CH), 
141.0 (Cq), 137.3 (Cq), 135.3 (Cq), 134.1 (CH), 133.9 (Cq), 133.3 (Cq), 131.9 (CH), 130.8 (Cq), 
129.7 (CH), 129.2 (CH), 129.1 (CH), 128.2 (CH), 128.0 (CH), 127.5 (CH), 127.4 (CH), 127.1 
(CH), 122.7 (CH), 119.1 (CH), 113.7 (CH), 111.7 (CH), 107.4 (CH), 55.4 (CH3).  
IR (ATR): 2920, 1724, 1695, 1594, 1489, 1146, 757 cm–1.  
MS (ESI) m/z (relative intensity): 431 (100) [M + Na]+, 409 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C27H20O4 + Na]+ 431.1254 found 431.1253.  
[α]D
20: -31.9 (c = 1.0, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 15.1 min, tr (minor) = 13.6 min, 98% ee. 
 
4-Fluorobenzyl (E)-3-(2'-formyl-6-methyl-[1,1'-biphenyl]-2-yl)acrylate (74bf): The 
general procedure L was followed using 2'-methyl-[1,1'-biphenyl]-2-carbaldehyde (73b) (40 
mg, 0.20 mmol) and 4-fluorobenzyl acrylate (38f) (108 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 5:1) yielded 74bf (53 mg, 70%).  
1H-NMR (400 MHz, CDCl3): δ = 9.61 (s, 1H), 8.06 (dd, J = 7.8, 1.4 Hz, 1H), 7.69 (dd, J = 7.5, 
1.5 Hz, 1H), 7.62–7.54 (m, 2H), 7.39–7.31 (m, 2H), 7.31–7.19 (m, 4H), 7.06–6.99 (m, 2H), 
6.31 (d, J = 16.0 Hz, 1H), 5.07 (s, 2H), 2.00 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 191.4 (CH), 166.1 (Cq), 162.5 (d, 1JC-F = 246.8 Hz, Cq), 
143.2 (CH), 142.5 (Cq), 138.2 (Cq), 137.3 (Cq), 134.2 (CH), 134.1 (Cq), 133.7 (Cq), 131.8 (d, 
4JC-F = 3.2 Hz, Cq), 131.7 (CH), 130.9 (CH), 129.9 (d, 3JC-F = 8.2 Hz, CH), 128.5 (CH), 128.5 
(CH), 128.0 (CH), 123.9 (CH), 119.2 (CH), 115.4 (d, 2JC-F = 21.6 Hz, CH), 65.4 (CH2), 20.8 
(CH3).  
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19F-NMR (375 MHz, CDCl3): δ = –113.8.  
IR (ATR): 2955, 1730, 1682, 1485, 1376, 1320, 744  cm–1.  
MS (ESI) m/z (relative intensity): 397 (100) [M + Na]+, 375 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C24H19FO3 + Na]+ 397.1210 found 397.1215.  
[α]D
20: -7.0 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 12.6 min, tr (minor) = 16.3 min, 98% ee. 
  
(E)-4-Bromophenyl -3-(1-(2-formylphenyl)naphthalen-2-yl)acrylate (74ag): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46 mg, 0.20 mmol) 
and 4-bromophenyl acrylate (38g) (135.6 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc = 5:1) yielded 74ag (45.6 mg, 50%) as yellow oil.  
1H-NMR (400 MHz, CDCl3): δ =  9.50 (s, 1H), 8.16 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.7 Hz, 
1H), 7.95–7.88 (m, 2H), 7.82–7.62 (m, 2H), 7.63–7.52 (m, 2H), 7.50–7.45 (m, 2H), 7.42 (t, J 
= 8.5 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.31–7.25 (m, 1H), 7.02–6.93 (m, 2H), 6.64 (d, J = 
16.6 Hz, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 191.2 (CH), 164.6 (Cq), 149.7 (Cq), 144.4 (CH), 140.9 (Cq), 
137.5 (Cq), 135.3 (Cq), 134.1 (CH), 134.0 (Cq), 133.3 (Cq), 132.4 (CH), 132.0 (CH), 130.7 (Cq), 
129.3 (CH), 129.1 (CH), 128.2 (CH), 128.1 (CH), 127.7 (CH), 127.5 (CH), 127.1 (CH), 123.3 
(CH), 122.6 (CH), 118.8 (Cq), 118.7 (CH).  
IR (ATR): 2935, 1712, 1682, 1355, 1250, 1146, 1014, 920 cm–1.  
MS (ESI) m/z (relative intensity): 479 (100) [M + Na]+, 457 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C26H1779BrO3 + Na]+ 479.0253 found 479.0245.  
[α]D
20: -34.0 (c = 1.5, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1 mL/min, detection at 273 nm): tr 
(major) = 20.4 min, tr (minor) = 23.1 min, 97% ee.   
 




(E)-4-nitrophenyl-3-(1-(2-formylphenyl)naphthalen-2-yl)acrylate (74ah): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46.4 mg, 0.20 mmol) 
and 4-nitrophenyl acrylate (38h) (115.9 mg, 0.60 mmol). Isolation by column chromatography 
(n-hexane/EtOAc = 1:1) yielded 74ah (40.6 mg, 48%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.53 (s, 1H), 8.28 (d, J = 9.1 Hz, 2H), 8.19 (d, J = 7.7 Hz, 
1H), 8.03 (d, J = 8.8 Hz, 1H), 7.99–7.89 (m, 2H), 7.80 (td, J = 7.5, 1.5 Hz, 1H), 7.76–7.54 (m, 
3H), 7.51–7.37 (m, 2H), 7.36–7.25 (m, 3H), 6.68 (d, J = 15.9 Hz, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 191.2 (CH), 163.9 (Cq), 155.5 (Cq), 145.4 (CH), 145.3 (Cq), 
140.8 (Cq), 137.9 (Cq), 135.3 (Cq), 134.2 (Cq), 134.1 (CH), 133.3 (Cq), 132.0 (CH), 130.5 (Cq), 
129.4 (CH), 129.2 (CH), 128.3 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 127.2 (CH), 125.2 
(CH), 122.5 (CH), 122.4 (CH), 117.9 (CH).  
IR (ATR): 3018, 1696, 1661, 1215, 751, 720, 683 cm–1.  
MS (ESI) m/z (relative intensity): 446 (100) [M + Na]+, 424 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C26H17NO5 + Na]+ 446.0999 found 446.0998.  
[α]D
20: -10.6 (c = 0.2, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1 mL/min, detection at 273 nm): 
tr (major) = 27.0 min, tr (minor) = 42.4 min, 96% ee.  
   
4-Acetylphenyl (E)-3-(1-(2-formylphenyl)naphthalen-2-yl)acrylate (74ai): The general 
procedure L was followed using 2-(naphthalen-1-yl)benzaldehyde (73a) (46 mg, 0.20 mmol) 
and 4-acetylphenyl acrylate (38i) (114 mg, 0.60 mmol). Isolation by column chromatography 
(n-hexane/EtOAc = 4:1) yielded 74ai (54 mg, 64%) as colourless oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.51 (s, 1H), 8.16 (ddd, J = 7.9, 1.5, 0.6 Hz, 1H), 8.02–7.96 
(m, 3H), 7.95–7.92 (m, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.77 (td, J = 7.5, 1.5 Hz, 1H), 7.70–7.54 
(m, 3H), 7.46–7.34 (m, 2H), 7.32–7.24 (m, 1H), 7.23–7.17 (m, 2H), 6.66 (d, J = 15.9 Hz, 1H), 
2.59 (s, 3H).  
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13C-NMR (100 MHz, CDCl3): δ = 196.8 (Cq), 191.2 (CH), 164.3 (Cq), 154.4 (Cq), 144.7 (CH), 
140.9 (Cq), 137.6 (Cq), 135.3 (Cq), 134.6 (Cq), 134.1 (CH), 134.0 (Cq), 133.3 (Cq), 131.9 (CH), 
130.7 (Cq), 129.8 (CH), 129.3 (CH), 129.1 (CH), 128.2 (CH), 128.1 (CH), 127.7 (CH), 127.5 
(CH), 127.1 (CH), 122.6 (CH), 121.7 (CH), 118.5 (CH), 26.6 (CH3).  
IR (ATR): 2925, 1733, 1682, 1596, 1201, 1130, 753, 658 cm–1.  
MS (ESI) m/z (relative intensity): 443 (100) [M + Na]+, 421 (5) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C28H20O4 + Na]+ 443.1254 found 443.1258.  
[α]D
20: -29.9 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 70:30, 0.75 mL/min, detection at 273 
nm): tr (major) = 17.2 min, tr (minor) = 21.4 min, 98% ee. 
 
(R,E)-3-(2'-formyl-6-methyl-[1,1'-biphenyl]-2-yl)-N-isopropylacrylamide (74bj): The 
general procedure L was followed using 2'-methyl-[1,1'-biphenyl]-2-carbaldehyde (73b) 
(39.3 mg, 0.20 mmol) and N-isopropylacrylamide (38j) (67.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc = 1:2) yielded 74bj (33.8 mg, 55%) as a white solid. 
M.P. 145–150 °C.  
1H-NMR (400 MHz, CDCl3): δ = 9.59 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.66 (td, J = 7.5, 1.5 
Hz, 1H), 7.58–7.48 (m, 2H), 7.38– 7.24 (m, 2H), 7.24–7.12 (m, 2H), 6.16 (d, J = 15.4 Hz, 1H), 
5.40 (d, J = 7.9 Hz, 1H), 4.13–4.00 (m, 1H), 1.97 (s, 3H), 1.18–1.08 (m, 6H).  
13C-NMR (100 MHz, CDCl3): δ = 191.7 (CH), 164.4 (Cq), 142.8 (Cq), 138.7 (CH), 137.9 (Cq), 
137.3 (Cq), 134.5 (Cq), 134.4 (Cq), 134.1 (CH), 130.9 (CH), 130.8 (CH), 128.5 (CH), 128.3 
(CH), 128.0 (CH), 123.7 (CH), 122.8 (CH), 41.5 (CH), 22.8 (CH3), 22.7 (CH3), 20.8 (CH3).  
IR (ATR): 2924, 1694, 1652, 1541, 1456, 1225, 1195, 755 cm–1.  
MS (ESI) m/z (relative intensity): 330 (100) [M + Na]+, 308 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C20H21NO2 + Na]+ 330.1465 found 330.1470.  
[α]D
20: +9.2 (c = 0.25, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1 mL/min, detection at 273 nm): 
tr (major) = 13.2 min, tr (minor) = 12.0 min, 96% ee. 




(E)-Butyl -3-(1-(2-formyl-1H-pyrrol-1-yl)naphthalen-2-yl)acrylate (397aa): A modified 
procedure A was followed using 1-(naphthalen-1-yl)-1H-pyrrole-2-carbaldehyde (396a) (44.3 
mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol) with L-tert-leucine (7.9 mg, 
30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 5:1) yielded 397aa (38.9 
mg, 56%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.46 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 8.2 Hz, 
1H), 7.86 (d, J = 8.8 Hz, 1H), 7.65–7.56 (m, 1H), 7.56–7.46 (m, 1H), 7.37–7.28 (m, 2H), 7.18 
(d, J = 8.5 Hz, 1H), 7.09 (s, 1H), 6.69–6.62 (m, 1H), 6.52 (d, J = 16.0 Hz, 1H), 4.20 (t, J = 6.6 
Hz, 2H), 1.75–1.62 (m, 2H), 1.50–1.38 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 178.5 (CH), 166.4 (Cq), 139.1 (Cq), 138.3 (CH), 135.6 (CH), 
134.5 (Cq), 134.4 (Cq), 132.2 (CH), 131.5 (Cq), 129.7 (Cq), 129.5 (CH), 128.1 (CH), 128.0 
(CH), 127.8 (CH), 123.2 (CH), 122.6 (CH), 121.6 (CH), 111.5 (CH), 64.5 (CH2), 30.6 (CH2), 
19.1 (CH2), 13.7 (CH3).  
IR (ATR): 2957, 1712, 1671, 1305, 1196, 1150, 787, 741 cm–1.  
MS (ESI) m/z (relative intensity): 370 (100) [M + Na]+, 348 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C22H21NO3 + Na]+ 370.1414 found 370.1419.  
[α]D
20: -43.1 (c = 0.4, CHCl3).  
HPLC separation (Chiralpak® ID-3, n-hexane/i-PrOH 80:20, 1 mL/min, detection at 273 nm): 
tr (major) = 15.2 min, tr (minor) = 16.6 min, 99% ee. The analytical data correspond with those 
reported in the literature. [276] 
 
(E)-1-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodec-1-en-1-yl)naphthalen-1-
yl)-1H-pyrrole-2-carbaldehyde (398aa): A modified procedure A was followed using 1-
(naphthalen-1-yl)-1H-pyrrole-2-carbaldehyde (396a) (44.3 mg, 0.20 mmol) and 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodec-1-ene (301a) (267.7 mg, 0.60 mmol) 
with L-tert-leucine (7.9 mg, 30 mol %). Isolation by column chromatography (n-hexane/DCM 
= 1:1) yielded 398aa (69.2 mg, 52%) as a yellow oil.  
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1H-NMR (400 MHz, CDCl3): δ = 9.43 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 8.2 Hz, 
1H), 7.72 (d, J = 8.7 Hz, 1H), 7.61–7.50 (m, 1H), 7.52–7.43 (m, 1H), 7.27 (dd, J = 4.0, 1.6 Hz, 
1H), 7.15 (d, J = 7.5 Hz, 1H), 7.06–6.97 (m, 1H), 6.72 (dt, J = 16.1, 2.4 Hz, 1H), 6.60 (dd, J = 
4.0, 2.5 Hz, 1H), 6.17 (dt, J = 16.2, 11.8 Hz, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 178.3 (CH), 135.4 (Cq), 134.6–134.3 (m, CH+Cq), 134.3 
(Cq), 131.9 (CH), 131.3 (Cq), 129.7 (CH), 128.7 (Cq), 128.3 (CH), 128.1 (CH), 127.9 (CH), 
123.1 (CH), 122.6 (CH), 122.1 (CH), 117.8 (t, J = 23.1 Hz, CH-CF2), 111.6 (CH).  
19F-NMR (375 MHz, CDCl3): δ = –80.7 (m), –111.5 (m), –121.3 (m), –121.9 (m), –122.7 (m), 
–123.1 (m), –126.1 (m).  
IR (ATR): 2925, 1671, 1239, 1201, 1146, 1113, 762, 746, cm-1.  
MS (ESI) m/z (relative intensity): 688 (100) [M + Na]+, 666 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C25H12F17NO + Na]+ 688.0540 found 688.0535.  
[α]D
20: -38.3 (c = 0.75, CHCl3).  
HPLC separation (Chiralpak® ID-3, n-hexane/i-PrOH 99:1, 1 mL/min, detection at 273 nm): 
tr (major) = 6.1 min, tr (minor) = 6.7 min, 98% ee.  
5.9.2. Late stage Diversification 
 
 
(R, E)-Butyl 3-(2-(3-formylphenanthren-4-yl)-3-methylphenyl)acrylate (74ha): A 
modified procedure L was followed using 4-(o-tolyl)phenanthrene-3-carbaldehyde (73h) 
(59.2 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol) with L-tert-leucine (7.9 
mg, 30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 5:1) yielded 74ha 
(33.8 mg, 40%) as a yellow oil and 73h (32.0 mg, 54%) as yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.59 (s, 1H), 8.28 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 8.2 Hz, 
1H), 7.95–7.82 (m, 3H), 7.77 (d, J = 7.9 Hz, 1H), 7.63–7.40 (m, 4H), 7.24–7.05 (m, 2H), 6.26 
(d, J = 15.8 Hz, 1H), 3.94 (t, J = 6.5 Hz, 2H), 1.86 (s, 3H), 1.52–1.38 (m, 2H), 1.24–1.10 (m, 
2H), 0.83 (t, J = 7.4 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 192.3 (CH), 166.2 (Cq), 141.9 (CH), 141.7 (Cq), 139.4 (Cq), 
137.8 (Cq), 137.4 (Cq), 134.6 (Cq), 133.7 (Cq), 133.0 (Cq), 132.4 (CH), 131.3 (Cq), 131.2 (CH), 
130.0 (CH), 129.4 (CH), 129.2 (CH), 128.4 (Cq), 127.5 (CH), 127.0 (CH), 126.7 (CH), 125.6 
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(CH), 124.9 (CH), 124.4 (CH), 120.5 (CH), 64.2 (CH2), 30.5 (CH2), 20.4 (CH3), 19.0 (CH2), 
13.6 (CH3).  
IR (ATR): 2933, 1701, 1650, 1590, 1410, 1251, 1115, 1045, 795 cm–1.  
MS (ESI) m/z (relative intensity): 445 (100) [M + Na]+, 423 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C29H26O3 + H]+ 423.1955 found 423.1959.  
[α]D
20: +238.1 (c = 0.8, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 99:1, 1 mL/min, detection at 273 nm): tr 




1H-NMR (600 MHz, CDCl3): δ = 9.69 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 7.99 (dd, J = 8.3, 0.9 
Hz, 1H), 7.90–7.82 (m, 2H), 7.80 (d, J = 8.8 Hz, 1H), 7.51–7.44 (m, 3H), 7.41 (dd, J = 7.7, 1.4, 
1H), 7.38 (dd, J = 7.5, 1.4 Hz, 1H), 7.27 (dd, J = 7.5, 1.4 Hz, 1H), 7.16–7.12 (m, 1H), 1.93 (s, 
3H).  
13C-NMR (150 MHz, CDCl3): δ = 193.1 (CH), 144.6 (Cq), 138.7 (Cq), 137.2 (Cq), 136.8 (Cq), 
133.6 (Cq), 133.0 (Cq), 131.4 (Cq), 130.9 (CH), 130.8 (CH), 130.3 (CH), 129.3 (CH), 129.1 
(CH), 128.8 (CH), 128.4 (Cq), 127.4 (CH), 126.9 (CH), 126.5 (CH), 126.5 (CH), 126.4 (CH), 
123.9 (CH), 20.1 (CH3).  
IR (ATR): 2937, 1710, 1599, 1432, 1211, 1105, 1020, 710 cm–1.  
MS (ESI) m/z (relative intensity): 319 (100) [M + Na]+, 297 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C22H16O + Na]+ 319.1093 found 319.1098.  
[α]D
20: +21.2 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IB-3, n-hexane/EtOAc 99:1, 1 mL/min, detection at 273 nm): tr 
(major) = 7.3 min, tr (minor) = 7.1 min, 77% ee. 
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(S)-4-(2-Formyl-6-methylphenyl)phenanthrene-3-carbaldehyde (399): To a solution of 
74ha (30 mg, 0.07 mmol, 1 equiv) in THF (1.8 mL) and H2O (0.9 mL), K2OsO4.2H2O (4 mg, 
0.011 mmol, 15 mol %) and NaIO4 (149 mg, 0.7 mmol, 10 equiv) were added at 25 °C, the 
reaction mixture was stirred at 50 °C for 16 h. The reaction mixture was then stopped by the 
addition with sat. aqueous Na2S2O3 (5 mL) and stirred vigorously for 30 min. The biphasic 
reaction mixture was extracted with EtOAc (3 × 20 mL) and then the combined organic layers 
were washed with brine (20 mL), dried over Na2SO4, and concentrated. The crude product was 
purified by flash column chromatography (n-hexane/EtOAc = 3:1) to provide 399 (19.3 mg, 
85%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.63 (s, 1H), 9.49 (s, 1H), 8.30 (dd, J = 8.3, 1.2 Hz, 1H), 
8.16–8.11 (m, 1H), 8.10–8.05 (m, 1H), 7.99–7.84 (m, 3H), 7.80–7.68 (m, 2H), 7.52 (ddd, J = 
8.3, 6.9, 1.2 Hz, 1H), 7.34 (d, J = 9.2 Hz, 1H), 7.17 (ddd, J = 8.7, 7.0, 1.4 Hz, 1H), 2.01 (s, 
3H).  
13C-NMR (100 MHz, CDCl3): δ = 191.5 (CH), 190.9 (CH), 142.2 (Cq), 139.6 (Cq), 138.4 (Cq), 
137.3 (Cq), 136.4 (CH), 135.2 (Cq), 133.8 (Cq), 133.4 (Cq), 131.5 (CH), 131.0 (Cq), 130.3 (CH), 
129.6 (CH), 129.4 (CH), 128.8 (Cq), 127.5 (CH), 127.1 (CH), 126.9 (CH), 126.9 (CH), 125.7 
(CH), 124.5 (CH), 19.9 (CH3).  
IR (ATR): 2925, 1710, 1643, 1555, 1400, 1320, 1290, 850 cm–1.  
MS (ESI) m/z (relative intensity): 347 (100) [M + Na]+, 325 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C23H16O2 + Na]+ 347.1043 found 347.1038.  
[α]D
20: +42.8 (c = 1.0, CHCl3).  
 
 
(S)-4-(2-Methyl-6-vinylphenyl)-3-vinylphenanthrene (400): A flame dried round bottom 
flask was charged with 399 (16 mg, 0.05 mmol, 1 equiv). THF (1.5 mL) was added and the 
mixture is stirred until dissolution of the substrate. The solution was cooled to -78 °C. A second 
flame dried round bottom flask was charged with methyltriphenylphosphonium bromide (71.5 
mg, 0.2 mmol, 4 equiv). THF (1.5 mL) was added and the suspension was cooled to -78 °C. n-
Butyllithium (3.8 equiv, 0.19 mmol) was added to the suspension of the phosphonium salt. The 
orange solution was warmed to rt for 10 min, and then cooled to -78 °C. The orange solution 
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of the phosphorus ylide was slowly transferred via canula to the solution of 399. The reaction 
mixture was warmed to rt and stirred for 1 hour. Silica gel was directly added to the reaction 
mixture and the solvent was evaporated under vacuum. The crude product was purified by flash 
column chromatography (n-hexane/EtOAc = 15:1) to provide 400 (15.9 mg, 99%) as a yellow 
oil.  
1H-NMR (400 MHz, CDCl3): δ = 7.97 (d, J = 1.6 Hz, 2H), 7.89–7.73 (m, 3H), 7.68 (d, J = 7.8 
Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.50–7.42 (m, 2H), 7.34 (d, J = 7.5 Hz, 1H), 7.13 (ddd, J = 
8.7, 6.9, 1.6 Hz, 1H), 6.45– 6.31 (m, 1H), 6.27–6.15 (m, 1H), 5.76 (dd, J = 17.4, 1.4 Hz, 1H), 
5.58 (dd, J = 17.4, 1.4 Hz, 1H), 5.16 (dd, J = 11.0, 1.5 Hz, 1H), 4.89 (dd, J = 11.0, 1.5 Hz, 1H), 
1.80 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 140.6 (Cq), 136.8 (Cq), 136.6 (Cq), 135.8 (Cq), 135.6 (Cq), 
135.5 (CH), 135.0 (CH), 133.6 (Cq), 133.3 (Cq), 131.4 (Cq), 130.2 (CH), 129.1 (CH), 128.8 
(Cq), 128.8 (CH), 128.0 (CH), 127.9 (CH), 127.7 (CH), 126.2 (CH), 126.0 (CH), 126.0 (CH), 
124.0 (CH), 123.4 (CH), 115.5 (CH2), 114.9 (CH2), 20.1 (CH3).  
IR (ATR): 2932, 1550, 1472, 1355, 1259, 1231, 980, 720 cm–1.  
MS (EI) m/z (relative intensity): 320 (20), 305 (20), 276 (100), 263 (10), 228 (30).  
HR-MS (EI): m/z calcd. for [C25H20] [M]+ 320.1560 found 320.1558.  
[α]D
20: +10.8 (c = 1.0, CHCl3).  
 
 
10-Methyldibenzo[c,g]phenanthrene (401): A flame-dried microwave vessel, equipped with 
a magnetic stirrer was charged with 400 (9.6 mg, 0.03 mmol) under N2. Anhydrous CH2Cl2 
(1.5 mL) was added and the mixture was stirred until dissolution of all the substrates. The 
Grubbs II catalyst (2.5 mg, 0.003 mmol, 10 mol %) was added, the tube was sealed. The 
reaction vessel was irradiated in a microwave at 95 °C for 1 h. The reaction mixture is 
concentrated in vacuo and purified by flash column silica gel chromatography (n-
hexane/EtOAc = 30:1) to afford [5]-helicene 401 (7.4 mg, 86 %) as a colourless oil.  
1H-NMR (600 MHz, CDCl3): δ = 7.96–7.90 (m, 5H), 7.89 (d, J = 8.4 Hz, 1H), 7.88–7.86 (m, 
1H), 7.84 (dd, J = 8.4, 0.7 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 7.5 Hz, 1H), 7.45 
(ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.21–7.17 (m, 1H), 7.12 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 1.54 (s, 
3H).  
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13C-NMR (150 MHz, CDCl3): δ = 136.0 (Cq), 133.2 (Cq), 132.9 (Cq), 131.9 (Cq), 131.5 (Cq), 
131.2 (Cq), 130.4 (Cq), 128.6 (CH), 128.5 (Cq), 127.8 (CH), 127.8 (CH), 127.1 (CH), 127.1 
(CH), 126.3 (CH), 126.2 (CH), 126.1 (CH), 126.0 (CH), 125.6 (CH), 125.5 (CH), 125.2 (CH), 
125.1 (CH), 124.9 (Cq), 23.2 (CH3).  
IR (ATR): 2922, 1532, 1452, 1260, 1096, 1018, 798, 695 cm–1.  
MS (EI) m/z (relative intensity): 292 (30), 277 (100), 261 (10), 228 (10), 138 (30).  
HR-MS (EI): m/z calcd. for C23H16 [M]+: 292.1252, found 292.1246.  
[α]D
20: -20.4 (c = 0.25, CHCl3).  
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 98:2, 1 mL/min, detection at 273 nm): tr 
(major) = 3.6 min, tr (minor) = 3.9 min, 95% ee. 
 
(+)(E)-n-Butyl-3-(1-(3-formylphenanthren-4-yl)naphthalen-2-yl)acrylate (74ia): A 
modified procedure L was followed using 4-(naphthalen-1-yl)phenanthrene-3-carbaldehyde 
(73i) (66.4 mg, 0.20 mmol) and n-butyl acrylate (38a) (76.9 mg, 0.60 mmol) with L-tert-
leucine (7.9 mg, 30 mol %). Isolation by column chromatography (n-hexane/EtOAc = 5:1) 
yielded 74ia (35.5 mg, 42%, E/Z = 96:4) as a yellow oil and 73i (38.0 mg, 55%) as yellow 
solid. M.P.: 130-132 °C.  
1H-NMR (400 MHz, CDCl3): δ = 9.38 (s, 1H), 8.35 (dd, J = 8.2, 1.7 Hz, 1H), 8.22–8.10 (m, 
2H), 8.03–7.89 (m, 4H), 7.85 (dd, J = 7.9, 1.6 Hz, 1H), 7.54 (dd, J = 8.2, 1.5 Hz, 1H), 7.40 (dd, 
J = 7.5, 6.9, 1.2 Hz, 1H), 7.32–7.17 (m, 4H), 6.94 (dd, J = 8.6, 1.6 Hz, 1H), 6.41 (d, J = 15.8 
Hz, 0.96H, E), 5.67 (d, J = 12.3 Hz, 0.04H, Z), 3.97 (t, J = 6.5 Hz, 2H), 1.54–1.40 (m, 2H), 
1.29–1.14 (m, 2H), 0.84 (t, J = 6.5 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 192.1 (CH), 166.2 (Cq), 141.3 (CH), 140.2 (Cq), 138.1 (Cq), 
137.3  (Cq), 134.2 (Cq), 134.1 (Cq), 133.7 (Cq), 133.4 (Cq), 131.8 (Cq), 131.4 (CH), 130.7 (Cq), 
130.4 (CH), 129.6 (CH), 129.5 (Cq), 129.3 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.5 
(CH), 127.0 (CH), 126.8 (CH), 126.6 (CH), 126.3 (CH), 124.4 (CH), 123.3 (CH), 120.7 (CH), 
64.2 (CH2), 30.5 (CH2), 19.0 (CH2), 13.7 (CH3).  
IR (ATR): 2933, 1698, 1652, 1559, 1421, 1222, 885 cm–1.  
MS (ESI) m/z (relative intensity): 481 (100) [M + Na]+, 459 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C32H26O3 + Na]+ 481.1774 found 481.1773.  




20: +178.2 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 15.4 min, tr (minor) = 12.1 min, 96% ee. 
 
(R)-4-(Naphthalen-1-yl)phenanthrene-3-carbaldehyde (73i):1H NMR (600 MHz, CDCl3): 
δ = 9.45 (s, 1H), 8.27 (d, J = 8.3 Hz, 1H), 8.11 – 8.06 (m, 2H), 7.99 (dd, J = 8.3, 0.9 Hz, 1H), 
7.88 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.81 (dd, J = 7.8, 1.5 Hz, 1H), 7.62 (dd, J = 
8.3, 6.9 Hz, 1H), 7.52–7.48 (m, 1H), 7.47 (dd, J = 6.9, 1.2 Hz, 1H), 7.38–7.33 (m, 2H), 7.27 
(ddd, J = 8.3, 6.7, 1.0 Hz, 1H), 7.20 (dd, J = 8.7, 1.0 Hz, 1H), 6.86 (ddd, J = 8.7, 6.9, 1.5 Hz, 
1H).  
13C-NMR (150 MHz, CDCl3): δ = 192.9 (CH), 143.1 (Cq), 137.2 (Cq), 136.9 (Cq), 134.2 (Cq), 
133.7 (Cq), 133.6 (Cq), 133.2 (Cq), 131.0 (CH), 130.8 (Cq), 129.7 (CH), 129.4 (Cq), 129.0 (CH), 
128.9 (CH), 128.5 (CH), 128.3 (CH), 127.3 (CH), 127.2 (CH), 127.2 (CH), 126.7 (CH), 126.4 
(CH), 126.2 (CH), 126.0 (CH), 125.9 (CH), 123.9 (CH).  
IR (ATR): 2955, 1678, 1569, 1417, 1232, 685 cm–1.  
MS (ESI) m/z (relative intensity): 355 (100) [M + Na]+, 333 (20) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C25H16O + Na]+ 355.1093 found 355.1095.  
[α]D
20: -4.5 (c = 1.2, CHCl3). HPLC separation (Chiralpak® ID-3, n-hexane/i-PrOH 99:1, 1.0 




(-)(E)-n-Butyl-3-(1-(3-formylphenanthren-4-yl)naphthalen-2-yl)acrylate (74ia): A 
modified procedure L was followed using recovered 4-(naphthalen-1-yl)phenanthrene-3-
carbaldehyde 73i (30 mg, 0.09 mmol, 76% ee) and n-butyl acrylate (38a) (34.6 mg, 
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0.27 mmol) with D-tert-leucine (3.6 mg, 30 mol %). Isolation by column chromatography (n-
hexane/EtOAc = 5:1) yielded ent-74ia (23.9 mg, 58%, E/Z = 96:4, 96% ee).  
[α]D
20: -30.2 (c = 0.4).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 95:5, 1.0 mL/min, detection at 273 nm): 
tr (major) = 11.9 min, tr (minor) = 14.9 min, 96% ee. 
 
4-(2-Formylnaphthalen-1-yl)phenanthrene-3-carbaldehyde (402): To a solution of 74ia 
(32.1 mg, 0.07 mmol, 1 equiv) in THF (1.8 mL) and H2O (0.9 mL), K2OsO4.2H2O (4 mg, 0.011 
mmol, 15 mol %) and NaIO4 (149 mg, 0.7 mmol, 10 equiv) were added at 25 °C, the reaction 
mixture was stirred at 50 °C for 16 h. The reaction mixture was then quenched with sat. aqueous 
Na2S2O3 (5 mL) and stirred vigorously for 30 min. The biphasic reaction mixture was extracted 
with EtOAc (3 × 20 mL) and then the combined organic layers were washed with brine (20 
mL), dried over Na2SO4, and concentrated. The crude product was purified by column 
chromatography (n-hexane/EtOAc = 3:1) to provide 402 (22.3 mg, 86%) as a yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 9.60 (s, 1H), 9.42 (s, 1H), 8.38 (dd, J = 8.3, 1.5 Hz, 1H), 
8.27–8.18 (m, 3H), 8.09 (d, J = 8.2 Hz, 1H), 8.00–7.91 (m, 2H), 7.88 (dd, J = 7.9, 1.5 Hz, 1H), 
7.69 (ddd, J = 8.3, 6.7, 1.5 Hz, 1H), 7.53–7.47 (m, 1H), 7.46–7.37 (m, 2H), 7.06 (d, J = 8.8 Hz, 
1H), 6.94 (ddd, J = 8.8, 7.0, 1.2 Hz, 1H).  
13C-NMR (100 MHz, CDCl3): δ = 191.3 (CH), 190.9 (CH), 143.5 (Cq), 137.8 (Cq), 137.1 (Cq), 
136.1 (Cq), 134.8 (Cq), 133.9 (Cq), 133.3 (Cq), 132.4 (Cq), 131.7 (CH), 130.8 (CH), 130.2 (Cq), 
130.1 (Cq), 129.9 (CH), 129.9 (CH), 129.5 (CH), 128.7 (CH), 128.4 (CH), 127.3 (CH), 127.2 
(CH), 126.9 (CH), 126.8 (CH), 126.6 (CH), 124.3 (CH), 123.0 (CH).  
IR (ATR): 2935, 1712, 1695, 1555, 1496, 1246, 1114, 795 cm–1.  
MS (ESI) m/z (relative intensity): 383 (100) [M + Na]+, 361 (30) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C26H16O2 + Na]+ 383.1043 found 383.1044.  
[α]D
20: -11.4 (c = 0.9, CHCl3).  
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 30.8 min, tr (minor) = 12.7 min, 96% ee. 




3-Vinyl-4-(2-vinylnaphthalen-1-yl)phenanthrene (402’): A flame dried round bottom flask 
was charged with 403 (17.8 mg, 0.05 mmol, 1 equiv). THF (1.5 mL) was added and the mixture 
was stirred until dissolution of the substrate. The solution was cooled to -78 °C. A second 
flame-dried round bottom flask was charged with methyltriphenylphosphonium bromide (71.5 
mg, 0.2 mmol, 4 equiv). THF (1.5 mL) was added and the suspension was cooled to -78 °C. n-
Butyllithium (3.8 equiv, 0.19 mmol) was added to the suspension of the phosphonium salt. The 
orange solution was warmed to rt for 10 min, and then cooled back to -78 °C. The orange 
solution of phosphorus ylide was slowly transferred via canula to the solution of 402. The 
reaction mixture was warmed to rt and stirred for 1 hour. Silica gel was directly added to the 
reaction mixture and the solvent is evaporated under vacuum. The crude product was purified 
by column chromatography (n-hexane/EtOAc = 15:1) to provide 402’ (17.7 mg, 99%) as 
yellow oil.  
1H-NMR (400 MHz, CDCl3): δ = 8.12–8.00 (m, 3H), 8.01–7.92 (m, 2H), 7.87 (d, J = 8.8 Hz, 
1H), 7.83–7.75 (m, 2H), 7.45 (ddd, J = 8.8, 5.5, 2.4 Hz, 1H), 7.40–7.29 (m, 2H), 7.23–7.15 (m, 
2H), 6.89 (ddd, J = 8.8, 6.9, 1.6 Hz, 1H), 6.38 (dd, J = 17.5, 11.0 Hz, 1H), 6.21 (dd, J = 17.5, 
11.0 Hz, 1H), 5.80–5.68 (m, 2H), 5.07–4.98 (m, 2H).  
13C-NMR (100 MHz, CDCl3): δ = 138.0 (Cq), 137.0 (Cq), 135.6 (CH), 134.7 (CH), 134.1 (Cq), 
133.7 (Cq), 133.6 (Cq), 133.5 (Cq), 133.3 (Cq), 132.7 (Cq), 131.0 (Cq), 129.9 (Cq), 129.5 (CH), 
128.7 (CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 127.6 (CH), 126.8 (CH), 126.6 (CH), 126.4 
(CH), 126.3 (CH), 126.0 (CH), 125.9 (CH), 123.9 (CH), 123.1 (CH), 115.5 (CH2), 115.4 (CH2).  
IR (ATR): 2925, 1596, 1482, 1455, 1396, 1346, 1314, 785, 748, 699 cm–1.  
MS (EI) m/z (relative intensity): 356 (70), 328 (80), 313 (100), 298 (70), 215 (10).  
HR-MS (EI): m/z calcd. for C28H20 [M]+: 356.1560, found 356.1559.  
[α]D
20: +130.5 (c = 1.0, CHCl3).  
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[6]-helicene (403): A flame-dried microwave vessel, equipped with a magnetic stirrer, was 
charged with 402’ (10.7 mg, 0.03 mmol). CH2Cl2 (1.5 mL) was added and the mixture was 
stirred until dissolution of all the substrate. Grubbs II (2.5 mg, 0.003 mmol, 10 mol %) was 
added, and the tube was sealed. The reaction vessel was irradiated in a microwave at 95 °C for 
1 h. The reaction mixture was concentrated in vacuo and purified by column silica gel 
chromatography (n-hexane/EtOAc = 30:1) to afford [6]-helicene 403 (8.6 mg, 88%) as a 
colourless oil.  
1H-NMR (600 MHz, CDCl3): δ = 8.02–7.94 (m, 4H), 7.94–7.88 (m, 4H), 7.83–7.79 (m, 2H), 
7.58 (ddt, J = 8.6, 1.2, 0.6 Hz, 2H), 7.20 (ddd, J = 8.0, 6.8, 1.1 Hz, 2H), 6.67 (ddd, J = 8.4, 6.8, 
1.4 Hz, 2H).  
13C-NMR (150 MHz, CDCl3): δ = 133.1 (Cq), 131.7 (Cq), 131.2 (Cq), 129.9 (Cq), 128.0 (Cq), 
127.9 (CH), 127.7 (CH), 127.5 (CH), 127.2 (CH), 126.9 (CH), 126.2 (CH), 125.5 (CH), 124.6 
(CH), 124.1 (Cq).  
IR (ATR): 2922, 1496, 1259, 1095, 1070, 795, 749, 610 cm–1.  
MS (EI) m/z (relative intensity): 328 (80), 313 (90), 300 (100), 162 (20).  
HR-MS (EI): m/z calcd. for C26H16 [M]+: 328.1247, found 328.1242.  
[α]D
20: -350.1 (c = 1.0, CHCl3).  
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH 99:1, 1 mL/min, detection at 273 nm): tr 
(major) = 7.3 min, tr (minor) = 8.5 min, 96% ee. 
 
(R)-4-(2-Hydroxynaphthalen-1-yl)phenanthren-3-ol (405): 402 (15 mg, 0.04 mmol) and m-
chloroperbenzoic acid (mCPBA) (75%, 23 mg, 0.1 mmol) were refluxed in CH2Cl2 (1.5 mL) 
for 48 h. The reaction mixture was allowed to cool and then aqueous Na2S2O3 was added to 
destroy the excess of mCPBA. The suspension mixture was neutralized with aqueous NaHCO3. 
The solution was extracted with CH2Cl2 (3 × 50 mL). The combined extracts were washed with 
brine (4×100 mL) and dried with anhydrous magnesium sulfate. Removal of the solvent gave 
a brown solid, which was dissolved in MeOH (3 mL) and hydrolyzed under nitrogen with 
aqueous KOH (2.5 equiv). After 2 h MeOH was evaporated and the solution was acidified to 
pH2 with a concentrated HCl solution. The product was finally extracted with CH2Cl2 and 
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chromatography on silica gel (n-hexane/EtOAc = 1:2) provided the desired product 405 (7.0 
mg, 51%) as a white solid.  
1H-NMR (600 MHz, CDCl3): δ = 8.07–7.99 (m, 2H), 7.93 (dd, J = 8.1, 1.0 Hz, 1H), 7.81–7.74 
(m, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.51–7.48 (m, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.40–7.36 (m, 
2H), 7.34 (ddd, J = 7.9, 6.9, 1.1 Hz, 1H), 7.30–7.28 (m, 2H), 6.90 (ddd, J = 8.6, 7.0, 1.6 Hz, 
1H), 5.11 (s, 1H), 5.04 (s, 1H).  
13C-NMR (150 MHz, CDCl3): δ = 154.0 (Cq), 151.9 (Cq), 133.7 (Cq), 132.6 (Cq), 132.5 (CH), 
131.7 (CH), 130.7 (Cq), 12989 (Cq), 129.5 (Cq), 128.6 (CH), 128.6 (Cq), 128.6 (CH), 127.9 
(CH), 127.5 (CH), 126.6 (CH), 126.1 (CH), 125.8 (CH), 125.2 (CH), 124.6 (CH), 123.9 (CH), 
118.2 (CH), 116.9 (CH), 114.5 (Cq), 112.4 (Cq).  
IR (ATR): 2912, 1680, 1540, 1420, 1260, 846, 755 cm–1.  
MS (ESI) m/z (relative intensity): 359 (100) [M + Na]+, 337 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C24H16O2 + Na]+ 359.1043 found 359.1044. 
[α]D
20: -4.9 (c = 0.35, CHCl3).   
HPLC separation (Chiralpak® IA-3, n-hexane/i-PrOH 90:10, 1.0 mL/min, detection at 273 nm): 
tr (major) = 36.8 min, tr (minor) = 27.8 min, 96% ee. 
 
(R)-4-(2-Carboxynaphthalen-1-yl)phenanthrene-3-carboxylic acid (404): To a stirred 
solution of compound 402 (15 mg, 0.04 mmol) and 2-methylbut-2-ene (36.4 mg, 0.52 mmol) 
in tBuOH (1.5 mL) were added a saturated solution of NaClO2 (14.4 mg, 0.16 mmol) and 
NaH2PO4.2H2O (31.2 mg, 0.20 mmol). The mixture was stirred at 30 °C for 18 hours. The 
mixture was treated with saturated NH4Cl and extracted with EtOAc. The combined organic 
layers were washed with brine, dried over Na2SO4, filtered, concentrated, and purified by 
chromatography on silica gel (n-hexane/EtOAc/AcOH = 1:1:0.1) to give compound 404 (12.4 
mg, 82%) M.p. >200 °C.  
1H-NMR (400 MHz, CD3CO2D): δ = 8.32 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 8.3 Hz, 1H), 8.22–
8.19 (m, 2H), 8.02 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.83 (dd, J = 8.1, 1.5 Hz, 1H), 
7.53 (ddd, J = 8.1, 6.2, 1.7 Hz, 1H), 7.37–7.31 (m, 1H), 7.26–7.17 (m, 2H), 7.14 (d, J = 8.8 Hz, 
1H), 6.87 (ddd, J = 8.7, 7.0, 1.7 Hz, 1H).  
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13C-NMR (150 MHz, CD3CO2D): δ = 173.4 (Cq), 172.5 (Cq), 144.5 (Cq), 139.6 (Cq), 136.9 
(Cq), 136.8 (Cq), 134.1 (Cq), 133.9 (Cq), 131.8 (Cq), 131.0 (CH), 130.9 (Cq), 130.7 (Cq), 130.1 
(CH), 129.5 (CH), 129.3 (CH), 129.1 (CH), 128.4 (CH), 128.1 (CH), 128.1 (CH), 128.0 (Cq), 
127.8 (CH), 127.7 (CH), 127.5 (CH), 127.3 (CH), 127.1 (CH).  
IR (ATR): 2922, 1719, 1595, 1455, 1168, 1142, 748, 699 cm–1.  
MS (ESI) m/z (relative intensity): 415 (100) [M + Na]+, 393 (10) [M + H]+.  
HR-MS (ESI): m/z calcd. for [C26H16O4 + Na]+ 415.0941 found 415.0940.  
[α]D
20: -19.9 (c = 0.8, CHCl3).   
HPLC separation (Chiralpak® IB-3, n-hexane/i-PrOH/TFA 92:8:.0.08, 1.0 mL/min, detection 
at 273 nm): tr (major) = 18.7 min, tr (minor) = 25.9 min, 96% ee. 
5.9.3. Mechanistic Studies for the Atroposelective C–H Activation 
5.9.3.1. H/D-exchange experiment  
 
The representative procedure L was followed using 73a (46.4 mg, 0.20 mmol, 1 equiv), n-butyl 
acrylate (38a) (76.9 mg, 0.6 mmol, 3 equiv), Pd(OAc)2 (4.49 mg, 10 mol %), L-tert-leucine 
(5.24 mg, 20 mol %) and LiOAc (26.4 mg, 2 equiv) in AcOD (4.5 mL) at 60 °C for 12 h. At 
ambient temperature, the reaction mixture was diluted with EtOAc (3.0 mL) and the solvents 
were removed in vacuo. The crude mixture was purified by flash column chromatography on 
silica gel to afford the desired product 74aa (34 mg, 47%) and 73a (23.2 mg, 50% reisolated). 





5.7.3.2. KIE Studies 





Two parallel reactions of 73g and [D]5-73g with 38a were performed to determine the KIE by 
comparison of the initial reaction rates through 1H-NMR-analysis with triphenylmethane as the 
the internal standard. A suspension of 73g (46.4 mg, 0.20 mmol, 1.00 equiv) or [D]5-73g (47.4 
mg, 0.50 mmol, 1.00 equiv), 38a (76.9 mg, 1.50 mmol, 3 equiv), Pd(OAc)2 (4.49 mg, 10 mol 
%), L-tert-leucine (5.24 mg, 20 mol %) and LiOAc (26.4 mg, 2 equiv) and triphenylmethane 
(48.9 mg, 0.20 mmol) in AcOH (5.6 mL) was stirred at 60 °C. Aliquots (30 μL) were 
periodically removed to provide the following conversions as determined by 1H-NMR: 
 
Table 36. Conversion-time table 
t / min 10 20 30 40 50 60 
74ga / % 2.41 7.11 9.02 10.38 13.18 15.2 
[D]n-74ga 
/ % 
0.2 3.21 3.71 5.31 6.05 7.43 
 
5.7.3.3. Nonlinear Effect Study 
Six parallel independent reactions of 73a (46.4 mg, 0.20 mmol), 38a (76.9 mg, 0.60 mmol), 
Pd(OAc)2 (4.49 mg, 10 mol %), L-tert-leucine (10−100% ee, 5.24 mg, 20 mol %) and LiOAc 
(26.4 mg, 2 equiv) were heated at 60 °C in AcOH (4.5 mL) for 20 h. At ambient temperature, 
the reaction mixture was diluted with EtOAc (3.0 mL) and the solvents were removed in vacuo. 
The crude mixture was purified by flash column chromatography on silica gel to afford the 
desired product 74aa. The enantiomeric excess was determined by HPLC on chiral stationary 
phase. 
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Table 37. Nonlinear effect study for the asymmetric C–H olefination. 
Entry ee of L-tert-leucine ee of the product [74aa] 
1 0 0 
2 11.2 9.3 
3 28.8 29.1 
4 51.2 51.5 
5 68.8 67.5 
6 91.2 88.9 
7 100 97.3 
 
 
5.10. Crystallographic Data 
 
The crystal structures of 357da, 363e and 256aj were measured and solved by Dr. Christopher 
Golz. 
5.10.1. Determination of Absolute Stereochemistry of 357da 
357da (40 mg, 0.14 mmol, e.r. 92:8) was recrystallized from n-hexane/CH2Cl2 to furnish 
optically pure product (15 mg, 0.05 mmol, e.r. 99:1) as mother liquor. HPLC separation 
(Chiralpak® IF-3, n-hexane/i-PrOH 95:5, 1.0 mL/min, detection at 273 nm): tr (major) = 14.1 
min, tr (minor) = 16.1 min, 99.4:0.6 e.r. 
 






Crystals suitable for X-Ray crystallography were grown by slow evaporation from 
n-hexane/CH2Cl2. 
5.10.1.1. X-Ray Crystallographic Analysis of 357da    
 
Table 38. Crystal data of 357da 
Compound 357da 
CCDC Number CCDC 1857899 
Empirical formula C19H19NO2 
Formula Weight 293.35 
Temperature 100.03 
Crystal System monoclinic 















Crystal size/mm3 0.525 × 0.462 × 0.094 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.102 to 155.35 
Index ranges -10 ≤ h ≤ 10, -16 ≤ k ≤ 16, -18 ≤ l ≤ 18 
Reflections collected 6284 
Independent reflections 6284 [Rint = 0.0300, Rsigma = 0.0301] 
Data/restraints/parameters 6284/136/540 
Goodness-of-fit on F2 1.064 
Final R indexes [I>=2σ (I)] R1 = 0.0300, wR2 = 0.0827 
Final R indexes [all data] R1 = 0.0301, wR2 = 0.0827 
Largest diff. peak/hole / e Å-3 0.26/-0.13 





Table 39. Selected bond lengths [Å] and angles [°] for 357da 
O1-C2 1.215(3) C2-O2-C1 117.2(2) 
O2-C1 1.448(3) C10-N1-C5 109.00(17) 
O2-C2 1.338(3) O1-C2-O2 123.1(2) 
N1-C5 1.379(3) O1-C2-C3 125.1(2) 
N1-C10 1.377(3) O2-C2-C3 111.8(2) 
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C2-C3 1.482(3) C4-C3-C2 117.3(2) 
C3-C4 1.398(3) C4-C3-C8 120.8(2) 
C3-C8 1.409(3) C8-C3-C2 121.8(2) 
C4-C5 1.391(3) C5-C4-C3 117.7(2) 
C5-C6 1.419(3) N1-C5-C4 130.3(2) 
C6-C7 1.403(3) N1-C5-C6 107.56(18) 
C6-C9 1.425(3) C4-C5-C6 122.2(2) 
C7-C8 1.381(3) C5-C6-C9 106.59(18) 
C9-C10 1.372(3) C7-C6-C5 118.9(2) 
C10-C11 1.503(3) C7-C6-C9 134.5(2) 
C11-C12 1.528(3) C8-C7-C6 119.41(19) 
C11-C13 1.547(3) C7-C8-C3 120.99(19) 
C13-C14 1.515(3) C10-C9-C6 107.54(19) 
C14-C15 1.397(3) N1-C10-C11 120.88(18) 
C14-C19 1.395(3) C9-C10-N1 109.32(19) 
C15-C16 1.386(3) C9-C10-C11 129.80(19) 
C16-C17 1.379(4) C10-C11-C12 111.03(17) 
C17-C18 1.388(3) C10-C11-C13 110.73(16) 
C18-C19 1.390(3) C12-C11-C13 111.86(17) 
  C14-C13-C11 113.08(16) 
  C15-C14-C13 120.61(19) 
  C19-C14-C13 121.46(18) 
  C19-C14-C15 117.9(2) 
  C16-C15-C14 120.8(2) 
  C17-C16-C15 120.7(2) 
  C16-C17-C18 119.5(2) 
  C17-C18-C19 120.0(2) 
  C18-C19-C14 121.16(19) 
 
 
5.10.2. Determination of Absolute Stereochemistry of 363e 
363e (70 mg, 0.20 mmol, 82:18 e.r.) was recrystallized from CH2Cl2 at RT by slow evaporation 
to obtain suitable crystals for X-Ray crystallography. HPLC separation of crystal 363e 
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(Chiralpak® ID-3, n-hexane/EtOAc 90:10, 1.0 mL/min, detection at 273 nm): tr (major) = 8.6 




5.10.2.1. X-Ray Crystallographic Analysis of 363e    




Table 40. Crystal data of 256aj 
Compound 363e 
CCDC Number CCDC 2012314 
Empirical formula C19H19BrN2 
Formula Weight 355.27 
Temperature 100.0 
Crystal System orthorhombic 












Crystal size/mm3 0.344 × 0.172 × 0.155 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.37 to 61.036 
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Index ranges -12 ≤ h ≤ 12, -18 ≤ k ≤ 18, -19 ≤ l ≤ 18 
Reflections collected 54097 
Independent reflections 4808 [Rint = 0.0218, Rsigma = 0.0107] 
Data/restraints/parameters 4808/0/201 
Goodness-of-fit on F2 1.067 
Final R indexes [I>=2σ (I)] R1 = 0.0188, wR2 = 0.0501 
Final R indexes [all data] R1 = 0.0194, wR2 = 0.0509 
Largest diff. peak/hole / e Å-3 0.55/-0.19 
Flack parameter 0.0083(14) 
 
Table 41. Selected bond lengths [Å] and angles [°] for 363e 
Br1-C1 1.9134 (16) C6-C1-Br1 118.57(12) 
N1-C4 1.397 (2) C6-C1-C2 123.22(15) 
N1-C8 1.410 (2) C3-C2-C1 119.93(15) 
N1-C14 1.416 (2) C2-C3-C4 118.00(15) 
N2-C14 1.336 (2) N1-C4-C5 107.50(14) 
N2-C18 1.335 (2) C3-C4-N1 130.62(15) 
C1-C2 1.397 (2) C3-C4-C5 121.88(15) 
C1-C6 1.383 (2) C4-C5-C7 107.48(14) 
C2-C3 1.388 (2) C6-C5-C4 119.67(15) 
C3-C4 1.393 (2) C6-C5-C7 132.84(15) 
C4-C5 1.416 (2) C1-C6-C5 117.24(15) 
C5-C6 1.406 (2) C5-C7-C12 128.90(14) 
C5-C7 1.430 (2) C8 -C7 -C5 
 
107.64(14) 
C7-C8 1.366 (2) C8-C7-C12 123.39(14) 
C7-C12 1.501 (2) N1-C8-C9 124.30(14) 
C8-C9 1.499 (2) C7-C8-N1 109.45(14) 
C9-C10 1.558 (2) C7-C8-C9 125.96(15) 
C9-C13 1.530 (2) C8 -C9 -C10 
 
107.93(14) 
C10-C11 1.526 (2) C8-C9-C13 111.97(14) 
C11-C12 1.528 (2) C13-C9-C10 108.24(14) 
C14-C15 1.392 (2) C11-C10-C9 112.86(15) 
C15-C16 1.390 (2) C10-C11-C12 110.35(15) 
C16-C17 1.393 (2) C7-C12-C11 109.53(14) 
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C17-C18 1.397 (2) N2-C14-N1 115.55(14) 
C17-C19 1.505 (2) N2-C14-C15 123.07(16) 
C4-N1-C8 107.92(13) C15-C14-N1 121.38(15) 
C4-N1-C14 124.61(14) C16-C15-C14 118.31(16) 
C8-N1-C14 125.71(14) C15-C16-C17 119.87(16) 
C18 -N2 -C14 
 
117.42(15) C16-C17-C18 116.58(16) 
C2-C1-Br1 118.21(12) C16-C17-C19 122.65(17) 
  C18-C17-C19 120.76(16) 
  N2-C18-C17 124.62(16) 
    
5.10.3. X-Ray Crystallographic Analysis of 256aj    
 
Table 42. Crystal data of 256aj 
Compound 256aj 
CCDC Number CCDC 1910199 
Empirical formula C25H15N3O 
Formula Weight 373.40 
Temperature 99.95 
Crystal System monoclinic 












Crystal size/mm3 0.379 × 0.351 × 0.052 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.91 to 59.128 
Index ranges -54 ≤ h ≤ 54, -9 ≤ k ≤ 9, -19 ≤ l ≤ 17 
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Reflections collected 31821 
Independent reflections 5081 [Rint = 0.0295, Rsigma = 0.0196] 
Data/restraints/parameters 5081/0/262 
Goodness-of-fit on F2 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.0410, wR2 = 0.1015 
Final R indexes [all data] R1 = 0.0479, wR2 = 0.1090 




Table 43. Selected bond lengths [Å] and angles [°] for 256aj 
O1–C1 1.2182(13) C9–C10 1.3996(16) 
N1–C1 1.3978(13) C9–C12 1.4425(15) 
N1–C4 1.4170(13) C10–C11 1.3817(15) 
N1–C17 1.4260(13) C13–C14 1.3925(16) 
N2–C18 1.3686(13) C14–C15 1.3961(19) 
N2–C22 1.3206(14) C15–C16 1.3907(18) 
N3–C12 1.1448(16) C17–C18 1.4228(14) 
C1–C2 1.4766(15) C17–C25 1.3735(15) 
C2–C3 1.3933(15) C18–C19 1.4227(14) 
C2–C16 1.3898(15) C19–C20 1.4185(15) 
C3–C4 1.4729(14) C19–C23 1.4182(15) 
C3–C13 1.3912(15) C20–C21 1.3652(17) 
C4–C5 1.3433(14) C21–C22 1.4141(16) 
C5–C6 1.4741(14) C23–C24 1.3673(17) 
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C6–C7 1.4025(15) C24–C25 1.4092(16) 
C6–C11 1.4020(14) C1–N1–C4 112.09(9) 
C7–C8 1.3859(15) C1–N1–C17 121.05(9) 
C8–C9 1.515(3) C4–N1–C17 126.86(8) 
C22–N2–C18 116.81(9) C11–C10–C9 119.29(10) 
O1–C1–N1 124.93(10) C10–C11–C6 120.96(10) 
O1–C1–C2 129.39(10) N3–C12–C9 179.31(14) 
N1–C1–C2 105.67(9) C3–C13–C14 117.70(11) 
C3–C2–C1 108.35(9) C13–C14–C15 121.68(11) 
C16–C2–C1 129.61(10) C16–C15–C14 120.58(11) 
C16–C2–C3 122.04(10) C2–C16–C15 117.56(11) 
C2–C3–C4 108.88(9) C18–C17–N1 120.31(9) 
C13–C3–C2 120.42(10) C25–C17–N1 118.85(9) 
C13–C3–C4 130.70(10) C25–C17–C18 120.84(10) 
N1–C4–C3 104.99(8) N2–C18–C17 119.19(9) 
C5–C4–N1 129.95(10) N2–C18–C19 122.97(9) 
C5–C4–C3 125.06(10) C19–C18–C17 117.83(9) 
C4–C5–C6 128.86(10) C20–C19–C18 117.51(10) 
C7–C6–C5 122.87(9) C23–C19–C18 119.92(10) 
C11–C6–C5 118.35(10) C23–C19–C20 122.57(10) 
C11–C6–C7 118.78(10) C21–C20–C19 119.20(10) 
C8–C7–C6 120.96(10) C20–C21–C22 118.80(10) 
C7–C8–C9 119.06(10) N2–C22–C21 124.66(10) 
C8–C9–C12 120.08(10) C24–C23–C19 120.51(10) 
C10–C9–C8 120.78(10) C23–C24–C25 120.07(10) 
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When ent-CA14 was used: 






















































































1 mmol scale reaction: 
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